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Abstract 
Airway remodeling and inflammation are the hallmarks of asthma. Both airway smooth 
muscle (ASM) mass and extracellular matrix (ECM) deposition are increased in the central 
and peripheral airways of asthmatic patients, which contribute to airway obstruction. Few 
studies have investigated the ability of current asthma medications to reverse airway 
remodeling, especially the increased ASM mass. Inhaled corticosteroids (ICS) and long-acting 
β2-agonist combinations (ICS/LABA) are more effective than ICS monotherapy to control 
asthma exacerbations. However, their efficacy at modifying bronchial inflammation and 
remodeling at the peripheral level of the lung is not well-described. In fact, most work has 
been performed using endobronchial biopsy samples obtained from asthmatic subjects, which 
completely disregard the alterations occurring in peripheral airways. Ethical considerations 
limit the possibility of biopsying the peripheral airways in humans due to the invasiveness of 
the procedure. Equine asthma, or heaves, is a naturally-occurring disease of adult horses and a 
recognized animal model of human asthma characterized by neutrophilic inflammation as well 
as ASM and ECM remodeling of peripheral airways.  
This thesis has assessed the contribution of ICS and LABA, alone or combined, to the reversal 
of remodeling and inflammation in central and peripheral airways using the equine asthma 
model. To attain this goal, we have first optimized and validated the application of 
endobronchial biopsy and endobronchial ultrasound (EBUS) in the equine species. EBUS 
reliably estimates the bronchial ASM. Subsequently, asthmatic horses with ongoing airway 
remodeling and inflammation were treated with ICS, LABA, ICS/LABA, or antigen 
avoidance. Lung function, airway remodeling and inflammation were then weekly assessed for 
3 months. Our results demonstrated a 30% decrease of peripheral ASM remodeling attained 
with ICS and ICS/LABA pharmacological treatment. A decrease of a similar magnitude of 
peripheral ASM was previously reported after 6 and 12 months of ICS monotherapy and 
antigen avoidance, respectively. A synergistic effect of ICS/LABA was observed on ECM 
deposition and alveolar neutrophils. ICS/LABA decreased the ECM fraction of the ASM layer 
both peripherally and centrally, while the same effect on the lamina propria was observed only 
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in central airways. Both ICS/LABA and ICS monotherapy decreased submucosal 
inflammation in central airways, while only ICS/LABA and antigen avoidance decreased 
bronchoalveolar neutrophilia. 
In conclusion, our results suggest that the enhanced therapeutic effect of ICS/LABA over ICS 
monotherapy in asthmatic patients was associated with a reduction of ECM deposition, mainly 
observed within the large airways, and possibly also with a decreased alveolar neutrophilia. 
However, ICS/LABA did not provide any additional benefit to ICS monotherapy in terms of 
peripheral ASM remodeling as both induce a 30% decrease of the ASM mass in 3 months. 
 
 
Keywords: asthma, animal model, horse, remodeling, airway smooth muscle, extracellular 
matrix, corticosteroids, long-acting β-agonists. 
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Résumé 
L’asthme bronchique est caractérisé par un remodelage et une inflammation des voies 
aériennes. La masse du muscle lisse ainsi que la déposition de matrice extracellulaire sont 
augmentées dans la paroi des bronches asthmatiques, ce qui contribue à l’obstruction 
respiratoire. Peu d’études ont évalué les effets des traitements utilisés dans l’asthme sur le 
remodelage bronchique, et surtout peu de données sont disponibles concernant les effets sur le 
muscle lisse.  La combinaison de corticostéroïdes et de β2-agonistes à longue durée d’action 
administrée par inhalation  permet de mieux contrôler les crises d’asthme par rapport à la 
monothérapie avec des médicaments corticostéroïdes.  Cependant, l’action spécifique de la 
combinaison sur le remodelage et sur l’inflammation des bronches périphériques n’est pas 
décrite. Surtout, il reste à clarifier si l’administration de la combinaison est avantageuse par 
rapport à la monothérapie corticostéroïde.  La plupart des études réalisées chez l’homme 
utilisent des tissus bronchiques obtenus par biopsie endobronchique, qui ne sont pas 
représentatifs du processus pathologique affectant les voies respiratoires périphériques. Leur 
inaccessibilité par des méthodes non invasives est la raison pour laquelle si peu de données 
existent sur la pathophysiologie des voies périphériques chez les patients asthmatiques. 
L’asthme équin, aussi connu comme « le souffle », est une pathologie obstructive des chevaux 
adultes considérée comme un modèle animal d’asthme humain. Elle est caractérisée par un 
remodelage des bronches périphériques et par une inflammation bronchoalvéolaire de type 
neutrophilique.  
En étudiant le modèle équin, cette thèse a évalué la contribution des médicaments 
corticostéroïdes et de β2-agonistes à longue durée d’action, administrée comme monothérapies 
ou en combinaison, sur la réversibilité du remodelage et de l’inflammation de voies aériennes 
dans l’asthme bronchique. A cette fin, nous avons d’abord optimisé et validé l’application de 
la biopsie endobronchique et de l’échographie endobronchique chez le cheval adulte. Nos 
résultats indiquent que les échantillons obtenus par biopsie endobronchique sont inadéquats 
pour l’évaluation quantitative de la masse du muscle lisse chez le cheval. Cependant, ils 
permettent d’étudier les changements quantitatifs des structures épithéliales et de la lamina 
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propria, ainsi que les aspects qualitatifs du muscle lisse. L’échographie endobronchique, quant 
à elle, permet d'estimer la masse du muscle lisse bronchique, et ce, chez des chevaux sains et 
chez des chevaux asthmatiques. Cette thèse démontre aussi que le traitement de 12 semaines 
avec des corticostéroïdes induit une diminution significative de la masse du muscle lisse 
périphérique, qui n’est pas amélioré davantage par l’administration concomitante d’un β2-
agoniste à longue durée d’action. Cette diminution est toutefois incomplète. Un effet positif et 
synergique de la combinaison a également été observé au niveau de la déposition de matrice 
extracellulaire. La combinaison a produit une diminution significative de la quantité de 
matrices déposées dans la lamina propria et dans la couche du muscle lisse dans les bronches 
centrales, alors que l’effet été limité à la couche du muscle lisse dans les bronches 
périphériques. La combinaison n’améliore pas le contrôle de l’inflammation bronchique ni 
bronchiolaire par rapport aux monothérapies ; cependant, elle diminue la neutrophilie 
bronchoalvéolaire de façon synergique. 
 
 
Mots-clés : asthme, modèle animal, cheval, remodelage, muscle lisse bronchique, matrice 
extracellulaire, corticostéroïdes, β2-agonistes à longue durée d’action. 
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Introduction 
Central and peripheral airways sustain remodeling and inflammation in asthma (Bergeron, Al-
Ramli et al. 2009). In particular, the airway smooth muscle (ASM) is increased and has the 
ability to induce an exaggerated bronchoconstriction in response to normally non-harmful 
stimuli, which is the main cause of airflow obstruction in asthma (Martin, Duguet et al. 2000). 
The amount, composition, and distribution of extracellular matrix (ECM) proteins within the 
bronchial wall can also profoundly affect lung function (Bosse, Riesenfeld et al. 2010). 
Multiple studies performed on asthmatic patients have investigated the effect of treatments on 
the reversibility of airway remodeling and inflammation, and most of them have studied 
samples of central airways obtained by endobronchial biopsies (Hoshino, Takahashi et al. 
1999, Chakir, Shannon et al. 2003, Vignola, Riccobono et al. 2005). However, a growing body 
of evidence supports a central role of the small peripheral airways in disease pathobiology 
(Sturton, Persson et al. 2008, Contoli, Bousquet et al. 2010, Burgel 2011, Manoharan, 
Anderson et al. 2014). There is also increasing awareness that current therapeutic guidelines 
for asthma do not guarantee an adequate control of peripheral airway dysfunction (namely 
remodeling and inflammation) (Anderson, Zajda et al. 2012, Lipworth 2013). Peripheral 
airway assessment is challenging due to their anatomical inaccessibility, which is why their 
role in asthma has been overlooked for a long time. Equine asthma, or heaves, is a naturally-
occurring disease of adult horses and a recognized animal model of human asthma (Leclere, 
Lavoie-Lamoureux et al. 2011). It is characterized by peripheral remodeling of the ASM and 
ECM, and by bronchoalveolar neutrophilic inflammation (Leclere, Lavoie-Lamoureux et al. 
2011, Setlakwe, Lemos et al. 2014). Peripheral lung biopsies can be harvested from asthmatic 
horses for direct evaluation of small airway remodeling and inflammation (Lugo, Stick et al. 
2002, Relave, David et al. 2008, Relave, David et al. 2010). Using this technique, our 
laboratory has previously shown that airway remodeling can be reversed by inhaled 
corticosteroids (ICS) monotherapy (Leclere, Lavoie-Lamoureux et al. 2012). However, the 
effect (a 30% reduction of ASM mass) was only partial as asthmatic horses still remained with 
twice as much ASM compared to control subjects even after 1 year of treatment. An 
insufficient deposition of the drug peripherally may explain the incomplete effect, and is 
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supported by the residual bronchoconstriction observed in ICS-treated animals (Leclere, 
Lavoie-Lamoureux et al. 2012). In human asthma, ICS and long-acting β2-agonist 
combinations (ICS/LABA) are more effective than ICS monotherapy to control disease 
exacerbations, but their efficacy compared to ICS on bronchial remodeling and inflammation 
are not well-described, particularly at the peripheral level of the lung. The objective of this 
thesis was to investigate and compare the effects of common anti-asthma medications on 
aspects of peripheral airway remodeling that cannot be studied in man due to ethical 
constraints. Specifically, we studied whether ICS/LABA enhances the reversibility of 
peripheral remodeling and the control of airway inflammation compared to ICS or LABA 
monotherapy. Of note, we simultaneously monitored the effect of these treatments on central 
airways, in order to identify whether the central remodeling or inflammation are related and 
may predict peripheral alterations. Due to the paucity of information available on the 
pathophysiology of peripheral airway remodeling in asthma and its reversibility with 
treatments, we believe that the results of this thesis are important and can be translated to 
human asthma. 
 3 
What this study adds to the field 
Airway wall remodeling is a characteristic finding in human asthma. It involves several 
components of the bronchial wall, with ASM and ECM likely mostly contributing to airway 
obstruction. These changes have been reported in both the central and peripheral airways in 
asthma, but few studies have investigated the effectiveness of commonly administered asthma 
treatments at inducing their reversal, especially in peripheral airways. The involvement of 
small airway dysfunction in asthma is increasingly recognized, but tools for studying the 
progression of disease at this level are not readily available. Also, how (and whether) 
peripheral remodeling and inflammation are reflected by changes observable in central 
airways remains unsettled. The studies described in this thesis have employed an equine model 
of neutrophilic asthma to address these questions. The results obtained provide evidence that 
the combination of ICS/LABA is not superior to ICS monotherapy for ASM remodeling 
reversibility or bronchial inflammation control. Bronchoalveolar neutrophilia is inhibited by 
ICS/LABA, while ICS and LABA monotherapies were ineffective. It remains to be 
determined whether ICS/LABA effectively increases peripheral deposition of the drug 
compared to ICS alone, or whether oral corticosteroids improve the reversibility of peripheral 
remodeling, before concluding that a portion of ASM remodeling is resistant to treatment. We 
have also shown that, peripherally at least, ASM remodeling is reversible in a shorter period of 
time compared to ECM remodeling, and that the reversibility of ECM remodeling appeared to 
be determined by the degree of airway wall inflammation. We could not identify remodeling 
or inflammatory features of central airways reflecting peripheral structure or function, 
indicating that central and peripheral bronchi act as separate compartments of the lung and not 
as a continuum. Finally, we have also significantly contributed to the advancement of 
veterinary medicine by optimizing respiratory research tools that can be employed in future 
studies and by describing new physiopathological mechanisms associated with equine asthma. 
 
  
Literature review 
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Normal anatomy and physiology of the lower respiratory tract  
 
 
 
« Among the various cell types that populate the body, we might think of airway smooth 
muscle as the Hell’s Angel of cells, sitting on a Harley-Davidson, unshaven, a cigarette in one 
hand, a can of beer in the other, and a tattoo on its arm reading Born to Lose. » 
 
C.Y. Seow and J. J. Fredberg, 
J Appl Physiol (2001) 91:938-52 
 
 
The lower respiratory tract extends from the larynx to the most distal portions of the lung 
parenchyma. Its role is to provide the tissues with oxygen and to remove their volatile 
metabolites as carbon dioxide, contributing to the maintenance of a balanced blood pH. Also, 
important metabolic and endocrine functions are accomplished in the lungs such as the 
activation of angiotensin I, or the removal of serotonin, bradykinin, as well as some 
prostaglandins and leukotrienes from the blood (Joseph, Puttaswamy et al. 2013). 
 
Structure and function of the airways 
Airways of the lower respiratory tract are considered as conducting airways when their walls 
do not contain alveoli and do not allow gas exchange, or as transitional airways when there 
are alveoli protruding from their walls and gas exchanges can occur. The formers comprise 
trachea, bronchi and bronchioles until terminal non-respiratory bronchioles, while the latter 
comprises the alveolar ducts. Distally to alveolar ducts there are alveolar sacs and alveoli. 
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These are not considered airways but, together with transitional airways and vessels, they 
form the respiratory tissue or lung parenchyma (West 2008). Airways can further be classified 
as cartilaginous (bronchi) or membranous (bronchioles) depending on the presence or 
absence, respectively, of cartilage within their wall. Also airways are classified as intra- or 
extra-pulmonary based on their anatomical location. 
The basic microscopic anatomy of the conducting airways is similar along the bronchial tree, 
consisting of a pseudo-stratified epithelium overlying subepithelial tissue where connective 
tissue, vessels, glands and smooth muscle are present, with cartilage and adventitia located 
outermost (Figure 1). The bronchial epithelium is pseudo-stratified and ciliated. It is mainly 
composed of columnar ciliated and mucus-secreting goblet cells in trachea and proximal 
bronchi. Columnar ciliated cells and goblet cells decrease in quantity in smaller bronchi, and 
most of them are replaced by cuboidal epithelial cells and by Club cells (previously named 
Clara cells (Winkelmann and Noack 2010, Irwin, Augustyn et al. 2013)), respectively, in the 
bronchioles. The cuboidal bronchial respiratory epithelium completely disappears in the 
alveolar ducts. The bronchial epithelium lies on a basement membrane that provides 
attachment for epithelial cells, mainly composed of collagen IV, laminin, and proteoglycans, 
with elastic fibers within it.  
 
Figure 1. Bronchial anatomy. ECM: extracellular matrix; ASM: airway smooth muscle.  
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The lamina reticularis is the deepest portion of the basal membrane, adjacent to the lamina 
propria of the submucosa. Collagen I, III, V, and tenascin amongst others form the lamina 
reticularis, which is strongly connected to the other portions of the basal membrane (namely 
the lamina rara and the lamina densa) by strands of collagen VII (Liesker, Ten Hacken et al. 
2009). The lamina propria is made up mainly of connective tissue, in which vessels, nerves 
and elastic fibers are dispersed (Brinkman, Brooks et al. 1969). Airway vessels from the 
bronchial circulation are arranged in two plexuses within the bronchial wall: a submucosal 
plexus, running through the lamina propria between the ASM bundles and epithelium, and a 
peribronchial plexus, supplying the adventitia externally to the ASM layer (Carroll, Cooke et 
al. 1997). Collagen I and III are the main components of the lamina propria, with several 
proteoglycans and other glycoproteins. In the bronchial submucosa, beneath the lamina 
propria, there are smooth muscle fibers, cartilage, and tracheobronchial glands, all surrounded 
by supporting connective tissue. Caudally to terminal non-respiratory bronchioles, the lamina 
propria disappears, and only ASM and the elastic network continue in a spiral fashion 
surrounding the alveoli. Cartilage is disposed as parallel “C-shaped” rings along the trachea 
and main bronchi, and it becomes smaller and more irregular in segmental and lobular 
bronchi, completely disappearing in bronchioles (Fraser 2005).  
Smooth muscle fibers are disposed as bundles either in the open portion of the cartilage rings 
(in the trachea, where they are recognized as the trachealis muscle), or between the lamina 
propria and the cartilage. Smooth muscle bundles make up roughly 3-5 and 14-18% of the 
central and peripheral bronchial wall in adult patients, respectively, with their orientation 
varying along the bronchial tree (Hale, Olsen et al. 1968, Dunnill, Massarella et al. 1969, 
Takizawa and Thurlbeck 1971, Sobonya 1984, Saetta, Di Stefano et al. 1991). Overall, they 
are more regularly and circumferentially oriented in the proximal airways, whilst they are 
arranged in branching and anastomosing bundles forming oblique and irregular spirals in the 
lower airways (Smiley-Jewell, Tran et al. 2002). Their disposition around smaller airways has 
been described as helical or geodesic (James and Carroll 2000). Of note, the orientation of the 
ASM bundles along the bronchial axis depends on the degree of lung inflation, with higher 
lung volumes increasing the angle of orientation as a consequence of the longitudinal stress 
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imposed on the airways. Taking this into account, the estimated angle of orientation of the 
ASM bundles has been described as small in central airways (<5th generation) and 
approximately 15 degrees in membranous airways. Furthermore, the distribution is often 
asymmetric, particularly in the more proximal airways, so that, in case of bronchospasm, 
ASM orientation tends to favor one direction of coiling over the other (Ebina, Yaegashi et al. 
1990, Lei, Ghezzo et al. 1997). Ebina and colleagues (1990) showed that the thickness of 
ASM relative to airway diameter increases towards the periphery in man. Although the 
absolute volume of smooth muscle decreases with decreasing airway size, the volume fraction 
of smooth muscle in the airway wall increases in smaller peripheral airways, and this in spite 
of a reported tendency for the density of the bronchial smooth muscle bundles to diminish as 
one moves from the central to the peripheral airways (Lei, Ghezzo et al. 1997). The same 
group also showed that the thickness of ASM layer relative to the airway diameter could vary 
up to 10-fold within the same group of airways, possibly in relation to changes in smooth 
muscle thickness within a bronchial segment, subject size, sex or age, site sampled, degree of 
muscle contraction and possibly even racial-related differences. The bronchial smooth muscle 
bundles are surrounded by connective tissue whose ECM is composed of both collagenous 
and non-collagenous elements, such as elastin, proteoglycans, and other glycoproteins. They 
are secreted by structural cells such as fibroblasts, myofibroblasts, and smooth muscle cells 
themselves. Although the mechanisms regulating their turnover (synthesis, deposition, and 
degradation) within the lung are not completely elucidated, a strong body of evidence 
supports the balance of metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases 
(TIMPs) within the bronchial tissue as the major determinant of ECM homeostasis.   
Within the airways, each structural component has a recognized role contributing to the 
normal physiology of the lung (summarized in Table 1) with the only exception of the ASM, 
whose function, if any, is still unknown. A few theories have been proposed concerning the 
role of bronchial smooth muscle in ontology (Murphy, Summer et al. 2008): 
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1. in the developing fetal lung, the ASM has been shown to contract with a regular 
peristaltic rhythm, generating distending pressures that could promote the development 
and maturation of the lung; 
2. the contraction of ASM could serve  to improve ventilation/perfusion matching and/or 
decrease dead space ventilation in case of reduced blood flow to a specific district of the 
lung; 
3. during coughing episodes, ASM contraction may increase the velocity of gas movement 
to promote the expulsion of foreign bodies or noxious particulate materials; 
4. the ASM may act as a damper, by balancing the hysteresis between small airways and 
alveolar units; 
5. mucus propulsion (Bullowa and Gottlieb 1922); 
6. lastly, the ASM may simply be an ‘‘evolutionary oversight,’’ that is, a vestige of the 
lung’s origin from an organ, the foregut, already programmed to develop smooth 
muscle, with no true physiologic purpose. 
Furthermore, at present, there is no disease entity or appreciable physiological deficit 
associated with loss of ASM contraction (Seow and Fredberg 2001). 
The lung is a relatively stable organ with low rates of cell turnover, particularly in the 
airways. With less than 1% of epithelial cells proliferating at any given point in time (Ayers 
and Jeffery 1988, Demoly, Simony-Lafontaine et al. 1994, Leigh, Kylander et al. 1995), there 
appears to be little need for local cellular self-renewal under normal circumstances. 
Nevertheless, following injury, the epithelium has great ability to repair in a very short time 
by means of processes of dedifferentiation, migration and proliferation of adjacent cells 
(Erjefalt and Persson 1997, Yahaya, Baker et al. 2011). Proliferation and possibly migration 
of subepithelial cells seem to be involved in this process as well, as documented by studies of 
induced epithelial damage in a sheep model and by the observation of increased quantity of 
subepithelial myofibroblasts in asthmatic patients after experimental allergen exposure 
(Gizycki, Adelroth et al. 1997, Yahaya, Baker et al. 2011). The proliferation rate of ASM 
cells in normal conditions is considered as negligible (Chernyavsky, Croisier et al. 2014). 
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Subepithelial cells proliferating in normal conditions are scarce and mostly represented by 
endothelial cells and cells in close proximity to the mucus glands (Yahaya, Baker et al. 2011). 
On the other hand, turnover of the ECM is impressively rapid; it is estimated that 10-15% of 
the lung ECM is renewed every day (Dunsmore, Lee et al. 1996, Roberts and Burke 1998).  
 
Table 1. Normal function of airway components.  
Airway structure Normal function 
Epithelium Physical barrier against inhaled particles  
Lamina reticularis Structural support for epithelial attachment 
Lamina propria Structural support of the bronchial wall 
Determines mechanical properties of the bronchial wall 
May regulate ASM  proliferative/synthetic function 
Submucosal vessels Trophic support of the airways 
Smooth muscle ? 
Adventitia Sustains structure  
Guarantees airway-parenchyma interdependence  
 
 
Structure and function of the lung parenchyma 
Within the functional respiratory tissue, which is composed of alveolar ducts, alveolar sacs, 
and alveoli, alveolar units are demarcated by septa composed of a continuous layer of 
squamous epithelial cells overlying a thin interstitium. Capillaries as well as connective tissue 
and several cells responsible for maintaining alveolar shape and defense lie within the septal 
interstitium. The alveolar epithelium consists primarily of type I and type II alveolar cells. 
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Type I cells are more numerous, they cover approximately 95% of the alveolar surface, and 
their function is related to the transport of substances in either direction across the air-blood 
barrier. Type II alveolar cells are generally located close to the junctions among different 
alveoli, they are responsible for production of surfactant and renewal of the alveolar 
epithelium by differentiation into type I cells. A basement membrane is present underneath 
the alveolar epithelial cells, intimately connected with the basement membrane of the 
capillary endothelium. Elastic and collagen fibers, as well as myofibroblasts, are irregularly 
distributed within the connective matrix between epithelial and endothelial basement 
membranes (Fraser 2005). 
 
Age-related changes of pulmonary structure and function 
The physiological aging process undoubtedly impacts the structure and function of the lungs. 
Anatomically, the airways and their components increase in volume during infancy until 
complete development of the body, with the smooth muscle occupying a slightly greater 
proportion of the airway wall in children compared to adults (James and Carroll 2000). The 
aging lung is characterized by higher levels of collagen deposition and decreased elastin 
expression, which contribute to the decreased elastic recoil observed with age (Thannickal, 
Murthy et al. 2015). Lung function decline with aging in healthy individuals is associated to 
alterations of the lung parenchyma and terminal conducting airways. Reduced mucociliary 
clearance and altered surfactant composition are also reported in aged individuals (Miller 
2010, Ramly, Kaafarani et al. 2015). 
 
Mechanisms of airway patency 
When the lungs are removed from the thoracic cage, they immediately collapse due to their 
elastic recoil. Bronchial lumen is also significantly reduced when lungs are collapsed, and this 
independently of the presence or absence of cartilage in the airway wall, because of the highly 
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developed elastic network connecting all structures within the lung. Several mechanisms 
contribute to maintain airway patency in vivo and to oppose the collapsing force induced by 
reduced lung elastic recoil at low lung volumes. First of all, it is the intimate relationship 
between airway dimension and lung volume that prevents bronchial collapse even at very low 
lung volumes. This is known as airway or parenchymal tethering, or airway-parenchymal 
interdependence (Bates and Lauzon 2007). Airway stiffness itself as well contributes to 
airway patency in vivo. Lastly, the lining fluid exerts surface tension acting inwardly to close 
the airways, especially the smallest ones. The secreted surfactant, on the other hand, reduces 
the surface tension of the lining fluid and thereby contributes to airway patency (Veldhuizen 
and Haagsman, 2000). 
 
Mechanics of breathing 
The act of breathing is accomplished by respiratory cycles. For each human breath, one active 
inspiratory and one passive expiratory process occur, during which the air is forced in and out 
of the alveoli as a result of the changing intrapulmonary (or alveolar) pressures. Indeed, the 
contraction of the diaphragm (and other respiratory muscles) during inspiration expands the 
thorax which, in turn, induces lung expansion. Following the increase in lung volume, the 
alveolar pressure drops as a consequence of Boyle’s law and produces a pressure gradient that 
makes the air move from the mouth to the alveoli. As stated by Ohm’s law: the airflow 
between two points is directly proportional to the pressure difference across the two points. 
Similarly, during expiration, the lung passively recoils due to its elastic properties and its 
volume decreases. Alveolar pressure then increases compared to the pressure at the mouth, 
which allows air to move from the alveoli towards the atmosphere. Any alteration of the 
airway lumen (bronchoconstriction, space-occupying lesion or mucus) between two points of 
the bronchial tree is an obstacle for the (theoretically1) laminar airflow generated by the 
                                                 
1 In the airways there is usually a combination of both laminar and turbulent flow (called "transitional flow") in 
the center of the airway and near the bronchial wall, respectively. True laminar flow probably only occurs in the 
smallest airways, where linear velocity of the air is very low. 
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pressure difference existing between them. In order to maintain a constant airflow ( ሶܸ ), the 
pressure gradient between the two points (ΔPL) must be increased proportionally to the 
resistance of the lung (RL): 
ܴ௅ = 	
∆ ௅ܲ
ሶܸ  
Lung resistance is expressed in cm H2O/L/s, and it is the sum of airway resistance (normally 
about 80% of RL) and tissue resistance (lung parenchyma and chest wall, counting for 20% of 
RL). The Poiseuille’s law states that airway resistance is directly proportional to the length of 
the airway and the viscosity of the gas, and inversely proportional to the radius to the fourth 
power (i.e.: a 2-fold decrease in bronchial radius increases airway resistance by 16-fold). 
Thus, the main determinant of airway resistance is airway diameter which, in turn, results 
from: 
• ASM contraction (bronchospasm), 
• airway wall thickening (edema and/or remodeling), 
• airway lumen occlusion (i.e. by mucus and cell accumulation or space occupying 
lesions), 
• lung volume (at higher volumes, the parenchyma pulls on the airways keeping them 
wide open). 
For a given flow, resistance to air passage is thus greatest in individual small airways 
compared to large ones due to their small diameter. However, the total resistance to airflow 
contributed by the small airways taken together is very low (on average 10% in health) as 
they represent numerous parallel pathways, whose transversal area can be summed up. Under 
normal circumstances it has been calculated that the greatest resistance to airflow resides in 
the medium-sized bronchi (Macklem 1998). 
The elastic recoil of the lung is fundamental for breathing. The slope of the pressure-volume 
curve represents lung compliance (Cdyn, expressed in L/cm H2O), which is a measure that 
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describes the ease by which the lungs stretch and expand in response to a given pressure. It is 
calculated using the formula: 
ܥௗ௬௡ = 	
∆ܸ
∆ ௅ܲ 
where V is lung volume and PL is pleural pressure. The compliance of the lungs demonstrates 
hysteresis; that is, the PL is different on inspiration and expiration for identical volumes. Also, 
compliance is volume dependent. Elastance (EL, expressed in cm H2O/L and also known as 
elastic resistance) is, by definition, the reciprocal of compliance (E = 1/Cdyn), and describes 
the pressure change that is required to elicit a unit volume change of the lungs. This is a 
measure of the resistance of a system to expand or to shrink. Elastance is an indirect 
expression of the work that has to be exerted by the inspiratory muscles to expand the lungs. 
An increased elastance needs to be counteracted by an increased power of the muscles during 
inspiration, leading to an increased work of breathing (work of breathing is the physical work 
that has to be carried out by the muscles of respiration to overcome the elastic and non-elastic 
resistance of the respiratory system). The elastance of the whole respiratory system depends 
on the elastance of the chest wall and that of the lungs. Changes in the elastance (and 
therefore the compliance) of the chest wall are uncommon. In contrast, the elastance of the 
lungs is affected by many respiratory diseases. Thus, variations in the elastance of the 
respiratory system are mainly due to alterations of the elastance of the lungs, which is 
governed by two main factors: 
• the elastic recoil forces of the lung (mainly regulated by the properties of the 
pulmonary elastin network, but also by the altered deposition of fibrous tissue), 
• the surface tension at the air-alveolar interface (depending on the surfactant quantity 
and composition). 
Conversely to resistance, compliance and elastance of the lungs are mainly determined by the 
physical properties of the small airways and lung parenchyma. 
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Even in healthy subjects, heterogeneity exists among the behavior of different airways and 
alveoli. However, taken together, the behavior of the lungs can be compared to that of a 
balloon sealed over the end of a pipe, which can be simplified using a mathematical approach 
called the linear single-compartment model (Bates 1993). This model has a clear anatomical 
analogy to the lung; the pipe represents the conducting airways and the balloon represents the 
elastic parenchymal tissue. There is also a functional analogy, as the balloon can be inflated 
and deflated through the pipe in the same way that a lung inspires and expires. 
Mathematically, is it expressed as: 
∆ ௅ܲ = ൫ܴ௅ ∙ 	 ሶܸ ൯ + (ܧ௅ 	 ∙ 	 ்ܸ ) 
where VT is tidal volume (in L) and K is the pulmonary end expiratory pressure (in cm H2O). 
This equation states that the pressure gradient required to increase lung volume by VT is 
proportional to the resistive and elastic properties of the lung, and it will increase at increasing 
RL and EL.  
Functional anatomy of the lower respiratory tract 
During breathing, the airway structures undergo dynamic morphological changes due to 
physical constraints and mechanical stress imposed by the changing intrathoracic pressures. 
Airways are subjected to two types of stretches or stresses: a radial stretch, acting outwardly 
all around the airway wall, and a longitudinal stretch, related to the elongation of the lung; 
both occurring during inspiration. The opposite occurs during expiration. Intra-thoracic 
airways reach a maximal and minimal cross-sectional area at end-inspiration and end-
expiration, respectively. This is of particular interest during dynamic measurement of airway 
wall thickness or airway size. 
Until recently, dynamic measurements of airway size or length were not possible, and general 
knowledge on this topic has been increasing exponentially in the last decade. With the advent 
of new imaging technologies, reliable measurements can now be performed. Airway wall area 
remains unchanged or undergoes minimal changes across the breathing cycle (Coxson, 
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Quiney et al. 2008), while airway wall thickness and lumen area vary. Specifically, airway 
lumen increases and bronchial thickness decreases during inspiration, as a result of 
bronchodilation. Significant changes are observed in the airway lumen area during quiet 
breathing in large (8-25 mm in diameter), intermediate (2-8 mm), and small airways (< 2 
mm), with the latter being the site where this phenomenon is most remarkable (McLaughlin, 
Williamson et al. 2008). This occurs probably because they are more compliant than larger 
airways, and because of their strict interdependence with the pulmonary parenchyma. In 
patients with COPD, variations of the bronchial lumen up to 150-200% have been reported 
during deep breathing maneuvers (Matsuoka, Kurihara et al. 2008).  
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Mechanisms implicated in asthma pathobiology 
 
 
 
« Breathing remains unaccountably easy. Indeed, it is this lightness of breathing in the 
healthy challenged lung, rather than the labored breathing that is characteristic of the 
asthmatic lung, that in many ways presents the greater challenge to our understanding of the 
determinants of acute airway narrowing. » 
 
J.J. Fredberg and S.A. Shore 
“The Unbearable Lightness of Breathing” 
J Appl Physiol (1999) 86:3-4 
 
 
Asthma is a chronic disease, considered as multifactorial, diffuse, and heterogeneous in 
nature. Different pathophysiological mechanisms are involved in disease development, both 
intrinsic and extrinsic to the patient. Specifically, genetic predisposition or dysregulated 
immunity, as well as several environmental triggers have been shown to take part in asthma 
pathogenesis. Whether the intrinsic causes of asthma are inherited or acquired during life 
remains a matter of debate (Wenzel 2012, Kudo, Ishigatsubo et al. 2013). Asthma is 
considered a diffuse disease, as it affects the entirety of the lung. It is however heterogeneous, 
as different regions of the bronchial tree can be differently affected (Elliot, Jones et al. 2015).  
Pathophysiologically, asthma is defined as an obstructive and inflammatory disease. Both 
airway remodeling and excessive narrowing contribute to the airflow obstruction observed in 
asthmatic patients. An increased smooth muscle mass and reactivity to normal stimuli 
(hyperresponsiveness) are the most important determinants of airflow obstruction (Lambert, 
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Wiggs et al. 1993, Oliver, Fabry et al. 2007). While the leading role of bronchospasm during 
asthma attacks has long been recognized, the implication of inflammation to asthma 
pathophysiology was only described few decades ago, and its contribution to disease 
development and/or maintenance is still ill-defined. Several structural and immune cells 
contribute to the asthmatic response within the bronchi. Interestingly, among these cells, ASM 
cells have marked immunomodulating properties, making them potentially significant 
contributors to the inflammatory features observed in asthmatic airways (Damera, Tliba et al. 
2009).  
The relationship existing between bronchospasm, remodeling, and inflammation in asthma is 
far from clear. It has been speculated for some time that inflammation represents the initiating 
insult, causing remodeling and airway responsiveness (Kudo, Ishigatsubo et al. 2013). 
However, recent evidence argues against this theory and suggests that bronchospasm and 
remodeling themselves might in turn induce or facilitate inflammation (Damera, Tliba et al. 
2009, Grainge, Lau et al. 2011). 
 
Airway hyperresponsiveness 
Airway hyperresponsiveness (AHR)  is defined as an excessive decline of lung function upon 
ASM activation. AHR is a well-recognized feature of the asthmatic disease, however the 
primary contributors to this phenomenon remain to be elucidated (Martin, Duguet et al. 2000). 
Whether and to which extent ASM cell hypercontractility (abnormally increased degree of 
contraction) and hyperreactivity (contractile response in the presence of normally non-
harmful stimuli) contribute to the development of AHR is still unknown. While ASM seems 
intuitively to be the key of such pathological behavior of the airways, a large amount of 
evidence supports that other non-contractile components of the airway wall as well as of the 
pulmonary parenchyma can contribute to the pathogenesis of AHR (Bosse, Riesenfeld et al. 
2010). In other words: while ASM contraction is likely to be the central point, the load against 
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which the muscle contracts as well as the environment in which the muscle is placed must be 
taken into account (Figure 2)  [65].   
 
Smooth muscle-related determinants of AHR 
Both static and dynamic modeling of pulmonary mechanics identify ASM as the most 
important determinant of airway narrowing and AHR (Lambert, Wiggs et al. 1993, Oliver, 
Fabry et al. 2007). Airway smooth muscle mass is increased in asthmatics and such increase is 
associated with the severity of the disease (James, Bai et al. 2009). However, whether such 
increase coexists with phenotypic changes affecting ASM contractile, proliferative or 
secretory properties and to what extent they would contribute to AHR in asthma remains 
unclear (Hirota, Nguyen et al. 2009). The possibility that functional anomalies of the ASM 
cells represent a central determinant of AHR and asthma pathogenesis must be kept in mind.  
 
Figure 2. Determinants of airway patency and hyperresponsiveness. The arrows indicate 
forces (pressures) acting on the bronchial wall. In red are indicated alterations observed in 
asthma.     
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Anatomical factors. ASM is organized in bundles running along the bronchial wall in a spiral 
fashion (Bates and Martin 1990). In such spirals, ASM orientation seems to acquire a wide 
range of angles along the airways, following a distribution pattern likely conserved among 
species and among different airway generations (Smiley-Jewell, Tran et al. 2002). The 
magnitude of ASM obliquity along the bronchi has been judged as unlikely to result in 
physiologically important changes in airway length during bronchoconstriction (Lei, Ghezzo 
et al. 1997). Contrarily, airway caliber would be significantly affected (Bates and Martin 
1990). It has been speculated that AHR might even result simply from a stiffening of the 
airway in the longitudinal direction (Bates and Martin 1990), a situation possibly reflecting 
the act of breathing at high lung volumes as during an asthma attack. Paradoxically, an in 
silico model of the bronchial tree suggested that bronchial malfunction related to asthma 
could be a « necessary consequence of the optimized efficiency of the structure of the human 
bronchial tree » (Mauroy, Filoche et al. 2004). In other words, an AHR could be the drawback 
of a bronchial tree anatomically optimized to be physiologically efficient.  
Remodeling. The smooth muscle mass is increased in asthmatic airways (James, Elliot et al. 
2012). As the force produced by the smooth muscle is proportional to its cross-section (Chin, 
Bosse et al. 2012), the asthmatic smooth muscle could cause AHR simply because a greater 
force would act against the mechanisms of airway patency. This could occur in the absence of 
mechanical alterations of the ASM in asthma, and is supported by mathematical models of the 
lung (Wiggs, Bosken et al. 1992, Lambert, Wiggs et al. 1993). However, the unchanged FEV1 
(forced expiratory volume in 1 second) reported after ASM reduction obtained by bronchial 
thermoplasty in severe asthmatics (Pavord, Thomson et al. 2013, Denner, Doeing et al. 2015) 
argues against the hypothesis that AHR in asthma is just the result of the increased smooth 
muscle mass. The mechanical properties of ASM cells are influenced by their curvature. 
Particularly, cell stiffness is maximal at curvature similar to those expected in terminal 
membranous bronchioles (diameter 1.5 mm) and decreases at smaller or greater curvatures. 
Cell contractility instead is thought to be inversely proportional to airway dimension, as it 
decreases consistently as the curvature increases (Montaudon, Desbarats et al. 2007, West 
2008, Xu, Chen et al. 2011). It is possible that hypertrophy and hyperplasia of ASM might 
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alter the distribution of ASM cell orientation in asthmatic airways (Lei, Ghezzo et al. 1997), 
accentuating airflow heterogeneity during bronchospasm. In vitro, ASM cell alignment 
depends on the strain they are exposed to (Morioka, Parameswaran et al. 2011, Ghezzi, Risse 
et al. 2013). Airway smooth muscle orientation has the potential to influence the mechanics of 
airway narrowing by influencing the vector of forces acting on the airway wall during 
bronchoconstriction. That is, a portion of the forces developed by ASM contraction could 
potentially shorten the airway in addition to narrowing its lumen (Lei 1997).  
Phenotype plasticity. Two different populations (phenotypes) of ASM cells are recognized in 
vitro, characterized by increased contractile or synthetic properties (Hirota, Nguyen et al. 
2009), which were first described in 1997 (Ma, Li et al. 1997). Of note, the phenotype is not a 
constant property of the ASM cell. It can instead vary depending on the chemical and 
mechanical environment the cell is exposed to (Hirota, Nguyen et al. 2009). A large body of 
evidence supports the hypothesis that asthmatic ASM cells express a more 
proliferative/synthetic and less contractile phenotype compared to healthy ASM cells in vitro 
(Wright, Trian et al. 2013). Whether this is true also in vivo remains to be determined. The 
fact that hyperplasia is a recognized mechanism of increased ASM mass in asthmatic subjects, 
and that ASM cells are now recognized as immunomodulatory cells able to secrete a various 
array of pro-inflammatory molecules (James, Elliot et al. 2012, Wright, Trian et al. 2013) 
sustains this theory. 
Length adaptation. Two very important and unique properties of the smooth muscle have 
been described that highlight its adaptable nature. Length adaptability was first proposed in 
1995 to explain that the force generated by smooth muscle contraction is (relatively) 
independent of its length (Pratusevich, Seow et al. 1995). In fact, when the smooth muscle 
length is changed, a decline of its strength is initially observed but it gradually recovers over 
time. In situ, length adaptation may be initiated by a change in transmural pressure (causing 
bronchoconstriction or bronchodilation), which is a primary physiological determinant of 
ASM length. When healthy subjects are prevented from taking deep breaths for 20-30 
minutes, they indeed develop AHR (Skloot, Permutt et al. 1995). The recognized 
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bronchoprotective and bronchodilatory effects of deep inspirations observed in healthy 
subjects have been ascribed to this mechanism as well. However, despite the fact that bronchi 
of asthmatic subjects can dilate as much as those of healthy patients in vivo (Brown, 
Scichilone et al. 2001), the bronchoprotective effect of deep inspirations is impaired in 
asthmatics, suggesting that length adaptation alone is not the sole explanation of AHR in 
asthma. Recent studies performed using intact airway sections instead of isolated smooth 
muscle strips further support the inability of smooth muscle length adaptation alone to cause 
AHR, especially at the central level, because of the coupling existing between airway wall 
and ASM layer (Ansell, McFawn et al. 2015, Dowie, Ansell et al. 2016).   
Force adaptation. Force adaptation has been described more recently as the ability of the 
muscle to increase its force-generating capacity in response to stimulation (Bosse, Chin et al. 
2009). Differently from length adaptation, force adaptation in vitro is not inhibited by 
oscillating maneuvers simulating breathing pattern (Pascoe, Jiao et al. 2012). Length and 
force adaptation can coexist and have additive effects (Bosse, Chin et al. 2010) . The 
significance of this finding in asthmatic airways, chronically exposed to bronchoconstrictive 
stimuli, appears straightforward but has not been proven yet.  
Myosin isoforms. Smooth muscle myosin heavy chain (SMMHC) is a cytoplasmic structural 
protein that is a major component of the contractile apparatus in smooth muscle cells. It is 
expressed as four different isoforms, generated by alternative splicing of the myosin gene. In 
particular, two of these isoforms regulate the velocity of contraction of the myosin head once 
it is attached to the actin filament. At a molecular level, they differ by the presence [(+)insert, 
also called SM-B] or absence [(-)insert, also called SM-A] of a 7–amino acid insert within the 
protein structure. The (+)isoform induces a propulsion velocity of the actin filament twice as 
fast as the (-)isoform, and it is overexpressed in human and equine asthmatic bronchial tissue 
compared to healthy subjects (Leguillette, Laviolette et al. 2009, Boivin, Vargas et al. 2014). 
A more rapid smooth muscle contraction could contribute to the blunted response of asthmatic 
patients to deep inspirations. 
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Fluidity. Muscle contractile properties are equilibrated dynamically. In vivo, non-activated 
ASM is continuously exposed to force fluctuations (stress) that induce cell length variations 
(strains), which significantly inhibit its contractile capacity (Krishnan, Trepat et al. 2008). In 
asthmatics, ASM is activated by different stimuli likely reducing its strain and conferring 
quasi-static conditions. Using an immediate terminology (partly borrowed from the past), the 
group of Fredberg described the normal ASM as “fluid” and the asthmatic ASM as “frozen” 
(Krishnan, Trepat et al. 2008). One of the possible molecular explanations of this theory is 
that, during breathing, a number of cross-bridges between the myosin head and the actin 
filament are broken up mechanically and prematurely compared to the complete myosin duty 
cycle. This reduces the number of cross-bridges and the force-generating capacity of the 
muscle when it is in its fluid state (Fredberg, Inouye et al. 1999). In fact, when healthy 
individuals are restrained from taking deep breaths, their ASM “freeze” in a contracted 
position after only 15 minutes, becoming hyperresponsive to the same extent as asthmatic 
smooth muscle (Krishnan, Trepat et al. 2008). 
The contractile properties of ASM have been studied in healthy subjects, in asthmatics and in 
animal models of asthma, in order to understand if any abnormality of the ASM could explain 
the exaggerated response to contractile stimuli observed in asthma. Main results of previous 
studies made on human tissues in static conditions have been variable and quite inconclusive, 
especially in light of the fact that ASM behavior in vivo is better represented by oscillatory 
conditions (Fredberg, Inouye et al. 1999). Furthermore, many studies included a too limited 
number of specimens to guarantee statistically sound comparisons between groups (de 
Jongste, Mons et al. 1987, Bramley, Thomson et al. 1994, Thomson, Bramley et al. 1996). 
Limitations of the early approaches used to study ASM mechanical properties are now 
recognized (Bai, Bates et al. 2004). Among others, as heterogeneity has been appreciated in 
ASM derived from different anatomical regions, most strikingly between trachea and bronchi 
(Bramley, Thomson et al. 1994, Ma, Li et al. 1997, Matusovsky, Kachmar et al. 2015), it 
seems inappropriate to compare specimens from different anatomical regions or to draw 
conclusions concerning the bronchial behavior from studies employing tracheal specimens. 
Having said that, comparing samples obtained from the same anatomical region between 
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asthmatics and non-asthmatics may however identify abnormalities in ASM behavior related 
to the disease. Two recent studies (Chin, Bossé et al. 2012, Ijpma, Kachmar et al. 2015) found 
no difference in the intrinsic properties of ASM in asthma, supporting the hypothesis that is it 
the environment where the muscle is located rather than the muscle itself, the main 
determinant of AHR in asthma.  
 
Non-smooth muscle determinants of AHR 
Lung volume and airway-parenchyma interdependence. Airways are intimately connected to 
the pulmonary parenchyma, so that increasing lung volume stretches the bronchi both 
longitudinally and transversally, decreasing airway resistance. Such airway wall tension is 
primarily determined by non-contractile airway wall components when ASM is relaxed, but it 
is progressively transferred to the ASM during its active contraction (Martin, Duguet et al. 
2000, Bosse, Riesenfeld et al. 2010). Lung expansion provides an elastic force contrasting that 
induced by ASM contraction. However, parenchyma and ASM are not directly linked; 
between them lies the external bronchial layer made of loose connective tissue, lymphatics 
and bronchial microvessels in small airways, in addition to cartilage and submucosal glands in 
large airways. This layer may attenuate force transmission between the two compartments, 
especially when its morphological and mechanical features are altered such as in asthma 
(Martin, Duguet et al. 2000, Dolhnikoff, da Silva et al. 2009).  
Airway wall morphology and remodeling. The spatial arrangement and volumes of the 
constituents of the airway wall are crucial in determining how the contraction of the ASM 
affects airway narrowing and airflow obstruction (Bosse, Riesenfeld et al. 2010). Specifically, 
the disposition and mechanical features of tissues lying around and within the ASM layer 
must be considered. Increasing the volume of tissues outside the ASM may lead to an 
uncoupling of the system, modifying the patterns of force transmission from lung parenchyma 
to the airway wall. On the other hand, the increased deposition of structures lying inside the 
ASM layer represents a higher load for the ASM to contract against (which theoretically 
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would be beneficial during bronchospasm), but also some space-occupying material 
protruding towards the airway lumen and reducing its caliber, facilitating airway obstruction 
(Lambert, Wiggs et al. 1993). Especially during ASM contraction, even small reductions of 
the airway lumen may increase dramatically airway resistance (Lambert, Wiggs et al. 1993). 
Remodeling of the ECM among and surrounding the ASM cells also deserves to be 
considered. Due to its relative stiffness, this ECM “cage” is thought to limit the contraction-
induced cross-sectional widening of the smooth muscle bundle, and thus its excessive 
shortening. This theory is known as the radial constraint hypothesis (Meiss 1999), and it is 
supported by the reduced fraction of ECM proteins observed within the ASM layer of severe 
compared to moderate asthmatics (Pini, Hamid et al. 2007). 
Heterogeneity. Structural and mechanical properties of the bronchial tree vary in time or 
among different bronchial generations. Pathological entities affecting such properties – such 
as asthma –further increase the heterogeneity of the lung (Bosse, Riesenfeld et al. 2010). 
Using a mathematical model, it has been shown that airway resistance can significantly 
increase in response of uneven bronchial tone along the bronchial tree (Bates 1993). Airway 
smooth muscle mechanical heterogeneity is also recognized at tissue and cellular level (Ma, 
Li et al. 1997) which, in addition to anatomical heterogeneity, can produce AHR (Bosse, 
Riesenfeld et al. 2010). Any factor contributing to lung heterogeneity can finally lead to 
increased airway resistance and amplify the effect of contractile stimuli on respiratory 
physiology. 
Inflammation. Evidence exists linking the increased inflammatory infiltrate into the ASM 
layer and its increased proliferation (Ramos-Barbon, Fraga-Iriso et al. 2010). For this reason, 
inflammation could indirectly induce AHR by increasing the ASM mass in asthmatic airways. 
Furthermore, inflammatory cells may produce and secrete multiple bronchoconstrictor agents 
(Bossé 2014) that can contribute to overstimulate the asthmatic ASM cells.  
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Airway remodeling 
Asthmatic airways are characterized by marked structural changes affecting most of their 
histologic components, and commonly referred to as airway remodeling. It significantly 
contributes to airflow obstruction in asthma, particularly during episodes of 
bronchoconstriction. Airway remodeling can affect small and/or large airways, possibly in 
relation with the asthma inflammatory phenotype (Elliot, Jones et al. 2015).  
Remodeling has been considered for a long time as the consequence of chronic tissue 
inflammation and dysregulated repair. However, the similar degree of remodeling observed in 
recent compared to long-standing mild asthmatics (Boulet, Turcotte et al. 2000), the 
demonstration of bronchial remodeling in wheezing children (Saglani, Payne et al. 2007, 
O'Reilly, Ullmann et al. 2013), and the impressively quick remodeling response observed 
after antigen challenge in asthmatic patients (Kariyawasam, Aizen et al. 2007) argue against 
the fact that a chronic insult is necessary in order to develop airway remodeling. Different 
studies have shown that the degree of remodeling is related to the severity and not to the 
duration of the disease (Chetta, Foresi et al. 1997, James, Bai et al. 2009).   
Due to the importance of the small airways in asthma pathogenesis and to the difficulty of 
sampling (Contoli, Bousquet et al. 2010, Burgel 2011), a lot of of attention has been focused 
on understanding whether the morphological changes observed in large and small airways are 
correlated (Postma, Brightling et al. 2015). To date, the information available about small 
airway remodeling comes from a limited number of studies performed on autopsy specimens 
which have provided precious insights into the contribution of the silent portion of the lung to 
the asthmatic disease.    
 
Epithelium 
The bronchial epithelium is the first physical barrier (complemented by the mucociliary 
escalator) to external airborne antigens and thus the structure in direct contact with all 
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inspired molecules that can reach the lungs. As such, it is a structure with important 
immunoregulatory roles, able to orchestrate complex innate and acquired responses to several 
triggers (Damera, Tliba et al. 2009).  There is evidence supporting an impaired function of the 
airway epithelium in asthma (Swindle, Collins et al. 2009), in part mirrored by an altered 
structure. Increased susceptibility to injury and altered repair are considered to be important 
inducers of airway wall remodeling in asthma. 
Bronchial epithelial fragility and detachment has been associated with asthma for long time, 
due to the high number of epithelial cells observed in sputum samples or within the bronchial 
lumen in histologic preparations. The evidence provided by in vitro studies of stressed and 
fragile airway epithelium in asthmatic airways (Swindle, Collins et al. 2009), incapable of 
adequate repair mechanisms (Puddicombe, Torres-Lozano et al. 2003), supports the fact that 
the macroscopic shedding of the bronchial epithelium often observed in endobronchial biopsy 
samples is now considered as being merely artefactual (Holgate 2011). The data obtained by 
Labonté and colleagues argue that the asthmatic epithelium could be macroscopically 
damaged only in the more proximal airways (Labonte, Laviolette et al. 2008), questioning 
whether the sampling site of endobronchial biopsy could have represented a confounder in 
previous studies.  
Bronchial epithelial hyperplasia has been observed in severe compared to mild asthmatics and 
correlates with epithelial cell proliferation in some studies (Demoly, Simony-Lafontaine et al. 
1994, Druilhe, Wallaert et al. 1998, Vignola, Chiappara et al. 2001, Cohen, E et al. 2007). 
However, two points need to be raised: first, the thickness of airway epithelium of severe 
asthmatics is not different from that of healthy subjects; second, severe asthmatics need 
corticosteroid treatment, which can profoundly modulate cell proliferation and apoptosis 
(Salmon, Koto et al. 1998, Dorscheid, Wojcik et al. 2001, Al-Wadei, Takahasi et al. 2005, 
Gallelli, Pelaia et al. 2010). In this perspective, whether epithelial hyperplasia does occur in 
severe asthma or it is the result of corticosteroid-induced alteration in epithelial cell cycle 
remains to be determined.  
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The observation of a thinner epithelium in mild asthmatics compared to healthy controls in 
the absence of increased cell apoptosis and occasionally in the presence of increased 
proliferation (Benayoun, Letuve et al. 2001, Vignola, Chiappara et al. 2001, Cohen, E et al. 
2007) suggests that epithelial shedding and dysregulated repair could be a feature of the 
disease, successfully controlled by corticosteroid treatment. On the other hand, allergen 
challenge appears to increase epithelial proliferation in subjects with mild asthma without 
inducing epithelial shedding (Ricciardolo, Di Stefano et al. 2003), supporting a real 
thickening of airway mucosal layer in the more severe forms of the disease.  
Mucostasis is an overlooked trait of asthmatic airways, certainly contributing to the 
obstructive nature of the disease. The amount of mucus within the airways results from the 
balance between the number of goblet cells and mucus glands, their synthetic and secretory 
activity, and the clearance ability of ciliated cells. Alterations in all of these mechanisms have 
been proposed as contributors to mucostasis in asthma. Because mucus is principally a 
mixture of mucin glycoproteins and plasma proteins, it is also possible that abnormalities at 
the vascular endothelial level could result in excess airway mucus (Fahy 2001). Even mild 
asthma is associated with goblet cell hyperplasia and increased (up to 3-fold) stored mucin in 
the bronchial epithelium, whereas in moderate asthmatics both stored and secreted pools are 
increased (Ordonez, Khashayar et al. 2001, Samitas, Zervas et al. 2011). These findings 
suggest that acute degranulation of hyperplastic goblet cells may represent a mechanism for 
exacerbations in mild and moderate asthma. This hypothesis however is not supported by a 
previous study showing a stable or increased quantity of mucus stored in the bronchial 
epithelium of mild asthmatics 1 or 48 hours after antigen inhalation (Hays, Woodruff et al. 
2001). Chronic degranulation of goblet cells may contribute to chronic airway narrowing in 
moderate to severe asthma (Ordonez, Khashayar et al. 2001). 
In response to acute or chronic airway injuries, the increase in percentage of goblet cells can 
occur by selective cellular proliferation, also called hyperplasia, or by cell transdifferentiation. 
The latter is defined as the conversion of a specific differentiated cell type into another type of 
differentiated cell. It belongs to a wider class of cell-type switches termed metaplasia 
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(Boucherat, Boczkowski et al. 2013). As goblet cells are normally found in bronchi but not in 
bronchioles, their increase in cartilaginous airways is termed goblet cell hyperplasia and their 
appearance in small membranous airways is defined as goblet cell metaplasia (Tesfaigzi 
2008).  
 
Extracellular matrix 
The ECM is a dynamic and complex network of macromolecules whose primary aim is to 
form a scaffold for the airways. It acts as mechanical support but also plays a crucial role in 
the maintenance of airway function and structure, being involved in many cellular events such 
as adhesion, migration, synthesis, and proliferation (Hirst, Twort et al. 2000, Johnson, 
Burgess et al. 2004, Dekkers, Schaafsma et al. 2007, Araujo, Dolhnikoff et al. 2008, Liesker, 
Ten Hacken et al. 2009). The bronchial ECM is composed of collagen, proteoglycans, elastin, 
and other glycoproteins. They are mainly synthetized and secreted by fibroblasts within the 
submucosa. The content of ECM is regulated by several mediators, mainly metalloproteinases 
(MMPs) and their counterpart, tissue inhibitors of metalloproteinases (TIMPs). The ECM 
deposition is altered in asthmatic airways (Kuwano, Bosken et al. 1993) (Figure 3). Most of 
the studies published on this subject are focused on structural changes occurring within the 
lamina propria, while less is known concerning adventitial alterations, mainly because of the 
difficulty of sampling this outer region even in the large airways.   
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Figure 3. Summary of the alterations in ECM seen in asthma.  ECM is altered at the level 
of the lamina propria, adventitia, and alveolar attachment in asthmatic patients. MMPs: 
metalloproteinases. 
 
The earliest ECM change recognized in asthma was the increased basal membrane thickness. 
Specifically, it is not the real basal membrane that is increased but the underlying lamina 
reticularis, due to increased deposition of collagen III and tenascin in the presence of an 
increased number of subepithelial fibroblasts (Roche, Beasley et al. 1989, Laitinen, Altraja et 
al. 1997, Hoshino, Nakamura et al. 1998, Liesker, Ten Hacken et al. 2009). Whether reticular 
basement membrane thickness is related to asthma severity is not well established, as studies 
comparing mild and severe asthmatics have come to different conclusions (Chetta, Foresi et 
al. 1997, Benayoun, Druilhe et al. 2003, Bourdin, Neveu et al. 2007). Nevertheless, it has 
been reported to correlate with the degree of remodeling of smooth muscle and submucosal 
mucous gland in large cartilaginous airways, and with inner wall area and area of smooth 
muscle in small cartilaginous airways However, is was not related to airway wall remodeling 
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in membranous airways (James, Maxwell et al. 2002). Allergen challenge in patients with 
mild asthma induces activation of submucosal fibroblasts and increased tenascin deposition 
within the reticular basement membrane (Phipps, Benyahia et al. 2004). As tenascin is a 
glycoprotein markedly expressed during tissue repair processes (Laitinen, Altraja et al. 1997), 
it has been speculated that the increased reticular basement membrane thickness results from 
previous damage, possibly chronic.   
Within the lamina propria of central airways, proteoglycan deposition is increased in 
asthmatics compared to control subjects (Huang, Olivenstein et al. 1999, de Kluijver, 
Schrumpf et al. 2005, Pini, Hamid et al. 2007). The lamina propria of asthmatic patients is 
characterized also by enhanced collagen I deposition (Minshall, Leung et al. 1997). Increased 
type I and type III collagen fibers have been detected in the large airways of patients with 
severe compared to milder form of the disease, but does not differ between mild asthmatics 
and healthy subjects (Chu, Halliday et al. 1998, Benayoun, Druilhe et al. 2003, Chakir, 
Shannon et al. 2003). Interestingly, although severe asthmatics having an increased deposition 
of both collagen and proteoglycans in the lamina reticularis, larger mucous glands (Benayoun, 
Druilhe et al. 2003), and increased vessel density compared to mild asthmatics, the thickness 
of their lamina propria is reduced compared to moderate asthmatics (Pepe, Foley et al. 2005). 
A similar counterintuitive result has been observed in patients with occupational asthma, 
whose bronchial lamina propria was thinner than those of healthy controls (Sumi, Foley et al. 
2007). One possible explanation for this finding is the centripetal expansion of the markedly 
increased ASM layer observed in this group of asthmatics (Pepe, Foley et al. 2005). 
Alternatively (or as a consequence of this inward expansion of the smooth muscle layer), 
collagen fibers could be more densely packed in asthma (Roche, Beasley et al. 1989). Scarce 
information is available concerning morphologic changes at the adventitial level in large 
bronchi. However, an increased deposition of ECM (i.e. perichondral fibrosis) seems to occur 
in asthma (Carroll, Elliot et al. 1993, Haraguchi, Shimura et al. 1999), which is not explained 
by an increased deposition of collagen (Dolhnikoff, da Silva et al. 2009) and could possibly 
decrease airway-parenchymal interdependence and thereby allow excessive airway narrowing 
(Macklem 1996).  
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Small peripheral airways as well show extensive quantitative remodeling of their ECM, both 
at the level of the lamina propria and of the adventitia, and related to the degree of severity of 
the disease (Carroll, Elliot et al. 1993, Kuwano, Bosken et al. 1993). Specifically, collagen I is 
increased while collagen III was shown to be decreased at both levels, which is indicative of a 
profibrotic process (Dolhnikoff, da Silva et al. 2009). Collagen III is related to tissue 
distensibility while collagen I is the major matrix element that resists tensile stresses. The 
observed alterations argue in favour of the presence of stiffer and less distensible airways in 
asthma (Dolhnikoff, da Silva et al. 2009). Airway wall distensibility is indeed decreased in 
asthmatics, possibly in relation with bronchial ECM remodeling (Wilson, Li et al. 1993, 
Brown, Salome et al. 2007). 
Conflicting data exist concerning alterations of elastin within the lamina propria of large and 
peripheral bronchi. In healthy subjects, elastic fibers are complexly intertwined with collagen 
and other ECM elements. They are initially organized in longitudinal bundles in the main 
bronchi and they gradually become oriented more circularly and form two layers: one beneath 
the basement membrane and perpendicular to it (superficial thin network) and one in the 
deeper submucosa, close to the smooth muscle (deep thick network) (Bousquet, Lacoste et al. 
1996, Kamel, Beckert et al. 2009). Elastic fibers of asthmatic central bronchi were initially 
described as enlarged (or hypertrophic) and fragmented, but overall not increased in quantity 
compared to healthy subjects (Gabbrielli, Di Lollo et al. 1994, Godfrey, Lorimer et al. 1995, 
Bousquet, Lacoste et al. 1996). Also, the alterations observed in asthmatics were not linked to 
the severity or duration of asthma (Bousquet, Lacoste et al. 1996). Since then, few studies 
have addressed this question using quantitative approaches, showing a reduced or unchanged 
quantity of elastin in asthmatic airways most of the time (Reddel, Weiss et al. 2012).  
Evidence of the increased and dysregulated deposition of ECM proteins observed in vivo is 
supported by in vitro studies. Proteoglycan synthesis is increased in asthmatic fibroblasts 
cultured and subjected to mechanical strain (Ludwig, Ftouhi-Paquin et al. 2004). Furthermore, 
their reduced proliferation rate linked to such increase in extracellular protein synthesis has 
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raised the hypothesis of different phenotypes of fibroblasts in the airways of asthmatics and 
controls (Nihlberg, Andersson-Sjoland et al. 2010). 
 
Airway smooth muscle 
The ASM mass can increase at every level of the bronchial tree in asthma (Huber and 
Koessler 1922, Ebina, Yaegashi et al. 1990, Carroll, Elliot et al. 1993, Girodet, Allard et al. 
2015), and this is accompanied by an increased number and size of these cells, respectively 
referred to as myocyte hyperplasia and hypertrophy (Ebina, Takahashi et al. 1993, James, 
Elliot et al. 2012). An increase in myocyte mitochondria has also been reported in asthma 
(Girodet, Allard et al. 2015). Recently, the potential contribution of ECM deposition within 
the smooth muscle layer and of cellular (fibroblast/myofibroblast) migration have also been 
recognized (Pini, Hamid et al. 2007, Bentley and Hershenson 2008, James, Elliot et al. 2012, 
Yick, Ferreira et al. 2012). Although the crisscross arrangement of smooth muscle bundles 
within the bronchial wall could help prevent buckling in the airway during muscle shortening 
(Lei, Ghezzo et al. 1997), an increased smooth muscle mass facilitates airway closure during 
bronchospasm (Lambert, Wiggs et al. 1993, Oliver, Fabry et al. 2007) and it is indeed 
associated with the severity of the disease (Chetta, Foresi et al. 1997, James, Bai et al. 2009, 
Macedo, Hew et al. 2009). As previously discussed, not only the abundance of ASM but also 
its orientation and possibly the shape of its cells can influence the degree of airway 
obstruction in disease (Bates and Martin 1990, Lambert, Wiggs et al. 1993, Alford, Nesmith 
et al. 2011, Ye, Aratyn-Schaus et al. 2014).  
The relative contribution of hyperplasia versus hypertrophy to the increase in smooth muscle 
mass is not well established as different studies have produced contrasting results (Woodruff, 
Dolganov et al. 2004, James, Elliot et al. 2012). Whether their respective contribution changes 
in relation to the severity of the disease is also ambiguous. It is worth mentioning that real 
hyperplasia (defined as an increased number of cells per basal membrane length or per airway 
tract) is difficult to assess in central airways in vivo. This is because the relationship between 
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basal membrane and smooth muscle may be strongly and unpredictably influenced by 
sampling in endobronchial biopsy samples. For this reason, myocyte hyperplasia is often 
indirectly assessed by measuring ASM cell proliferation rate or the balance between 
proliferation and apoptosis. On the other hand, hypertrophy is hard to assess directly as cell 
borders are not readily identifiable on histological preparations. For this reason, cell size is 
also often calculated indirectly by dividing the smooth muscle area or volume by the number 
of myocyte nuclei counted within that space. ASM hypertrophy in proximal airways was 
identified as a selective determinant of severe persistent asthma in one study (Benayoun, 
Druilhe et al. 2003). A possible pitfall of this approach is related to the presence of ECM 
elements within the muscle bundles (Figure 4) which can be altered in asthma (Pini, Hamid et 
al. 2007, James, Elliot et al. 2012) and, if not properly identified and excluded from the 
muscle volume, could bias the results.  
 
 
Figure 4. ECM fraction in the ASM layer. The smooth muscle layer of central (left panel) 
and peripheral airways (right panel) contains ECM proteins. Deposits of collagen (yellow, 
white arrows) and elastin (black, black arrows) can readily be visualized among smooth 
muscle fibers (pink).  Staining: hematoxylin-eosin-phloxine-saffron (HEPS) in the left panel, 
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and Russell-Movat’s pentachrome in the right panel. Scale is the same for both images (scale 
bar = 50 μm). 
 
That said, true myocyte hyperplasia in large airways has been consistently identified in fatal 
asthma in studies in which stereology-based approaches were employed (Ebina, Takahashi et 
al. 1993, James, Elliot et al. 2012). Also, one study investigating myocyte hyperplasia in 
endobronchial biopsy samples of mild asthmatics has reported an increased number of 
myocytes per surface of basal membrane (Woodruff, Dolganov et al. 2004). Increased 
myocyte proliferation has been reported in large ASM of moderate-to-severe asthmatics as an 
indirect index of hyperplasia (Hassan, Jo et al. 2010, Ramos-Barbon, Fraga-Iriso et al. 2010). 
The increased proliferation rate of ASM cells has been associated with the switching of these 
cells from a physiological contractile to a “synthetic/proliferative” phenotype (Hirota, Nguyen 
et al. 2009). Further in vitro studies have shown in more detail that the synthesis of structural 
or inflammatory molecules and proliferation can be differentially regulated by distinct stimuli 
(Ward, Harris et al. 2008, Alexander, Murgai et al. 2012). This finding, joined with the 
existence of a “hypercontractile phenotype” mediated by the expression of the fast-contracting 
isoform of the myosin (Leguillette, Laviolette et al. 2009), implies that up to four myocyte 
phenotypes with virtually different physiological roles may coexist in the airways of 
asthmatic patients (Table 2). That said, it is important to stress that when we talk about ASM 
cells with different phenotypes, for example with a contractile vs. a proliferative phenotype, 
we refer to ASM cells that are likely to maintain both contractile and proliferative ability, but 
in which one function slightly or markedly prevails over the other. For this reason, even if we 
simplistically refer to one or another cell phenotype, it is more likely that an imponderable 
number of intermediate phenotypes of ASM cells exist simultaneously.  
An increased deposition of proteoglycans (versican and hyaluronan) between and around the 
smooth muscle bundles was observed by Roberts in 1995, who described their distribution 
within the airways as «in bordering areas that appear to be "space" following routine formalin 
fixation and paraffin embedding», concluding that «These "spaces" are hydrated 
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proteoglycan-rich domains in life» (Roberts 1995). The ECM surrounding the smooth muscle 
layer is overall decreased in the large airways of fatal and severe asthmatics compared to the 
less severe forms of the disease (Pini, Hamid et al. 2007, James, Elliot et al. 2012). However, 
no differences were observed when the deposition of specific components of the ECM was 
assessed separately (Yick, Ferreira et al. 2012). 
 
Table 2. Myocyte phenotypes. 
ASM cell phenotype Description 
Contractile In normal conditions, most myocytes are contractile cells. 
They express α-SMA, myosin, and desmin.  
Hyperproliferative* Myocytes with a decreased contractile function (reduced 
expression of α-SMA, myosin, and desmin) undergoing 
exaggerated proliferation (increased expression of 
proliferation markers such as Ki67 or PCNA).  
Synthetic* Myocytes with a decreased contractile function synthetizing 
increased quantities of immunoregulatory or structural 
proteins (cytokines, chemokines, collagen). 
Hypercontractile Myocytes characterized by an increased expression of the 
(+)insert isoform of the SMMHC, which promotes a faster 
contraction. 
α-SMA: alpha-smooth muscle actin, PCNA: proliferating cell nuclear antigen, SMMHC: 
smooth muscle myosin heavy chain. *: possibly different features of a single phenotype.  
 
Cell migration has not been definitely demonstrated in asthmatics. However, the finding of 
increased myofibroblasts in the submucosa of asthmatics (Brewster, Howarth et al. 1990, 
Gabbrielli, Di Lollo et al. 1994), which is even more marked after allergen exposure (Gizycki, 
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Adelroth et al. 1997, Kelly, Chakir et al. 2006, Kelly, O'Connor et al. 2010), supports this 
theory. Figure 5 summarizes the alterations sustained by ASM cells in asthma. 
 
 
Figure 5.  Summary of the alterations in ASM seen in asthma.   
 
 
Angiogenesis 
Compelling evidence suggests that angiogenesis occurs in asthma (Dunnill 1960, Carroll, 
Cooke et al. 1997, Li and Wilson 1997, Tanaka, Yamada et al. 2003), most likely as a 
consequence of chronic inflammation and tissue damage (Rydell-Tormanen, Johnson et al. 
2008, Rydell-Tormanen, Uller et al. 2009, Yahaya, Baker et al. 2011, Van der Velden, Barker 
et al. 2012). Angiogenesis is the growth of new blood vessels from existing ones, whereas 
microvascular remodeling involves the presence of structural alterations (usually 
enlargement) without the formation of new vessels. Vascularity is increased in bronchial 
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biopsy samples from asthmatics compared to healthy subjects, both in terms of number and 
dimensions of the vessels (Li and Wilson 1997, Hoshino, Nakamura et al. 2001), which 
causes an increased submucosal blood flow in the bronchi (Lazaar and Panettieri 2003). An 
increased vascularity of the submucosal plexus has been reported in medium and small size 
airways of asthmatics, which correlated with the degree of airway obstruction (Hashimoto, 
Tanaka et al. 2005). Furthermore, the presence of immature newly formed vessels contributes 
to the increased vascular permeability, increased vascular leakage and edema commonly 
reported in asthma (Harkness, Kanabar et al. 2014). The percentage of the lamina propria 
occupied by vessels is similar in mild asthmatics and healthy subjects (Orsida, Ward et al. 
2001, Hashimoto, Tanaka et al. 2005).  It is worth mentioning that vessels are mainly located 
in close proximity (<150-200 μm) to the epithelium, and a thicker lamina propria as that 
occasionally observed in asthmatics could “dilute” the vascular density in this group, 
minimizing the difference existing between controls and asthmatics (Orsida, Ward et al. 
2001). 
The role of lymphangiogenesis in asthma has also been gaining attention in the last years 
(Baluk, Tammela et al. 2005, Zgraggen, Ochsenbein et al. 2013). As angiogenesis is present 
during chronic inflammation, hyperpermeable and activated new vessels lead to continuous 
extravasation of inflammatory cells and fluid into the inflamed tissue, which accumulate when 
the draining capacity of local lymphatics is overwhelmed. The lack of studies on lymphatic 
remodeling in the lung compared to other organs is due to the fact that in this organ the 
commonly used lymphatic marker LYVE-1 (lymphatic vessel endothelial hyaluronan 
receptor-1) stains both lymphatic and blood vascular endothelial cells, preventing an adequate 
differentiation of these two structures. However, recent study using the specific lymphatic 
marker podoplanin has revealed that fatal asthmatics have decreased lymphatics in their 
airways compared to aged-matched controls, suggesting an impaired drainage of airway 
edema as a potential mechanism contributing to the severe airway obstruction observed in 
these patients (Ebina 2008). The ability of Th-2 cytokines to inhibit lymphangiogenesis in 
vitro and in vivo in animal models further strengthens this finding (Savetsky, Ghanta et al. 
2015, Shin, Kataru et al. 2015).  
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Cartilage 
Alterations in bronchial cartilage have been sporadically reported, consistent with cartilage 
proteoglycan degradation in distal airways (Roberts 1995) or increased cartilage area in 
medium size bronchi of severe asthmatics compared to mild patients and controls (Carroll, 
Elliot et al. 1993). In endobronchial biopsies, the volume fraction occupied by the cartilage is 
similar between asthmatics and healthy patients, and seems to be strictly dependent on the 
sampling site (Labonte, Laviolette et al. 2008). Evidence of cartilage degeneration consistent 
with loss of cellular or pericellular metachromasia (territorial matrix) and pyknotic or absent 
chondrocytes has also been observed in asthmatics, correlating with the number of neutrophils 
infiltrating the airway wall (Haraguchi, Shimura et al. 1999). 
 
Lung parenchyma 
Remodeling of the lung parenchyma in asthma has been often disregarded in the past but very 
recent studies have showed that significant changes are already present even in patients with 
mild asthma (Nihlberg, Andersson-Sjoland et al. 2010). Specifically, increased collagen 
deposition and decreased decorin and biglycan have been reported in asthmatics with well-
controlled disease, while an increase in decorin has been reported in uncontrolled asthma 
(Nihlberg, Andersson-Sjoland et al. 2010, Weitoft, Andersson et al. 2014).  Lung granulomata 
have also been repeatedly found in severe asthmatics (Wenzel, Vitari et al. 2012). 
 
Airway inflammation 
The concept of asthma as a chronic inflammatory condition is relatively recent, and an 
exaggerated inflammatory response to normally non-harmful stimuli has been so far 
recognized as the underlying force preceding (and possibly producing) asthma exacerbations 
(Maneechotesuwan, Essilfie-Quaye et al. 2007). The role of inflammation is asthma is 
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multiple. A large amount of inflammatory mediators is liberated within the bronchial wall and 
lumen during or before asthma exacerbations, which may act at three levels:  
• they may precipitate bronchospasm by directly inducing ASM cell contraction (i.e.: 
cysteinyl leukotrienes, histamine, thromboxane)   
• they may foster remodeling by causing structural damages or alteration to the 
bronchial structures (i.e.: metalloproteinases, elastases, TGF-β-induced fibrosis, IL-
13-induced goblet cell metaplasia (Boucherat, Boczkowski et al. 2013)) 
• they may act as a positive stimulus for the recruitment of other inflammatory cells 
(i.e.: IL-8, TNF-α). 
Although inflammation is commonly considered the primum movens (first cause) of asthma, 
there are exceptions to this thought that deserve to be mentioned. As stated by Holgate: 
«while asthma is an inflammatory disorder of the conducting airways, inflammation itself 
does not explain the origin(s) of this disease nor why the airways are so susceptible to a range 
of different environmental factors» (Holgate 2011). Asthma was unanimously considered an 
eosinophilic, Th-2 biased inflammatory disease. It is now recognized that only half of 
asthmatics display a Th2-biased inflammatory response (Fahy 2015) and that a subset of 
patients exists (phenotype) in which neutrophils rather than eosinophils represent the most 
abundant inflammatory cell type in bronchial secretions. Neutrophilic asthmatics are 
commonly, but not always, affected by more severe forms of asthma and less responsive to 
corticosteroid treatment compared to eosinophilic asthmatics (Macedo, Hew et al. 2009, 
Moore, Hastie et al. 2013, Chung, Wenzel et al. 2014). This phenotypic heterogeneity, joined 
with the relative ineffectiveness of anti-Th2 monotherapies for asthma treatment (Fahy 2015), 
has brought awareness that the Th2-biased immune process alone is inadequate to explain the 
pathogenesis and persistence of  asthma in adults, a concept also known as the «Th-2 
paradigm insufficiency» (Chanez, Wenzel et al. 2007). The mechanisms behind these diverse 
inflammatory profiles are likely complex and currently incompletely understood. While a 
Th2-immune response is involved in the eosinophilic severe asthma phenotype, the immune 
mechanisms underlying the neutrophilic phenotype are not well described. Th1 and Th17-
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biased inflammation could be involved, as well as alterations of the innate immunity. 
Neutrophilic moderate-to-severe asthma is characterized by increased expression of IL-8 and 
IL-17 compared to mild asthma and healthy subjects (Park, Jung et al. 1998, Ordonez, 
Shaughnessy et al. 2000, Chakir, Shannon et al. 2003). The persistence of inflammation in 
neutrophilic asthma in spite of treatment may also result from deficiencies in endogenous 
homeostatic processes that promote resolution of inflammation (Chung, Wenzel et al. 2014). 
In this regard, a recently developed mathematical model has shown how the inflammation 
resolution speed after a severe exacerbation can significantly affect airway remodeling 
(Chernyavsky, Croisier et al. 2014). 
Asthmatics experiencing a rapid decline in lung function and ultimately a loss of disease 
control are those who have experienced the most severe exacerbations (Matsunaga, Hirano et 
al. 2015). This finding supports the hypothesis that asthma exacerbations are associated with 
the progression of airway functional changes that lead to persistent airflow limitation, 
although the causality between the occurrence of asthma exacerbations and loss of lung 
function remains to be demonstrated. 
Importantly, while emphasis has been placed on assessing inflammation by analysis of 
bronchoalveolar lavage fluid (BALF) or sputum samples, its relationship to cellular profiles 
within airway or lung tissues is poor (Lemiere, Ernst et al. 2006, Macedo, Hew et al. 2009). 
Possibly, it is because many structural cells may operate incognito, playing important pro-
inflammatory roles that remain undetected in morphological studies of inflammatory 
infiltrate. In fact, while a multitude of in vitro studies have investigated the inflammatory 
potential of fibroblasts, myofibroblasts, and ASM cells (Damera, Tliba et al. 2009, Alkhouri, 
Poppinga et al. 2014), their role in vivo is still commonly overlooked. Central and peripheral 
airways, as well as the lung parenchyma of asthmatics have increased inflammatory infiltrate 
compared to control subjects (Laitinen, Laitinen et al. 1993, Kraft, Djukanovic et al. 1996, 
Laitinen, Laitinen et al. 1996, Hamid, Song et al. 1997). Tissue inflammation appears to be 
similar in large airway biopsy samples obtained from asthmatics experiencing disease of 
different severity and with significantly different values of lung function and methacholine 
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responsiveness (Lemiere, Ernst et al. 2006, Macedo, Hew et al. 2009), which would argue 
against a direct effect of airway tissue inflammation in AHR and remodeling. However, 
severe asthma is characterized by an increased number of total inflammatory cells within the 
small airways compared to other pulmonary compartments (Balzar, Wenzel et al. 2002), 
which is limited to the eosinophils in mild-to-moderate asthmatics (Hamid, Song et al. 1997). 
These data strongly support a central role for small airways in asthma pathophysiology. Given 
the absence of differences in the distribution of inflammatory cell types infiltrating large and 
small airways, the assumption was made that large airway inflammation is qualitatively 
representative of small airway inflammation (Carroll, Lehmann et al. 1996). Significant 
correlations have not been reported however, and the growing interest in small airway 
structure and function (Postma, Brightling et al. 2015) hints at the inadequacy of large airway 
findings alone to explain the clinical aspects of the disease.  
 
Functional consequences 
It is hard to define what the causes are in asthma pathophysiology. The disease is 
characterized by severe airflow obstruction caused by bronchoconstriction and excessive 
mucus secretion within the airway lumen. Airway caliber results from the balance of opposite 
forces acting on the bronchial wall, which are severely altered in asthma due to 
hyperresponsiveness, remodeling, and inflammation. Airway hyperresponsiveness can induce 
remodeling and an inflammatory response by mean of the stress exerted on structural cells by 
exaggerated strain (Manuyakorn 2014, Gosens and Grainge 2015, Park, Fredberg et al. 2015). 
Airway inflammation itself may accentuate bronchial responsiveness as several 
bronchoconstrictive mediators are secreted by inflammatory cells (Bjornsdottir and Cypcar 
1999) that can prevent complete airway expansion fostering excessive airway narrowing 
(Bosse, Chapman et al. 2011). Several products of inflammation can influence tissue 
remodeling as well (Fahy, Corry et al. 2000, Ramos-Barbon, Presley et al. 2005). Meanwhile, 
remodeling can profoundly impact AHR by altering force generation and distribution among 
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the different compartments of the bronchial walls and lung parenchyma (Bosse, Riesenfeld et 
al. 2010, Bosse, Solomon et al. 2010) through several mechanisms: 
• an increased ASM mass produces greater forces upon constriction, which overwhelm 
the mechanisms that maintain airway patency;  
• abnormal quantities or composition of the ECM may affect airway mechanics in 
asthma, both through geometric effects and through direct changes in tissue 
biomechanics (i.e. versican may increase lung stiffness by inhibiting elastin-binding 
proteins and interfering with the assembly of elastic fibers (Merrilees, Ching et al. 
2008); on the other hand, increased ECM degradation can accentuate/facilitate ASM 
contractility (Roberts 1995)); 
• the loss of integrity of elastic fibers could prevent uniform intrapulmonary tension 
distribution, accentuating airflow heterogeneity and hyperresponsiveness (Bousquet, 
Lacoste et al. 1996). 
 
 
The role of small vs large airways 
The whole bronchial tree displays pathological alterations in asthma. There is no doubt, 
however, that large and small airways differ in many physiological aspects (Table 3), which 
would explain their variable contribution to several pathological traits. This dichotomy is 
maintained in asthma, but cellular function was found to be altered in disease, even in mildly 
affected subjects with normal lung function (Nihlberg, Andersson-Sjoland et al. 2010).  
Whether central or peripheral bronchospasm is the major determinant of obstruction during 
acute exacerbations remains a matter of debate (Thompson, Douglass et al. 2013). During 
periods of disease control, central airway remodeling significantly correlates with the degree 
of airflow obstruction measured by spirometry (Kaminska, Foley et al. 2009). On the other 
hand, the more severe forms of the disease – that is, patients needing higher doses of 
treatment to be controlled, or still incompletely controlled despite high dose treatments – are 
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characterized by a greater degree of remodeling and inflammation in the distal bronchi and 
lung parenchyma (Carroll, Elliot et al. 1993, Weitoft, Andersson et al. 2014). These 
observations suggest that large airway pathology better reflects disease clinical expression, 
while small airway pathology long-term disease control.  
 
Table 3. Differences between small and large airways.  
Small (peripheral) airways Large (central) airways 
Absence of cartilage Presence of cartilage 
Absence of goblet cells and mucus glands Presence of goblet cells and mucus glands 
Non-ciliated epithelium Ciliated epithelium 
Low gas velocity and true laminar flow High gas velocity and mixed flow (turbulent 
close to the airway wall and laminar at the 
center of the airway lumen) 
Surfactant within the epithelial lining fluid - 
 
 
Highlights and unanswered questions 
Airway inflammation, remodeling, and hyperresponsiveness are intimately interconnected and 
the precise pathophysiology of these contributors to asthma is incompletely described. The 
implication of small airways in asthma, especially in its severe form, is increasingly 
recognized, but tools for studying the progression of the disease at this level are not readily 
available. On the other hand, central airways can be easily accessed and sampled, but whether 
changes observed at the central level are representative of peripheral airway pathology 
remains to be established. 
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Means of assessment of airway remodeling in asthma  
 
 
In vivo studies of airway structure and function in asthma have been hampered somewhat by 
the limited availability of tissue specimens (Lazaar and Panettieri 2003). Provided that 
histology still remains the gold standard for the evaluation of tissue remodeling and 
inflammation, biopsy samples are very small and they supply limited (if any) information on 
the functional and mechanical properties of the airways. In order to gather this kind of 
information, large tissue samples are required, which cannot be obtained in vivo in man. For 
this reason, a series of indirect tools have been employed in the last years to evaluate 
bronchial function, remodeling, and inflammation in a non-invasive way. They are briefly 
introduced hereafter, with a special emphasis on those employed for the assessment of ASM. 
 
Histology 
Histology is considered the gold standard technique for detection and quantification of airway 
remodeling and inflammation along the bronchial tree (Jeffery, Holgate et al. 2003). 
Representative tissue samples can be obtained in vivo by means of biopsy techniques. 
Endobronchial biopsy yields central airway samples obtained with forceps during 
bronchoscopy (Jeffery, Holgate et al. 2003). In regard of sample size and integrity, best 
results are reported to be obtained when larger instruments are used. Accumulated evidence 
suggests that reusable forceps should not be used for more than 5 bronchoscopies in human 
medicine (Jeffery, Holgate et al. 2003). It is a safe technique, which provides satisfying 
samples in 60% of cases on average (Van Vyve, Chanez et al. 1992, Labonte, Laviolette et al. 
2008). Samples obtained by transbronchial biopsies or lung resections (performed for other 
reasons) have been used to study small airways in vivo. These techniques are characterized by 
a low safety profile compared to endobronchial biopsies, with complications such as 
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pneumothorax occasionally reported. Satisfactory samples are obtained in 28% of cases 
(Balzar, Wenzel et al. 2002). All biopsy-based techniques however are characterized by two 
major disadvantages which limit their usefulness in asthma: first, they yield non-repeatable 
samples, which partly precludes the possibility of longitudinal studies to be performed on the 
same bronchial region, and second, they provide only partial samples of the airway wall. 
Airway smooth muscle mass normalization by the length of the basal membrane or of the 
internal perimeter is commonly performed in histomorphometry (James, Hogg et al. 1988, 
McParland, Pare et al. 2004, James, Green et al. 2008, Elliot, Budgeon et al. 2015), which 
cannot be done when endobronchial biopsy samples are used. Also, only the carinae are 
sampled and the full thickness of the central bronchial wall is rarely sampled using 
endobronchial biopsy forceps, which prevents random sampling and further questions their 
reliability for the quantitative assessment of the most abaxial structures of the airways, such as 
the ASM (Woodruff and Innes 2006).  
For research purposes, tissues should be obtained based on stereology-based sampling, that is: 
randomly and systematically. This method minimizes variability associated to subject, sample 
site, and sample sections. However, in vivo sampling is inevitably biased. Also, insufficient, 
imprecise, or inadequate tissue sampling does not guarantee an adequate study power and, 
even worse, could introduce a bias in the results. Considering intra- and inter-subject 
variation, it has been calculated that >15 cases are needed to detect a 100% difference in ASM 
remodeling in large cartilaginous airways between asthmatics and controls using autopsy 
lungs (James and Carroll 2000). A similar number of subjects allow the demonstration of 
differences of inflammatory cells in endobronchial biopsy samples (Sont, Willems et al. 
1997). No such data are available for small membranous airways. To obtain random 
endobronchial biopsy samples, it has been recommended that a list of 10 to 15 potential 
biopsy sites located in the second, third and fourth airway generations of the right and left 
lung be generated before starting the procedure. Three to eight sites from this list must then be 
randomly selected and biopsies performed. Ideally, both lungs would be sampled equally, but 
due to practical issues and potential complications, it is accepted to take all eight biopsies 
from the same lung. Variability between different histological sections of the same biopsy 
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specimen has been reported to be 5%, suggesting that the evaluation of a single histological 
section for each endobronchial biopsy provides reliable results. A valuable sample should 
ideally have a subepithelial area, excluding artifact, cartilage, or blood clots, of at least 0.3 to 
0.5 mm2. Samples of blood and mucus, scrapings of epithelium, and fragments of glands are 
unacceptable (Jeffery, Holgate et al. 2003, Woodruff and Innes 2006). Although not 
described, the same protocol could be used to determine sites of transbronchial biopsy 
sampling, being careful to reduce to a minimum the number of biopsies harvested due to the 
high complication rate. Two to four biopsies per subject are considered to provide reliable 
data (Balzar, Wenzel et al. 2002). 
In order to guarantee optimal staining, the biopsy samples must be processed rapidly and 
using standardized protocols. A rigorous approach maximizes the possibilities to discriminate 
subtle yet clinically important differences between groups (Jeffery, Holgate et al. 2003). For 
example, different tissue fixation techniques may result in variable degrees of tissue 
shrinkage. Formalin fixation and paraffin embedding induce tissue shrinking (10% on 
average, but can be as much as 50% depending on the temperature and the organic solvents 
used during the procedure). As variation in shrinkage is probably random and occurs in all 
tissues, it is not likely that it represents a significant problem when comparing groups where 
similar processing protocols have been used. Standard staining techniques are generally used 
successfully for quantitative analysis of ASM mass or total collagen deposition (Araujo, 
Dolhnikoff et al. 2008, James, Elliot et al. 2012), whereas immunohistochemistry is required 
to differentiate ECM components (Bergeron, Hauber et al. 2005, Araujo, Dolhnikoff et al. 
2008) or for assessing the expression of specific proteins involved in disease pathophysiology. 
Some components of the bronchial submucosa other than smooth muscle could be mistaken 
for smooth muscle cells using a histological stain such as hematoxylin and eosin, which 
differentiates poorly between muscle and non-muscle tissue elements. This may lead to an 
incorrect estimation of ASM mass, especially at lower magnifications, at which individual 
smooth muscle fibers are less clearly identified. Other staining techniques such as Masson 
(trichrome) or Movat (pentachrome) can adequately identify and differentiate muscle from 
connective tissue and are thus preferable (Jeffery, Holgate et al. 2003).  
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Quantitative evaluation of bronchial structures has often been performed bi-dimensionally. 
This implies measuring the number or the area occupied by the structure of interest within a 
transversely-cut airway. As mentioned before, in order to compare airways of different size 
and degree of contraction, a measuring unit independent of bronchial dimension and 
constriction was developed. It was validated initially as a normalizing method for the 
assessment of smooth muscle mass, and it consisted in dividing the area occupied by ASM 
around the airway by the length of the basal membrane or of the internal perimeter of the 
bronchus (James, Hogg et al. 1988, Herszberg, Ramos-Barbon et al. 2006). It has to be noted 
that methods of quantitation of ASM mass in endobronchial biopsy samples are still not 
validated or standardized. This means that measuring units of ASM mass vary among the 
different studies, which makes it virtually impossible to compare them and to draw general 
conclusions. The use of stereological approaches is now strongly suggested, as they provide 
unbiased estimation of tridimensional structure distribution (Muhlfeld, Knudsen et al. 2013, 
Schneider and Ochs 2013). An official ATS/ERS Research Policy Statement has recently 
been published together with an extensive review providing general recommendations on 
which stereological methods are to be used in quantitative microscopy of the lung in 
respiratory research (Hsia, Hyde et al. 2010, Muhlfeld and Ochs 2013, Ochs and Muhlfeld 
2013). 
 
Diagnostic imaging 
Imaging techniques currently used to investigate airway wall thickness include high-
resolution computed tomography (HRCT), endobronchial ultrasound (EBUS), and optical 
coherence tomography (OCT). Noble gases (mainly helium and xenon) magnetic resonance 
imaging (MRI), single photon emission computed tomography (SPECT), positron-emission 
tomography (PET) are other research tools that can provide indirect measurements of 
bronchial remodeling and activation based on the distribution of inhaled particles or airflow 
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heterogeneity assessment (Laurent and Tunon de Lara 2011). Unfortunately, none of them can 
differentiate and specifically allow the assessment of the smooth muscle layer. 
High-resolution computed tomography has been used in several studies and different 
techniques have been developed for assessment of bronchial wall thickness both in small and 
in large airways. Despite several algorithms developed to optimize airway wall measurement, 
the technique is still imprecise, especially when used to evaluate small airways. Indeed, the 
resolution of common CT scanners does not allow precise measurements of small airways 
thickness (Coxson 2008, Walker, Gupta et al. 2012) and no consensus on the appropriate 
method for measuring airways has been reached among researchers (Coxson and Lam 2009). 
High-resolution computed tomography measurements overestimate airway wall area and 
underestimate airway lumen area (de Jong, Muller et al. 2005). Nevertheless, a correlation 
between airway wall measurements obtained using CT and those obtained using histology has 
been shown (Nakano, Wong et al. 2005). 
Endobronchial ultrasound and OCT are techniques with comparable outcomes but based on 
different principles. Image acquisition is based on reflectance and return of ultrasound waves 
for EBUS and on infrared light for OCT (Kurimoto, Murayama et al. 1999, Coxson and Lam 
2009). The advantages for these techniques are that no radiation is required thus they have a 
better safety profile than HRCT and they have a good resolution to allow accurate 
measurements of small airway walls. Although they both require bronchoscopy, OCT 
overcomes a problem strictly related to EBUS, such as the need of a coupling between the 
probe and the airway wall. It cannot however clearly distinguish between different airway 
wall layers as EBUS does. 
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Brief introduction to the endobronchial ultrasonography 
History 
Endoscopic ultrasound was first used in human gastroenterology to investigate intestinal wall 
involvement in neoplasms and infiltrative diseases (Kim and Telford 2009). The application 
of endoscopic ultrasound (EUS) to the respiratory tract was first described by Hürter and 
Hanrath in 1992 (Hurter and Hanrath 1992), and it was named EBUS. The first transducer 
consisted of a single-element, rotating transducer placed at the tip of a metal shaft. The 
rotation of the transducer allowed obtaining 360° images of the surrounding tissues, 
producing cross-sectional images of the bronchi. The ultrasound frequency of the first EBUS 
transducer was 20 MHz, the maximum field of view was reported to be 5 cm in diameter 
under optimal conditions, and the limit of the radial resolution in the order of 200 μm. Since 
1999, EBUS is commercially available (Burgers, Herth et al. 2001) and its use in human 
respiratory medicine has progressively increased. 
 
Technique and instrumentation 
The instruments used to perform EBUS consist of a flexible videoendoscope with a working 
channel of 2.2-3.6 mm in diameter, a high frequency echo-transducer, and software for image 
analysis. 
There are currently two main types of probes available which can be used to perform EBUS: 
radial probes and curvilinear probes (Medford 2010). Radial probes can be further divided 
into ultra-miniature probes and radial balloon probes (Haas, Vachani et al. 2010). Radial 
probes are high-frequency, circulating probes. The transducer rotates on its own axis at high 
speed and generates 360° (cross-sectional) images of the bronchial walls and their 
surrounding tissues (Figure 6A). Ultra-miniature probes differ from radial balloon probes 
because of the absence or presence, respectively, of an inflatable balloon on their surface. 
Because physical contact is required, ultraminiature probes are generally used while placed 
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inside a sheath provided with a water-inflatable balloon. The balloon can be water-inflated up 
to a diameter of 1.5-2 cm. A pressure-dependent safety mechanism might be present 
preventing an excessive inflation of the balloon (Figure 7).  
 
Figure 6. EBUS probes. A) Radial probes consist of a small disc-shaped ultrasound 
transducer oriented perpendicularly to the airway longitudinal axis and attached to a motor 
drive. Images are acquired during high-speed rotation of the transducer and depict the 
bronchial wall cross-sectionally (360°). B) Curvilinear probes have a fixed electronic 
transducer oriented so as to produce a sector-shaped (50° angle) image parallel to the long 
axis of the endoscope 
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Radial probes have been available at frequencies ranging from 12 to 30 MHz, with 20 MHz 
being the frequency more commonly used for clinical purposes (Sheski and Mathur 2008). 
The 30 MHz probe is no longer available on the market. A single probe, if carefully handled, 
is reported to approximately last 50 to 75 examinations (Falcone, Fois et al. 2003, Sheski and 
Mathur 2008). 
 
Figure 7. Pressure-dependent safety mechanism of the inflatable balloon. The distal 
extremity of the balloon is provided with an elastic ring which fits into a circular depression 
on the tip of the EBUS probe. Once the probe is in the airway, water is injected into the 
balloon to inflate it. If the pressure inside the balloon is too high, the elastic ring is released 
and water flows out. Image obtained from http://www.olympus-
europa.com/medical/en/medical_systems/mediacentre/ media_detail_6476.jsp, accessed on 
02/06/2016.  
 
Few studies have compared the image quality of the bronchial wall obtained using EBUS 
probes of different frequencies (Dong, Takahashi et al. 2001, Kurimoto, Murayama et al. 
2002, Nakamura, Endo et al. 2004). Data suggest that images obtained with 30 MHz probes 
are characterized by better quality and resolution but limited penetration compared to those 
obtained with 20 MHz probes. Average times reported to perform a radial EBUS examination 
vary between 8 and 20 minutes (Falcone, Fois et al. 2003). The learning curve associated to 
the EBUS technique is quite slow. The European Respiratory Society and the American 
Thoracic Society recommend 40 supervised procedures followed by 25 procedures per year 
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for radial EBUS to maintain skills, while the American College of Chest Physicians 
guidelines advise a minimum of 50 supervised procedures followed by 5 to 10 procedures per 
year (Bolliger, Mathur et al. 2002, Ernst, Silvestri et al. 2003). Linear EBUS is likely to 
require 40-50 supervised procedures as well in order to acquire the necessary skills (Medford 
2010). 
 
 
Sonographic airway anatomy 
Bronchial and tracheal walls are imaged ultrasonographically as multilayered structures. 
Hypo- and hyperechoic layers alternate regularly, with the innermost layer being hyperechoic 
(Figure 8).  
In the most recent human studies, ultrasonographic imaging of the cartilaginous airways 
detects a maximum of five layers (Soja, Grzanka et al. 2009, Kita, Fujimura et al. 2010). 
However, there are reports in which authors were able to detect only three layers (Hurter and 
Hanrath 1992), while others identified six (Baba, Sekine et al. 2002) or even seven distinct 
layers (Becker 1996, Herth, Ernst et al. 2003, Nakamura, Endo et al. 2004). Of note, studies in 
which seven layers were detected ultrasonographically lacked a validation step identifying the 
corresponding microscopic structure. The stratigraphy of the airway wall varies depending on 
the bronchial site imaged. Specifically, the presence of a cartilage plate in the bronchial wall 
is associated with an increased number of echoic layers. This also means that it is virtually 
impossible to have a cross-sectional image of an airway in which the same layer disposition is 
observed all around, as the airways are not encircled by complete cartilaginous rings. Instead, 
is it expected that the number of layers and their thickness vary around the airway wall.  
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Figure 8. Multilayered structure of the bronchial wall at EBUS. The five colored arrows 
on the left indicate the five layers of the bronchial wall (green: first layer [L1], white: second 
layer [L2], red: third layer [L3], yellow: fourth layer [L4], and blue: fifth layer [L5]).  The 
yellow thick arrows on the right indicate the thickness of L2. In the left bottom panel, the 
probe is in the bronchial lumen with the balloon inflated to allow coupling with the airway 
wall.  
 
Marginal echoes are artifacts produced by ultrasound wave reverberation. They are identified 
as hyperechoic bands propagating from hyperechoic structures toward the travelling direction 
of the waves (that is, centrifugally). The presence of marginal echoes must be kept in mind 
when evaluating an endobronchial sonogram, as they actually “cover” a portion of the 
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underlying hypoechoic layer (Figure 9). They cannot be clearly identified and removed or 
subtracted. In fact, the first, third and fifth layer themselves are marginal echoes. Kurimoto 
and colleagues (Kurimoto, Murayama et al. 1999) investigated the localization and magnitude 
of marginal echoes in airway sonograms. They can be visualized as echoes propagating 
outwards and starting at the epithelial layer, the inner border of cartilaginous plates, and the 
adventitia. The marginal echo propagating from the epithelial layer has been recognized as the 
more prominent in human bronchi.  
 
 
Figure 9. Marginal echoes in EBUS images. Yellow arrows indicate marginal echoes. They 
can be identified between an inner hyperechoic and an outer hypoechoic layer, and they play a 
role in the thickness of both layers: the hyperechoic inner layer will appear on the sonogram 
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thicker than it is in reality because its marginal echo will be included in the total thickness. As 
a consequence, the following external hypoechoic layer will be displayed in the sonogram as 
thinner than it is in reality. White brace: marginal echo of the inner border of the cartilage. 
Red brace: thickness of the bronchial cartilage. Scale bar: 1 mm.  
 
Although discrepancies exist concerning the number of echographic layers detectable in 
cartilaginous portions of the airways, there is general agreement that in membranous portions 
of the airways three layers are identifiable. The only exception is the first report of EBUS by 
Hurter and Hanrath (1992), in which they described the membranous airway wall as a 
monolayered structure. Baba and colleagues (2002) have successively speculated that the low 
contrast and high gains used for EBUS in that initial report (justified by the aim to describe 
not only airway structures but also adjacent vessels and lymph nodes) could have been the 
reason why the bronchial wall appeared as monolayered.  
Based on the most recent observations, the first layer at the luminal side is a hyperechoic 
layer, which has been described to represent the surface of the latex balloon (when present), 
the epithelium, and a variable portion of the submucosa. The second layer is hypoechoic and 
there is evidence that it represents the remaining part of the submucosa and the smooth 
muscle. Vessels, nerves and glands are also present within the second layer. The marginal 
echo of the first layer extends from the inner margin of the epithelium (or from the inner 
surface of the balloon) to a variable part of the inner submucosal tissue (Kurimoto, Murayama 
et al. 1999). The first two sonographic layers represent the same structures both in 
cartilaginous and membranous portions of the airways. The second layer may be occasionally 
compressed by and mixed with the balloon echo (Baba, Sekine et al. 2002) and thus 
differentiation between the first and the second layer may be challenging. On the contrary, 
boundary lines between the second and the third layer (cartilaginous portions) on the 
sonogram are generally well demarcated and represent a reliable image of the real tissue 
organization in that area (Miyazu, Miyazawa et al. 2002). 
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In membranous portions of the airways, the third layer is described as the last layer detectable 
by most of the authors, representing the adventitia. Using a 20 MHz probe, Baba (2002) 
reported a six-layered structure of the membranous portions of the extra-pulmonary airways 
where the third and fourth layers, hyper- and hypoechoic, respectively, represented the 
longitudinal muscle and the bronchial glands. The fifth hyperechoic layer was considered the 
sum of marginal echo and adventitia, and the sixth as the adventitia. These findings were 
confirmed microscopically. 
In cartilaginous portions of the airways, the third, fourth and fifth layers identify the 
cartilaginous plates. The third layer is hyperechoic and represents the inner border of the 
bronchial cartilage (endochondrium). The fourth layer is hypoechoic and represents the body 
of the bronchial cartilage. The fifth layer is highly hyperechoic and it represents the outer 
border of the cartilage (pericondrium) and the adventitia. The marginal echo of the third layer 
starts at the luminal side of the bronchial cartilage and it might extend up to half of the 
cartilage body, whilst the marginal echo of the fifth layer starts at the outer margin of the 
bronchial cartilage and extends to the adventitia (Kurimoto, Murayama et al. 1999). Authors 
that recognized a sixth layer described it as hypoechoic (Becker 1996, Miyazu, Miyazawa et 
al. 2002) or slightly hyperechoic (Baba, Sekine et al. 2002) and suggested it may represent 
supporting connective tissue or the adventitia itself, respectively. The seventh hyperechoic 
layer was described as an image of adventitia, when identifiable (Table 4).   
At present, all but one study reported have been performed by means of subjective 
interpretation of the ultrasonographic images. In these cases, the layers were detected by 
independent, experienced observers. Layer differentiation can also be accomplished by means 
of dedicated software, which allows more accurate and objective interpretation of the images. 
Using NIH Image (National Institutes of Health, Bethesda, MD) different tonalities of the 
grayscale characterizing each pixel of the sonogram representing the bronchial wall are 
analyzed. When only the pixels disposed along a radius of the circle formed by the bronchial 
wall are considered, a “W-shaped” curve is obtained as a result, where every change in 
direction of the curve represents the change from a layer to the subsequent one in the EBUS 
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image. A maximum of seven layers could be detected in the cartilaginous portions of 
intrapulmonary airways using 30 MHz radial microprobe-obtained sonograms and this 
method of analysis (Nakamura, Endo et al. 2004). 
Anatomical orientation in the tracheobronchial tree is difficult, and a good knowledge of 
thoracic anatomy and physiology is necessary to perform the EBUS technique. Both 
respiration and cardiac pulsation may lead to artifacts in the images collected (Baba, Sekine et 
al. 2002, Falcone, Fois et al. 2003). Generally, esophagus, main arteries and veins are used as 
anatomic landmarks in human medicine. Contrasts have been used to better visualize 
pulmonary vessels during both trans-cutaneous (Gorg 2007) and bronchoscopic (Hurter and 
Hanrath 1992) ultrasound examination. 
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Table 4. US findings of the tracheobronchial wall.
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Layer Echodensity US findings
Becker et al. Herth et al. Nakamura et al. Kurimoto et al./Miyazu et al. Baba et al. Hurter et  al.
Cartilaginous 
airways (trachea)
Cartilaginous 
airways
Cartilaginous 
airways
Membranous 
airways
Cartilaginous 
airways
Membranous 
airways
Cartilaginous 
airways
Non-
cartilaginous 
portions of 
cartilaginous 
1st hyperechoic bright echo 
enhanced by 
adjacent balloon
mucosa balloon sheath 
and bronchial 
epithelium
marginal echo 
containing the 
epitelium and 
initial part  of 
submucosal 
t issue
marginal echo 
containing the 
epitelium and 
initial part  of 
submucosal 
t issue
interface echo 
containing 
epithelium and 
lamina propria
interface echo 
containing 
epithelium 
and lamina 
propria
endo-
chondrium
UNILAMINAR 
STRUCTURE
2nd hypoechoic submucosa submucosa submucosal layer 
and bronchial 
smooth muscle 
layer
submucosal 
t issue
smooth muscle submucosa with 
lamina propria, 
smooth muscle 
and 
extramuscular 
layers; layer 
occasionally 
compressed and 
mixed with the 
balloon echo
submucosa 
with lamina 
propria, 
smooth 
muscle and 
extramuscular 
layers
cartilage
3rd hyperechoic strong echo of 
inner cartilage 
and 
endochondrium
endochondrium marginal echo of 
the luminal 
aspect of the 
bronchial 
cartilaginous 
layer
marginal echo 
of the inner 
side of the 
bronchial 
cartilage
adventitia interface echo, 
cartilage
longitudinal 
muscle
peri-
chondrium
4th hypoechoic connective tissue 
of inner cartilage
cartilage bronchial 
cartilaginous 
layer
bronchial 
cartilage
cartilage bronchial 
glands
epithelium and epithelium and 
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*: not described in the article, but can be detected in the article’s figures. 
5th hyperechoic strong echo of 
outer cartilage, 
perichondrium
perichondral 
layer
marginal echo of 
the outer 
cartilaginous 
layer
marginal echo 
starting from 
the outer side 
of the 
bronchial 
cartilage and 
containing 
adventitia
interface echo, 
adventitia
interface 
echo, 
adventitia
6th hypoechoic supporting 
connective tissue
connective tissue * in some cases 
in tracheal wall
adventitia adventitia
7th hyperechoic adventitia adventitia * in some cases 
in tracheal wall
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Current and future applications 
Current indications for the use of EBUS in human respiratory medicine are staging and 
diagnosing lung cancer, evaluating mediastinal lymphadenopathy, as well as assessing airway 
wall infiltration and peripheral nodules involvement in neoplastic diseases (Burgers, Herth et 
al. 2001, Kurimoto, Murayama et al. 2002, Anantham, Koh et al. 2009). Most of the clinical 
experiences and published papers employ EBUS for ultrasound-guided transbronchial needle 
aspiration (US-TBNA) (Herth, Becker et al. 2004, De Leyn, Lardinois et al. 2007, Medford, 
Bennett et al. 2010), for which 7.5 MHz curvilinear probes are used. Endobronchial 
ultrasonography is employed also for locating mediastinal and bronchogenic cysts, for 
diagnosing relapsing polychondritis and sarcoidosis (Miyazu, Miyazawa et al. 2003, Garwood, 
Judson et al. 2007), as well as for detecting thrombi of the pulmonary artery and central 
pulmonary emboli (Kennedy, McWilliams et al. 2007, Aumiller, Herth et al. 2009). 
Current research is focused on the assessment of pulmonary vascular disease (Medford 2010) 
and airway remodeling associated with asthma and chronic obstructive pulmonary disease 
(Yamasaki, Tomita et al. 2003, Shaw, Wakely et al. 2004, Soja, Grzanka et al. 2009, Soja, 
Loboda et al. 2015), which may represent further future clinical applications for EBUS. 
Differently from EUS (endoscopic ultrasound) probes, EBUS transducers do not allow 
visualization of contrast agents at present (Reddy, Ioncica et al. 2011, Saftoiu 2011). A model 
of 3D-EBUS has been developed as well, but its application in vivo has been difficult, leading 
to poor results (Andreassen, Ellingsen et al. 2005). Until now, the use of EBUS has not been 
described in veterinary medicine. 
 
Advantages and limitations 
As every other technique, EBUS offers several advantages but is not free of limitations. Main 
advantages are represented by: 
• minimal invasiveness; 
• repeatability over time; 
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• direct and real-time visualization of the airway wall at specific locations of interest; 
• ability to assess small airways and peripheral areas of the lungs; 
• high sensitivity as a prognostic tool in human respiratory medicine (mainly oncology), 
further increased when coupled with other complementary diagnostic techniques as 
HRCT (High Resolution Computed Tomography);  
• low radiation exposure. 
 
On the other hand, the following points have been considered as limitations of the EBUS 
technique: 
• technically speaking, the resolution of 20 MHz probes is not sufficient to differentiate 
the several histological layers constituting the airway wall (Miyazu, Miyazawa et al. 
2002, Wakamatsu, Tsushima et al. 2006), to visualize the basement membrane (Baba, 
Sekine et al. 2002), or to differentiate the smooth muscle from the lamina propria 
(Kurimoto, Murayama et al. 1999, Soja, Grzanka et al. 2009). However, 20 MHz 
probes were used in the majority of the studies performed and satisfactory results could 
generally be obtained in terms of submucosal thickness (second layer, L2). 
• Specific regions of the bronchial tree cannot be reached with this technique, such as the 
upper lobes of the lungs. In general, the limiting factor is represented by the bending 
ability of the bronchoscope.  
• Only a small area of the lung can be visualized at a time (Omori, Takiguchi et al. 
2002). 
• The latex balloon itself represents a source of different problems: first, when inflated, 
the balloon might alter the appearance of the inner bronchial layers, causing a 
misinterpretation of the sonograms. The balloon itself appears as a hyperechoic 
structure on ultrasound images and its thickness is generally added to the thickness of 
the first layer (L1) which represents the bronchial mucosa. Furthermore, by 
overdistending the airways, the balloon could alter bronchial morphology and prevent 
an adequate differentiation of echographic layers. EBUS measurements are indeed 
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characterized by different degrees of accuracy for different layers, with the outermost 
being the most accurate (Kurimoto, Murayama et al. 1999, Baba, Sekine et al. 2002). 
Secondly, the maximum diameter of the balloon is 2 cm, which is not enough to allow 
an optimal coupling between the bronchial walls and the probe in larger airways. 
However, in human medicine, this problem is encountered only when trying to image 
the tracheal wall. As inflating the balloon in the trachea also prevents normal 
breathing, the procedure must be completed in a short period of time (Herth, Ernst et 
al. 2003, Wakamatsu, Tsushima et al. 2006).  
• Training and learning curve for this technique are time-consuming and a trained staff is 
required (Bolliger, Mathur et al. 2002, Miyazu, Miyazawa et al. 2002, Ernst, Silvestri 
et al. 2003, Sheski and Mathur 2008, Anantham, Koh et al. 2009, Haas, Vachani et al. 
2010, Medford 2010). 
• EBUS alone is not diagnostic for any lung disease (Kurimoto, Murayama et al. 2002).  
 
Lung function 
Lung function is often evaluated in human studies to indirectly assess pulmonary remodeling.  
Spirometry is the most used technique for lung function assessment in man; it is based on air 
volume and flow generated during maximal expiration (from total lung capacity to residual 
volume). The forced expiratory volume in 1 second (FEV1) corresponds to the amount of air 
that can be expelled during the first second of maximal expiration. It is a commonly employed 
parameter for evaluating airway obstruction. A consistent correlation of FEV1 with airway 
wall thickness was shown (Niimi, Matsumoto et al. 2000, Hoshino, Matsuoka et al. 2010). A 
correlation has been also demonstrated between residual volume and airway wall thickness or 
lumen area, suggesting that airway wall thickening and subsequent lumen obstruction result in 
air trapping in asthmatic subjects (Kosciuch, Krenke et al. 2009). Lung function also correlates 
with AHR and airway inflammation in some but not all studies (de Jong, Muller et al. 2005). 
These contrasting results may be partly due to the fact that pulmonary remodeling affects to a 
greater extent smaller airways, while spirometry mainly reflects large airways impaired 
function (Johnson and Hamid 2012, van den Berge, ten Hacken et al. 2013). Impulse 
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oscillometry has been suggested as a better tool to investigate small airway function (Pisi, 
Tzani et al. 2013). Lastly, the measure of airway distensibility (the change in anatomic dead 
space with lung volume) has been proposed as a physiological variable correlated to airway 
remodeling in asthmatic subjects (Ward, Johns et al. 2001). 
 
Highlights and unanswered questions 
Histology is the gold-standard technique to assess airway remodeling. Among the several 
structures involved in asthma pathophysiology, the ASM is of particular interest due to its 
crucial role in bronchoconstriction. Measuring the ASM mass in central and peripheral airway 
would provide data of paramount importance concerning disease pathophysiology or 
prognosis (James, Bai et al. 2009, Elliot, Jones et al. 2015, Girodet, Allard et al. 2015). 
However, tissue sample harvesting in vivo, especially from the peripheral lung regions, 
represents a real challenge in respiratory research and it is rarely performed. On the other 
hand, endobronchial biopsies produce partial and non-full-thickness samples of the bronchial 
wall, which lack a standardized and validated method for ASM quantification. Lung function 
and imaging techniques have been used to estimate peripheral remodeling, but they cannot 
specifically differentiate the several components of the bronchial wall. Endobronchial 
ultrasound may provide interesting information on central bronchial remodeling, but the 
studies performed until now on human patients have limits. Further work is required to 
establish the validity of this technique for the estimation of ASM remodeling. 
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Reversibility of asthma and available treatments 
 
Several epidemiological studies have demonstrated that asthma remission may occur in 
affected children. Specifically, in about two thirds of children diagnosed with asthma, the 
disease “quietens down” by puberty, and only one third of these patients who were asthma-
free at puberty have asthma symptoms in their mid-twenties (Brewczynski and Brodziak 
2015). On the contrary, adult-onset asthma is unanimously considered a chronic disease, 
“incurable” in most cases, although clinical symptoms of airway obstruction can be well 
managed by means of appropriate pharmacological treatments in most cases (Chanez, Wenzel 
et al. 2007).  Asthma remission rates of 0.6% to 2% per year have been reported (Ronmark, 
Jonsson et al. 1999, Holm, Omenaas et al. 2007), but residual airway obstruction and 
hyperresponsiveness are maintained even after years of clinical remission (Boulet, Turcotte et 
al. 1994), probably mirroring the incomplete reversibility of airway remodeling and 
inflammation (Broekema, Volbeda et al. 2010, Broekema, Timens et al. 2011).  
Current GINA (Global Initiative for Asthma) guidelines state that asthma treatments should be 
administered based on the clinical needs of the patients (GINA, 2015). Short-term asthma 
control has two recognized goals: to control the clinical symptoms and to decrease the risk 
factors for adverse outcomes; both of them aiming at reducing the exacerbation rate in the 
long-term. Of note, the assessed outcomes in the short-term are limited to patient perception of 
the disease and supported by lung function data, with lung inflammation and remodeling being 
rarely evaluated, if at all. At present, indeed, neither sputum nor FeNO-guided treatment is 
recommended for the general asthma population (Chung, Wenzel et al. 2014, 2015).  
Asthma treatments are thus effective in treating acute airway narrowing and possibly reducing 
inflammation. However, whether they can reverse bronchial remodeling or not – or to which 
extent – is often disregarded or considered a secondary outcome. Structural changes at the 
bronchial level are likely to be early events in the pathogenesis of asthma, as supported by the 
increased ASM mass observed in newly diagnosed asthmatic children (Regamey, Ochs et al. 
2008). It has also been postulated that ASM remodeling might precede asthma presentation. 
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This concept is known as “premodeling” (Holgate, Holloway et al. 2004), and has been 
strengthened by the finding that preschool wheezers who developed asthma later in life had 
increased ASM mass compared to those who did not (O'Reilly, Ullmann et al. 2013). The 
early nature of bronchial remodeling in asthma suggests that most structural changes are 
already well-established when the treatment is started, which might prevent a thorough 
reversal. The ability of currently employed asthma treatments to reverse airway remodeling is 
largely unknown. Identifying therapeutic strategies able to maximize remodeling reversal 
could bring important prognostic advantages. For this reason, it is expected that modulation of 
airway remodeling will become an important endpoint for long-term asthma control in the 
near future (Sandstrom 2010).  
Two key issues need to be considered when assessing the influence of therapeutic 
interventions on airway remodeling: first, whether the process of interest is considered to be 
reversible at all (i.e.: in severe asthma, disruption of alveolar walls attaching to bronchi may 
occur, which is irreversible and which irreversibly alters the mechanical balance between 
bronchial dimension and lung volume), and second, whether the processes are overall 
beneficial or adverse for the patient (taking into account the fact that the same process, a 
reduction of collagen deposition for instance, might have different outcomes when it occurs 
within the lamina propria, within the smooth muscle layer, or even in the bronchial adventitia). 
Furthermore, as hard as it may be, pros and cons of any intervention aiming at specific airway 
remodeling reversal should also possibly be considered in term of both their short- and long-
term effects.   
Airway smooth muscle excessive contraction has long been recognized as the most important 
determinant of airway obstruction in asthma (Huber and Koessler 1922, Lambert, Wiggs et al. 
1993, Oliver, Fabry et al. 2007), and most of the initial treatments for asthmatic patients were 
intended to target this abnormal contractile response. In parallel to the discovery of airway 
inflammation as a hallmark of asthma, antinflammatory treatments began to be used, allowing 
an adequate control of the disease even in the absence of bronchodilators. This finding shifted 
the attention from the ASM to the immune response as the major trigger/initiator of asthma. A 
new «era» began during which the asthmatic inflammatory response has been extensively 
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studied, as well as the environmental causes associated with it, and several treatments have 
been developed to specifically antagonize the effect of the main inflammatory mediators in 
asthma. Despite the promising results obtained in rodent animal models, most of these 
treatments proved to be ineffective in asthmatic patients (summarized in Table 5), and 
corticosteroids remain the most efficacious and safest class of drug to be used for asthma 
control. Although clinical improvement of the disease usually begins within days of initiating 
treatment, the full benefit may only be evident after 3 or 4 months. It is recognized that in 
severe and chronically under-treated disease, it may take even longer (GINA, 2015). 
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Table 5. Efficacy of asthma treatments on rodent animal models and asthmatic patients. 
 Rodents Man 
Antinflammatory agents   
   Inhaled corticosteroids ✓ ✓ 
   Systemic corticosteroids ✓ ✓ 
   Anti-leukotrienes ✓ (✓),* 
   Cromones ✓ (✓),* 
   Non-steroidal antinflammatory drugs  - 
Bronchodilators   
   β-adrenergic agents (✓) * 
   Anticholinergic agents ✓ (✓),* 
Phosphodiesterase (PDE) inhibitors   
   Methylxanthine inhibitors ✓ (✓),* 
   Selective PDE inhibitors ✓ - 
Antioxidants ✓ (✓),* 
Expectorant, mucolytic and mucokinetic agents (✓) - 
Immunomodulators ✓ (✓) 
Antibiotics   
   Macrolides ✓ (✓),* 
Cellular therapy   
   Adoptive transfer of stem cells ✓ ? 
✓: treatment with demonstrated efficacy in that species. (✓): treatment whose efficacy in that 
species is supported by a low level of scientific evidence. - : treatment with no demonstrated 
efficacy in that species. ? : treatment with unknown efficacy in that species. * : treatment 
suggested as possible add-on therapy in selected cases. Modified from Bullone and Lavoie 
(2015). 
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NON-PHARMACOLOGICAL TREATMENTS 
In the context of this thesis, it is appropriate to mention that some asthma phenotypes largely 
benefit also from non-pharmacological treatment. Non-pharmacological treatments available 
for asthmatics are of two types: one consisting in environmental changes, commonly referred 
to as antigen or allergen avoidance, and one intended to surgically resolve bronchospasm by 
ASM ablation using bronchial thermoplasty, a recently developed technique. 
 
Antigen avoidance 
The level of evidence supporting antigen avoidance strategies for asthma control varies 
according to the level of evidence linking specific antigens to the asthmatic response. That is, 
antigen avoidance is presently accepted as the cornerstone of disease control only in cases of 
work-related asthma (GINA, 2015). As a matter of fact, antigen avoidance can hardly be 
accomplished in everyday life, possibly explaining the low success rate of this approach 
(Platts-Mills 2008). Few studies adequately exploring this treatment strategy in non-work-
related asthma have been performed. Among them, the most comprehensive studied a group of 
asthmatic children housed for 3 months at high altitude (1750 m) where environmental 
antigens, particularly dust mite, are reduced to a minimum for most of the year. They showed 
a significant reduction of AHR, eosinophilic sputum inflammation, and fractional exhaled NO 
in allergic asthmatic children (Boner, Peroni et al. 1993, Sensi, Piacentini et al. 1994, 
Piacentini, Martinati et al. 1996). A very limited number of studies have involved adult 
asthmatic patients, demonstrating overall a significant effect of antigen avoidance on bronchial 
hyperresponsiveness (Platts-Mills, Tovey et al. 1982, Walshaw and Evans 1986, Dorward, 
Colloff et al. 1988, Platts-Mills 2008). There is scarce information concerning the severity of 
airway inflammation and remodeling during non-pharmacologically induced clinical remission 
of asthma. A significant increase in reticular basement membrane thickness was reported in a 
group of young adults in clinical remission of asthma compared with control subjects (van den 
Toorn, Overbeek et al. 2001). However, that group of patients had only been symptom-free 
and off medication for 1 year at the time of assessment and still had significant ongoing 
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airway inflammation. When remodeling and inflammation were assessed in a group of patients 
with occupational asthma 14 years (on average) after cessation of the exposure, the only 
residual differences found in control patients were the thickness of the basal membrane and of 
the ECM layer between the bronchial epithelium and smooth muscle (Sumi, Foley et al. 2007). 
Of note, although no difference was observed for the ASM mass between the two groups, the 
mean ratio of ASM area to total biopsy area was twice as high in OA as in control subjects. In 
these studies, corticosteroid treatment was administered at the time of diagnosis but then 
discontinued. In this regard, their findings are supported by the results of another study 
comparing inflammation and remodeling in asthmatic patients (on and off corticosteroids) and 
asthmatics in complete or clinical remission (based on absence or presence of bronchial 
hyperresponsiveness). It was observed that the thickness of the basal membrane was reduced 
only in the group of asthmatics on inhaled corticosteroid treatment (Broekema, Timens et al. 
2011), despite similar levels of sputum and tissue inflammation. Overall, these studies suggest 
that bronchial remodeling in adult asthma is incompletely reversible, and that some aspects are 
strictly linked to pharmacological treatment. As for ASM remodeling, few studies have 
investigated the effect of treatments on ASM mass and there is limited information on its 
reversibility in human asthma. 
Work-related asthma provides an ideal model to study antigen avoidance (Sumi, Foley et al. 
2007). It also underlines the complex and heterogeneous nature of this disease. In fact, even if 
in these cases the sensitizing agent is generally recognized, the immune response varies 
depending on antigen size, with only high molecular weight antigens producing an allergic 
response. It is still uncertain whether low molecular weight irritants also act via IgE-mediated 
mechanisms, despite a Th-2 biased inflammatory response (Malo, Tarlo et al. 2015). Overall, 
antigen avoidance significantly improves the control of work-related asthma cases (GINA, 
2015). A remission rate (defined as the absence of residual AHR) up to 72% has been reported 
after 5 years of antigen avoidance in work-related asthma cases (Pisati, Baruffini et al. 2007), 
which is astonishingly higher compared to that reported in non-work related asthma 
(Ronmark, Jonsson et al. 1999, Holm, Omenaas et al. 2007). Furthermore, the prevalence of 
residual AHR in work-related asthmatics in remission seems to diminish over time after 
antigen exposure is stopped (Mapp, Corona et al. 1988, Paggiaro, Vagaggini et al. 1993, 
 72 
Lemiere, Cartier et al. 1996, Pisati, Baruffini et al. 2007), underlining the central role of 
antigen exposure in disease pathophysiology. Nevertheless, displaying mild instead of severe 
asthma symptoms at presentation seems to be the only clinical predictor of disease remission 
in these subjects (Bronnimann and Burrows 1986, Panhuysen, Vonk et al. 1997, Ronmark, 
Jonsson et al. 1999, Holm, Omenaas et al. 2007, Pisati, Baruffini et al. 2007). A window of a 
few months (<6) of exposure after disease appearance is considered the maximum exposure 
time still allowing complete disease remission to be attained (Pisati, Baruffini et al. 2007), 
suggesting that the presence of chronic inflammatory and remodeling processes lead to 
irreversible airway changes. Indeed, despite airway remodeling and lumen inflammation being 
reduced in asthmatic subjects after long-term antigen avoidance, their bronchial wall 
inflammation is unchanged and bronchial remodeling is still increased compared to healthy 
controls (Saetta, Maestrelli et al. 1992, Saetta, Maestrelli et al. 1995, Sumi, Foley et al. 2007). 
 
Bronchial thermoplasty  
Bronchial thermoplasty refers to the endoscopic-guided application of heat (65°C, in form of 
radiofrequency energy) directly on the central airways of affected patients. Only airways >3 
mm in diameter can be treated (Cox, Miller et al. 2004). Briefly, a catheter made of an 
expandable basket with four electrode arms is passed through the working channel of the 
endoscope and, once in the bronchi, it is opened to make contact with the airway wall 
circumferentially and 10 second-cycles of heat are applied throughout the central bronchial 
tree (Duhamel and Hales 2010).  
Primum non nocere, secundum purgare. The observation that smooth muscle is the only 
structure of the airway wall displaying long-term heat-sensitivity (Danek, Lombard et al. 
2004, Miller, Cox et al. 2005, Pavord, Cox et al. 2007) provided the first evidence of the very 
specific action of bronchial thermoplasty on the ASM, whose role in the airways, if any, 
remains unknown (Cox, Miller et al. 2004). Then, the acknowledgment that central airways 
contribute to airflow obstruction during disease exacerbations provided the rationale for 
attempting this treatment strategy in asthma. The recent observation that large (>4 mm in 
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diameter) but not small ASM mass is increased in cases of fatal compared to non-fatal asthma 
(James, Elliot et al. 2012) further supports this approach.  
After promising clinical trials, bronchial thermoplasty was approved by the U.S. Food and 
Drug Administration in 2010 as a treatment for selected severe asthmatic patients. Since then, 
there has been accumulating evidence supporting a positive effect of bronchial thermoplasty in 
term of disease control (decreased number of exacerbations (Castro, Rubin et al. 2010, Chakir, 
Haj-Salem et al. 2015)). Nevertheless, the dose of pharmacological treatment needed by the 
patients to control the clinical signs of asthma remains unchanged after bronchial thermoplasty 
(Pavord, Thomson et al. 2013). In pathophysiological terms, a significant decrease of AHR 
after bronchial thermoplasty has been documented only in dogs (Brown, Wizeman et al. 2005, 
Brown, Wizeman et al. 2007). Independently of hyperresponsiveness, the FEV1 (forced 
expiratory volume in 1 second) remains often unchanged after bronchial thermoplasty in 
severe asthmatics (Pavord, Thomson et al. 2013, Denner, Doeing et al. 2015), questioning the 
overall effect on airflow obstruction of this technique. Very few data are currently available 
also concerning the effect of bronchial thermoplasty on airway remodeling and inflammation. 
Evidence exists supporting the ability of bronchial thermoplasty at reversing airway lumen 
inflammation (Denner, Doeing et al. 2015) up to six weeks after the procedure. As for 
remodeling, the first 2 studies showing a decreased ASM mass after bronchial thermoplasty 
sampled exactly the same bronchial carinas on multiple occasions (Pretolani, Dombret et al. 
2014, Denner, Doeing et al. 2015), and one of them reported a great ASM reduction even at 
the non-treated sites (Pretolani, Dombret et al. 2014), raising concerns on whether the 
observed effect was real rather than a technical artifact (Bonta, d'Hooghe et al. 2015). 
However, a significant but smaller effect was also observed in a recent study sampling 
different carinae before and after the procedure, confirming the effectiveness of bronchial 
thermoplasty at decreasing ASM and further reporting a reduction of subepithelial ECM 
deposition (Chakir, Haj-Salem et al. 2015) lasting for up to 8 weeks.  
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PHARMACOLOGICAL TREATMENTS 
Pharmacological treatment of asthma is based on a 5-step protocol starting with the occasional 
use of inhaled β2-agonists and going up to moderate to high doses of inhaled corticosteroids 
and long-acting β2-agonists, possibly in conjunction with supplementary treatments such as 
oral corticosteroids or other targeted therapies such as anti-IgE, anti-leukotrienes, and long-
acting muscarinic agents (GINA, 2015).  
 
Drug delivery 
Systemic administration 
Systemic administration of a drug can be performed in several ways. The easiest and 
commonest is by far the oral route of administration, with intramuscular and intravenous 
injection being less common and often restricted to hospital use or to drugs that would be 
inactivated into the gastrointestinal tract. Oral administration of β2-agonists has been 
abandoned years ago, and oral corticosteroids are strictly reserved to severely affected patients 
in order to reduce to a minimum the incidence of the side-effects associated with their chronic 
use (Treadwell, Sever et al. 1964, McAllen 1970, Ryall, Sillence et al. 2006).  
 
Inhalation 
Delivery of drugs through inhalation (oral or nasal) is an attractive alternative to systemic drug 
delivery, and it is considered the best option for treating lung diseases. Inhalation therapy has 
multiple advantages over systemic drug administration: 
• requires smaller doses than systemic treatment; 
• drug delivery is targeted to the respiratory system for local pulmonary effect; 
• systemic side effects are fewer and less severe.  
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Inhalation therapy seems however to be characterized by a reduced patient adherence to 
treatment compared to oral administration (Cohn 2003), but the lower dosing frequency often 
associated with the oral therapy could have introduced a bias (Rand, Bilderback et al. 2007).  
The effectiveness of an inhalation therapy is dependent on the amount of the medication that 
reaches the intended site of deposition, which, in turn, depends on the physical and chemical 
properties of the drug particles, on the characteristics of the delivery device used, as well as on 
the breathing pattern of the patient. In particular, particle size is the major determinant of the 
site of deposition of the drug in the respiratory tract. Particles larger than 5 μm, also called 
droplets, deposit by impaction in the oropharynx or upper airways, not reaching the lung. 
Particles of 0.5-5 μm in size deposit by sedimentation or diffusion in the most caudal portions 
of the bronchial tree and alveoli, while particles smaller than 0.5 μm are generally exhaled 
(CCADD, 2000). Inhaled particles with an aerodynamic particle size <2 μm are considered 
optimal, especially if in monodispersity (Ibrahim, Verma et al. 2015), although an increased 
risk of phagocytosis by alveolar macrophages has been described for particles of this size with 
particular chemical properties (Muralidharan, Malapit et al. 2015).   
 
Corticosteroids  
Corticosteroids are the only drug with proven efficacy at decreasing asthma mortality (Suissa, 
Ernst et al. 2000). Different pathological aspects of asthma, namely AHR, inflammation and 
remodeling, have shown different time courses for improvement as well as different outcomes 
depending on the lung region assessed (central vs peripheral).  
 
Mechanism of action 
Corticosteroids are a class of anti-inflammatory drugs with a very broad spectrum of targets. 
As such, their effect is mediated mainly by their repressive action on transcription factors 
regulating the expression of pro-inflammatory genes, such as NF-Kappa β or AP-1. Activation 
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of anti-inflammatory genes and non-transcriptional effects of corticosteroids are also 
recognized as minor mechanisms of action (Barnes 2006). Of particular interest for asthma, 
corticosteroids can exert non-genomic effects regulating both inflammatory cell activation and 
smooth muscle contractile properties (Sun, Miao et al. 2006, Zhou, Liu et al. 2008, Mendes, 
Rebolledo et al. 2014, Mendes, Cadet et al. 2015).   
 
Side effects 
Despite the safer profile of ICS compared to systemic corticosteroids, adverse effects have 
been reported to occur with long-term administration (Hanania, Chapman et al. 1995, Dahl 
2006, Barnes 2007), particularly in the elderly (Mattishent, Thavarajah et al. 2014).  
 
Effect on inflammation  
Soon after the observation that inflammation was present even in the airway of mild 
asthmatics during periods of disease remission (Djukanovic, Roche et al. 1990), the effect of 
corticosteroid at reducing the number and activation of inflammatory cells was described both 
at the level of central airway walls and conducting airways down to the alveoli, by means of 
endobronchial biopsies and bronchoalveolar lavage, respectively (Djukanovic, Wilson et al. 
1992, Janson-Bjerklie, Fahy et al. 1993, Ward, Pais et al. 2002, de Kluijver, Schrumpf et al. 
2005). Since then, sputum has been validated as an indicator of bronchoalveolar inflammation 
in asthma (Nocker, Out et al. 2000), and studies have confirmed the antinflammatory effect of 
corticosteroids in most, but not all, patients. Many bronchial structural cells have recognized 
immunomodulatory properties. While corticosteroids significantly reduce the expression of 
inflammatory mediators in epithelial cells, fibroblasts, and ASM cells in vitro, their role in 
vivo remains unclearly defined (Yick, Zwinderman et al. 2013). Recently, the rapid-onset 
inhibition of blood flow (vasoconstriction) induced by corticosteroids in the airways of 
asthmatics has also been proposed as a mechanism contributing to the antinflammatory action 
of these drugs (Mendes, Rebolledo et al. 2014). 
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Several studies have demonstrated a reduction of lymphocyte, eosinophils, and neutrophils in 
the epithelium and subepithelial layer in the central airways of asthmatics treated with both 
inhaled and systemic corticosteroids (Chanez, Bourdin et al. 2004). Nevertheless, whether 
they exert significant antinflammatory effects also in the distal lung (small airways and 
parenchyma) is not clear (Martin 2002). One study specifically investigating the effect of a 6-
week treatment with inhaled corticosteroids on peripheral lung inflammation in asthmatics 
reported a significant improvement only in the number of lung eosinophils, while neutrophils 
increased, and the other inflammatory cells remained unvaried (Hauber, Gotfried et al. 2003).  
 
Effect on hyperresponsiveness 
Long-term corticosteroid treatment decreases AHR in asthma (Ward, Pais et al. 2002). 
Nevertheless, whether the asthma-associated decline in lung function is prevented by this class 
of drug remains unsettled (Ernst 2006, Haahtela 2006, Lange, Scharling et al. 2006, Chanoine, 
Dumas et al. 2015), and even well-controlled asthmatics still show airway reactivity to 
abnormally low methacholine concentrations (Yick, Zwinderman et al. 2013). In this regard, a 
2-week period of inhaled fluticasone discontinued 24 h before allergen challenge did not offer 
any additional protection against the asthmatic response in terms of airway responsiveness (or 
sputum eosinophilia) compared with a single dose of the same drug administered immediately 
before allergen challenge (Parameswaran, Inman et al. 2000). The mechanisms by which 
corticosteroids impact AHR are not fully elucidated. Although corticosteroids can reduce 
inflammation, which contributes to AHR, they may also produce direct effects on ASM cells. 
On the other hand, the long-term effect observed of corticosteroids on AHR could be ascribed 
to their ability (demonstrated only in animal models) at reversing, although only partially, 
airway remodeling (Leclere, Lavoie-Lamoureux et al. 2012).  
As mentioned above, corticosteroids may directly affect ASM gene expression in vitro. 
However, whether the clinical benefits provided by corticosteroid therapy in the vast majority 
of asthma patients could result, at least in part, from their direct action on ASM remains an 
open issue that needs to be clarified. The only evidence that this could occur in vivo has been 
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provided by a recent study investigating the effect of a 2-week corticosteroid treatment on 
quantitative gene expression in laser-microdissected smooth muscle from endobronchial 
biopsy samples of mild asthmatics (Yick, Zwinderman et al. 2013). In their study, Yick and 
colleagues have shown for the first time in man that after 2 weeks of oral corticosteroid 
treatment, the expression of 15 genes was altered in central ASM from asthmatic patients. 
They also found that 2 of these genes significantly correlated with AHR. However, the fact 
that both treated and untreated groups were analyzed together, the absence of a healthy control 
group, and of any statistical correction for multiple comparisons slightly reduces the impact of 
this observation. In the same study, myocardin expression was increased after treatment (Yick, 
Zwinderman et al. 2013). Myocardin, a protein involved in the activation of the transcription 
factor SRF (serum response factor), has been associated with the contractile (differentiated) 
phenotype of smooth muscle cells of other tissues (i.e. vessels and intestine). Its 
overexpression in treated asthma patients suggests that corticosteroids could possibly 
modulate ASM phenotype switching in vivo.  
 
Effect on remodeling 
Based on in vitro studies, the effects of corticosteroids on airway remodeling could extend to 
all compartments of the bronchial wall. Nevertheless, in vivo evidence of airway remodeling 
reversal in steroid-treated asthmatic patients is limited by the fact that obtaining endobronchial 
biopsy samples is an invasive procedure whose interpretation is also complicated by the 
unavailability of pre-treatment data in most cases.  
As previously mentioned, whether epithelial hyperplasia and detachment are features of 
asthma or technical artifacts has not been definitely clarified. Nevertheless, epithelial fragility 
and dysfunction is a unanimously recognized trait of asthma (Knight and Holgate 2003). Few 
studies have investigated the effect of corticosteroid treatment on human bronchial epithelial 
structure or function in vivo, reporting an increased proliferation and a restitution of the 
epithelial thickness to normal values (Vignola, Chiappara et al. 2001), joined with a  reduction 
of epithelial cells in BALF (Ward, Pais et al. 2002). Also, a normalization of the ciliated to 
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goblet cell ratio has been reported following inhaled corticosteroid treatment (Laitinen and 
Laitinen 1995). 
Most studies investigating the effect of corticosteroid treatment on airway remodeling have 
focused on changes of the bronchial ECM in endobronchial biopsy samples. It is now 
recognized that long-term high-dose corticosteroids treatment can decrease the basal 
membrane thickness in central asthmatic airways (Trigg, Manolitsas et al. 1994, Laitinen, 
Altraja et al. 1997, Olivieri, Chetta et al. 1997). However, this reversal is not observed in 
patients receiving low-dose treatment for the same amount of time and showing a similar 
clinical improvement (Chetta, Zanini et al. 2003). Whether corticosteroids can also decrease 
the amount of ECM deposition within the lamina propria and to which extent in central and 
peripheral airways is far less settled. Endothelin, a protein involved in the process of lung 
repair and fibrosis, is increased in corticosteroid-naïve asthmatics compared to ICS-treated 
asthmatics and controls (Redington, Springall et al. 1997). It has been reported that 2 weeks of 
oral corticosteroid did not reverse collagen deposition (Chakir, Shannon et al. 2003), while a 
significant decrease was observed after 6 months of inhaled budesonide given at high dosage, 
modulated by tissue MMPs and TIMPs (Hoshino, Takahashi et al. 1999). On the other hand, a 
2-year treatment with low dose corticosteroids was not successful at decreasing collagen 
deposition within the lamina propria (Chakir, Loubaki et al. 2010). Another study reported that 
neither short-term fixed dose nor long-term (< 6 months) treatment with variable doses of 
inhaled steroids significantly altered the collagen content of the tissue (Godfrey, Lorimer et al. 
1995). The synthesis of ECM proteins is stimulated by TGF-β, which is increased in asthmatic 
airways and blood, and respiratory secretions (Halwani, Al-Muhsen et al. 2011). 
Corticosteroid treatment can partly decrease serum and sputum TGF-β expression in the long 
but not in the short-term (Chakir, Shannon et al. 2003, Kai, Nomura et al. 2007, Kawayama, 
Kinoshita et al. 2008, Manuyakorn, Kamchaisatian et al. 2008). Nevertheless, TGF-β levels 
remain higher in asthmatic patients compared to healthy subjects (Manuyakorn, 
Kamchaisatian et al. 2008, Yamaguchi, Niimi et al. 2008). Transforming growth factor-β 
expression within the bronchial wall is not affected by corticosteroid treatment at all 
(Tomkowicz, Kraus-Filarska et al. 2008). Elastin is another ECM component undergoing 
remodeling in asthma. However, corticosteroid treatment does not affect elastin content of the 
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tissue in large airways (Godfrey, Lorimer et al. 1995, Bousquet, Lacoste et al. 1996). Overall, 
these findings suggest that airway fibrosis and ECM deposition can be reversed by long-term 
corticosteroid treatment, but this effect is not mediated by a decrease of TGF-β expression in 
the airways.  
A single study has investigated the efficacy of corticosteroids at reversing established ASM 
remodeling in asthma (Bergeron, Hauber et al. 2005), showing that 6 weeks of treatment 
reduced the density of smooth muscle alpha-actin (SMA-α) peripherally but not centrally. No 
studies are currently available investigating by which mechanism this could have occurred in 
vivo. Corticosteroids appear to inhibit human ASM proliferation in vitro (Stewart, Harris et al. 
1999). However, this response can be blunted when ASM cells are seeded on collagen 
(Bonacci, Schuliga et al. 2006). Asthmatic smooth muscle is hyperproliferative and lies in an 
inflamed, fibrotic and collagen-rich microenvironment, which could inhibit corticosteroid 
responsiveness in terms of remodeling reversal. Whether the synthetic response of ASM cells 
is regulated by corticosteroids in asthmatics is not well established. Dexamethasone and 
fluticasone inhibit SMA-α expression in primary bronchial smooth muscle cells (Goldsmith, 
Hershenson et al. 2007). However, the synthesis of pro-inflammatory ECM proteins by 
asthmatic ASM cells is only partially controlled by corticosteroid therapy in vitro, and whether 
the same responses are attained in vivo is still unclear (Ammit, Burgess et al. 2009). It should 
be noted that ASM cells appear to be characterized by a species-specific response to several 
synthetic stimuli and treatments (Ammit, Burgess et al. 2009), implying that caution must be 
taken when translating results obtained in animal models to human asthma. No data are 
currently available on the effect of corticosteroids on ASM hypertrophy in human asthma. 
Studies in animal models of asthma have shown that corticosteroid therapy only partially 
reverses established ASM hypertrophy (Leclere, Lavoie-Lamoureux et al. 2012, Alrifai, Marsh 
et al. 2014). Corticosteroids could also be effective at inhibiting ASM cell migration in 
asthmatic airways, although currently available data are conflicting (Hoshino, Takahashi et al. 
1999, Kelly, O'Connor et al. 2010). 
Vasodilatation, increased vascular permeability, and angiogenesis are the three aspects of 
vascular remodeling in asthma. They all appear to be reversible with corticosteroid treatment, 
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particularly when administered at high doses (Chetta, Zanini et al. 2007, Feltis, Wignarajah et 
al. 2007).  
 
β2-adrenergic bronchodilators 
Adrenergic bronchodilators were first used for asthma more than 100 years ago (Tattersfield 
2006). They rapidly reverse bronchospasm, but they also are advocated some antinflammatory 
and antiremodeling properties, even when administered as monotherapy (Orsida, Ward et al. 
2001).  
 
Mechanism of action 
Many structural and inflammatory cells express β2-adrenergic receptors, suggesting that the 
physiologic role of catecholamines extends far beyond the regulation of the acute stress 
response, and might exert relevant immunomodulatory actions. In asthma, β2-adrenergic 
bronchodilators act mainly by promoting ASM relaxation, which dilates the airways and 
reverses airflow obstruction. In addition, they can inhibit cholinergic transmission, reduce 
vascular permeability, and increase mucociliary clearance, further contributing to airway 
patency (Tattersfield 2006).  
 
Side effects 
The administration of β2-adrenergic agonists might cause rapid and delayed side effects, due to 
different mechanisms. The rapidly occurring side effects appear concomitantly with the 
pharmacological effect of the drug, and are driven by the same mechanism of action; they are 
mainly represented by tachycardia and increased sweating. However, recently synthetized 
drugs administered by inhalation are characterized by an improved safety profile. The 
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continuous administration of β2-adrenergic agonists can also induce tachyphylaxis, or 
desensitization, which decreases the clinical efficacy of these drugs.  
Based on the results of a meta-analysis including more than 100 trials, regular beta agonists 
use is now discouraged (GINA, 2015) as it worsens asthma control and increases mortality 
(Levenson 2008). These drugs induce vasodilation as well as bronchodilation, which could 
facilitate the influx of inflammatory cells into the airways or participate in airway wall 
thickening. Two unresolved and intriguing questions are whether all long-acting β2-agonists 
confer the same risk and whether they have a dose-related safety profile (Dissanayake 2015).  
 
Effect on hyperresponsiveness 
Despite effectively bronchodilating the airways even when administered for extended periods 
of time (especially partial agonists such as salmeterol), β2-agonists do not improve airway 
responsiveness, which instead appears to increase (Cheung, Timmers et al. 1992, Boulet, 
Cartier et al. 1998).  
 
Effect on inflammation  
While effective at suppressing symptoms, β2-agonists given as a monotherapy could mask 
underlying deterioration of airway inflammation (Knight, Mak et al. 2015). Although in vitro 
studies have shown antinflammatory effects of β2-agonists, in vivo evidence is scarce and 
appears to be limited to the neutrophilic component of inflammation in some studies (Jeffery, 
Venge et al. 2002, Wallin, Pourazar et al. 2004, Maris, de Vos et al. 2005) but not in all 
studies (Kraft, Wenzel et al. 1997, Altraja, Laitinen et al. 1999, Roberts, Bradding et al. 1999, 
Tagaya, Kondo et al. 2015). While not reducing their number, β2-agonists are effective 
stabilizers of mast cells. Their effect is however limited in terms of time as tolerance occurs 
more readily in these cells compared to what is reported for smooth muscle relaxation. This 
could lead to a situation in which β2-agonists fail to prevent the release of inflammatory 
mediators from mast cells while still effectively controlling bronchospasm (Peachell 2006).  
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Effect on remodeling  
Limited in vivo data are available on the effect of β2-agonists alone on airway remodeling in 
human asthma. Their unsafe therapeutic profile when used as monotherapies now prevents 
such information from being obtained. Although restricted to a few studies, there is evidence 
that β2-agonists could modulate remodeling of the bronchial ECM in asthma when 
administered for extended period of time. Twelve weeks of treatment with salbutamol reduced 
the tenascin but not the collagen content of the bronchial wall in biopsies from mild asthmatic 
patients (Altraja, Laitinen et al. 1999), while only six weeks of salmeterol treatment had no 
effect on the underlying remodeling processes despite improving the clinical indices of the 
disease (Roberts, Bradding et al. 1999). β2-agonist administration improves the mucociliary 
clearance in asthmatics (Daviskas, Anderson et al. 2005). The recent and somehow surprising 
finding that bronchoconstriction itself can induce remodeling in asthmatic patients (Grainge, 
Lau et al. 2011) raises legitimate questions as to whether the opposite occurs as well, that is, 
whether bronchodilation per se could reverse airway remodeling.  
Data obtained from animal models of asthma suggest a possible implication of β2-agonists in 
airway remodeling regulation at multiple sites of the bronchial wall. In non-challenged mice, 
salbutamol stimulated epithelial cell proliferation and thickening in a dose and time dependent 
manner (Tamaoki, Tagaya et al. 2004), and appeared to induce goblet cell hyperplasia 
(Kamachi, Munakata et al. 2001, Riesenfeld, Sullivan et al. 2010). A large body of evidence 
obtained in vitro indicates that β2-agonists do inhibit ASM migration and proliferation, two 
processes strongly linked to airway remodeling, while their effect on ASM synthetic activity is 
still debated (Hirst, Martin et al. 2004, Ammit, Burgess et al. 2009). The synthesis of pro-
inflammatory mediators and of ECM proteins by ASM cells can be regulated by different 
mechanisms. Also, the composition of the ECM where ASM cells lie is thought to affect their 
proliferative and synthetic properties (Altraja, Laitinen et al. 1999, Hirst, Twort et al. 2000, 
Lambers, Qi et al. 2014). Whether β2-agonists are able to modulate ASM hypertrophy or 
phenotype switching is not established at this time.  
 
 84 
Combinations  
Asthma treatment guidelines propose combination therapy with inhaled corticosteroids (ICS) 
and bronchodilators (long acting β2-agonists, LABA) as the treatment of choice for moderate 
to severe disease when patients do not respond to ICS treatment alone at low-to-medium dose 
(GINA, 2015). Several trials have demonstrated that adding a LABA is more effective in 
terms of exacerbation rate and lung function improvement compared to doubling the dose of 
ICS in adult asthmatics (Greening, Ind et al. 1994, Woolcock, Lundback et al. 1996), although 
the same does not appear to be true for 4-fold increases in ICS dose (Pauwels, Lofdahl et al. 
1997). The rationale of adding a LABA instead of increasing ICS dose in asthma treatment is 
based on the following observations (reviewed by (Barnes 2002)): 
• ICS are characterized by a relatively flat dose/response curve, indicating that most of 
the effect of these drugs is obtained at lower doses; 
• inhaled β2-agonists are the most effective bronchodilators, and asthma is a disease 
characterized by the presence of bronchospasm; 
• β2-agonists exert some non-bronchodilator effects particularly interesting for asthma 
treatment, such as their ability to stabilize mast cell and inhibit plasma exudation; 
• a synergistic interaction existing between β2-agonists and corticosteroids at the 
receptor and transcriptional level, with corticosteroids preventing the loss of function 
(tachyphylaxis, desensitization) of β2-agonists with chronic use, whereas β2-agonists 
may potentiate the local anti-inflammatory action of corticosteroids. 
Over the years, β2-agonists have been shown to be more effective than muscarinic agents as 
add-on treatment to ICS in asthma (Chauhan and Ducharme 2014). As briefly summarized 
above, β2-agonists affect different aspects of the pathophysiology of asthma than 
corticosteroids and for most patients both treatments are needed to fully control symptoms. 
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Effect on hyperresponsiveness and inflammation 
The combination of ICS/LABA provides better control of lung function and AHR compared to 
either ICS or LABA alone (Lundback, Ronmark et al. 2006). Clinical studies also suggest a 
better control of inflammation with combination therapy compared to single ICS or LABA 
treatment (Li, Ward et al. 1999, Walters, Bjermer et al. 2000, Wallin, Sue-Chu et al. 2003, 
Tagaya, Kondo et al. 2015), supported by in vitro data. The combinations of ICS/LABA also 
show a more rapid onset of action compared to ICS alone in term of control of asthma 
symptoms, airflow limitation, airway inflammation, and AHR (Matsunaga, Kawabata et al. 
2013). Nevertheless, the paucity of studies comparing the same dose of ICS in the presence or 
absence of LABA does not permit to draw definitive conclusions on the specific advantage of 
adding a LABA to the ICS therapy.  New, extra-fine formulations of several ICS/LABA 
combination therapies appear to significantly improve peripheral airway function and 
inflammation in asthmatics (Lipworth 2013, Scichilone, Spatafora et al. 2013).  
 
Effect on remodeling 
Very little information is available concerning the effect of ICS/LABA combination on airway 
remodeling in asthma, especially in comparison to ICS monotherapy. Given their superiority 
at controlling asthma symptoms and exacerbation rate compared to ICS treatment alone, it is 
legitimate to wonder whether it is caused solely by a better control of the underlying 
inflammation or whether an enhanced degree of remodeling reversal is involved. It would be 
of interest to determine whether such improved remodeling reversal, if any, occurs before, 
concurrently, or after the observed decrease of inflammation in the central airways and 
whether the same effect is also observable in small peripheral airways.  
When used as add-on treatment to moderate doses of ICS in severe asthmatics, salmeterol 
significantly reduced the submucosal vascularization compared to increased doses of ICS or to 
placebo in central airways (Orsida, Ward et al. 2001). Another study has reported a decreased 
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expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR1 in 
endobronchial biopsy samples of asthmatics after 6 months of budesonide/formoterol 
treatment (Wang, Liu et al. 2008). In the same study, asthmatic patients showed as well 
reduced ASM mass and thickness, quantity of submucosal gland, fibrosis, and vascularization 
of their bronchial wall. In term of ASM mass, another study reported a protective role for the 
combination of budesonide/formoterol during antigen challenge in asthmatics. The 
combination prevented ASM remodeling and myofibroblast accumulation within the 
submucosa compared to both placebo and budesonide pretreatment alone (Kelly, O'Connor et 
al. 2010). Briefly, the in vitro data support an additive/synergistic role for ICS/LABA 
combinations at reversing asthma-associated inflammation and remodeling, both at the ECM 
and ASM level (Howarth, Knox et al. 2004, Todorova, Gurcan et al. 2006, Dekkers, Pehlic et 
al. 2012). 
 
Highlights and unanswered questions 
Pharmacological treatment is the best therapeutic option in asthma. The combinations of 
ICS/LABA represent the most advantageous treatment choice for patients not responding to 
ICS monotherapy in term of disease control (exacerbation rate and patient clinical perception 
of the disease), lung function improvement, and safety. Whether the enhanced efficacy of 
ICS/LABA compared to ICS alone is related to a better control of airway inflammation, 
remodeling, or to the ability to reach more peripheral bronchi remains to be established. 
Intuitively, adding a bronchodilator to ICS treatment would promote ICS deposition more 
distally within the bronchial tree. However, recent data point out that small airway dysfunction 
occurs in these patients despite treatment up to step 4 (medium-to-high dose of ICS/LABA) of 
current asthma guidelines (Anderson, Zajda et al. 2012), questioning whether these 
formulations can effectively reach the distal lung. Also, bronchial thermoplasty reduces 
exacerbation rate as well as remodeling and inflammation of the central airways but the same 
dose of pharmacological treatment is needed to maintain asthma control afterwards, 
suggesting that the bull’s eye of the disease lies in the “silent” zone of the lung. 
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In this perspective, new extra-fine drug formulations have been serendipitously discovered and 
found to improve penetration to the most peripheral portion of the lung (Zeidler and Corren 
2004). The main challenge is now to test their efficacy (more precisely: their superiority) at 
that level in terms of hyperresponsiveness, inflammation, and/or remodeling. As small 
peripheral airways cannot be sampled easily, a large multi-centric study has recently started 
with the aim of identifying specific and sensible markers of peripheral airway function 
(Postma, Brightling et al. 2015). It is however hard to believe that peripheral airway wall 
inflammation and remodeling can readily be assessed indirectly. There is an unmet need of 
reliable models for studying asthma remodeling and its reversal in response to treatment.  
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Equine asthma  
 
Approximately 10 to 20% of adult horses living in temperate climates develop a respiratory 
obstructive asthma-like condition (Hotchkiss, Reid et al. 2007) known under different names, 
the most recent being equine asthma (Lavoie 2015).Previously, the same disease was known 
as heaves, COPD (chronic airway obstruction), or RAO (recurrent airway obstruction). 
SPAOPD (summer-pasture associated obstructive airway disease) is the summer variant of 
heaves, while IAD (inflammatory airway disease) is its milder form. Figure 10 provides an 
exhaustive scheme of the current classification of these conditions. The severe form of the 
disease is typically associated with recurrent episodes of respiratory distress at rest, 
bronchoalveolar lavage neutrophilia and peripheral airway remodeling, and it is an accepted 
model for human asthma (Leclere, Lavoie-Lamoureux et al. 2011, Boivin, Vargas et al. 2014, 
Matusovsky, Kachmar et al. 2015).  
 
 
Figure 10. Equine asthma. IAD: inflammatory airway disease, RAO: recurrent airway 
obstruction, SPAOPD: summer-pasture associated obstructive airway disease. 
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Rationale for using the equine model 
The need of animal models of asthma is undiscussed. Rodent models have played, and still 
play, a crucial role for discovering genetic variations or cellular pathways involved in disease 
development and regulation. They are an irreplaceable tool in mechanistic molecular studies. 
Nevertheless, rodent models have proven unreliable when assessing the efficacy of asthma 
therapies, possibly because of the non-spontaneous and acute (days to months) nature of 
inflammation and remodeling compared to humans. In this perspective, equine asthma 
(particularly its severe form, named heaves) represents a unique translational model for the 
disease.  
 
Similarities between equine and human asthma  
Severe equine and human asthma share many pathophysiological and clinical similarities. 
Both diseases are characterized by the presence of bronchospasm, inflammation and 
remodeling of the lung (Leclere, Lavoie-Lamoureux et al. 2011).  
Bronchospasm –The main determinant of airflow obstruction in asthma is ASM contraction 
(Lambert, Wiggs et al. 1993, Oliver, Fabry et al. 2007). Severely asthmatic horses experience 
moderate to severe episodes of airflow obstruction (disease exacerbations) when exposed to 
barn dust, hay, and straw, during which pulmonary resistance and elastance are increased 
(Leclere, Lavoie-Lamoureux et al. 2011). The rapid improvement in lung function with 
bronchodilators demonstrates the involvement of an exaggerated ASM contraction in equine 
asthma (Derksen, Olszewski et al. 1999, de Lagarde, Rodrigues et al. 2014). Episodes of 
bronchospasm are reversible by treatment both in human and equine asthma. Bronchodilators 
are however short-acting and effective only for immediate relief. Whether asthmatic smooth 
muscle is hyperresponsive or not remains a matter of debate (Chin, Bosse et al. 2012). Tissues 
isolated from horses with heaves are not hyperresponsive (Yu, Wang et al. 1994, Olszewski, 
Robinson et al. 1999, Matusovsky, Kachmar et al. 2015). Nevertheless, smooth muscle 
isolated from intrapulmonary airways (3 to 7 mm in diameter) of asthmatic horses was shown 
to be hypercontractile compared to ASM isolated from healthy animals, at least in term of 
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maximal velocity of shortening (Matusovsky, Kachmar et al. 2015). A recent study of isolated 
bronchial smooth muscle strips supports the equine model as being mechanically 
representative of human asthma (Matusovsky, Kachmar et al. 2015).  
Corticosteroid therapy is the cornerstone of asthma treatment in both species, which 
underlines the inflammatory nature of both diseases. Antigen avoidance strategies are also an 
effective way of controlling both diseases (Leclere, Lavoie-Lamoureux et al. 2012, Malo, 
Tarlo et al. 2015). It is implemented more easily in horses by limiting/avoiding the exposure to 
hay and environmental dust associated with stabling. In human asthma however this approach 
is generally limited to those phenotypes with known environmental triggers, such as work-
related asthma. There is increasing awareness that housing conditions may strongly influence 
the natural history of the disease (Krieger, Jacobs et al. 2010, Keall, Crane et al. 2012).  
Inflammation – Human asthma is a chronic inflammatory disease. Although generally 
described as an allergic and eosinophilic disease, there is growing awareness of the role of 
neutrophil-mediated mechanisms in asthma pathogenesis, particularly in the more severe 
forms of the disease (Chanez, Wenzel et al. 2007). Only about half of asthmatic adults are 
atopic (Anderson 2008) and a Th2-biased response is detectable in only 50% of individuals 
with asthma (Lambrecht and Hammad 2012). Severe equine asthma is also a chronic 
inflammatory condition, characterized by BALF neutrophilia in most cases. Despite the 
absence of eosinophilic inflammation in BALF and bronchial tissues of severely affected 
horses (Leclere, Lavoie-Lamoureux et al. 2011, Dubuc and Lavoie 2014), allergic and IgE-
mediated mechanisms are likely to participate into disease pathogenesis (Kunzle, Gerber et al. 
2007, Tahon, Baselgia et al. 2009), and a Th2-biased response is observed in some but not all 
cases of severe equine asthma (Lavoie, Maghni et al. 2001, Ainsworth, Grunig et al. 2003).   
In man, the neutrophilic asthma phenotype is more frequently associated with the severe or 
work-related forms of the disease, but is observed also in mild asthmatics, and it appears to 
predict a poor response to corticosteroid treatment (Fahy 2009, Monteseirin 2009). It has been 
associated with a Th17-biased response, with a concomitant high expression of the 
chemoattractants IL-8 and TNF-α (Wenzel 2012). Severely asthmatic horses typically present 
with BALF neutrophilia. Also a significant proportion of mild asthmatic horses have a 
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neutrophilic inflammatory phenotype in their BALF, characterized clinically by the presence 
of persistent cough and increased mucus secretions in the airways (Bedenice, Mazan et al. 
2008, Ryhner, Muller et al. 2008, Koblinger, Nicol et al. 2011). Severe equine asthma is 
associated with increased expression of IL-8, IL-4, IL-17, TNF-α, and IL-1β in BALF cells 
(Franchini, Gill et al. 2000, Giguere, Viel et al. 2002, Debrue, Hamilton et al. 2005). 
Bronchoalveolar lavage or sputum neutrophilia has been shown to precede disease 
recrudescence after corticosteroids withdrawal and it is frequently observed during acute 
attacks of asthma (Fahy, Kim et al. 1995, Lamblin, Gosset et al. 1998, Maneechotesuwan, 
Essilfie-Quaye et al. 2007). Neutrophilic asthma is also associated with systemic 
inflammation, both in the human and equine form of the disease (Lavoie-Lamoureux, 
Beauchamp et al. 2012, Lavoie-Lamoureux, Leclere et al. 2012, Wood, Baines et al. 2012). 
Remodeling – As observed in human asthmatic patients, horses affected by severe asthma 
experience repeated episodes of airway obstruction occurring over periods of years or 
sometimes even decades. The first structural abnormality noticed in isolated asthmatic lungs 
was the increased quantity of bronchial smooth muscle (Huber and Koessler 1922). Similarly, 
almost a century later, the first quantitative demonstration of remodeling in severe equine 
asthma concerned bronchial smooth muscle (Herszberg, Ramos-Barbon et al. 2006). Beside 
the smooth muscle mass, many other aspects of remodeling have been studied and there seems 
to be marked overlap between structural alterations observed in human and equine asthma. It 
has to be noted that, until now, most of the studies performed investigating remodeling in 
asthmatic horses have focused on peripheral alterations. Contrarily, endobronchial biopsies 
from central airways have been the samples most commonly studied in human asthma, from 
which has arisen the notion that an increased thickness of the lamina reticularis (basal 
membrane) is a feature of asthma (Roche, Beasley et al. 1989). Neutrophilic asthma is 
however not characterized by thickening of the basement membrane (Fahy 2009).  
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Comparative anatomy and physiology of the lung 
Equine bronchial branching is monopodial: each main bronchus continues almost directly 
towards the lung periphery giving off a series of smaller branches (Nakakuki 1993). Human 
bronchial tree is characterized by a dichotomous branching pattern. That is, each bronchus 
divides in two distal bronchi whose diameter is bigger than half the diameter of the original 
bronchus (Weibel and Gomez 1962). From the trachea to terminal bronchioles, the airway 
branches up to 25 times in man (McLaughlin, Williamson et al. 2008), while the exact number 
of branches of the equine tracheobronchial tree has not been determined (Robinson and 
Furlow 2007). Subjective variations in the pattern of bronchial branching in horses seem to be 
greater than described in other species (O'Callaghan and Sanderson 1982, Olszewski, 
Robinson et al. 1999), possibly also related to the marked anatomical differences among 
several breeds. Horses differ from men and other mammals as they lack respiratory 
bronchioles (Tyler 1983, Robinson and Furlow 2007). Nevertheless, anatomically, equine 
lungs closely resemble human lungs for the adjacent disposition of airways and vessels 
(McLaughlin 1983, Magno 1990, Chen, Klein et al. 1992, Nakakuki 1993), which is not 
observed in the lungs of other animal species used as models for asthma. Indeed, similarly to 
humans but differently from rodents, horses have a double lung circulation (the bronchial one, 
supplying nutrients and oxygen to the cells that constitute the lungs, and the pulmonary one, 
which permits blood oxygenation and carbon dioxide removal). Furthermore, men and horses 
have cartilage in their conducting airways down to 3 to 5 mm in diameter, while rodents lack 
cartilage in their intrapulmonary airways, with the exception of their main-stem bronchi 
(Kennedy, Desrosiers et al. 1978).  
Physiologically, horses differ from men as they have a biphasic breathing strategy, with active 
involvement of the respiratory muscles. The respiratory cycle of the horse occurs around 
rather than above the relaxation volume of their respiratory system, defined as the volume at 
which passive lung recoiling forces (inward) equal passive chest wall expanding forces 
(outward). For this reason, end inspiration and end expiration are active processes (Koterba, 
Kosch et al. 1988), the latter requiring abdominal muscle contraction. In severe asthmatic 
horses, chronically experiencing an increased expiratory effort, the external abdominal oblique 
muscle may become markedly hypertrophic (Figure 11), producing a heave line.  
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Figure 11. Heave line in an asthmatic horse. White arrows point to the heave line on the 
right side of a horse with asthma. 
 
Advantages and disadvantages of the equine model 
Using equine asthma as an animal model for the human disease offers both technical and 
translational advantages. 
The environmental triggers of equine asthma exacerbations are well-known (barn dust, hay, 
and straw antigens). Disease status of asthmatic horses may thus be modulated as required by 
specific research needs, avoiding the use of compounds or antigens not naturally involved in 
disease development and possibly compromising the translational reliability of many animal 
models to human asthma. Thanks to their size, horses are especially well suited for prospective 
studies requiring multiple analyses repeated over time and on the same subjects. Venipuncture 
and blood analysis, but also bronchoscopy and BALF or tissue sample withdrawal can be 
performed repeatedly. Bronchoscopic procedures are performed in standing sedated animals, 
during which mucus, tracheal wash (TW) aspirates, BAL and/or bronchial epithelial brushing 
can be easily obtained. The equine tracheobronchial tree offers more than 40 reachable carinae 
for endobronchial biopsy collection (Robinson and Furlow 2007). Equine lungs also permit 
harvesting large peripheral lung biopsy samples by means of thoracoscopic surgery (Lugo, 
Stick et al. 2002, Relave, David et al. 2008, Relave, David et al. 2010), offering an ideal 
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approach for the study of small airway remodeling and its reversal over time. Furthermore, 
techniques such as spirometry and impulse oscillometry have been validated in horses, which 
permit to study lung function in this species (Couetil, Rosenthal et al. 2000, Van Erck, Votion 
et al. 2006).   
The equine model has unique similarities with human asthma from a pathophysiological point 
of view. First, as equine asthma is a chronic naturally-occurring disease, its pathogenesis is 
more likely to represent what occurs in human asthma compared rodents, in which the disease 
is experimentally induced and spontaneously reversible when chronic challenges are stopped 
(Johnson, Wiley et al. 2004). Second, from a physiological point of view, horses’ lifespan (≈ 
30 years) is undoubtedly more similar to that of man than those of other animal models of 
asthma such as rodents, cats or dogs. Lastly, as previously mentioned, equine and human 
asthma respond to the same pharmacological therapies. Several molecules targeting specific 
intracellular pathways or mediators with a proven role in asthma were effective when tested in 
mice, but not in horses or men, which confirms its suitability as a translational or preclinical 
model. For instance, p38 MAPK inhibitors and PDE4 inhibitors were poorly effective when 
administered as monotherapy in asthmatic horses (Kolm, Zappe et al. 2003, Lavoie, 
Thompson et al. 2008) and men (Lavoie, Pasloske et al. 2006, Chopra, Kanoje et al. 2008, 
Bhavsar, Khorasani et al. 2010), despite showing promising outcomes in rodent models (Ma, 
Medicherla et al. 2008, Kim, Kim et al. 2016).  
Using horses as an asthma model is however not free of drawbacks. A direct consequence of 
their large size is limited accessibility and higher cost for drugs, breeding facilities and 
equipment, procedure materials, and ordinary care. An equine tissue bank has been developed 
by our group for respiratory research (http://www.ertb.ca), which makes this model available 
to researchers lacking the facilities or the technical expertise required for handling these 
animals. Also, few antibodies have been validated for this species (Schnabel et al., 2013) and 
newly-discovered immune system cells may not yet be characterized in horses. The equine 
genome has been entirely sequenced (Wade et al., 2009), which facilitates the identification of 
homologous sequences among different species in order to improve cross-reactivity. Studying 
subjects of different breed, size, age and origin increases intra-group variability and further 
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complicates data analysis and interpretation. However, it provides a heterogeneous population 
similar the human one.  
 
Severe equine asthma model: state of the art  
Few studies have been published in which the asthmatic horse has been used as a model for 
human asthma in order to respond to specific questions concerning disease pathophysiology. 
New data emerging from these studies are however remarkable: the first evidence that 
peripheral ASM and ECM remodeling is at least partly reversible (even when naturally 
occurring and established for many years) by corticosteroid or antigen avoidance treatment 
was obtained in this species (Leclere, Lavoie-Lamoureux et al. 2012, Setlakwe, Lemos et al. 
2014), together with the convincing demonstration of a mechanical difference existing 
between tracheal and bronchial smooth muscle of asthmatic lungs (Matusovsky, Kachmar et 
al. 2015). The inhibitory effect produced by ICS on the expression of the (+)insert isoform of 
SMMHC in the central airways was first demonstrated in asthmatic horses (Boivin, Vargas et 
al. 2014). Evidence of the involvement of SRF and its cofactor myocardin in peripheral ASM 
remodeling has also been reported in this model (Chevigny, Guerin-Montpetit et al. 2015). 
However, asthma exacerbations protracted up to 30 days do not worsen peripheral ASM 
remodeling in asthmatic horses. These findings seem to contradict the enhanced decline in 
lung function observed in asthmatic patients experiencing multiple exacerbations (Bai, Vonk 
et al. 2007, Matsunaga, Hirano et al. 2015). However, the consequences of multiple episodes 
of asthma exacerbation may be greater on ASM remodeling compared to a single protracted 
episode (Chernyavsky, Croisier et al. 2014). The significant correlation observed in severe 
asthmatic horses in remission between the quantity of ECM lying between the epithelium and 
the smooth muscle and pulmonary resistance (Setlakwe, Lemos et al. 2014) suggests that an 
excessive collagen deposition could be the cause of the observed decline in lung function in 
these subjects. There are currently no precise data concerning the presence and reversibility of 
central airway remodeling in severe equine asthma. 
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Histopathologically, equine asthma was described decades ago as a chronic bronchiolitic 
process, eosinophilic in nature early in the course of the disease and successively causing 
peribronchiolar and parenchymal remodeling (Thurlbeck and Lowell 1964). However, at that 
time, the two different phenotypes of equine asthma now recognized (namely mild and severe, 
also known as IAD and RAO) were probably considered as a unique pathological entity. This 
would explain why recent studies focusing solely on the severe form do not recognize the 
presence of eosinophilic infiltrate (Dubuc and Lavoie 2014). Unfortunately, histopathological 
reports describing specific pulmonary findings of mild forms of equine asthma are not 
currently available to validate our explanation.   
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Hypothesis and objectives 
 
Small airway dysfunction is now considered a crucial component of asthma pathophysiology. 
Due to small airway inaccessibility, large airways are commonly sampled to monitor the 
disease response to several interventions. Structural changes of large and small airways in 
asthma are now recognized thanks to post-mortem studies systematically investigating 
remodeling and inflammation along the bronchial tree (Pini, Hamid et al. 2007, Araujo, 
Dolhnikoff et al. 2008, James, Elliot et al. 2012, Elliot, Jones et al. 2015). Nonetheless, it is 
not known whether remodeling and inflammation respond similarly to treatment or not, both 
in term of magnitude and rapidity of the effect. The preferential deposition of inhaled 
therapies in the oropharynx and large airways (Leach, Kuehl et al. 2012, Leach, Kuehl et al. 
2015) argues for a greater effect centrally than peripherally. In this thesis, the severe equine 
asthma model has been used to investigate this aspect of the disease.   
 
General hypotheses 
• Central airways develop structural remodeling in severe equine asthma.  
• Inhaled corticosteroid monotherapy reverses central airway remodeling in a shorter period 
of time compared to peripheral remodeling.  
• The combination of inhaled corticosteroid and long-acting β2-agonist enhances peripheral 
airway remodeling reversal via a greater control of inflammation. 
 
General objectives 
• To develop and validate a protocol that can reliably assess central airway remodeling in 
equine asthma, with a particular interest in ASM mass. 
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• To assess and compare the dynamics of central and peripheral airway remodeling reversal 
following long-term treatment with inhaled corticosteroids in the presence or absence of 
add-on bronchodilator administration (long acting β2-agonist). 
 
  
Methods 
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Experimental design 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Overall experimental design. ICS: inhaled corticosteroids; LABA: long acting β2-
agonists; EBUS: endobronchial ultrasound.  
  
In order to satisfy the objectives of this thesis, a series of studies was initially performed to 
determine the most appropriate approach to assess central airway remodeling in the equine 
model of asthma. Specifically, we investigated the reliability of endobronchial biopsies and 
endobronchial ultrasound (EBUS) for the estimation of ASM mass and evaluating any disease-
induced quantitative alteration. A histological score for endobronchial biopsy samples based 
on morphological and inflammatory parameters was developed and validated, as well as an 
optimized protocol for endobronchial ultrasonography of the equine bronchi in vivo. With 
these tools implemented and available, the main studies were undertaken. They aimed at 
characterizing qualitative and quantitative aspects, as well as the kinetics, of airway 
Main studies
ARTICLE 4:
General hypothesis:
• ICS/LABA combination accelerates airway remodeling 
reversal and reduces airway inflammation to a greater extent 
compared to ICS or LABA monotherapy in asthma.
Objective:
• to describe and compare the effects of inhaled 
corticosteroids, bronchodilators, or their combination  on central 
and peripheral airway remodeling and inflammation.  
Validation studies
ARTICLES 1,2, and 3:
Objectives:
• to investigate the role of EBUS and 
endobronchial biopsy as tools for the evaluation   
of central airway smooth muscle remodeling in  
asthma.
Corollary
ARTICLE 5:
Objectives:
• to investigate the  
effect of meteorological/ 
environmental conditions on  
asthma severity.
Timeline 
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remodeling and inflammation reversibility in response to drugs in equine asthma. Two 
longitudinal studies were performed during which the effects of 3-month of fluticasone 
monotherapy, salmeterol monotherapy, fluticasone/salmeterol combination, or antigen 
avoidance protocol were compared. A further study was then performed as a corollary, in 
order to investigate whether environmental heat could negatively affect lung function in severe 
asthmatic horses. This hypothesis stemmed from the observation made during the main studies 
that several animals experienced a worsening of their clinical signs on days of heatwave.   
 
  
Results 
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Article 1 
 
Technical and physiological determinants of airway smooth muscle mass in 
endobronchial biopsy samples of asthmatic horses 
 
Summary 
This article aims at investigating the exploitability and reliability of endobronchial biopsy 
samples in the assessment of central airway remodeling in equine asthma, with particular 
attention to the ASM component. The data obtained suggest that endobronchial sampling in 
horses is a safe procedure producing good quality samples of bronchial tissue. Endobronchial 
biopsies permit quantitative morphological analysis of the airway epithelium and ECM 
deposition and/or composition. However, the smooth muscle layer can be evaluated only 
qualitatively and not quantitatively in equine endobronchial biopsies. 
 
 
 
 
Contribution 
I participated in study design (70%), experimental procedures and data collection 
(management of horses and treatment administration, 100%; impulse oscillometry 
function testing, 80%; bronchoscopy procedures, 60%; endobronchial biopsy processing, 
100%; morphometric analysis, 100%; statistical analysis, 90%), and preparation of the 
manuscript (90%).  
 
 
 
Article published  
Journal of Applied Physiology (1985) (2014), 117(7):806-15.  
Reprinted with permission. Copyright © 2014 The American Physiological Society. 
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Abstract 
Morphometric analyses of endobronchial biopsies are commonly performed in asthma 
research but little is known concerning the technical and physiological parameters contributing 
to measurement variability. We investigated factors potentially affecting biopsy size, quality, 
and airway smooth muscle (ASM) content in heaves, an asthma-like disease of horses. 
Horses with heaves in clinical exacerbation (n=6) or remission (n=6) from the disease and 6 
controls were studied using a cross-over design. The effect of disease status, age, 
bronchodilation, biopsy forceps type and carina size on total biopsy area (Atot), ASM area 
(AASM), ASM% (AASM/Atot) and histologic quality were assessed. Concordance among 
different measuring techniques was also assessed. 
Compared to other groups, horses with heaves in exacerbation yielded larger biopsies 
(p<0.05). Better quality biopsies were obtained from carinae of small sizes compared to large 
ones (p=0.02), and carina size and forceps type significantly affected the ASM content of the 
biopsy (interaction, p<0.05).  AASM increased with age only in heaves-affected horses (r=0.9, 
p<0.05), and ASM% was negatively correlated with pulmonary resistance at 5 Hz in heaves-
affected horses (r=-0.74, p=0.01), likely because of the increased thickness of the extracellular 
matrix layer in this group (p=0.01).  
In conclusion, disease status, carina thickness, and the forceps used may significantly affect 
biopsy size, quality, and ASM content. Endobronchial biopsies are not appropriate samples for 
ASM quantification in heaves, and studies measuring ASM mass should not be compared 
when measuring techniques differ.  
 
 
Keywords: endobronchial biopsies, asthma, airway smooth muscle, remodeling, horse. 
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Introduction 
Endobronchial biopsies are important diagnostic and research tools in respiratory medicine. At 
present, they are the only means allowing histologic evaluation of central bronchial 
architecture, inflammation, and remodeling in patients with diseases such as asthma, COPD 
and cystic fibrosis. Nevertheless, few studies have systematically investigated factors likely 
affecting biopsy quality, and the measurement of their airway smooth muscle (ASM) content. 
Also, the effect of lung diseases on biopsy morphological parameters has not been addressed, 
although endobronchial biopsies are anecdotally known to be easier to obtain in asthmatic 
patients than in healthy individuals (10). Endobronchial biopsy in man is routinely performed 
under local anesthesia, following patient premedication with bronchodilating agents, 
commonly a β2-selective agonist followed or not by atropine (6). However, biopsy collection 
in the absence of inhaled β-adrenergic agonists has been performed in healthy and asthmatic 
patients without obvious adverse effect (30). No data are available evaluating the effect of 
prior bronchodilator treatment on biopsy size and quality. Also, little information is available 
on the contribution of the biopsy site or the type of forceps used to the quality of the biopsies 
(15).  
Endobronchial biopsies allow the study of ASM quantity and composition, which are 
considered central to airway obstruction in human asthma (5, 18, 19). Indeed, ASM mass is 
increased in small and large airways in asthmatics, likely induced by both cellular hyperplasia 
and hypertrophy (2). However, the lack of correlation between ASM mass in endobronchial 
biopsies and lung function in mild asthmatics (22) and in an asthma-like disease of horses 
(heaves) has been reported (16). Whether this is due to the variable makeup of contractile 
protein in ASM or technical bias due to the biopsy collection or to the measurement method 
used has not been studied.  Interestingly, when ASM mass was evaluated in bronchial biopsies 
of asthmatics as ASM percentage, a significant decrease was reported after antigen challenge. 
This finding was completely reversed by pretreating patients with a β2-adrenergic agonist for 
one week (12).  The same reduction in ASM mass (%) was observed in heaves after antigen 
challenge in which bronchodilator pretreatment was not employed (16).  
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We hypothesized that the administration of a bronchodilator prior to the biopsy collection 
ameliorates the specimen quality by inhibiting bronchospasm in asthma. The primary 
objectives were to evaluate I) the effect of bronchodilation, forceps type, and the size of the 
carina on histomorphometric analysis of endobronchial biopsies in healthy and diseased 
airways; II) the influence of different analysis methods on ASM mass; and III) the relationship 
between endobronchial biopsy ASM content and lung function. This study was performed in 
horses with heaves, as remodeling of the airways in this natural disease has many similarities 
with that of human asthma (17). This model allows easy and relatively non-invasive bronchial 
tissue collection from central airways in vivo.  
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Material and Methods 
Animals 
Eighteen horses of mixed breed and age (mean±SD: 15.1±5.1 years) from the equine research 
and teaching herds of the Faculty of Veterinary Medicine (Université de Montréal) were 
studied. Twelve horses had a documented history of heaves, while the 6 control horses were 
considered free of respiratory disease on the basis of history, physical examination, and 
negative response to hay challenge. This study was approved by the Animal Care Committee 
of the Université de Montréal (Protocol Rech-1324) and conducted in compliance with 
guidelines of the Canadian Council on Animal Care. 
 
Biopsy specimen collection and processing 
A videoendoscope (13mm Ø, CF-H180AL, Olympus, ON, Canada) was passed through a 
nostril down to the lower airways in horses sedated with detomidine (0.012 mg/kg IV) and 
butorphanol (0.01 mg/kg IV). Airways were locally anesthetized with lidocaine solution 
(0.5%). Only one lung was sampled during each experiment. The right lung was biopsied 
during the first day of the study and the left lung during the second day. Biopsies were 
collected starting from the most caudal carina available [2.9 or 1.9, as described by Smith 
(27)] and then moving cranially, until reaching the main carina, following the scheme 
illustrated in Figure 1. Importantly, carinae were paired right-left based on their dimensions 
and position along the bronchial tree in order to reproduce as much as possible the same 
conditions during the two experiments. Six biopsy specimens were obtained during each 
experiment. Biopsy sites were classified as small or large depending on carina size. Three 
small biopsies from small carinae and three from large carinae were collected during each 
experiment. The main carina of each horse was biopsied twice, at different sites. Biopsy 
specimens were formalin-fixed and then enclosed in agar cylinders (Figure 2). Two 5 µm-
thick histologic slides were obtained from each biopsy at 100-300 µm distances and stained 
with hematoxylin phloxine saffron (HPS). 
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Histologic analysis 
Slides were digitized at 20x magnification with NanoZoomer 2.0-HT system (Hamamatsu 
Photonics, SZK, Japan). Biopsies were scored 1 (very poor) to 5 (optimal) for histological 
quality (Table I). Total biopsy area (Atot), airway smooth muscle area (AASM), basal 
membrane length (BM) and the distance between epithelium and smooth muscle bundles were 
measured using ImageJ software (NIH, Bethesda, MD, USA)(Figure 3A, 3B and 3C). The 
AASM/Atot ratio (or ASM%), the AASM/BM and the AASM/BM2 ratios were calculated for each 
biopsy. Two further morphological parameters were calculated with newCast software version 
4.5.1.324 (Visiopharm, Denmark) using a stereology-based approach (Figure 3D). ASM 
volume fraction (Vv(ASM)) was measured by point counting and expressed as the fraction of the 
total number of points falling on smooth muscle (PASM) over the total number of points falling 
on the biopsy (Pref): 
ܸݒ஺ௌெ = 	
∑ ஺ܲௌெ
∑ ௥ܲ௘௙  
 
The volume to surface ratio of smooth muscle per length of basal membrane (Vv(ASM)/Sv(BM)) 
was calculated by counting points falling on smooth muscle (PASM) and line intersections with 
the basal membrane (IBM), as follow: 
ܸݒ஺ௌெ
ܵݒ஻ெ = 	
஺ܲௌெ 	 ∙ 	݈(݌)
2∑ ܫ஻ெ  
 
Where l(p) was a constant determined by the density of line probes and corresponded to 
0.02421. A minimum of 200 points was counted for ASM from at least two biopsies per horse. 
Coefficient of error of the measurements (CE) was calculated accepted only if <0.1. All 
measurements were performed blindly by the same investigator. 
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Respiratory mechanics 
Impulse oscillometry (IOS) was performed as described by van Erck (28) with the Equine 
MasterScreen IOS system (Jaeger GmbH, Würzburg, Germany). In brief, horses breathed 
through a mask connected to a loudspeaker generating multi-frequency impulses. The 
pressure-flow signal response of the respiratory system superimposed on the animal tidal 
breathing was measured by a pressure transducer connected to a pneumotachograph and 
placed directly in front of the face mask. Data were acquired for a minimum of 30 seconds and 
analyzed (LabManager, version 4.53, Jaeger GmbH, Würzburg, Germany and FAMOS, imc 
Mess-Systeme GmbH, Berlin, Germany) using Fast-Fourier transform to compute the 
resistance (R) and reactance (X) of the respiratory system at frequencies down to 1 Hz (25). 
Only values at frequencies ≤10 Hz were analyzed as they have been shown to reliably 
represent lung function in horses (13, 32). Recordings with a low coherence function were 
excluded from analyses (13).  
 
Study design 
A cross-over case-control study was performed. Six horses with heaves in clinical 
exacerbation of the disease (HE) and six control horses (C) were stabled and exposed to hay 
and dust starting two weeks before the study period. Six additional horses with heaves were 
kept at pasture and administered dexamethasone (0.06 mg/kg PO q24h) starting one week 
before the first biopsy collection and for the duration of the study in order to induce clinical 
remission of the disease (HR).  
Horses were studied twice, at a 4-day interval, with and without the administration of a 
bronchodilator agent (N-butylscopolammonium bromide, 0.3 mg/kg, Buscopan®, Boehringer 
Ingelheim, Germany)(4). The order of treatment (bronchodilator vs placebo) was randomly 
determined for each subject. Lung function was evaluated using IOS before (baseline) and 15 
minutes after sedation, independently of whether or not they received or not the bronchodilator 
5 minutes after sedation. During the first series of experiments, three of the six biopsies 
randomly chosen for each horse were obtained with a smooth oval disposable biopsy forceps 
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(2.85 mm in diameter, FB-234U, Olympus, ON, Canada), while the remaining three were 
taken with an alligator jaw disposable forceps (2.85 mm in diameter, FB-214U, Olympus, ON, 
Canada). During the second series, forceps selection was simply inverted.  
 
Statistics 
Statistical analysis was performed with SAS v.9.3 (Cary, NC, USA) and Prism 5 (GraphPad 
Software Inc, La Jolla, CA, USA). The effect of technical parameters (bronchodilator 
administration, forceps type, carina size and disease status) on morphological variables (Atot, 
AASM and ASM%) was studied with a repeated-measures linear model. The effect of technical 
parameters on biopsy quality was assessed with a generalized estimating equation model for 
ordinal variables. Technical parameters were always considered as intra-subject factors. The 
effect of multiple uses of the forceps on biopsy quality was assessed with the Cochran-Mantel-
Haenszel test, considering repeated measures observed for every subject. Re-biopsy 
parameters were analyzed with two-way ANOVA and Bonferroni post-test. One-way 
ANOVA or χ2 test was used for comparison of continuous variables or proportions between 
the 3 groups. Paired t-tests were used for comparison of lung function parameters before and 
after bronchodilator administration within the same group. Correlations were assessed with 
Pearson test when N>8 and data were distributed normally (Kolmogorov-Smirnov test) or 
Spearmen test when N<8 or data were not normally distributed. For all analysis, a p-
value<0.05 was considered as significant. 
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Results 
Biopsy specimens 
The procedure was well tolerated by all horses, with only mild bleeding occasionally noticed 
at the biopsy site. A total of 216 biopsies were collected during the study period, all of which 
were considered of appropriate size. Two biopsies were lost during the embedding process; 
214 biopsies were finally analyzed. 
Overall, 39.2% of biopsies were considered as being of good to optimal quality (score 4 and 
5), 20.6% as partially suitable for assessment (score of 3), and 40.2% were of poor or very 
poor quality (score of 2 and 1) and not suitable for analysis. Smooth muscle bundles were 
identified in 84.6% of biopsies, with no significant differences between groups (p=0.98).  
 
I.   Technical variables 
Disease status had a strong effect on Atot (p=0.003), with the size of the biopsies collected 
from heaves-affected horses during exacerbations being significantly larger than biopsies 
obtained from both horses with heaves in remission and control horses (p<0.05). No 
significant difference was found between Atot of heaves asymptomatic and control horses 
(Figure 4A). Biopsy AASM (p=0.38), ASM% (p=0.87), and the quality score of the biopsies 
(p=0.49) were not affected by disease status (Figure 4B, 4C and 4D, respectively). 
Bronchodilation did not affect Atot (p=0.16), AASM (p=0.2), ASM% (p=0.64) or quality score 
of the biopsies (p=0.11).  
The size of the carina and the forceps type did not significantly affect Atot (p=0.73 and p=0.3, 
respectively), AASM (p=0.46 and p=0.85) or ASM% (p=0.49 and p=0.5). However, significant 
interactions were found between the size of the carina and the forceps used, both for AASM and 
ASM% (p=0.046 and p=0.04, respectively). This was due to a trend for AASM (p=0.06) and 
ASM% (p=0.052) to be lower in large carinae compared to small ones with smooth oval 
forceps, but not with alligator jaw forceps (p=0.47 and p=0.36, respectively). There was also a 
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trend (p=0.058) for ASM% to be higher in biopsies obtained from small carinae with smooth 
oval forceps compared to those obtained with jaw alligator forceps. No difference was found 
between mean ASM% of biopsies obtained from large carinae with smooth oval forceps 
compared to those obtained with jaw alligator forceps (p=0.36).  
The quality of the biopsies was not influenced by the forceps used (p=0.08). However, the size 
of the carina had a significant effect on histologic quality of the biopsies (p=0.02). There was a 
2.2 times increased probability of obtaining an optimal quality biopsy when the sampling site 
was a small carina compared to a large one. Reutilizing the same forceps for collecting 
biopsies from 6 to 8 horses did not result in significant changes detectable on biopsy quality 
(p=0.61) or biopsy size (p=0.41).  
Only the main carina was biopsied twice at a 4-day interval in each horse, and at a distance 
allowing the avoidance of a biopsy being obtained that overlapped the site of the first biopsy 
taken. Re-biopsy did not significantly affect Atot (p=0.19). However a significant effect of the 
group was observed for Atot (p=0.009). Interestingly, Atot was increased in re-biopsies of 67% 
horses with heaves in exacerbation and controls, but not in horses with heaves in clinical 
remission. ASM% was significantly decreased in re-biopsies (p=0.005) and a similar trend 
was observed for AASM (p=0.05). Biopsy quality was similar in the first and second biopsies 
(p=0.65). 
 
II.   Analysis methods 
When only good quality biopsies (grades 3 to 5) were analyzed, smooth muscle content 
increased significantly compared to when all biopsies were analyzed together, independently 
of the parameter used for its quantification (from [mean±SD] 0.54±0.31 to 0.68±0.33 mm2 for 
AASM, p=0.0003; from 25±7% to 32±6% for ASM%, p=0.005). AASM and ASM% increased on 
average 26% and 23%, respectively, after exclusion of poor quality biopsies. Also, intra-
subject variability expressed as the coefficient of variation decreased significantly when only 
good quality biopsies were taken into account (p=0.002 with an average 25% reduction in 
variability for AASM, and p=0.0001 with an average 35% reduction in variability for ASM%). 
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Comparison between all and only good quality biopsies was not performed for AASM/MB, 
AASM/MB2, Vv(ASM) and Vv(ASM)/Sv(MB) as these parameters were calculated only for good 
quality biopsies. Considering only good quality biopsies, intra-subject variability of smooth 
muscle quantification varied significantly depending on the analysis method used (p=0.02), 
and it was higher when expressed as AASM compared to ASM% or Vv(ASM) for the same biopsy 
(p<0.05).  
In good quality biopsies, correlations between ASM% and its stereological equivalent Vv(ASM), 
and between ASM/BM and its stereology equivalent were significant in all groups, confirming 
the appropriateness of our counts. However, correlations among different measuring 
techniques are poor and vary significantly among groups. Also, the measuring technique can 
significantly affect the outcome of the study (see Table II and Figure 5). 
 
III.  Structure-function relationships and other physiological variables 
There was a significant difference in total lung resistance (R3, p=0.02), reactance (X3, 
p=0.009), and R5:R10 ratio (p=0.01) among the 3 groups of horses at baseline (Table III). 
Higher values of R3, X3 and R5:R10 were observed in horses with heaves in exacerbation 
compared to controls (p<0.05). Values of airway function (Z5, R3, X3) were not significantly 
different during the two days of experimentation for each group (p>0.05). The sedation with 
detomidine and butorphanol caused a significant increase of inspiratory resistance values, 
suggesting upper airway obstruction. Buscopan administration, but not placebo treatment, 
caused a bronchodilation in horses with heaves whether in exacerbation or in remission of the 
disease, as shown by the significant decrease in the R5:R10 ratio (29) (Table III and Figure 6).  
When only good quality biopsies were included in the analysis, baseline R5 values were 
positively correlated with ASM% (r=0.84, p=0.03) in control horses, but only when 
bronchodilation was induced (Figure 7A). Interestingly, a negative correlation was observed 
between baseline R5 and ASM% in heaves-affected horses after bronchodilation (horses with 
heaves in exacerbation and remission of the disease pooled together, p=0.01, r=-0.74) (Figure 
7B). The negative correlation could be explained by an increased volume of the extracellular 
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matrix in heaves affected horses, as the distance between epithelium and smooth muscle 
bundles was increased compared to controls ([mean±SD] 0.143±0.049 mm in horses with 
heaves and 0.082±0.031 mm in controls, p=0.01, Figure 8) and the external border of the 
smooth muscle bundle was less frequently identifiable in biopsies from these animals (32% 
and 13% of biopsies from controls and horses in exacerbation, respectively). 
When only good quality biopsies were considered, AASM was strongly correlated with age in 
both groups of horses with heaves (exacerbation: p=0.04, r=0.90; remission p=0.03, r=0.91) 
but not in control horses (p=0.85, r=0.10). Moreover, the regression lines derived from these 
data were significantly different between horses with heaves in exacerbation and remission of 
the disease (similar slopes, p=0.09; but different intercepts, p=0.02), as well as between horses 
with heaves in exacerbation and controls (different slopes, p=0.049). No significant 
differences were observed between horses with heaves in remission and controls, possibly 
because of the absence of very old horses in the control group (Figure 9A). The same trend 
was observed for Atot, but correlation coefficients did not reach significance (r=0.82, p=0.09 
for horses with heaves in exacerbation; r=0.63, p=0.17 for horses with heaves in remission and 
r=0.08, p=0.9 for controls). However, a significant difference was found between the 
regression lines constructed for the three groups from Atot values plotted versus age (similar 
slopes, p=0.6; different intercepts, p=0.0009; Figure 9B). 
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Discussion 
Previous studies reported a decrease in the ASM mass in endobronchial biopsies of asthmatic 
patients and horses with heaves after antigen exposure (12, 16). We postulated that 
methodological factors contributed to these findings, and therefore we investigated the effect 
of technical and physiological variables possibly affecting endobronchial biopsy quality and 
morphology. Contrary to what we had hypothesized, bronchodilation did not improve biopsy 
morphology or quality; however it allowed normalization of the structure-function 
relationships in our study. Indeed, when analyzing only biopsies obtained after 
bronchodilation, we detected significant negative correlations between ASM content of the 
biopsies (ASM%) and lung function in horses with heaves and controls, clearly linked to the 
remodeling features of the bronchial extracellular matrix. Also, biopsies obtained during 
heaves exacerbation (comparable to asthmatic attacks) were significantly larger (increased 
Atot) than those obtained during the remission phase of the disease (comparable to the 
controlled asthmatic state) or from control horses, indicating that disease status is a critical 
determinant of commonly employed histomorphometric parameters. Biopsies from medium 
and small carinae increase the probability of obtaining good quality biopsies with greater 
quantity of smooth muscle, especially when forceps with smooth cutting surfaces are 
employed. Nevertheless, quantification of ASM mass is not reliable when performed on 
equine endobronchial biopsies, independently on the sampling techniques and analysis 
methods. Indeed, as even larger forceps rarely sample the full depth of the smooth muscle 
layer, ASM mass assessment can be biased if growth of smooth muscle cells goes towards the 
adventitial layer.  
 
Effect of technical variables on biopsy size and quality  
The size and quality of the biopsy specimens can greatly affect the assessment of 
morphological and histopathological features (10). We used the largest biopsy forceps 
instrument passing through the working channel of the endoscope in order to maximize biopsy 
size (10, 23), which explains why we obtained larger biopsies than those generally obtained in 
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men (on average, Atot was 2 mm2 in horses and 1mm2 in man (15)). However, we likely 
sampled to a similar depth the bronchial tissues, as the central equine airways are also larger 
than human ones. Indeed, approximately 60% of our attempts provided samples suitable for 
histologic assessment, which is a similar result to that observed in adult asthmatics (15). Atot 
was significantly affected by disease status, with horses during disease exacerbations (~asthma 
attacks) yielding larger biopsies than control horses or horses in clinical remission of the 
disease. At first sight, these results contrast with findings in human in which no significant 
differences were found in Atot of biopsies from asthmatic and control patients (15, 23), or from 
severe and moderate asthmatic patients (11, 22). However, in these studies, asthmatic patients 
were under treatment or their disease was stable for months prior to sampling. Our results are 
thus in agreement with these findings, as no significant differences were shown between 
horses with heaves in remission of the disease and controls concerning the size of their 
biopsies. We attributed the increased Atot of biopsies of subjects with heaves in exacerbation to 
the increased tissue inflammation during the active phase of the disease, leading to edema and 
tissue fragility. Very little is known on tissue morphology during spontaneous asthmatic 
attacks in man due to ethical, management and safety concerns and equine heaves is perhaps 
the only animal disease that allows studying this aspect of the disease prospectively.  
Biopsy quality was significantly affected only by carina size. Smaller carinae were 2.2 times 
more likely to provide good quality biopsies than larger ones. Despite large forceps being 
used, main carina and carinae of the first generation of equine bronchi are often too thick to 
allow optimal forceps gripping, especially in symptomatic horses (14). On the other hand, 
contrarily to what is reported in man (15), almost all of the accessible carina sites in the horse 
are large enough to provide good quality endobronchial biopsies of the airway wall. This 
finding may explain why targeting smaller carinae improves the histological quality of the 
biopsy and the possibility to sample the ASM layer entirely in horses.    
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Effect of technical variables on ASM content 
In our study, endobronchial biopsy ASM mass was not significantly affected by disease status 
when all biopsies were analyzed together. Despite an obvious trend was observable for AASM 
in our data, the difference did not reach statistical values, probably because of three reasons: 
the relatively small number of animals employed, the fact of having three groups instead of 
two, and the high intra-group variability of data. However, excluding poor quality biopsies, we 
found a significant effect of disease status only when ASM was quantified as AASM. To the 
same extent, differences were not statistically significant between AASM of horses with heaves 
in exacerbation and in remission because of lack of statistical power. We are aware of a single 
previous study in which a significant difference was found between AASM of moderate and 
severe asthmatics (22). More often ASM remodeling is reported as ASM%, and differences 
between asthmatics and controls are observed in most (1, 23, 26) but not all (15, 20, 26) 
studies investigating this aspect. ASM% did not change significantly among groups in our 
study. Importantly, biopsies were collected from the same sites in all subjects in order to avoid 
differences arising only as a consequence of the different proportion of small versus large 
carinae sampled.  Indeed, we have shown that the carina size significantly affects the ASM 
content of the biopsy, especially when forceps with smooth cutting surfaces are employed.  
 
Re-biopsy findings 
The same carina may be biopsied twice or more in prospective human studies, due to limited 
number of sites for endobronchial biopsies in man (15). Because the effects of re-biopsying 
the same site on biopsy morphology or size are not known (10), we sampled the main carina 
on two occasions 4 days apart. Re-biopsy was associated with a generalized increase in Atot 
which we hypothesized was the consequence of the inflammation induced by the first biopsy, 
as this effect was prevented by the administration of dexamethasone (group in remission of the 
disease). Also the ASM mass decreased in the re-biopsies, indicating that inflammation-
induced submucosal edema possibly increased the distance between epithelium and ASM, as 
previously shown in asthmatics (22). As a consequence, short-term re-biopsy of the same site 
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should be avoided when investigating ASM mass or ECM content, even when performed at 
sites visually appearing to lack inflammation. Further studies may clarify how much time 
should elapse before a re-biopsy could be obtained without significant effect on tissue 
morphology in the absence of anti-inflammatory therapy.  
 
Comparison among different measuring techniques 
Endobronchial biopsy is the “gold standard” for the study of central airway remodeling (3). 
However, the high inter-subjects (up to 70%) and intra-subject (20%) biological variability 
(10), and the lack of standardization of the methods employed for tissue structure analysis (9) 
limit the usefulness of these measurements. Remarkably, identification of external ASM 
boundaries, which is required to ensure that the full thickness ASM was sampled, does not 
represent a parameter constantly considered for biopsy quality assessment. Stereology has 
been proposed as the method of choice for lung morphometric studies, as it provides accurate 
quantitative data (8). However, it requires that the reference space is known and sampling is 
unbiased (21). In endobronchial biopsies, the reference space is unknown, and sampling is 
biased as it is limited to carinae and by the penetrating capacity of the forceps used (31). Basal 
membrane length should be employed as a correction factor as it avoids the “reference trap” 
when the reference space is unknown (8). However, there is no method available to correct for 
the incomplete and variable (non-quantifiable) sampling of the ASM layer. For these reasons, 
we suggest to include in future studies only biopsies in which the external border of the ASM 
is clearly identifiable, to assure unbiased analysis. A further confounding factor when 
comparing different studies is the measure unit used. We have shown that data obtained using 
different measuring units on the same samples do not correlate, as it had been reported for 
human patients (15). For these reasons, direct and deliberate comparison of studies employing 
different units should be avoided. 
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Structure-function relationships 
As a secondary outcome, we analyzed the relationship between structural ASM parameters 
and physiologic functional data. We showed that values of resistance at 5 Hz correlated with 
ASM% in both controls and heaves-affected horses only after bronchodilation. These findings 
suggest that bronchospasm is induced by the biopsy procedure at least in control animals, 
which can possibly alter tissue remodeling measurements. In agreements with our findings, 
excluding data of asthmatic children unresponsive to bronchodilator therapy ameliorated the 
correlation between ASM mass in endobronchial biopsies and lung function (24), supporting 
the fact that inhibiting bronchoconstriction normalizes ASM remodeling data. In horses with 
heaves, less smooth muscle (%) was present in the biopsy as lung resistance increased. This 
was likely caused by the thickening of the extracellular matrix layer, widening the distance 
between epithelium and smooth muscle, as reported to also occur in asthmatics (1). In healthy 
man, ASM has been shown to increase linearly with airway diameter during infancy, but when 
adult age is reached, the proportion of ASM within the airway wall stabilizes (7). The same 
seems to be true for healthy horses. On the other hand, ageing (or disease duration) 
progressively increases the absolute quantity of ASM (AASM) in endobronchial biopsy samples 
of horses with heaves, but not its ASM% value. The reasons for these findings are still 
unclear, but likely reflect changes in tissue viscoelasticity and the shape of the carinae with 
ageing. Furthermore, the significant difference observed between the AASM regression lines of 
horses with heaves in exacerbation and in remission indicates that such increase in AASM 
occurs even more rapidly during active phases of the disease, possibly driven by inflammation 
which increases tissue fragility.  
 
Conclusions and perspectives 
In conclusion, our study provides evidence that while not affecting biopsy morphological 
parameters, bronchodilation improves the relationship between ASM in the central airways 
and lung function. Horses with heaves produce larger biopsies during disease exacerbations, 
with ASM mass being positively correlated with age and negatively correlated to disease 
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severity as measured by lung resistance. However, endobronchial biopsy provides 
inappropriate samples for quantitative studies of ASM remodeling, at least in horses. 
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Figures and tables 
Table I. Histologic quality score of biopsies.  
Biopsy Score Description 
  
1 Unacceptable tissue orientation, there is no continuity between epithelium, ECM and smooth muscle 
  
2 Good tissue orientation, tissue architecture not completely preserved.      
  
3 Good tissue orientation, tissue architecture preserved at least in a consistent part of the biopsy (>50%). 
  
4 Optimal tissue orientation for all the biopsy, minor area where continuity between tissues is lost. 
  
5 
Optimal tissue orientation for all the biopsy, tissue 
architecture is perfectly conserved. The parenchymal 
borders of the smooth muscle layer are clearly 
identifiable 
Tissue orientation, architecture, and structure preservation as well as presence of ASM were 
evaluated in order to classify the biopsies for their quality using a score from 1 (poor quality) 
to 5 (optimal quality). 
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Table II. Correlation among different measuring methods. 
  Control Heaves Remission 
Heaves 
Exacerbation 
All        
groups 
Difference 
between 
groups 
  Correlation 
AASM [mm2] - ASM ratio [%] .186 (.62) .383 (.44) .424 (0.41) .084 (.42) - 
AASM [mm2] - AASM /MB [mm] .082 (.76) .778 (.15) .355 (.46) .118 (.38) - 
AASM /MB [mm] - ASM ratio [%] .123 (.70) .007 (.93) .606 (-.27) .045 (.47) - 
AASM /MB2 [-] - ASM ratio [%] .075 (.77) .041 (.83) .598 (-.32) .073 (.44) - 
Vv ASM [-] - ASM [mm2] .129 (.69) .581 (.29) .26 (.62) .236 (.29) - 
Vv ASM [-] - ASM ratio [%] .016 (.89) .015 (.89) .004 (.98) <.0001 (.93) - 
Vv ASM [-] - AASM /MB [mm] .008 (.92) .003 (.96) .20 (.61) .0007 (.72) - 
Vv ASM [-] - AASM /MB2 [mm] .031 (.85) .011 (.91) .565 (.30) .004 (.64) - 
Vv ASM [-] - Vv ASM/Sv MB [mm] .488 (-.36) .093 (.74) .014 (.90) .011 (.57) - 
Vv ASM/Sv MB [mm] - AASM [mm2] .699 (.20) .485 (.36) .43 (.66) .08 (.42) - 
Vv ASM/Sv MB [mm] - ASM ratio [%] .80 (-.13) .005 (.94) .33 (.55) .035 (.51) - 
Vv ASM/Sv MB [mm] - AASM /MB [mm] .051 (.64) .039 (.83) .028 (.86) .0001 (.78) - 
Vv ASM/Sv MB [mm] - AASM /MB2 [mm] .927 (-.05) .098 (.73) .339 (.58) .002 (.66) - 
      
      
one-way 
ANOVA 
AASM [mm2]  - - - - .04 
ASM ratio [%] - - - - .96 
AASM /MB [mm] - - - - .32 
AASM /MB2 [] - - - - .70 
Vv ASM [] - - - - .72 
Vv ASM/Sv MB [mm] - - - - .41 
Data are expressed as the p (r) values resulting from Spearman (controls, heaves remission and 
heaves exacerbation) or Pearson (all groups) correlation tests or as p-values from one-way 
ANOVA test. Overall, there was poor correlation among different measuring methods, 
excepted for Vv ASM and ASM% and Vv ASM/SV BM and AASM /BM. Also, using different 
methods may lead to different results: a significant difference was indeed observed among 
group for AASM values (p=0.04) but not for the other measuring techniques (p>0.05).  
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Table III. Lung function measured by impulse oscillometry system (IOS). 
 Control Heaves Remission Heaves exacerbation p 
Baseline    
Group 
effect 
R3  0.0648 (±0.0177) 0.0805 (±0.0308) 0.1340 (±0.0381)§ .02 
X3  0.0074 (±0.0089) -0.008167 (±0.0301) -0.05683 (±0.0562)§ .009 
R5:R10 placebo 0.7052 (±0.19) 0.9309 (±0.2325) 1.214 (±0.1477)§ .01 
R5:R10 buscopan 0.8526 (±0.167) 1.219 (±0.696) 1.215 (±0.217) .06 
Z5 placebo  0.0720 (±0.0228) 0.09167 (±0.0204) 0.1050 (±0.0302) .08 
Z5 buscopan  0.0700 (±0.0187) 0.0767 (±0.025) 0.09833 (±0.0319) .25 
15' post sedation 
R5:R10 placebo 0.7761 (±0.059) 0.952 (±0.196) 1.16 (±0.289) .13 
R5:R10 buscopan 0.8854 (±0.198) 0.7447 (±0.132)† 0.904 (±0.172)† .21 
Z5 placebo 0.1167 (±0.055) 0.08167 (±0.0256) 0.1000 (±0.0473) .39 
Z5 buscopan 0.085 (±0.051)* 0.0740 (±0.0114) 0.095 (±0.0191) .35 
IOS was performed before and 15 minutes after sedation. Bronchodilator (buscopan) or 
placebo was administered 5 minutes after sedation. Data are expressed as mean (±SD). 
Resistance (R), reactance (X) and impedance (Z) values are expressed in kPa/L/s. P values 
reported express whether differences were observed among the 3 groups. §: Different from 
control group (one-way ANOVA and Dunns post-test). †: Different from R5:R10 buscopan at 
baseline (p=0.03 for HR and p=0.02 for HE, paired t-test). *: Tends to be different from Z5 
placebo at 15' post-sedation (p=0.07, paired t-test). 
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Figure 1. Biopsy collection scheme. Biopsy sites are indicated with stars. Biopsies were 
collected from the same sites in all horses. Biopsy sites were classified as small or large 
depending on carina size. Large carinae were defined as those where the accessory segmental 
bronchus (only for right lung), first segmental bronchus (or bronchi for the left lung) 
conducting air to the ventral part of the lung, and intermediate segmental bronchus stem from 
the main caudal lobar bronchus. Large carinae are shown within the blue boxes. The 
difference in carina thickness between large and small carinae can be easily appreciated. The 
yellow arrow indicates the site of the previous biopsy (4 days before) in the main carina; 
adjacent tissues are visibly inflamed and edematous. MCLB: main caudal lobar bronchus. 
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Figure 2. Biopsy processing protocol. Agar cylinders of 3 mm diameter and 20 mm in length 
were obtained by slowly pouring a heated (37-40°C) solution of 4% agar in manufactured 
molds, where biopsies were positioned with their vertical axis parallel to the vertical axis of 
the cylinders under stereoscopic microscope guidance (A). Cylinders were allowed to harden 
at room temperature (about 20°C) for 15 minutes before being randomly rotated on their 
vertical axis (B). A cut was made parallel to a random angle using a radial support. Agar 
cylinders were then positioned horizontally into the cassettes for paraffin embedding 
maintaining their random orientation, with their cut surfaces placed downward (C). 
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Figure 3. Histologic analysis of the biopsies. AASM and Atot are clearly outlined for an 
illustrative biopsy in panels A and B, respectively. In C, arrows indicate the measure of the 
distance between the epithelium and the ASM layer. Of note, areas of the biopsies in which 
collagen fibers were less dense due to significant focal tissue shrinkage or other procedural 
artifact (as those shown within the black box) were not considered for this type of measure. In 
D, a frame illustrating the software used for stereological analysis of the biopsies. Left panel 
shows a magnification of the yellow area in the small right panel. Within the left panel, line 
grids were used for basal membrane surface density. Note the yellow crosses at the 
intersection between line probes and basal membrane, indicating IBM. Also, blue crosses were 
used as probes for ASM mass, while blue crosses with green circles were used as probes for 
reference volume. Crosses marked with letters (A for Pref and B for PASM) were used for 
counts. 
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Figure 4. Effect of disease status on Atot (A), AASM (B), ASM% (C) and histological quality 
(D) of the biopsies. Each point represents the mean value of all biopsies obtained from each 
animal (quality 1 to 5), excluded the re-biopsy site of the main carina. In B and C, the biopsies 
in which ASM was not present were included and the value of 0.00 was used for calculating 
the means. HE: heaves exacerbation; HR: heaves remission; C: controls. 
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Figure 5. ASM remodeling expressed with 2 different measuring techniques in the same 
samples. Only good quality biopsies were used (score >2). In (A), data are expressed as 
ASM%, and no difference is observed among the 3 groups (p=0.96). In (B), data are expressed 
as AASM [mm2], and a significant difference is detected among the 3 group (p=0.04), with 
AASM of controls (C) being significantly lower than those of horses with heaves in 
exacerbation (HE, p<0.05).  
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Figure 6. Bronchodilator effect on R5:R10 ratio. When horses received placebo (saline, white 
points), no change was observed for the R5:R10 ratio at baseline and 15 minutes after 
sedation/placebo, meaning that airflow obstruction was not significantly affected by 
sedation/placebo administration in the 3 groups. When horses received bronchodilator 
(Buscopan®, black points), the R5:R10 ratio did not change in control horses but it 
significantly decreased in horses with heaves (both in exacerbation and in remission, p<0.05), 
indicating that airway obstruction was reduced after sedation/bronchodilator treatment in this 
group of animals. 
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Figure 7. Correlation between ASM% and baseline peripheral lung resistance during days in 
which buscopan was administered prior to EBB collection in control (A) and heaves-affected 
horses (B). HE: heaves exacerbation; HR: heaves remission; C: controls. 
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Figure 8. ECM thickness, evaluated as the distance between the bronchial epithelium and the 
ASM layer, is greater in horses with heaves compared to controls. Bronchodilation treatment 
had no significant effect on this parameter.  
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Figure 9. Correlation between age of horses and AASM (A) or total biopsy area (B). In horses 
with heaves, but not in controls, age is significantly correlated with AASM. Interestingly, 
disease exacerbation significantly shifts the regression line towards the left. A similar trend 
can be observed for total biopsy area (see the text for further details). 
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Article 2 
 
Development of a semi-quantitative histological score for the diagnosis of heaves in 
endobronchial biopsies of horses  
 
Summary 
This article investigates whether structural and inflammatory changes appreciable in 
endobronchial biopsies of horses with heaves can be assessed using a semi-quantitative score, 
and whether such score correlates with functional parameters of lung health. Based on the 
results of this study, the score we have developed allows differentiating asthmatic horses from 
controls only when endobronchial biopsies are obtained during disease exacerbations. 
Nevertheless, the sum of all structural/morphological parameters of the score correlates with 
lung function in asthmatic horses both in exacerbation and in remission of the disease, but not 
in controls, indicating that, overall, it provides a reliable estimation of the degree of airway 
remodeling in equine asthma.  
 
 
 
 
Contribution 
I participated in study design (90%), data generation (preparation of histological 
sections, 50%; performing the score, 20%), communication with experienced 
pathologists involved in the study (70%), data analysis (100%), and preparation of the 
manuscript (90%).  
 
 
 
 
Article submitted for publication 
Submission to the Journal of Veterinary Internal Medicine completed on 11/24/2015. 
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Abstract 
Background: Heaves is characterized by bronchospasm, airway remodeling, and inflammation. 
While bronchoalveolar lavage fluid (BALF) cytology normalizes during the asymptomatic 
phase of the disease, selected airway remodeling features persist in affected horses. Their 
identification in endobronchial biopsies would possibly facilitate the diagnosis of the disease 
even when horses are in clinical remission.  
Hypothesis: Airway inflammation and remodeling in endobronchial biopsies permits the 
differentiation of horses with heaves from controls, independently of their clinical status 
(exacerbation or remission).   
Animals: Fourteen healthy horses and 24 horses with heaves (12 in remission and 12 in 
exacerbation).  
Methods: The score was validated by 2 pathologists using biopsies obtained from 18 horses (6 
controls, 6 heaves exacerbation, and 6 heaves remission) whose lung function had been 
assessed with impulse oscillometry. Clinical and research application of the score was 
evaluated using biopsies obtained from another 20 horses (8 controls, 6 heaves exacerbation, 
and 6 heaves remission). 
Results:  The score was repeatable and could differentiate horses with heaves in exacerbation 
from horses with heaves in remission and controls (p<0.0001). The histological scores of 
horses with heaves in exacerbation (r=-0.88; p=0.04) and remission (r=-0.91; p=0.01) of the 
disease were strongly correlated with expiratory reactance values.  
Conclusions and clinical significance: The proposed histological scoring system is a reliable 
tool for the assessment of airway inflammation and remodeling of the large airways in horses. 
However, it does not discriminate horses with heaves in remission from control horses. 
Evaluation of endobronchial biopsies might be considered in future research and clinical 
studies.  
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Introduction 
Heaves is a chronic obstructive respiratory condition affecting adult horses. It is characterized 
clinically by periods of labored breathing at rest due to airflow obstruction2, which results 
from bronchospasm, chronic pulmonary remodeling, and mucus plugging in the airways3. 
Symptoms are largely reversible with therapy. Bronchoalveolar lavage fluid (BALF) cytology 
reveals neutrophilic inflammation during episodes of disease exacerbation4, but completely 
normalizes during periods of remission induced by antigen avoidance strategies5,6. Conversely, 
remodeling of the peripheral airways in heaves persists during disease remission7, and 
correlates with residual airflow obstruction6,8. Whether airway wall inflammation plays a role 
in perpetuating the disease during asymptomatic periods of the disease has not been studied, 
and could provide insights into heaves pathophysiology. The identification of specific 
parameters of tissue inflammation or remodeling in endobronchial biopsies of affected horses 
could facilitate both the diagnosis of heaves during disease remission and the response to 
treatment.  
Endobronchial biopsies (EBBs) yield bronchial samples that permit the assessment of 
bronchial surface epithelium, extracellular matrix (ECM), blood vessels, seromucous glands, 
and airway smooth muscle (ASM). Despite EBBs having been used in equine respiratory 
research for gene expression studies9-12, they are rarely evaluated histologically for 
inflammatory or remodeling features. However, they can be easily obtained, and would allow 
prospective studies to be performed in both research and clinical settings. We have recently 
developed a detailed protocol for EBB sampling and morphometrical analysis1. During that 
study, and using histomorphometric techniques, we described histopathological features 
characterizing EBBs of horses with heaves, which prompted us to develop a semi-quantitative 
scoring system for rapid and clinically applicable bronchial tissue assessment. We 
hypothesized that using this score we could differentiate horses with heaves from controls, 
independently of the clinical state of the disease (exacerbation or remission). The aims of this 
study were: 1) to develop and validate a semi-quantitative scoring system for evaluating 
bronchial inflammation and remodeling in equine EBBs, and 2) to estimate cut-off values of 
the score for differentiating healthy from heaves-affected animals.  
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Material and Methods 
Study design 
Phase 1 – Previously obtained endobronchial biopsies1 from 6 horses with heaves in 
exacerbation, 6 horses with heaves in remission of the disease, and 6 controls were scored by 2 
board certified pathologists (PH, Diplomate ACVP, and PJ, Fellow of the Royal College of 
Physicians of Canada) to assess the agreement. The correlation between the score of the 
board-certified veterinary pathologist and the lung function was studied to assess whether the 
score reliably assessed the degree of remodeling and inflammation leading to airflow 
obstruction. 
Phase 2 – Clinical application of the score. EBB tissues from 20 additional horses (8 controls, 
6 horses with heaves in exacerbation and 6 in remission) were obtained through the Equine 
Respiratory Tissue Bank (http://www.btre.ca). They were scored by the board-certified 
veterinary pathologist and, together with the EBBs described in phase 1, were used for 
investigating the effect of the environment on the score, the ability of the score to differentiate 
healthy and heaves-affected horses, and for calculating cut-off values for the groups. 
Phase 3 – Use of the score in research settings. To assess the potential application of this score 
in research setting, an equine internist (JPL) and a post-graduate student (MB) experienced at 
evaluating lung histological remodeling features associated with heaves were asked to score 
the EBBs, and their results were compared with those obtained by the board-certified 
veterinary pathologist.  
 
Animals 
Twenty-four horses with a diagnosis of heaves belonging to the research herd of the 
Respiratory Cellular and Molecular Biology Laboratory and 14 healthy horses from the 
teaching herd of the Faculty of veterinary medicine of the Université de Montréal were 
studied.  
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Phase 1 – Score development and validation. The characteristics of the horses studied in this 
phase and the experimental protocol have been previously described1. Briefly, horses were 
exposed to hay (6 horses with heaves in exacerbation and 6 controls) or kept at pasture for 2 
weeks and treated with dexamethasone (0.06 mg/kg PO q24h, 6 horses with heaves in 
remission) for 1 week before EBBs were obtained. Impulse oscillometry testing was 
performed on these horses before bronchoscopy using the Equine MasterScreen IOS systema 
and FAMOS softwareb, as previously described1,13. Bronchoscopies were performed on 
sedated animals (detomidine/butorphanol 0.01/0.015 mg/kg IV). Six endobronchial biopsies 
were obtained from previously selected sites within one randomly chosen lung of each animal. 
All procedures performed on the horses had been approved by the local Animal Ethics 
Committee (Rech-1324).  
Phase 2 – Among the 20 horses included in this phase of the study, 8 were controls kept 
stabled (EBBs were available also after 4 months at pasture in 5 horses, and were used to 
investigate the effect of the environment on the score) and 12 were horses with heaves (all 
kept stabled for >4 weeks, with horses in remission receiving oral dexamethasone at 0.06 
mg/kg q24h for 2 weeks prior to EBB collection). Lung function data obtained by impulse 
oscillometry were not available for these horses. Three to four endobronchial biopsies were 
obtained from unspecified sites of one lung for each animal. 
 
Histology processing 
Endobronchial biopsies were fixed for 24 h in 10% neutral-buffered formalin and then 
paraffin- embedded. Two consecutive histologic sections of 5-μm thickness were obtained 
from each biopsy and stained with HEPS (hematoxylin-eosin-phloxine-saffron) and modified 
Russell-Movat’s pentachrome14.  
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Scoring system 
A standardized semi-quantitative grading score was developed taking into account histological 
features thought to be important in heaves. Figure 1 describes the inflammatory and 
remodeling parameters studied and their scoring. Before performing the study, the board-
certified veterinary pathologist, the equine internist, and the post-graduate student were 
provided with a list of the parameters to be evaluated in the score and were asked to choose 
the biopsy considered of best quality from those available for each horse. This step allowed 
the operators to familiarize themselves with the variability of the parameters to be assessed in 
these samples. The biopsies chosen by the board-certified veterinary pathologist (one for each 
horse) were those used for subsequent blinded analysis. In phase 1 of the study, operators were 
also asked to monitor the time needed for scoring the biopsies and to make a presumptive 
diagnosis based on EBB findings (heaves vs control). 
 
Statistical analysis 
Phase 1 – Concordance between operators was evaluated using the Cohen’s Kappa test. The 
Pearson test was used for correlating scores and low frequencies (0.5 Hz) expiratory lung 
function values. 
Phase 2 and 3 – The effect of the environment on the score was assessed on the EBBs obtained 
from 5 control horses while stabled (>4 weeks) or at pasture (>3 months), using a paired t-test. 
Of these EBBs, only those obtained during stabling were included in the subsequent analysis. 
Also, the scores of the biopsies of 12 horses with heaves in remission (6 kept stabled and 6 
kept at pasture, all treated with dexamethasone for 1 to 2 weeks) were compared to assess the 
effect of the environment in horses with heaves using the Mann-Whitney U test. Differences 
between the scores of the 3 groups of horses were evaluated with one-way ANOVA with 
Tukey's post-hoc test. Sensitivity and specificity of the test for diagnosing heaves were 
calculated for different cut-off values. The Cochran-Mantel-Haenszel test with Bonferroni 
correction for multiple comparisons was used to identify the parameters of the score which 
better differentiated horses with heaves during exacerbation or remission of the disease, and 
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the group of horses with heaves in remission from the controls. Interclass correlation 
coefficient (ICC) and Cohen’s Kappa test were used to assess concordance among the 
operators. The Bland-Altman test was employed to calculate any significant bias between the 
operators.  
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Results 
Phase 1 – Score development and validation  
Agreement  
The agreement between the 2 pathologists for scoring the same biopsy was good (weighted 
kappa = 0.52). For each biopsy, the time needed for performing the score varied from 45 
seconds to 3 minutes for both pathologists (1’30’’/biopsy on average). 
 
Correlation between scores and lung function 
The expiratory reactance at 0.5 Hz was significantly correlated with the biopsy score both 
when the horses were in remission (r=-0.91; p=0.01) and exacerbation of the disease (r=-0.88; 
p=0.04). Coherence values15 of expiratory impulse oscillometry signals at 0.5 Hz were 
0.81±0.14 (mean±SD) for control horses, 0.79±0.08 for horses with heaves in remission, and 
0.75±0.12 for horses with heaves in exacerbation. The regression lines of both groups had 
similar slopes (p=0.9) but different intercepts (p=0.002). When the sums of the parameters 
linked to inflammation (epithelial and submucosal) were removed from the scores of horses 
with heaves in exacerbation, the regression line of the group in exacerbation shifted to the left 
without changing its slope and approached the line of the horses with heaves in remission 
(Figure 2). The gap remaining between these two regression lines was likely due to 
morphological differences still present between the 2 groups despite the treatment, most 
commonly represented by mucus gland hypertrophy and hyperplasia. Epithelial hyperplasia 
and ASM fibrosis also partially contributed to the morphological difference observed between 
horses in exacerbation and remission of heaves. The expiratory resistance at 0.5 Hz only 
tended to correlate with the biopsy score when the horses were in exacerbation of the disease 
(r=0.82; p=0.08). 
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Phase 2 – Clinical application of the score 
Effect of the environment  
The biopsy score was not affected by the environment in control horses (p=0.75) or in horses 
with heaves in remission (p=0.19). When the inflammatory parameters were analyzed 
separately, no difference was observed in epithelial (p=0.62) or submucosal infiltrate (p=0.37) 
in healthy horses kept at pasture or stabled. Horses with heaves in remission kept in both 
environments also had a similar degree of submucosal inflammation (p=0.24), while a 
tendency was observed for increased epithelial inflammation when stabled (p=0.06; fed hay, 
and bedded on shavings).  
 
Histological scores 
The scores were significantly different between groups (p=0.001). The score values of horses 
with heaves in exacerbation were significantly higher compared to those of horses with heaves 
in remission and controls (p=0.01 and p=0.001, respectively). No difference was observed 
between the scores of horses with heaves in remission and controls (p=0.8, Figure 3A). A 
value ≥5 of the score could differentiate a horse with heaves (in exacerbation or remission) 
from a control with a sensitivity of 54.2% and a specificity of 79%. A value ≥5 of the score 
allowed identification of horses with heaves in exacerbation compared to controls and horses 
with heaves in remission with 83.3% sensitivity and 77.4% specificity. The parameters of the 
score better differentiating horses with heaves in exacerbation from those in remission of the 
disease were the epithelial (p=0.02) and submucosal inflammatory infiltrate (p=0.005). None 
of the parameters studied could differentiate horses with heaves in remission from controls 
(Table 2). 
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Phase 3 – Use of the score in research settings 
There was a moderate agreement between the board-certified pathologist and the equine 
internist (weighted Kappa, 0.44), and with the post-graduate student (weighted Kappa, 0.45). 
The interclass correlation coefficient (ICC) for the 3 observers was 69%, indicating that the 
level of concordance among the 3 observers was good, although a significant difference was 
observed among the scores of the 3 operators (analysis of variance F(2,38)=5.17, p<0.01). The 
observed difference was ascribed to the fact that the internist tended to slightly overestimate 
lower scores and underestimate higher scores compared to the pathologist (slope significantly 
>0, p=0.02, with a mean bias of 0.37), while the student tended to overestimate higher scores 
compared to the pathologist (slope significantly <0, p=0.005, with a mean bias of -1.02). 
Nevertheless, the scores of all operators were significantly higher for the group of horses with 
heaves in exacerbation compared to the groups of horses with heaves in remission or controls 
(Figure 3B and 3C).  
 
 
  
 151 
Discussion 
Horses with heaves are clinically asymptomatic during periods of remission of the disease and 
BALF cytology also normalizes. However, peripheral airway inflammation is unaffected by 
the clinical status of the disease6, and could represent a means of diagnosis of heaves during 
remission phases. However, due to its invasiveness, sampling the peripheral airways is not 
practical for the monitoring of clinical cases. Using a scoring system for the assessment of 
inflammatory and remodeling parameters of the large airway wall, we demonstrated that 
bronchial inflammation differs significantly between periods of exacerbation and remission of 
heaves, but not between the asymptomatic phases of heaves and the healthy subjects. Our 
score significantly correlated with lung function in horses with heaves in remission and in 
exacerbation of the disease, providing a reliable measure of bronchial obstruction in this group 
of horses. As endobronchial biopsies are easily obtained in standing sedated horses, our 
findings represent a practical means for the assessment and monitoring of airway remodeling 
and inflammation in both clinical and research settings. 
Epithelial and subepithelial inflammation were important parameters differentiating horses 
with heaves in exacerbation from horses with heaves in remission and controls. This finding 
underlines the involvement of the large airway inflammation in the pathophysiology of 
heaves. Interestingly, while we have shown a reduction of central airway inflammation after 
short-term treatment, no changes were observed in the degree of inflammation of peripheral 
airways after 6 or 12 months of antigen avoidance and/or inhaled corticosteroid treatment in a 
group of horses with heaves6. Whether this is due to intrinsic differences in small airway 
compared to large airway physiology or to the inability of inhaled treatments to reach the most 
distal sites remains unclear. This also suggests that large airway inflammation in heaves is 
intermittent, occurring only during exacerbation periods of the disease, when it could possibly 
drive the appearance of overt bronchospasm, increasing airway obstruction and pulmonary 
resistance. Conversely, small airway inflammation persists even during remission periods of 
heaves, perhaps acting as an active site for disease maintenance or progression. Contrary to 
what we hypothesized, significant differences in the bronchial inflammatory infiltrate or 
morphology of horses with heaves in remission and controls were not observed. As stabling 
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increases lung inflammation in BALF in otherwise healthy horses5,7, we compared the scores 
of horses with heaves in remission and controls while at pasture vs stabled. Unexpectedly, 
neither the score nor the degree of inflammation in healthy horses was significantly affected 
by the environment. As for the horses with heaves in remission, the environment did not affect 
the biopsy total score but those kept stabled tended to have higher epithelial inflammation 
compared to those kept at pasture. 
The contribution of the airway epithelium to the pathogenesis of heaves remains ill-defined. 
Due to its proximity to the bronchial lumen and exposure to pro-inflammatory agents, it is 
likely affected by, and perhaps drives the pathological process in heaves. Whether and how 
this translates into discernible histological changes is unclear. The almost significant effect 
observed in our study of the environment on epithelial inflammation in horses with heaves in 
remission but not in controls supports the theory of a dysregulated inflammatory response 
(with delayed, reduced, or lack of inhibitory mechanisms) in heaves pathogenesis. Kaup and 
colleagues described the histology of large airways of horses suffering from heaves in the 
early 90s16. The main differences they observed between the 2 groups involved the bronchial 
epithelium, in which cellular infiltration by mononuclear leucocytes16 and mast cells17 were 
described. The inflammatory cells infiltrating the epithelial layer in our study were 
predominantly lymphocytes and neutrophils, but these findings need to be confirmed using 
specific markers, at least for the mononuclear leukocytes. Nevertheless, they are in agreement 
with the paucity of epithelial eosinophils observed in heaves18. Whether mucus producing 
cells are increased in the airways of horses with heaves compared with controls has been 
investigated both in central and peripheral airways, with contrasting results19-21. In our study, 
epithelial goblet cells were increased in horses with heaves in exacerbation compared to 
controls. Also they were increased in horses with heaves in remission compared to controls, 
but the difference was not significant after correction for multiple comparisons, possibly as a 
result of the short duration of antigen exposure. Notably, the environment in which horses 
with heaves in remission were kept (pasture vs stabling) did not affect any mucus-related 
parameter of the score. 
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Both the ECM and the smooth muscle mass are increased in the peripheral airways of horses 
with heaves6,8. However, whether the submucosal structures of the large airways of horses 
with heaves display histologic alterations as a consequence of the disease is not well 
established. Endoscopic studies have observed a thickening of the tracheal septum and an 
increased tendency for central airway collapse in horses with heaves compared to controls22,23. 
An increased thickness of the submucosal bronchial wall, most likely due to ASM 
hyperplasia/hypertrophy, has also been reported in central bronchial sections24. These findings 
suggest that the whole airway wall undergoes structural modifications, thus altering its 
physical properties. We observed more prominent submucosal glands in horses with heaves 
during disease remission compared to the controls, but the difference was not significant after 
correction for multiple comparisons. This however integrates the results of a previous work in 
which the submucosal glands in large airways were reported to be larger in horses with heaves 
than in controls, and significantly larger in horses with heaves in exacerbation compared to 
those in remission21. Together with the tissue inflammation, likely accompanied by edema of 
the bronchial wall, this could account for the increased thickness of the bronchial lamina 
propria observed in heaves1. The ASM-related parameters evaluated with the score could not 
reliably differentiate the groups that we studied. Based on what has been reported in small 
airway remodeling6, we did not expect a significant reduction of ASM mass or fibrosis to 
occur after only 2 weeks of treatment. However, the fact that endobronchial biopsies are 
inadequate tools for a reliable quantitative assessment of ASM in horses1 could have 
accounted for our inability to detect morphological alterations likely present in the group of 
horses with heaves in remission compared to the controls.  
As previously reported, the horses studied during phase 1 underwent IOS testing before and 
after sedation1. This is the first report of impulse oscillometry values obtained in horses at 
frequencies <1 Hz, and the expiratory coherence values indicate that measurements were of 
good quality (0.6 is considered the minimum coherence value for peripheral lung 
measurement15,25). The scores made by the certified pathologist were negatively correlated 
with low frequency expiratory reactance measured after 15 minutes of sedation for both horses 
with heaves in exacerbation and in remission, demonstrating the effect of both airway 
remodeling and inflammation on lung function. Importantly, low frequency IOS expiratory 
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values are not significantly affected by α2-agonist sedation in horses26, which justifies the use 
of post-sedation IOS values in our study. Also, reactance values are less affected by stabling 
conditions and time of the day compared to resistance values27. Furthermore, the head was 
maintained in a standard position with an angle of approximately 90° during IOS under 
sedation, which further standardized the measures. Sedation with α2-agonists has the 
additional advantage of dilating the equine airways28 (which explains why expiratory 
reactance of horses with heaves in remission and exacerbation are similar), emphasizing the 
remodeling component of obstruction at the expenses of bronchospasm. The observed 
decrease in low frequency reactance values proportional to the increase in the scores suggests 
that the degree of large airway remodeling significantly affects the elastic properties of the 
whole equine lung, and that the remodeling of the large airways is likely to parallel alterations 
of the peripheral airways. Even though this finding might seem counterintuitive, as we would 
expect airway remodeling to be proportional to airway resistance, it has been shown that 
airway distensibility (which decreases with increasing ECM deposition and ASM mass 
development) does have a measurable influence on the overall elastic properties/behavior of 
the lungs29. This concept assumes that small airways are also remodeled, which has already 
been demonstrated in heaves3,6. In further support of our data, it has been reported that 
increased central airway subepithelial fibrosis was negatively correlated with compliance in 
asthmatics30.  
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Conclusions 
The histological score that we have developed is a reliable tool for the assessment of airway 
inflammation and remodeling of the large airways in horses with heaves. The semi-
quantitative assessment of the parameters we have studied was rapid and repeatable with 
minimum training by operators already familiar with bronchial histology. A score ≥5 allows 
differentiating horses with heaves from controls with a sensitivity of 50%, which rises up to 
83% if the horse shows clinical signs. On the other hand, a horse with no respiratory signs and 
a biopsy score <5 is a healthy horses in 79% of cases. Although non-significant after 
correction for multiple comparisons, goblet cell hyperplasia and submucosal mucus gland 
hyperplasia and hypertrophy were the only parameters differentiating horses with heaves in 
remission from controls, with no apparent effect of the environment, warranting further 
investigation. The introduction of endobronchial biopsy assessment in future prospective 
studies and possibly in everyday practice could facilitate the diagnosis of heaves in 
asymptomatic horses, reveal uncovered mechanisms of respiratory diseases, as well as 
elucidate the role and kinetics of large airway inflammation and remodeling.  
 
 
 
 
 
 
Footnotes 
a LabManager version 4.53, Jaeger, Würzburg, Germany. 
b IMC, Meβsysteme, Berlin, Germany. 
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Figures and tables 
Table 1.  Differences among groups for individual parameters of the score. 
Parameter p value Direction of the effect 
(post-test) 
ANOVA Post-test  
HE vs HR 
Post-test 
HR vs C 
 
Epithelium 
Hyperplasia 0.009 0.06 0.29 HE≥HR 
Inflammatory infiltrate 0.02 0.02 0.92 HE>HR 
Goblet cells 0.03 0.56 0.04* HR≥C 
Desquamation 0.19 0.59 0.19  
Extracellular matrix 
Thickened BM 0.27 0.25 0.25  
Inflammatory infiltrate 0.01 0.005 0.98 HE>HR 
Mucus glands 0.28 0.42 0.47  
Airway smooth muscle 
Fibrosis 0.29 0.16 0.60  
Mucus glands 0.09 0.14 0.03* HR≥C 
ASM ending visible 0.67 0.41 0.44  
The combined scores were used for statistical analysis. HE: heaves exacerbation, HR: heaves 
remission, C: controls. > indicates the direction of the effect when significant differences were 
observed between groups (p values in bold), while ≥ indicate the direction of the effect when 
only tendencies to significant differences were observed. *: Non-significant after Bonferroni 
correction for multiple comparisons.   
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Figure 1. Histological parameters assessed with the score.  
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Figure 2. Effect of inflammation on the relationship between histological score and lung 
function in horses with heaves. Heaves exacerbation (-)inflammation: scores of HE from 
which the values of epithelial and subepithelial inflammation have been removed. Xe: 
expiratory reactance. 
  
 163 
 
 
Figure 3. Effect of the group on the histological scores. Results of the board-certified 
pathologist (A), of the specialist in internal medicine (B). and of the post-graduate student (C). 
To be noted, the operators in B and C had at least a 3-year experience at evaluating pulmonary 
remodeling in the equine species.   
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Article 3 
 
Endobronchial ultrasound reliably quantifies airway smooth muscle remodeling in an 
equine asthma model 
 
Summary 
Endobronchial biopsies are an unreliable tool for the quantitative assessment of the ASM mass 
in the central airways of asthmatic horses. This article demonstrates the reliability of 
endobronchial ultrasound at specifically assessing the smooth muscle layer within the central 
airways in the equine species. Using ex vivo and in vivo approaches, we show that the central 
smooth muscle mass is increased in asthmatic horses, albeit to a lesser extent compared to the 
peripheral one. Furthermore, based on the observed variation of remodeling occurring both 
inter- and intra-subject, we have developed and validated a protocol for the assessment of 
central airway remodeling with endobronchial ultrasound in horses.  
 
 
 
 
Contribution 
I participated in study design (70%), experimental procedures and data collection 
(management of horses and bronchoscopy, 60%; endobronchial ultrasound, 100%; lung 
harvesting (100%), sample processing for histology, 90%; histomorphometry and image 
analysis, 100%), statistical analysis (30%), and preparation of the manuscript (90%).  
 
 
 
Article published  
Plos ONE (2015), 10(9):e0136284. doi: 10.1371/journal.pone.0136284.  
Reprinted with permission. Copyright © 2015 Plos ONE.  
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Abstract               
Endobronchial ultrasonography (EBUS) revealed differences in the thickness of the layer 
representing subepithelial tissues (L2) between human asthmatics and controls, but whether 
this measurement correlates with airway smooth muscle (ASM) remodeling in asthma is 
unknown. In this study, we sought to determine the ability of EBUS to predict histological 
ASM remodeling in normal and equine asthmatic airways. We studied 109 isolated bronchi 
from the lungs of 13 horses. They underwent EBUS examination using a 30 MHz radial probe 
before being processed for histology. ASM remodeling parameters were evaluated in EBUS 
images (L2 thickness, L2 area, L2 area/internal perimeter (Pi) and L2 area/Pi2) and 
histological cuts (ASM area/Pi2), and compared. EBUS was then performed ex vivo on the 
lungs of 4 horses with heaves, an asthma-like condition of horses, and 7 controls to determine 
whether central bronchial remodeling could be detected with this technique. An optimized 
approach was developed based on data variability within airways, subjects, and groups, and 
then validated in 7 horses (3 controls, 4 with heaves) that underwent EBUS in vivo. L2 area 
was significantly associated to ASM area in isolated lungs (p<0.0001), in the absence of 
significant bias related to the airway size. Bronchial size significantly affected EBUS ASM-
related parameters, except for L2 area/Pi2. L2 area/Pi2 was increased in the airways of 
asthmatic horses compared to controls, both ex vivo and in vivo (p<0.05). Bronchial histology 
confirmed our findings (AASM/Pi2 was increased in asthmatic horses compared to controls, 
p<0.05). In both horses with heaves and controls, L2 was composed of ASM for the outer 75% 
of its thickness and by ECM for the remaining inner 25%. In conclusion, EBUS reliably 
allows assessment of asthma-associated ASM remodeling of central airways in a non-invasive 
way.                                       
 
 
Keywords: Bronchoscopy, airway wall, radial miniprobe, smooth muscle layer, extracellular 
matrix, RAO. 
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Introduction 
Airway smooth muscle (ASM) mass and phenotype as well as the amount and composition of 
extracellular matrix (ECM) mass are increased or altered in asthma [1]. Both large and small 
airways may suffer remodeling, the magnitude of which has been associated with disease 
severity [2-4]. Most human studies demonstrating remodeling of airway tissues have been 
performed on post-mortem specimens, especially when assessing peripheral airways or the 
most abaxial structures of the bronchial wall, such as ASM [5, 6].  Bronchoscopic biopsies 
may be valuable tools, but potentially suffer from issues of sampling [7]. There is a need for 
non-invasive methods to assess the airway wall structure in vivo, especially when assessing 
treatment-associated airway remodeling reversibility in asthma [4, 8].  
Endobronchial ultrasonography (EBUS) is a non-invasive addition to routine bronchoscopy. 
Using radial mini-probes, the whole bronchial wall may be imaged and most of its structural 
components identified [9-11]. Two studies have shown that EBUS remodeling parameters 
such as the thickness of the first and second US layer (L1 and L2, representing epithelial and 
subepithelial tissue thickness including smooth muscle, respectively) differed between 
asthmatics and healthy patients [12], and also that they correlated with lung function [12, 13].  
Increased thickness of the EBUS layer representing ASM and a variable portion of ECM (L2) 
was associated with greater values of basal membrane thickness [12]. However, whether 
EBUS allows for the specific assessment of ASM mass and its remodeling in asthma have not 
been demonstrated.  
We investigated the correlation between ultrasonographic and histomorphometric 
measurement of ASM in a spontaneously occurring asthma-like disease of horses (heaves) 
[14]. We hypothesized that heaves-affected horses exhibit large airway remodeling compared 
to control subjects. Our objectives were to establish the comparability of measurements of 
airway wall structures assessed by EBUS to histology, and to develop an optimized protocol 
for assessing remodeling of subepithelial structures in central equine airways in vivo.  
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Material and Methods 
Study design 
The study was conducted in 5 consecutive phases, as summarized in Table 1. First, needle-
puncture experiments were performed to describe the echographic anatomy of the laminar 
structures composing the equine bronchial wall. Then, isolated bronchial specimens were 
studied for direct comparison between EBUS and histology. Ex vivo examinations of equine 
lungs were performed as a “proof of concept” and for optimization of the technique used. In 
vivo EBUS examinations were then performed on a limited number of horses, subsequently 
euthanized in order to confirm our findings.  
 
Animals  
Seven horses underwent in vivo EBUS examination at the Veterinary Teaching Hospital 
(CHUV) of the Université de Montréal before being euthanized for reasons unrelated to 
respiratory diseases. Horses were humanely euthanized by intravenous injection of 
pentobarbital sodium. Available details of these animals are reported in Table 2. All 
procedures described on living animals were performed in accordance with the guidelines of 
the Canadian Council on Animal Care and approved by the Animal Ethics Committee of the 
Université de Montréal (Rech-1663)(Table S2 reports the ARRIVE checklist).  
 
Isolated lungs and bronchial tissues 
Isolated lungs and bronchial tissues studied in phase 1, phase 2 and phase 3 of our work were 
obtained at a local slaughterhouse (Viande Richelieu Meat Inc, Massueville, QC, Canada) or 
from autopsy samples of horses euthanized at the CHUV of the Université de Montréal for 
reasons unrelated to respiratory diseases. The owners of the horses gave their consent for their 
animals to be used for this study. The lungs studied in phase 3 were obtained from 3 of the 4 
horses with heaves and from 1 of the 7 healthy horses studied in the in vivo experiment.   
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Equipment 
All EBUS materials and equipment were purchased from Olympus (Richmond Hill, ON, 
Canada). Scans were obtained with a 30 MHz radial mini-probe (UM-S30-25R) connected to a 
dedicated ultrasound unit (EU-ME1). For in vivo EBUS, probes were inserted within a 
balloon-ended sheath (MH-246R) and passed through the working channel of a 
videoendoscope (CF-H260DL/I). EBUS experiments were recorded using iMovie on a 
MacBook Pro computer.  
 
EBUS procedure 
In vivo bronchoscopies were performed under sedation (detomidine 0.02 mg/kg and 
butorphanol 0.01 mg/kg injected IV) and topical anesthesia (lidocaine solution 0.5%). The 
videoendoscope was inserted through a nostril and advanced until it wedged within the main 
caudal lobar bronchus. Images were collected from all bronchial segments within reach, up to 
the main bronchi. Ex vivo examinations were similarly performed on lungs kept on ice until 
examined (<6 hours following euthanasia). One lung per animal was examined. Lungs 
showing macroscopic alterations were excluded. 
 
EBUS image acquisition 
Videos were analyzed at slow motion and good quality EBUS images were saved as tiff files. 
Quality of EBUS scans was assessed on the basis of resolution and definition of the layered 
structure, as well as on uniformity and completeness of the acquired scan.  
 
Needle Puncture Experiments 
Bronchial sections ~3-mm long and ~10-mm wide were randomly collected from the lungs. 
Needle-puncture experiments were performed as previously described [11]. Briefly, samples 
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were flattened and fixed with two 18G needles to a polystyrene surface (Figure 1A); a third 
smaller needle (27G) was then inserted longitudinally into the airway wall under stereoscopic 
microscope guidance. With the samples submerged in saline solution, EBUS images were 
captured when all needles were visible (Figure 1B). Airways were then fixed and paraffin 
embedded with the needles kept in place in order to reproduce histological cuts similar to the 
EBUS views. The layer in which the needle was identified in EBUS images was compared to 
the histological structure in which it was found at histology (Figure 1C). 
 
Isolated bronchial specimen analysis (EBUS vs histology) 
Eight to 10 complete bronchial sections were randomly chosen and carefully dissected from 
each lung. Bronchi were immersed in saline solution and EBUS images acquired before 
processing for histology. The following measurements were made: bronchial diameter (D, 
calculated as the mean of 2 perpendicular diameters measured in each airway), internal 
perimeter (Pi), lumen area (LA), thickness of the first and second layer (L1 and L2, 
respectively, calculated as the mean of 5 values measured at predetermined sites) as well as 
the area of the second layer (L2 area). Images were excluded from analyses if the bronchial 
wall was not clearly identifiable for >180° (missing angle). L2 area/Pi and L2 area/Pi2 ratios 
were calculated. After formalin fixation and paraffin embedding, sections of 5-μm thickness 
were obtained, stained with Movat's pentachrome and digitized at 2.5-5x magnification, using 
a Leica camera (DCF320, Leica Microsystems, Cambridge, UK) and Photoshop CS5 (Adobe 
Systems Inc., San Jose, CA, USA). Histological images were scored from 1 to 4 (Table S1 in 
File S1), based on tissue architecture preservation and perpendicularity of the cut. Images 
scored 1 were excluded from analysis. Images scored 2 were considered only if the missing 
angle was <90°. For all airways, the mean of 2 diameters (D), internal perimeter (Pi), lumen 
area (LA) and ASM area (AASM) were measured (Figure 2), and AASM/Pi2 ratio calculated. 
All measurements were made blindly using ImageJ (version 1.48c, NIH, Bethesda, MD, 
USA).  When images were incomplete, the subtended angle of the analyzed part was recorded 
and measurements were transformed into complete measurements proportionally. Fourteen 
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EBUS images and 14 bronchial sections, selected randomly, were analyzed by the same 
observer three times at ≥ one week interval in order to assess repeatability of measures.  
 
Composition of L2 
The composition of L2 was studied using the EBUS images obtained in vivo and the 
histological sections obtained at post-mortem from the same lungs. As airways are naturally 
distended in vivo during EBUS but they contract during the fixation and embedding processes 
necessary for histology, we developed a method to estimate the mean thicknesses of the ECM 
(lamina propria) and ASM layers for maximally dilated airways (Figure 3). In brief, airways 
were treated as a series of concentric annuli in which the thickness of the epithelial layer was 
considered as negligible. In our model, Pi values measured in histological sections 
corresponded to the circumference of the smaller circle of the inner annulus (representing 
ECM), and were used to calculate its radius (r’). The radius of the larger circle (R’) of the 
inner annulus was then calculated as a function of ECM area and Pi. The difference between 
the larger and the smaller radii of the inner annulus (R’-r’) corresponded to the ECM 
thickness. The same approach was used to calculate ASM thickness (R-r), with R’ being used 
as the smaller radius of the outer annulus (r). To validate our approach, the calculated ECM 
and ASM thicknesses were compared with values measured using standard histomorphometric 
techniques [3, 7, 16] on the same histological sections: the mean value of 5 measures 
performed randomly for each airway represented our measured ECM and ASM thickness.  
Finally, the sum of ECM and ASM thickness calculated at histology (histologic submucosal 
thickness) was compared to the sum of L1 and L2 thickness (EBUS submucosal thickness). 
The percentage of the total airway thickness occupied by ECM and ASM at histology was 
calculated and related to the thickness and composition of L1 and L2.  
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Statistical analysis 
Statistical analyses were performed with SAS v.9.3 (Cary, NC, USA). Mixed linear models 
with “subject” used as a random effect, and Bland-Altman tests were used to compare 
measurements from EBUS and histology. Mixed linear models with “group” and “bronchial 
size” as fixed effects were used for group comparisons including random factors to take into 
account the non-independent measures from the same subject for different bronchial sizes and 
for repetitions within bronchial size. A priori contrasts were performed, adjusting the alpha 
level of each comparison with the Bonferroni sequential procedure, to compare group means 
at each bronchial size. Two types of airways were defined depending on the size of Pi 
(intermediate: Pi ≤31 mm; large: Pi>31 mm). Mixed covariance linear models were used for 
studying how variables varied with Pi; the “group” was used as a fixed effect, “Pi” was used 
as a co-factor and “subject” as a random effect.  
Variance component analyses were performed for the repeatability of EBUS and bronchial 
section measurements. The same analysis was also carried out within individuals for repeated 
measurements of L1, L2, L2 area/Pi and L2 area/Pi2. The effect of bronchial size (3 classes, 
based on Pi: 0-16 mm, 16-31 mm and >31 mm) was studied with a mixed linear model with 
“group” and “Pi class” as fixed effects. A priori contrasts were performed, again with the 
sequential Bonferroni procedure, to compare group means within each Pi class. The 
coefficient of variation (CV) was calculated for airway values obtained from 2, 3, and 4 
images, to determine how many images should be analyzed to provide a reliable estimate. The 
level of statistical significance was set at 0.05 throughout.  
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Results 
Phase 1 - Needle Puncture Experiments 
Experiments were performed on 26 bronchial samples from 6 horses.  The first hyperechoic 
layer (L1) corresponds to the epithelium and to a variable portion of the underlying ECM. The 
second hypoechoic layer (L2) corresponds to the remaining fraction of ECM and smooth 
muscle (Figure 4). When cartilage is present, L3, L4 and L5 correspond to the cartilage 
internal surface, cartilage thickness, and external cartilage surface and adventitia, respectively. 
Occasionally, a second, more abaxial cartilage could be identified. In the absence of cartilage, 
L3 corresponds to the adventitia.  
 
Phase 2 - EBUS-histology comparison 
A total of 109 isolated bronchi obtained from 13 horses were scanned and subsequently 
processed for histology. Repeatability of histologic measurements was excellent with an intra-
class correlation coefficient of 99.0% for Pi, 98.5% for AASM, and 95.5% for AASM/Pi2 
values. Repeatability of EBUS measurements was also generally good with an intraclass 
correlation coefficient (ICC) of 99.6% for Pi, 81.6% for L1, 87.3% for L2, 94.2% for L2 
area/Pi, and 92.3% for L2 area/Pi2 values. Overall, a good agreement was observed between 
the two methods for all parameters measured, except for L2 area/Pi2 and AASM/Pi2 (see data in 
Table 3 and Figure S1). Bland-Altman tests revealed that EBUS tended to underestimate Pi 
when compared to histology, and differences tended to get larger as values of Pi increased 
(Figure S2). Also, EBUS overestimated D values for small bronchi and underestimated them 
for large bronchi. However, these differences in D were considered clinically negligible, as the 
mean difference between the 2 measurements was 0.14 mm.  
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Phase 3 - Ex vivo test and optimization 
Four lungs obtained from horses with heaves and 7 from controls were studied after removal 
from the thoracic cage. None of the lungs showed significant macroscopic alterations. A mean 
of 8 to 10 airways was analyzed in each lung. Our first aim was to investigate whether a 
difference in submucosal remodeling could be observed ex vivo between horses with heaves 
and controls, in the absence of any noise generated by respiratory movements. Airways of 
similar sizes were analyzed in both groups (Pi [mean±SD] 20.6±4.9mm in heaves; 
21.2±3.5mm in controls, p=0.65). When bronchi of both groups of horses were analyzed 
together, values of L1, (p=0.0003), L2 (p=0.001), and L2 area/Pi (p=0.004) were significantly 
larger in large rather than intermediate airways. Conversely, L2 area/Pi2 was larger in 
intermediate rather than in large airways (p=0.02), which we ascribe to the effect of the 
disease (remodeling). In both groups of horses, L1, L2 and L2 area/Pi increased with Pi, while 
L2 area/Pi2 decreased (statistical details are provided in Figure 5). When analyzing only 
intermediate airways, the slope of the curve of the control group for L2 area/Pi2 was not 
significantly different from zero (slope=-0.00022, p=0.13).  The slope of the relationship 
between L2 area/Pi2 and Pi was significantly higher in the heaves group than in the control 
group (p=0.01). L2 (p=0.009), L2 area/Pi (p=0.004) and L2 area/Pi2 (p=0.02), but not L1 
(p=0.4) values, were significantly larger in horses with heaves than in the controls. L2 area/Pi 
(p=0.006) and L2 area/Pi2 (p=0.003) were also greater in intermediate airways of horses with 
heaves than in controls. L2 tended to be thicker in intermediate bronchi of horses with heaves 
than controls, although it did not reach statistical significance (p=0.06). In large bronchi, only 
L2 area/Pi values were greater in horses with heaves than controls (p=0.006) (Figure 5). 
Secondly, we aimed at optimizing our imaging technique using an approach as similar as 
possible to those we use in vivo. The greatest variation observed in all EBUS parameters 
measured ex vivo (L1, L2, L2 area/Pi and L2 area/Pi2) was attributable to the size of the 
airways in individual horses. However, analyzing 8-10 airways per horse of similar mean size 
allowed yielding significantly higher inter-group variation compared to inter-subject variation 
within the same group (Table 4). CV analysis showed that a minimum of 3 images of good 
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quality for each airway provided a reliable estimate of the real values of all the parameters 
analyzed.  
 
Phases 4 and 5 - In vivo EBUS and histological validation 
EBUS was performed in vivo in 7 animals (4 horses with heaves and 3 controls), all of which 
were then euthanized and EBUS immediately repeated on 4 of them (3 heaves and 1 control, 
as the lungs of the other animals were severely contaminated with blood). EBUS was 
performed on the same lung imaged in vivo using the same approach, in order to compare the 
results. A similar number of airways was analyzed on the two occasions (10.7±4/horse in vivo 
and 9.5±4/horse ex vivo, p=0.6). Three to 4 images were analyzed for each airway. Lung 
collapse occurring with lung removal from the thoracic cage did not significantly change the 
values of L2, L2 area/Pi, and L2 area/Pi2 (p=0.46, p=0.79 and p=0.17, respectively). L1 tended 
to be thicker when measured ex vivo (p=0.09), however. This supports and validates the ex 
vivo findings we have described above. 
In vivo, in both groups of horses, L1, L2 and L2 area/Pi increased with Pi, while L2 area/Pi2 
decreased (statistical details are provided in the legend of Figure 6). As previously shown ex 
vivo, the slope of the relationship between L2 area/Pi2 and Pi was not statistically different 
from zero in intermediate airways of control horses (slope=-0.00026, p=0.08). The slopes of 
the relationships between L2 and Pi, and between L2 area/Pi and Pi were significantly higher 
in horses with heaves than controls (p=0.02 and p=0.04, respectively). L2 (p=0.03), L2 area/Pi 
(p=0.005), and L2 area/Pi2 (p=0.04), but not L1 (p=0.27) values, were significantly larger in 
horses with heaves than in controls. L2 area/Pi was significantly larger in intermediate airways 
of horses with heaves than in controls (p=0.003). L2 and L2 area/Pi2 values tended to be 
greater in intermediate airways of horses with heaves than in controls (p=0.03 and p=0.02, 
respectively, but not statistically significant after Bonferroni correction). In large bronchi, only 
L2 area/Pi values were higher in horses with heaves than controls (p=0.04) (Figure 6C). Power 
analysis indicated that n=6 horses per group would be needed to show a statistically significant 
effect 80% of the times if there was a 30% difference of L2 thickness or a 60% difference of 
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L2 area/Pi2 between the two groups when n≈10 bronchi of similar size are analyzed in each 
subject (Table 5).  
Post-mortem histological analyses were performed. Morphometrical analysis of 8 to 10 
bronchial sections per lung confirmed that AASM/Pi2 was significantly larger in horses with 
heaves than in the controls (p=0.04) pooling all bronchi. Overall, AASM/Pi2 values were larger 
in intermediate than in large bronchi (p=0.02) and a significant difference between horses with 
heaves and controls was observed in intermediate (p=0.03) but not in large bronchi (p=0.29). 
AECM/Pi2 values were similar between the two groups across all bronchi (p=0.26) and also 
when measured in intermediate and large bronchi separately (p>0.1 for both, Figure 7). 
 
Composition of L2 
The mean thickness of ASM in the airways of both heaves-affected and control horses varied 
with airway size (p=0.0009). For this reason, we analyzed only airways with Pi<26mm, whose 
number and mean Pi was similar in both groups (Table 6). ASM and ECM calculated 
thickness were increased in the airways of asthmatic horses compared to controls (p=0.057 
and p=0.02, respectively). Interestingly, both ASM and ECM thickness were overestimated 
when measured manually compared to when it was calculated using our derived measurements 
(mean±SD reduction of 33.3±12.1% for ASM and of 28.5±12.5% for ECM calculated values, 
Figure 8). Histologic submucosal thickness (the sum of ECM and ASM calculated 
thicknesses) was increased in horses with heaves compared to controls (p=0.027). The 
submucosal composition of the equine airways is affected by both disease and airway size 
(Figure 9). Indeed, the slopes of ECM% and ASM% were significantly different in the 2 
groups (p=0.02) and a significant association between Pi and ECM% and between Pi and 
ASM% was found in horses with heaves (p=0.04) but not in controls (p=0.2). No significant 
differences were identified between the mean proportional content of ECM or ASM relative to 
the total submucosal layer between controls and heaves-affected horses (p=0.3 for both). L1 
represented entirely ECM in horses of both groups. L2 represented ECM and ASM in similar 
proportion in both groups of horses. Indeed, on average, 22% of L2 represented ECM and 
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78% represented the ASM in control horses, while 28% of L2 represented ECM and 72% 
represented ASM in horses with heaves (p=0.6 for both) (Figure 10). 
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Discussion 
Airway remodeling is a central feature of asthma. ASM mass is increased in central airways, 
more prominently in severe and fatal asthma [2]. However, its quantification in vivo is 
difficult, as imaging techniques such as computerized tomography or magnetic resonance 
imaging do not allow visualization of ASM, and endobronchial biopsies often provide 
incomplete sampling [8]. While EBUS has revealed an increase in L2 thickness in asthmatics 
compared to healthy subjects, which has been linked to ASM remodeling indirectly by means 
of bronchoprovocation tests [13], this is the first report directly comparing L2 remodeling with 
EBUS and ASM remodeling in histology. Using EBUS, we found that in the central airways 
of horses L2 is composed mainly by ASM (about 75% of its thickness) with the remaining 
25% representing ECM, independently from the presence or absence of heaves-associated 
remodeling. Indeed, EBUS reliably quantified the ASM mass in both healthy and asthmatic 
animals, providing accurate estimates compared to histology, and this despite the high 
variation in remodeling likely to occur even within the same airway as reported in man [17]. 
Our in vivo results support EBUS usefulness for monitoring bronchial remodeling over time or 
during pharmacological treatments in this model. Importantly, its relative non-invasiveness 
will permit evaluating the same sites at different points in time. 
Echographic anatomy of the equine bronchial wall is similar to that of man [11, 13] and sheep 
[18], in which this technique has previously been reported. The thickness of the first EBUS 
layer (L1), representing the bronchial epithelium and the most axial part of the underlying 
ECM, was not affected by disease status in our study. Contrarily, the thickness of the second 
EBUS layer (L2), representing the more abaxial part of the ECM and the ASM, was 
significantly increased in horses with heaves compared to controls. Curiously, L2 (and not L1) 
thickness has been shown to correlate with basal membrane thickness in human asthma 
although a significant difference between the thickness of L1 was observed in the same study 
between asthmatics and controls [12]. As L2 represents ASM and a variable part of the ECM 
[11] which does not include the basal membrane, its significant relationship with basal 
membrane thickness in asthmatics was more likely a spurious correlation rather than a 
histologic confirmation of EBUS findings. Indeed, it has been shown that the reticular 
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basement membrane thickness of central airways is correlated with submucosal airway 
remodeling in cartilaginous airways of asthmatics [8]. Increased basal membrane thickness has 
not been reported in heaves to our knowledge. However, preliminary observations from our 
laboratory suggest that basal membrane thickening is only an occasional finding in heaves, 
validating the fact that no difference was observed in L1 thickness between the 2 groups that 
we studied. Our results highlighted that ASM was mostly responsible for the increased L2 
thickness in EBUS images of asthmatic horses compared to controls, and demonstrated that 
not only small [19, 20] but also large airways can exhibit remodeling in heaves. The 
significant association observed between values of AASM and L2 area, the absence of 
systematic bias for ASM quantification between histology and EBUS, and the similarity of 
ECM mass in the 2 groups found in this study already suggested that L2 changes in asthmatic 
horses mainly reflected ASM mass increases. This was confirmed by the finding that ASM 
represents on average 75% of L2 in both control and asthmatic horses. Horses experiencing 
exacerbations of the disease showed increased ECM mass in endobronchial biopsies 
(measured as the distance between the epithelium and the ASM layer) compared to controls 
[7]. In our study, we also found that ECM calculated thickness was increased in intermediate 
bronchi of asthmatic horses compared to controls. However, values of AECM/Pi2 were similar 
in both groups. As both ASM and ECM thickness increase at increasing Pi, it is possible that 
despite Pi of the airways analyzed in both groups being similar, the small gap between the 
mean values of airway size of the 2 groups could have accounted for the statistical 
significance. Alternatively, as ECM represents constantly 25% of L2 and L2 thickness is 
increased in heaves, it is likely that ECM sustains a certain degree of remodeling in heaves, 
but it could be mild and thus lost with normalization (correction by Pi2). Finally, analyses for 
ECM/Pi2 were made on intermediate airways with Pi<31mm while analyses for ECM 
thickness were made on airways with Pi<26 mm, in order to have the same number of airways 
of similar Pi in both groups. It is possible that values of airways with 26mm<Pi<31mm could 
have accounted for the difference observed.  
We have attempted for the first time to describe the composition of L2 in the asthmatic 
airways by studying naturally occurring equine heaves. Our results indicate that ASM 
accounts for approximately 75% of L2 in both healthy and diseased animals, with ECM 
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representing the remaining 25%. Our finding of a constant portion of L2 being occupied by 
ASM is in agreement with the results of a previous study in which a significant correlation 
between L2 thickness and airway hyperresponsiveness was found in asthmatic patients [13]. 
Indeed, two different studies have shown that the increase in ASM mass is potentially the most 
important structural determinant explaining hyperresponsiveness in asthmatics [21, 22]. Data 
obtained on lungs of healthy and asthmatic human lungs suggest that the proportion of the 
submucosa occupied by the ASM in man might be lower compared to those we found in 
horses in airways of similar size [5, 23]. Nevertheless, the thickness of the submucosal tissues 
measured at EBUS appears to be similar between the two species, considering airways of 
similar size [12].  
We have also explored for the first time the relationship between bronchial size and ASM 
remodeling as estimated by EBUS (L2 thickness or L2 area). L2 thickness increased linearly 
with bronchial size in both asthmatic and healthy equine airways, which is in agreement with 
the ASM distribution along the bronchial tree (expressed as ASM thickness) in man [24]. 
Remarkably, such increase was steeper in asthmatic airways compared to controls. This 
finding, supported by our histological findings, indicates that heaves can display a phenotype 
similar to the type II form of asthma as defined by Ebina [23], characterized by remodeling of 
small [25] and large airways, at least in some cases. We also explored L2 area/Pi2 ratio, as its 
histological equivalent AASM/Pi2 is commonly used for ASM mass normalization [25, 26]. Pi2 
accounts for the relatively greater amount of both ASM and ECM components in small than in 
large bronchi [27, 28]. As previously demonstrated for AASM/Pi2, the slope of the curve of L2 
area/Pi2 ratio plotted against airway size (expressed as Pi) was non-significant in intermediate 
airways of control horses, confirming appropriateness of normalization. The lack of 
correlation between L2 area/Pi2 ratio and its histological equivalent AASM/Pi2 was possibly due 
to amplification of the bias of Pi (underestimated by EBUS, especially in larger airways) when 
raised to the power of 2. However, since bias of Pi measures was constant in both groups, we 
judged it correct to compare their L2 area/Pi2 ratio values in our analysis.   
Variability among different airways constituted the main source of variation in our ex vivo 
study for the remodeling parameters assessed. This finding was expected due to our study 
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design, in which airways of different size were studied in each subject. However, the second 
greatest source of variation was represented by the group (heaves vs control) for all parameters 
studied, supporting the role of EBUS in the assessment of central remodeling in heaves. 
Similar findings were observed in vivo. A greater variation among different images of the 
same airway was observed in vivo compared to ex vivo, possibly due to the respiratory 
movements. L2 area/Pi2 variation among different airways was greater ex vivo than in vivo. 
We ascribed this finding to the fact that different degrees of pulmonary collapse could have 
occurred in the lungs of different animals or at different levels of the bronchial tree within the 
same lungs. The finding that L1, L2, and L2 area/Pi are affected by airway size highlights the 
importance of sampling airways of similar sizes in different subjects in order to avoid 
sampling bias when these parameters are used.  
From a clinical perspective, our results support the implementation of EBUS as a tool for 
assessing large airway remodeling in asthmatic patients. Despite its relatively low 
invasiveness (compared for instance to the endobronchial biopsy procedure) and relative ease 
of analysis of measurements, this technique is underemployed in asthma possibly because of 
its slow learning curve [29, 30], and paucity of data supporting its use to assess airway 
remodeling in asthma. Our findings that EBUS reliably assesses ASM mass in proximal 
airways in heaves, combined with the previous report correlating EBUS L2 thickness and lung 
function in asthma [13], support the use of this technique for evaluating the efficacy of 
treatments at reducing ASM mass in asthmatics.  EBUS may also prove useful for defining 
specific asthma phenotypes based on different ASM remodeling patterns along the bronchial 
tree [31], possibly predicting their response to specific treatments. In this perspective, the 
assessment of a single airway as described in previous studies investigating airway remodeling 
with EBUS [12, 13]  does not take into account the heterogeneity existing among different 
airways or even among different sections of the same airway [17], and could represent an 
important source of bias even when the same airway is evaluated in all subjects. Our study 
showed that the assessment of 8 to 10 bronchi reliably estimated the ASM mass in both heathy 
and asthmatic horses, and it was always performed in less than 15 minutes, which do not 
exceed times reported in man for a standard EBUS procedure [32].   
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Our study has some limitations. First, we could not obtain physiological data of the horses 
studied in vivo. Indeed, most horses undergoing euthanasia were client-owned, and the short 
period of time elapsing between euthanasia decision and death did not allow lung function 
testing. The number of horses employed in the in vivo phase is limited, but as in vivo data 
reflected what previously observed ex vivo we believe that it was sufficient to support our 
conclusions. Finally, the morphometric analyses performed on ECM were limited to the 
lamina propria, as we did not consider the ECM elements outside the ASM layer. This was 
mainly due to technical difficulties, as collagen fiber shredding often preventing a reliable 
assessment of ECM mass outside the ASM layer. Previous studies evaluating ECM 
remodeling in horses with heaves and asthmatic patients have used the same approach both in 
small and in large airways [3, 7, 16, 20].  
In conclusion, our results indicate that EBUS provides reliable estimates of ASM remodeling 
in both asthmatic and healthy airways, and allows differentiation of such conditions based on 
remodeling features. Contrarily to endobronchial biopsies, it offers the possibility of studying 
non-carinae-derived bronchial tissue and to do it prospectively in the same airways as physical 
removal of bronchial tissue is not required. Finally, EBUS represent a promising technique for 
assessment of drug efficiency in reversing asthma-associated remodeling over time in a safe 
and non-invasive way.   
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Figures and tables   
 
Table 1. Study design.  
Phase Aim(s) Methods Samples/Animals 
1 Describing equine echographic 
bronchial anatomy 
NPE 26 bronchial samples from lungs of 6 slaughtered 
horses* 
2 Comparing measures of interest 
performed with EBUS and 
histology  
EBUS and histology   109 bronchial samples from lungs of 13 
slaughtered horses* 
3 Ex vivo technique optimization 
and “proof of concept” 
EBUS on isolated 
 lungs 
lungs from 4 horses with heaves and 7 controls  
4 In vivo EBUS EBUS on  horses 4 horses with heaves and 3 controls  
5 Validation                                      
a. assessing the effect of lung 
removal from the thorax 
(collapse) on EBUS;               
b. histological validation . 
EBUS and histology 
on post-mortem 
specimens of horses 
studied in phase 4 
same horses studied in phase 4 
 
* Lungs with obvious macroscopic alterations were excluded from the study. NPE: needle 
puncture experiments; EBUS: endobronchial ultrasound. 
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Table 2. Details of the animals studied in vivo. 
Horse  Group Age      
[years] 
Breed Disease status Clinical 
score 
Weight 
[kg] 
Mucus 
score 
Septum 
thickness 
Bronchiectasis DeltaPL 
[cmH2O] 
RL 
[cmH2O/L/sec] 
1 Control 12 QH  - 2/8 480 0/5 2/4 no   
2 Control 25 QH  - 3/8 450 0/5 0/4 regional   
3 Control 8 Pony  - 2/8 253 0/5 1/4 no   
4 Heaves 27 QH Remission 4/8 438  1/5 2/4 yes   
5 Heaves 14 STB Symptomatic 6/8 430  1/5 3/4 yes 25 1.8 
6 Heaves 15 QH Symptomatic  5/8 450  2/5 4/4 yes   
7 Heaves 27 Polo Pony Symptomatic 6/8 450  3/5 2/4 regional   
 
QH: Quarter Horse; STB: Standardbred. Clinical scores were assessed as defined by Robinson [33]. Septum thickness was assessed 
as defined by Koblinger [15]. Ante-mortem BAL data were not available. Pulmonary mechanics were available only for one horse, 
as it belonged to our research herd.  
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Table 3. Mixed linear models and Bland-Altman tests for comparison between EBUS and histologic measurements. 
    Mixed linear model Bland-Altman test (EBUS-histology) 
Parameter N p-value R2 Difference      
mean (SD) 
Mean           
mean (SD) 
Slope1           Intercept2       Systematic 
bias 
Perimeter [mm] 101 <0.0001 0.20  -5.04 (6.99)  22.67 (8.52) -0.42, p<0.0001 4.46, p=0.02 yes 
Diameter [mm] 101 <0.0001 0.30  0.14 (1.51)  4.7 (2.15) -0.15, p=0.04 0.87, p=0.03 yes 
Lumen area [mm2] 21 <0.0001 0.80  -4.59 (15.98)  34.07 (42.67) -0.15, p=0.08 0.44, p<0.98 no 
AASM*L2 area [mm2] 98 <0.0001 0.31  -0.0534 (1.843) 3.3263 (2.99) -0.01, p=0.083 0.005, p<0.99 no 
AASM/Pi*L2 area/Pi [mm] 98 0.001 0.16  0.0312 (0.0634) 0.1323 (0.06) 0.27, p=0.02 -0.004, p<0.78 yes 
AASM/Pi2*L2 area/Pi2 [-] 98 0.45 0.030  0.0029 (0.0038) 0.0062 (0.002) 0.93, p<0.0001 -0.003, p=0.006 yes 
 
1 p values refer to the null hypothesis that the slope=0. 
2 p values refer to the null hypothesis that the intercept=0. 
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Table 4. Variance component analysis. 
Ex vivo analysis 
Parameter Variation (%) 
Group Subject Airway Images  
L1 0 8.5 72.2 19.3 
L2 27.1 3.3 55.7 13.9 
L2 area/Pi 38.4 5.1 41.5 15 
L2 area/Pi2 32.5 0 42.5 25 
In vivo analysis 
Parameter Variation (%) 
Group Subject Airway Images  
L1 7.2 12.6 53.6 26.6 
L2 33.6 0 43.1 23.3 
L2 area/Pi 46.3 0 30.2 23.5 
L2 area/Pi2 29.7 7.4 10.3 52.6 
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Table 5. Power analysis for in vivo EBUS.  
Parameter Expected magnitude 
of the effect 
N 
L2 15% 22 
 30% 6 
  60% 2 
L2 area/Pi 15% 80 
 30% 21 
  60% 7 
L2 area/Pi2 15% 76 
 30% 21 
  60% 6 
  
N represents the number of subjects needed to obtain a statistically significant effect of the 
group 80% of the times for different effect sizes (expressed as %) using the methodology 
described earlier.  
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Table 6. Data used for determining L2 composition. 
 Controls Heaves p value 
Histology 
N [airways/horse] 4.67±0.57 5±2.16 0.58 
Pi [mm] 18.94±1.91 20.09±3.93 1.00 
ECM  thickness [mm] 0.0833±0.014 0.1356±0.025 0.02 
ASM thickness [mm] 0.0762±0.008 0.1254±0.04 0.057 
Submucosal thickness [mm] 0.160±0.011 0.261±0.05 0.027 
Submucosal ECM % at histology 52±3.2 53.5±2.9 0.3 
Submucosal ASM % at histology 48±3.2 46.5±2.9 0.3 
EBUS 
N [airways/horse] 7.67±5303 8.5±3.70 0.85 
Pi [mm] 16.19±1.71 19.86±1.61 0.11 
L1 thickness [mm] 0.11±0.003 0.127±0.010 0.06 
L2 thickness [mm] 0.177±0.022 0.269±0.021 0.004 
Submucosal thickness [mm] 0.287±0.024 0.397±0.015 0.024 
Submucosal L1% at EBUS 38.5±2.5 32.1±3.2 0.037 
Submucosal L2% at EBUS 61.5±2.5 67.9±3.2 0.037 
Composition of L1 
ECM% 100 100 1 
ASM% 0 0 1 
Composition of L2 
ECM% 22.1±8.9 28.1±5.7 0.63 
ASM% 77.9±8.9 71.9±5.7 0.63 
Others 
Shrinkage (%) 44.28±4.88 47.41±7.92 0.7 
Values are presented as mean±SD of the values obtained from the airways of 4 horses with 
heaves and 3 controls. Bold characters indicate significance as results of t-tests. Mean values 
per horse were used as statistical unit.  
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Figure 1. Illustrative images of a needle puncture experiment (NPE). Note the echo 
produced by the needle inserted longitudinally to the long axis of the bronchus in B (white 
arrow), and its corresponding histological localization as identified in C (black arrow). Dotted 
lines represent needles positioned transversally to the longitudinal axis of the bronchus. 
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Figure 2. Measurements made on EBUS (A) and histological (B) images. Only a part of L2 
area and ASM area have been encircled in yellow, to allow the reader appreciate the rest of the 
image. L: US layer; D1 and D2: perpendicular diameters (blue dotted lines); LA: lumen area 
(filled light green area); Pi: airway perimeter (continuous green line).   
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Figure 3. Scheme of a distended bronchial wall. In our mathematical model, the bronchial 
wall was treated as a structure composed of multiple concentric annuli. Excluding the inner 
annulus, representing the epithelial layer (in purple, negligible in thickness), we considered the 
submucosa as composed by two annuli representing the ECM (yellow) and ASM (pink). Pi 
corresponded to the yellow circumference in our model.  
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Figure 4. Comparison of EBUS and histological composition of equine airways. In the 
absence of cartilages, L3 was represented by the adventitia.  
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Figure 5. Effect of group and airway size on L1 thickness (A), L2 thickness (B), ratio L2 
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area/Pi (C), and ratio L2 area/Pi2 (D) in ex vivo EBUS. Raw data (before statistical 
corrections) are presented as mean per animal in the graphs on the left, and as mean per airway 
in the graphs on the right. L1 and L2 thickness was similar in horses with heaves and controls 
across all bronchi (p=0.4 and p=0.1, respectively). Contrarily, L2 area/Pi and L2 area/Pi2 ratios 
were greater in horses with heaves than controls across all bronchi (p=0.004 and p=0.02, 
respectively). L1 values were similar in intermediate (Pi<31mm, p=0.82) and large bronchi 
(Pi>31mm, p=0.32) analyzed separately. L2 tended to be thicker in intermediate bronchi of 
horses with heaves than in controls (p=0.06) but not in large bronchi (p=0.5). Both L2 area/Pi 
and L2 area/Pi2 ratios were greater in intermediate bronchi of horses with heaves then controls 
(p=0.006 and p=0.003, respectively), but only L2 area/Pi ratios were greater also in large 
bronchi (p=0.04; p=0.3 for L2 area/Pi2 ratios). Overall, L1, L2 and L2 area/Pi values were 
greater in large than intermediate bronchi (p=0.0003, p=0.001, and p=0.002, respectively), 
while L2 area/Pi2 values were greater in intermediate than in large bronchi (p=0.02). L1, L2, 
and L2 area/Pi increased significantly with Pi in both groups (p<0.0001 for all), while L2 
area/Pi2 decreased significantly with increasing Pi (p<0.0001). The slope of the relationship 
did not differ between the two groups for L1, L2 and L2 area/Pi (p=1, p=0.14, p=0.66, 
respectively), but it was significantly greater in the heaves group than in controls for L2 
area/Pi2 (p=0.01).  #: significantly different from controls. *: significant difference between 
values of intermediate and large bronchi (pooling the two groups). 
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Figure 6.  Effect of group and airway size on L1 thickness (A), L2 thickness (B), ratio L2 
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area/Pi (C), and ratio L2 area/Pi2 (D) in in vivo EBUS. Raw data (before statistical 
corrections) are presented as mean per animal in the graphs on the left, and as mean per airway 
in the graphs on the right. L1 was similar in horses with heaves and controls across all bronchi 
(p=0.27). Contrarily, L2 thickness, L2 area/Pi and L2 area/Pi2 ratios were greater in horses 
with heaves than controls across all bronchi (p=0.03, p=0.005 and p=0.04, respectively). L1 
values were similar in intermediate (Pi<31mm, p=0.13) and large bronchi (Pi>31mm, p=0.63) 
analyzed separately. L2 tended to be thicker in intermediate bronchi of horses with heaves 
than in controls (p=0.03, non-significant after correction) but not in large bronchi (p=0.13). 
Both L2 area/Pi and L2 area/Pi2 ratios were greater in intermediate bronchi of horses with 
heaves then controls (p=0.003 and p=0.02, respectively), but only L2 area/Pi ratios were 
greater also in large bronchi (p=0.04; p=0.22 for L2 area/Pi2 ratios). Overall, L1, L2 and L2 
area/Pi values were greater in large than intermediate bronchi (p=0.002, p=0.005, and p=0.01, 
respectively), while L2 area/Pi2 only tended to be greater in intermediate than in large bronchi 
(p=0.05). L1, L2, and L2 area/Pi increased significantly with Pi in both groups (p<0.001 for 
all), while L2 area/Pi2 decreased significantly with increasing Pi (p<0.001). The slope of the 
relationship did not differ between the two groups for L1 and L2 area/Pi2 (p=0.86 and p=0.49, 
respectively), and it was significantly greater in horses with heaves for L2 and L2 area/Pi 
(p=0.02 and p=0.04, respectively).  Filled dots represent heaves and open dots represent 
controls. #: significantly different from controls. *: significant difference between values of 
intermediate and large bronchi (pooling the two groups). 
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Figure 7.  Effect of group and airway size on AASM/Pi2 (A) and AECM/Pi2 (B) measured on 
histological sections.  Raw data (before statistical corrections) are presented as mean per 
animal in the graphs on the left, and as mean per airway in the graphs on the right. 
Histological analysis confirmed in vivo and ex vivo EBUS findings concerning ASM 
remodeling. The slope of the AASM/Pi2 relationship was similar between the 2 groups (p=0.26), 
but heaves-affected horses had significantly higher values compared to controls (p=0.04). The 
slope of the AECM/Pi2 relationship tended to be different between the 2 groups (p=0.07), but 
heaves-affected horses had similar values compared to controls (p=0.26).  #: significantly 
different from controls. *: significant difference between values of intermediate and large 
bronchi (pooling the two groups).  
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Figure 8. Effect of the method used for measuring ASM (A) and ECM (B) thickness in 
histologic bronchial samples. Results are shown as mean values per horse. 1Mean value of 5 
measures of ASM or ECM thickness performed manually and randomly around the bronchial 
circumference (ECM was measured from the basal membrane to the ASM inner border, 
avoiding regions where obvious collagen fiber shredding occurred). 2Thickness of the ASM or 
ECM calculated as function of the ASM or ECM area and airway Pi, as if it was a continuous 
and homogeneous layer for an airway completely distended (Pi corresponds to the inner 
circumference of an annulus). Statistical differences were calculated with paired t-tests.  
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Figure 9. Composition of the submucosal tissues at histology. Values are presented as 
percentage of the submucosal tissue occupied by ECM and ASM for each airway. N=14 for 
controls and 20 for heaves. On average, a greater percentage of submucosal thickness was 
occupied by ASM in smaller airways of horses with heaves compared to controls. This 
tendency reverses as the airway size increases. However, as the submucosal thickness is 
increased in horses with heaves compared to controls, the absolute thickness of the ASM layer 
still remains greater in horses with heaves than in controls for airways with Pi<26mm.    
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Figure 10. Composition of L2 is similar in asthmatic and control horses. The inner 25% is 
occupied by ECM while the remaining outer 75% is occupied by ASM. Notice that most of 
the ECM thickness lies behind the echo of L1. 
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Supporting information 
 
Table S1. Histological quality score.  
Airway section Score Description 
 
1 
Airway wall missing for >90° or cut oblique to the 
perpendicular axis of the airway or significantly 
altered tissue architecture 
 
2 
Cut perpendicular or slightly oblique to the airway 
longitudinal axis or airway wall missing for >45°, 
well preserved tissue architecture 
 
3 
Cut perpendicular to the airway longitudinal axis, 
airway wall components (epithelium/ASM) missing 
for 15-45°, well preserved tissue architecture 
 
4 
Cut perpendicular to the airway longitudinal axis, 
complete airway wall, very well preserved tissue 
architecture 
 
Images with score 1, 2 and 3 were taken at 2.5x magnification, while image scored 4 was 
taken at 5x magnification (scale bars = 1 mm in all figures).   
 206 
 
Table S2. The ARRIVE Guidelines Checklist.  
 
  
 
 
The ARRIVE Guidelines Checklist 
Animal Research: Reporting In Vivo Experiments 
Carol Kilkenny1, William J Browne2, Innes C Cuthill3, Michael Emerson4 and Douglas G Altman5 
1The National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK, 2School of Veterinary Science, 
University of Bristol, Bristol, UK, 3School of Biological Sciences, University of Bristol, Bristol, UK, 4National Heart and Lung Institute, Imperial 
College London, UK, 5Centre for Statistics in Medicine, University of Oxford, Oxford, UK. 
 
ITEM RECOMMENDATION Section/ Paragraph 
Title 1 Provide as accurate and concise a description of the content of the article 
as possible. 
 
Abstract 2 Provide an accurate summary of the background, research objectives, 
including details of the species or strain of animal used, key methods, 
principal findings and conclusions of the study. 
 
INTRODUCTION  
Background 3 a. Include sufficient scientific background (including relevant references to 
previous work) to understand the motivation and context for the study, 
and explain the experimental approach and rationale. 
b. Explain how and why the animal species and model being used can 
address the scientific objectives and, where appropriate, the study’s 
relevance to human biology. 
 
Objectives 4 Clearly describe the primary and any secondary objectives of the study, or 
specific hypotheses being tested. 
 
METHODS  
Ethical statement 5 Indicate the nature of the ethical review permissions, relevant licences (e.g. 
Animal [Scientific Procedures] Act 1986), and national or institutional 
guidelines for the care and use of animals, that cover the research. 
 
Study design 6 For each experiment, give brief details of the study design including: 
a. The number of experimental and control groups. 
b. Any steps taken to minimise the effects of subjective bias when 
allocating animals to treatment (e.g. randomisation procedure) and when 
assessing results (e.g. if done, describe who was blinded and when). 
c. The experimental unit (e.g. a single animal, group or cage of animals). 
A time-line diagram or flow chart can be useful to illustrate how complex 
study designs were carried out. 
 
Experimental 
procedures 
7 For each experiment and each experimental group, including controls, 
provide precise details of all procedures carried out. For example: 
a. How (e.g. drug formulation and dose, site and route of administration, 
anaesthesia and analgesia used [including monitoring], surgical 
procedure, method of euthanasia). Provide details of any specialist 
equipment used, including supplier(s). 
b. When (e.g. time of day). 
c. Where (e.g. home cage, laboratory, water maze). 
d. Why (e.g. rationale for choice of specific anaesthetic, route of 
administration, drug dose used). 
 
Experimental 
animals 
8 a. Provide details of the animals used, including species, strain, sex, 
developmental stage (e.g. mean or median age plus age range) and 
weight (e.g. mean or median weight plus weight range). 
b. Provide further relevant information such as the source of animals, 
international strain nomenclature, genetic modification status (e.g. 
knock-out or transgenic), genotype, health/immune status, drug or test 
naïve, previous procedures, etc. 
 
 
The ARRIVE guidelines. Originally published in PLoS Biology, June 20101 
Housing and 
husbandry 
9 Provide details of: 
a. Housing (type of facility e.g. specific pathogen free [SPF]; type of cage or 
housing; bedding material; number of cage companions; tank shape and 
material etc. for fish). 
b. Husbandry conditions (e.g. breeding programme, light/dark cycle, 
temperature, quality of water etc for fish, type of food, access to food 
and water, environmental enrichment). 
c. Welfare-related assessments and interventions that were carried out 
prior to, during, or after the experiment. 
 
Sample size 10 a. Specify the total number of animals used in each experiment, and the 
number of animals in each experimental group. 
b. Explain how the number of animals was arrived at. Provide details of any 
sample size calculation used. 
c. Indicate the number of independent replications of each experiment, if 
relevant. 
 
Allocating 
animals to 
experimental 
groups 
11 a. Give full details of how animals were allocated to experimental groups, 
including randomisation or matching if done. 
b. Describe the order in which the animals in the different experimental 
groups were treated and assessed. 
 
Experimental 
outcomes 
12 Clearly define the primary and secondary experimental outcomes assessed 
(e.g. cell death, molecular markers, behavioural changes). 
 
Statistical 
methods 
13 a. Provide details of the statistical methods used for each analysis. 
b. Specify the unit of analysis for each dataset (e.g. single animal, group of 
animals, single neuron). 
c. Describe any methods used to assess whether the data met the 
assumptions of the statistical approach. 
 
RESULTS  
Baseline data 14 For each experimental group, report relevant characteristics and health 
status of animals (e.g. weight, microbiological status, and drug or test naïve) 
prior to treatment or testing. (This information can often be tabulated). 
 
Numbers 
analysed 
15 a. Report the number of animals in each group included in each analysis. 
Report absolute numbers (e.g. 10/20, not 50%2). 
b. If any animals or data were not included in the analysis, explain why. 
 
Outcomes and 
estimation 
16 Report the results for each analysis carried out, with a measure of precision 
(e.g. standard error or confidence interval). 
 
Adverse events 17 a. Give details of all important adverse events in each experimental group. 
b. Describe any modifications to the experimental protocols made to 
reduce adverse events. 
 
DISCUSSION  
Interpretation/ 
scientific 
implications 
18 a. Interpret the results, taking into account the study objectives and 
hypotheses, current theory and other relevant studies in the literature. 
b. Comment on the study limitations including any potential sources of bias, 
any limitations of the animal model, and the imprecision associated with 
the results2. 
c. Describe any implications of your experimental methods or findings for 
the replacement, refinement or reduction (the 3Rs) of the use of animals 
in research. 
 
Generalisability/ 
translation 
19 Comment on whether, and how, the findings of this study are likely to 
translate to other species or systems, including any relevance to human 
biology. 
 
Funding 20 List all funding sources (including grant number) and the role of the 
funder(s) in the study. 
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Figure S1. Reliability of EBUS compared to histology (mixed lineal model). Results of 
mixed linear models for the association between the measures of perimeter (A), diameter (D), 
lumen area (E), ASM area vs L2 area (B), ASM area/Pi versus L2/Pi (C) and ASM/Pi2 versus 
L2 area/Pi2 (F) obtained with EBUS and histology. Each dot represents the mean of the 
measures made for a single airway.  
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Figure S2. Reliability of EBUS compared to histology (Bland-Altman tests). Comparison 
of measures of perimeter (A), ASM area (B), ASM area/Pi (C), diameter (D), lumen area (E) 
and ASM area/Pi2 (F) obtained with EBUS or histologic images studied with Bland-Altman 
tests. Each dot represents the mean of the measures made for a single airway. Continuous lines 
represent the mean difference between the two measuring methods (EBUS-histology). Dotted 
lines define the area where 95% of the differences should occur assuming a normal 
distribution of the differences. A negative difference means that EBUS values are smaller than 
the corresponding histology measurements. 
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Article 4  
 
Fluticasone/salmeterol synergistic effects on asthma-associated airway remodeling and 
inflammation  
 
Summary 
Combined inhalation of corticosteroids and long acting β2-agonists (ICS/LABA) is more 
effective than ICS monotherapy at controlling asthma exacerbations. However, whether 
ICS/LABA can achieve a better control of inflammation or remodeling is not well established, 
especially at the peripheral airway level. In equine asthma (heaves), the enhanced therapeutic 
effect of ICS/LABA over ICS monotherapy was associated with a reduction of ECM 
deposition, mainly observed within the large airways, and also with a decreased neutrophilia 
in the bronchoalveolar lavage. However, ICS/LABA was not advantageous over ICS 
monotherapy for reversing ASM remodeling and submucosal inflammation. 
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I contributed to the study design (40%), treatment administration (80%), data collection 
and analysis (lung function, 90%; bronchoscopies, 70%; thoracoscopies, 25%; post-
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immunohistochemistry, 90%; histomorphometry, 100%; statistical analysis, 70%), and 
preparation of the manuscript (90%).  
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At a Glance Commentary 
Scientific knowledge on the subject: 
Asthma is incurable, perhaps because peripheral airway remodeling is only partially reversible 
by the administration of anti-inflammatory therapies such as inhaled corticosteroids (ICS). 
Recent findings indicate that bronchospasm may contribute to remodeling of the airways 
independently of inflammation. This suggests that the combination of ICS and bronchodilators 
such as long acting β2-agonists (ICS/LABA) could achieve a better control of asthmatic 
airway remodeling compared to ICS monotherapy.  
What this study adds to the field: 
We studied equine heaves, a model of neutrophilic asthma, to assess the contribution of ICS, 
LABA, and their combination to reversing remodeling and inflammation in central and 
peripheral airways. Our results suggest that the enhanced therapeutic effect of ICS/LABA over 
ICS monotherapy in asthmatic patients may be associated with a reduction of extracellular 
matrix deposition, mainly observed within the large airways, and possibly also with a 
decreased neutrophilia in the bronchoalveolar lavage fluid. However, ICS/LABA does not 
provide any additional benefit to ICS monotherapy in terms of peripheral airway smooth 
muscle remodeling and submucosal inflammation as both induce a 30% decrease of the airway 
smooth muscle mass in 3 months. 
 
This article has an online data supplement, which is accessible from this issue's table of 
content online at http://atsjournals.org.   
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Abstract 
Rationale: Asthmatic airways are inflamed and undergo remodeling. Inhaled corticosteroids 
and long-acting β2-agonist combinations are more effective than inhaled corticosteroid 
monotherapy in controlling disease exacerbations, but their efficacy compared to inhaled 
corticosteroids on bronchial remodeling and inflammation is unknown.  
Objectives: To evaluate the contribution of inhaled fluticasone and salmeterol, alone or 
combined, to the reversal of inflammation and remodeling in central and peripheral airways. 
Methods: Asthmatic horses with ongoing airway remodeling and inflammation were treated 
with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance (6 horses per 
group) for 12 weeks. Lung function, central and peripheral airway remodeling and 
inflammation were assessed at multiple time points. 
Measurements and Main Results: Fluticasone/salmeterol and fluticasone monotherapy 
decreased peripheral airway smooth muscle remodeling after 12 weeks (p=0.007 and p=0.02, 
respectively). On average, a 30% decrease was observed with both treatments. 
Fluticasone/salmeterol achieved this effect mainly by reversing myocyte hypertrophy, while 
no precise pattern was observed in horses treated with fluticasone monotherapy. In central 
airways, fluticasone/salmeterol synergistically reversed extracellular matrix remodeling after 
12 weeks, both within the lamina propria (decreased thickness, p=0.005) and within the 
smooth muscle layer (p=0.004). Both fluticasone/salmeterol and fluticasone monotherapy 
decreased submucosal inflammation within central airways (p<0.05), while only 
fluticasone/salmeterol decreased bronchoalveolar neutrophilia (p=0.03) to the same extent as 
antigen avoidance already after 8 weeks.  
Conclusions: Fluticasone/salmeterol combination synergistically decreased extracellular 
matrix remodeling in central airways and bronchoalveolar lavage neutrophilia. 
Fluticasone/salmeterol and fluticasone monotherapy equally reversed peripheral airway 
smooth muscle remodeling and central airway inflammation. 
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Keywords: extracellular matrix, smooth muscle, endobronchial ultrasound, lung biopsy, 
animal models.  
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Introduction  
Bronchial wall remodeling is a hallmark of asthma (1). Airway smooth muscle (ASM), whose 
increase is proportional to disease severity (2-4) and caused by cellular hyperplasia and 
hypertrophy (5), is the major contributor to airway obstruction (6-8). Multiple studies have 
focused on central ASM remodeling using samples obtained by endobronchial biopsy (EBB) 
(2, 4). However, EBBs provide partial-thickness samples of the central airways. Furthermore, 
only carinae can be studied (9), while post mortem studies on entire lungs have shown that, in 
nonfatal asthmatics, the most marked alterations occur in the peripheral airways (3, 10).  
Compelling evidence suggests that both inflammation and bronchospasm-induced mechanical 
stress may contribute to airway remodeling (11, 12). Combining anti-inflammatory and 
bronchodilating treatments has a synergistic effect on disease control, possibly ascribable to 
their enhanced anti-inflammatory effects (13). Nevertheless, few studies have addressed the 
advantages of their combination on airway remodeling reversal in asthma. Inhaled 
corticosteroids (ICS) and long-acting β2-agonists (LABA) can reverse subepithelial fibrosis 
and angiogenesis (14, 15), whereas their effect on ASM is unclear. One study investigating 
how ICS monotherapy affects ASM remodeling suggested that asthma-associated established 
structural changes might be reversible only in peripheral airways (16). However, a reduction 
of parenchymal myofibroblasts rather than ASM mass could have accounted for the difference 
observed. Ultimately, whether ICS or the ICS/LABA combination can reverse established 
airway remodeling and whether they are equally effective centrally and peripherally remains 
undetermined.   
Peripheral airway dysfunction is associated with poor asthma control (17) and the 
effectiveness of currently employed asthma treatments at this level is questionable (18). 
Indirect small airway assessment in asthma is limited by the paucity of diagnostic tools 
available (19). Direct sampling is challenging and requires invasive procedures such as 
transbronchial biopsies or partial lung resection (20), whose implementation in human studies 
is limited by ethical considerations. In this respect, animal models represent the best available 
option for investigating small airway pathophysiology and response to treatment in asthma. 
Adult horses exposed to barn antigens can develop equine asthma (heaves), a disease 
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characterized by central and peripheral remodeling and inflammation (21, 22). Equine lung 
samples can be easily harvested, which makes asthmatic horses ideal models for the 
translational study of the reversibility of remodeling in asthma (21). A 6-month ICS treatment 
can partially reverse peripheral ASM remodeling in equine asthma, while submucosal ECM 
content decreases only after 1 year (23). We hypothesized that combination therapy with 
ICS/LABA enhances peripheral remodeling reversal compared to ICS alone, by synergistic 
anti-inflammatory and anti-remodeling effects. This study was designed for evaluating the 
specific contribution of anti-inflammatory and bronchodilator treatments, alone or combined, 
to lung function, inflammation and remodeling reversal in the equine asthma model. 
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Methods  
Animals and experimental design 
After 5 weeks of antigen exposure consisting of stabling and hay-feeding, asthmatic horses 
were treated for 12 weeks with one of four treatments. In study I, horses were either moved to 
a low-antigenic environment (pasture, considered the gold standard approach for controlling 
airway inflammation in heaves (23)) or administered inhaled fluticasone/salmeterol (Advair® 
250 HFA MDI, GlaxoSmithKline, 2500/250 μg q12 h). During study II, horses were 
administered either inhaled fluticasone (Flovent® HFA MDI, GlaxoSmithKline, 2500 μg q12 
h) or salmeterol (Sigma-Aldrich, 250 μg q8 h (24)). Horses receiving pharmacological 
treatments were kept in the offending environment (stable and hay diet). Pulmonary function, 
bronchoalveolar lavage (BAL), EBBs, peripheral lung biopsies, and endobronchial ultrasound 
(EBUS) were performed at regular intervals as described in the online supplement (Figure 
E1). The protocol was approved by the Ethics Committee of the Université de Montréal 
(Rech-1324). 
 
Histomorphometry 
Morphometry was performed on Russell-Movat-stained tissues using ImageJ (NIH, Bethesda, 
USA) and newCAST (Visiopharm, Hoersholm, Deanmark). In peripheral lung biopsies, the 
area occupied by ASM, extracellular matrix (ECM), and elastic fibers (EF) as well as myocyte 
nuclei were measured/counted manually (ASM, ECM, nuclei) or by point counting (EF), and 
corrected by the square of the basal membrane length (Pi2) to account for variation in airway 
size (25). ASM bundle composition (fraction occupied by myocytes, collagen, and elastin) 
was assessed by point counting. ASM cell size was indirectly calculated (ASM area x myocyte 
fraction of ASM bundle/myocyte nuclei). In EBBs, ASM area, ASM composition, ASM cell 
size, and lamina propria thickness (epithelium-ASM distance) were assessed (26). 
Proliferating myocytes (PCNA+/α-smooth muscle actin+ cells) were identified using 
immunohistochemistry (27) and counted manually. Myocyte proliferation density was 
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expressed as proliferating cells per ASM area. Airway inflammation was assessed semi-
quantitatively (score range: 0-2). 
 
Statistical analysis 
Statistical analysis was performed with SAS v.9.3 (Cary, NC, USA). Studies I and II were 
analyzed separately. Data not normally distributed were log10 transformed. A repeated-
measures linear model was employed with “time” as within-subject factor, “treatment” as a 
between-subjects factor, and “disease severity” as a cofactor. A priori contrasts with 
Benjamini-Hochberg correction were used for testing differences among groups and times (all 
time-points vs. baseline). Inflammation scores were analyzed with the Cochrane-Mantel-
Haenszel test for ordinal data. Paired t-test was used for analysis of residual 
bronchoconstriction after bronchodilator administration and peripheral ASM mass. A linear 
mixed model with “subject” as random-effect was used for studying associations between 
different parameters. Depending on data distribution, Spearman or Pearson test was used for 
correlations.   
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Results 
Animals 
Table 1 reports physiological details of the horses studied. 
 
Lung function 
At baseline, all horses had severe airway obstruction as demonstrated by their increased 
pulmonary resistance and elastance compared to normal values (Figure 1A,C). The 
combination of fluticasone/salmeterol normalized pulmonary resistance and elastance from 
week 1 to 12. Antigen avoidance induced a similar rapid decrease in elastance, while 
resistance decreased only after 4 weeks (Figure 1A), and remained above normal values in 4/7 
horses at 12 weeks. When fluticasone and salmeterol were administered separately, they both 
decreased resistance and elastance after 1 week of treatment, which was maintained until week 
12 only by fluticasone. The effect of salmeterol on pulmonary function was partly lost in 3 out 
of 6 horses after 8 weeks of treatment and was only temporarily restored by a single dose of 
oral dexamethasone (0.06 mg/kg) administered at the end of week 8 (28) (Figure 1C). At 
week 12, the bronchoreversibility test showed the presence of residual bronchoconstriction in 
antigen avoidance and salmeterol-treated horses (Figure 1B,D). 
 
Airway luminal inflammation 
Antigen exposure induced BAL fluid (BALF) neutrophilia (>20%) in all groups at baseline. 
Antigen avoidance reduced neutrophilia after 1 week, but only 3/7 horses had normal values 
(<5%) by week 12. Despite ongoing antigen exposure, fluticasone/salmeterol reduced BALF 
neutrophilia starting from week 8, with 3/6 horses reaching normal values at week 12 (Figure 
2A). Neither fluticasone nor salmeterol monotherapy affected BALF neutrophilia (Figure 2B). 
Total cell counts were higher in animals treated with fluticasone/salmeterol and fluticasone 
compared to antigen avoidance and salmeterol treated animals, respectively (p<0.001). 
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Peripheral remodeling reversal 
Peripheral airway remodeling was assessed in 10±4 [mean±SD] airways/horse/time during 
study I and 10±3 during study II (range: 3-25). Average airway Pi was 811±221 μm in study I 
and 883±456 μm in study II (range: 160-1996 μm); it was similar between groups and time 
points studied.  
At baseline, the ASM mass was similar in all treatment groups (Figure 3A-B). It was 
comparable to previously reported values of ASM remodeling in asthmatic horses (23, 27, 29). 
In the peripheral ASM layer, ECM was mainly comprised of elastin with rare collagen 
deposition (Table 2). Overall, peripheral ASM mass was greater in severe compared to 
moderate asthmatic horses, independently of treatment or time (p=0.004). On average, 
fluticasone/salmeterol reduced ASM mass by 27% (range: 3-45%) at 12 weeks when 
compared to baseline (p=0.007, Figure 3A). Conversely, antigen avoidance had no effect on 
ASM mass. Inhaled fluticasone alone, but not salmeterol, also reversed ASM remodeling at 12 
weeks (p=0.02, average reduction 33.6%, range: 4-62%, Figure 3B), to the same extent 
observed with fluticasone/salmeterol.  
Values of ASM mass at baseline and at 12 weeks were correlated in fluticasone/salmeterol 
(r=0.84, p=0.03), antigen avoidance (r=0.85, p=0.03), salmeterol (r=0.81, p=0.048), but not in 
fluticasone-treated horses (r=-0.07, p=0.9). ASM cell size (Figure 3C) and ECM fraction of 
ASM (Figure 4E) were decreased with fluticasone/salmeterol, contributing respectively to 
80% and 20% of the observed reduction of peripheral ASM mass at 12 weeks. Conversely, 
fluticasone alone did not affect myocyte hypertrophy or ECM fraction of the ASM layer 
(Figure 3D, 4F). Further details on ECM fraction remodeling reversal are provided online 
(Figure E2). Antigen avoidance resulted in a transient decrease of myocyte area at 4 weeks 
(Figure 3C). The number of ASM nuclei/Pi2 remained unvaried along the study period despite 
the fact that the quantity of proliferating myocytes per ASM area decreased with time in all 
groups (Figure 4B-C, 3E-F). In both studies, ASM mass correlated with ASM nuclei/Pi2 at 
baseline (r=0.92, p<0.0001 in study I; r=0.87, p=0.0003 in study II) and after 12 weeks 
(r=0.87, p=0.0002 in study I; r=0.8, p=0.001 in study II), whereas after 4 weeks of treatment 
the correlation was significant only for fluticasone-treated horses (r=0.85, p=0.03).  
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The normalized quantity of collagen and elastin in the lamina propria of peripheral airways 
was unaffected by 12 weeks of either treatment studied (Figure 5). 
 
Central airway inflammation 
Horses of all groups had severe inflammation of the epithelial and subepithelial compartments 
of their central airways at baseline. The effect of the treatments on central airway 
inflammation is reported in Figure 7. Epithelial inflammation was reduced by 
fluticasone/salmeterol after 1 week of treatment and continued to decrease until 12 weeks. The 
anti-inflammatory effect of fluticasone in bronchial epithelium was evident starting at week 4. 
Antigen avoidance and salmeterol did not exert any beneficial effect on epithelial 
inflammation. Subepithelial inflammation was reduced after 8 weeks of fluticasone/salmeterol 
treatment, while the effect was observed after 4 weeks with fluticasone alone. Only a trend 
(p=0.05) could be observed at 12 weeks for antigen avoidance treatment, while salmeterol did 
not affect subepithelial inflammation at all. 
 
Central remodeling reversal 
On average, 5 endobronchial biopsies/horse/time were analyzed in both studies (range: 3-6), of 
which 3.5±1.8 considered of good/optimal quality in study I and 3.8±1.4 in study II, with no 
differences between groups and time points studied.  
At baseline, EBUS yielded values similar to those previously published using this technique in 
asthmatic horses, indicating increased ASM (25). While antigen avoidance was ineffective, 12 
weeks of fluticasone/salmeterol reduced submucosal remodeling as indicated by EBUS 
(Figure 6B). A concomitant decrease in ASM area within endobronchial biopsies was 
observed (Figure 8A), and coincided with a reduction of the ECM fraction of central ASM 
(Figure 8D) and with a decreased density of proliferating myocytes (Figure 8B). Fluticasone 
and salmeterol administered separately did not affect ASM area (Figure 9A). Only fluticasone 
decreased myocyte proliferation at 4 and 8 weeks (Figure 9B). Conversely, we observed a 
 222 
 
tendency towards reduction of the ECM fraction within the ASM bundles in salmeterol-treated 
horses after 12 weeks (Figure 9D). Further details on reversal of ECM fraction remodeling are 
available online (Figure E3). Overall, the biopsy ASM area correlated with the collagen 
fraction of ASM in study I (p=0.03) whereas only a trend was detectable in study II (p=0.1), 
independently of treatment or time. Despite the fact that myocytes of all groups reached a 
similar size starting at 4 weeks of treatment, and maintained this size until week 12, the 
reduction was not significant in fluticasone/salmeterol and in salmeterol treated horses, due to 
the smaller size of their myocytes at baseline (Figure 8C, 9C). The thickness of the lamina 
propria decreased to values similar to those previously reported in healthy horses (26) after 12 
weeks of  fluticasone/salmeterol (Figure 8E), whereas it was partially decreased by salmeterol 
alone after 4 and 8 weeks. The effect was lost at 12 weeks (Figure 9E). Neither antigen 
avoidance nor fluticasone therapy affected lamina propria thickness. 
 
Comparison between central and peripheral ASM  
ASM bundle composition differed in peripheral and central airways, independently of 
treatment or time. Overall, ECM fraction was higher centrally than peripherally (p=0.0002). 
Within the ECM fraction, collagen predominated centrally while elastin prevailed peripherally 
(p<0.0001, Table 2). A linear relationship was observed in study I between central and 
peripheral myocyte size (p=0.007), independently of treatment or time. 
 
Relationship between EBUS and histological findings in central and peripheral airways 
Central ASM remodeling assessed with EBUS (L2 area/Pi2: area of the subepithelial layer 
corrected by the perimeter squared) negatively correlated with endobronchial biopsy ASM 
area at baseline in all horses (r=-0.62, p=0.04) and at 12 weeks only in fluticasone/salmeterol-
treated horses (r=-0.85, p=0.06). A negative correlation was expected as an increased 
thickness of the lamina propria prevents a deep sampling within the smooth muscle layer. 
Similarly, EBUS-assessed central ASM remodeling correlated with peripheral ASM mass 
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(ASM/Pi2) at baseline in all horses (Figure 6C) and at 12 weeks only in 
fluticasone/salmeterol-treated horses (r=0.88, p=0.03). 
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Discussion 
In the present study we examined the dynamics and kinetics of airway remodeling reversal 
following antigen avoidance or administration of ICS, LABA, or their combination in an 
equine asthma model. We also investigated whether the administration of 
fluticasone/salmeterol was advantageous over fluticasone monotherapy for pulmonary 
remodeling reversal and inflammation control. Notably, both peripheral and central airways 
were studied, together with the specific contribution of salmeterol monotherapy, which is 
precluded in human asthma due to safety concerns (30). The results indicate that 
fluticasone/salmeterol combination has a synergistic anti-inflammatory effect on luminal 
neutrophilia but it is equally effective as fluticasone monotherapy at reversing peripheral ASM 
remodeling in 3 months. Also, fluticasone/salmeterol synergistically facilitates ECM 
remodeling reversal in the central airways. 
ASM is increased in asthma, which greatly contributes to airway obstruction (1). The efficacy 
of asthma treatments in reversing established ASM remodeling, particularly peripherally, is 
not established. With this perspective, the importance of the present study is three-fold. 
Firstly, it confirms that peripheral ASM remodeling reversal is possible in vivo (23). 
Secondly, it provides insights into the kinetics and dynamics of such reversal. Lastly, it 
corroborates the hypothesis that peripheral remodeling is partly irreversible by currently-
employed asthma treatments. The observation of persistently increased ASM and uncontrolled 
small airway dysfunction in asthmatic patients considered adequately treated (5, 10, 31) 
further supports this theory. However, it raises the question as to whether current treatments 
are adequate. Asthma treatment efficacy is assessed using spirometry and patient-reported 
symptom perception tests, two unreliable indicators of peripheral airway disease (32). 
Persistent small airway inflammation in a patient otherwise responding to therapy is thus not 
surprising in asthma, and may foster remodeling. Equine asthma can be effectively controlled 
with high-dose ICS or oral corticosteroids as reliever therapy and low-dose ICS as 
maintenance therapy (23). Nevertheless, in the present study we have administered high-dose 
fluticasone or combined fluticasone/salmeterol as both relief and maintenance therapy, in 
order to assess whether supplemental treatment may improve small airway dysfunction. In 
agreement with our hypothesis, fluticasone/salmeterol enhanced the control of BALF 
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inflammation (typically neutrophilic in asthmatic horses) compared to ICS monotherapy. 
However, and unexpectedly, reversal of ASM remodeling did not improve beyond that 
achieved with fluticasone alone. Several reasons may explain these results. The most obvious 
would be that a portion of ASM remodeling is irreversible. Including the current study, three 
different studies performed in asthmatic horses have achieved, on average, a maximal 30% 
decrease of peripheral ASM, independently of dose, duration and type of treatment (23). 
«Premodeling» (congenital remodeling preceding symptoms) has been hypothesized in asthma 
(33) and would be consistent with our findings, but has not been confirmed. Alternatively, a 
disproportion between the detrimental effects of inflammation during the establishment of 
remodeling and the beneficial effects of inflammation control during reversal of remodeling 
could also explain our observations. Based on a mathematical model of ASM growth in 
disease, years of complete inflammation control may be required to counterbalance the ASM 
mass increase caused by a short period of severe airway inflammation (34). Conversely, 
persistent mild-degree inflammation, as observed in asthma despite treatment (35, 36), would 
freeze ASM mass in its remodeled state, preventing reversal. As the reduction of BALF 
inflammation was observed at 12 weeks in our study, the treatment effect may have been too 
short (<4 weeks) to fully appreciate any consequence for ASM remodeling. Also, the 
inappropriateness of BAL cytology for the assessment of small airway inflammation (36) and 
the ability of salmeterol to enhance peripheral mucociliary clearance (37-39) could have 
introduced a bias to our results. However, at least for mucociliary clearance, an effect on total 
cell number rather than neutrophil percentage would have been expected. The reported ability 
of β2-agonists to potentiate corticosteroid-induced neutrophil survival (40) also argues against 
the possibility that BALF neutrophilia amelioration in our study is artefactual. The molecular 
basis of the synergistic anti-inflammatory effect of ICS/LABA combinations has been 
documented in vitro (13). Some studies also suggest that salmeterol may selectively inhibit IL-
8 concentration in BALF and neutrophil influx into asthmatic airways in vivo (41, 42). Our 
findings support the potential of fluticasone/salmeterol to reduce pulmonary neutrophilia in 
asthma. Importantly, this effect was not observed with fluticasone or salmeterol 
monotherapies, which highlights the requirement for synergy. Assuming that neutrophilic 
inflammation control is maintained over time by fluticasone/salmeterol, further studies will be 
needed to understand whether it can potentiate reversal of ASM remodeling.   
 226 
 
Increased or altered ECM deposition occurs in the submucosa of asthmatic airways, possibly 
as a consequence of fibroblast and myofibroblast activation, and myocyte switching from a 
contractile to a synthetic phenotype (43). The present study demonstrates the ability of 
fluticasone/salmeterol to synergistically reverse increased ECM deposition, which is in 
agreement with in vitro data (13). Also, it shows that the onset and magnitude of this effect 
differs across bronchial structures (lamina propria vs. smooth muscle) and sites (peripheral vs. 
central). Within the ASM layer, ECM deposition was reversed both peripherally and centrally 
by fluticasone/salmeterol, while they were ineffective as monotherapies. On average, this 
effect explains 20% of the reduction in ASM observed in peripheral airways and 50% in 
central airways, assuming that changes observed by EBUS proportionately reflect ASM 
dynamics (25). Contrarily, significant effects within the lamina propria were observed only 
centrally. At this level, fluticasone and salmeterol monotherapies showed either a partial or 
transient effect, while their combination normalized the lamina propria thickness based on 
data obtained in healthy horses (26). This is in agreement with the previous observation that 6 
months of fluticasone treatment did not reduce peripheral collagen deposition within the 
lamina propria in asthmatic horses (23). The existence of intrinsic differences between central 
and peripheral fibroblasts may explain these results (44). Alternatively, the lower peripheral 
deposition of inhaled drugs (45) could also have contributed. The clinical consequences of a 
decreased ECM deposition in asthma are unclear, and may vary depending on the airway 
compartment involved (46). In asthmatic horses, collagen deposition in the lamina propria of 
peripheral airways correlated with pulmonary resistance when bronchospasm is absent (47). 
Further studies including bronchoprovocation tests before and after reversal of remodeling 
could help elucidate the role of ECM deposition, or its reversal, in asthma. 
Myocyte hyperplasia and hypertrophy are recognized features of ASM remodeling in asthma 
(5). Whether currently-administered treatment can reverse ASM cell hypertrophy and/or 
hyperplasia in human asthma is unknown. Using the equine asthma model, characterized by 
ASM hypertrophy and hyperplasia (29), previous studies have shown that 1 year of fluticasone 
monotherapy reduced peripheral ASM hyperplasia (23). Our results confirm and expand these 
observations. Indeed, while all the treatments tested decreased the density of proliferating 
myocytes, none of them reversed peripheral hyperplasia and only the combination of 
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fluticasone/salmeterol was effective in reducing peripheral hypertrophy after 12 weeks. In 
contrast, central ASM hypertrophy was reversed in less than 4 weeks by all treatments, 
suggesting that is it not related to tissue inflammation. Our finding that the transient decrease 
of central myocyte proliferating density occurred earlier with fluticasone/salmeterol compared 
to fluticasone alone is supported by in vitro studies (48). Additionally, myocardin, a protein 
promoting contractile over proliferative phenotype switching in smooth muscle cells (49), is 
increased by oral corticosteroid administration in asthmatic central ASM (50), supporting an 
anti-proliferative effect of corticosteroids in vivo. In summary, hyperplasia was not reversed 
by 3 months of either treatment; centrally hypertrophy, when present, was rapidly reversed by 
all treatments, independently of tissue inflammation, while the reversal of hypertrophy in the 
periphery required a longer time. 
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Conclusions 
This study shows that both fluticasone and fluticasone/salmeterol decrease peripheral ASM 
mass in less than 3 months in neutrophilic asthma. The synergistic anti-inflammatory effect 
exerted by fluticasone/salmeterol on BALF neutrophils was not mirrored by a simultaneous 
decrease of peripheral ASM mass compared to fluticasone monotherapy. 
Fluticasone/salmeterol also showed a synergistic effect on ECM remodeling within the lamina 
propria and ASM of central airways, which was uncoupled from submucosal inflammation 
control. ASM hypertrophy reversal occurred earlier centrally than peripherally during periods 
of asthma control. Peripheral hyperplasia probably requires more than 3 months of treatment 
to reverse. Salmeterol alone transiently decreased ECM deposition within the bronchial wall, 
but did not control inflammation. These results were obtained using a naturally-occurring 
equine asthma model. All the animals studied had intermittent clinical signs for more than 4 
years on average (range: 2-11 years) and manifested established airway remodeling. Our 
findings could help understanding the effect of currently administered treatments on airway 
remodeling in human asthma. 
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Figures and tables 
 
Table 1. Horses’ description. 
 Study I Study II 
Antigen 
avoidance 
Fluticasone/ 
Salmeterol 
p value Fluticasone Salmeterol p value 
N 7* 6  6 6  
Age [years] 18.5±6.3 15.3±4.5 0.36 14.3±5.6 15.2±3.7 0.66 
Weight [kg] 487±91 544±115 0.34 513±57 543±74 0.82 
Sex [f/m] 4/3 5/1 0.56 5/1 3/3 0.54 
Disease duration† 
[years] 
4.6±2.6 3.3±1.4 0.42 4.5±3.5 4.0±1.3 0.69 
Disease severity 
[moderate/severe] 
3/4 5/1 0.56 3/3 3/3 1 
Values are expressed as means ± S.D. * One horse in the antigen avoidance group underwent 
all sampling except peripheral lung biopsies. †: For horses with unknown history, disease 
duration was estimated as starting one year before the moment they joined the research herd, a 
possible  underestimation.  
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Table 2. ASM bundle composition during equine asthma exacerbations (baseline).  
 
 Peripheral ASM bundles Central ASM bundles 
 Myocytes Collagen Elastin Myocytes Collagen Elastin 
Antigen avoidance 87±6 0.6±0.6 12±6 84±6 15±6 0.9±0.7 
Fluticasone/Salmeterol 84±6 0.4±0.4 15±6 77±6 20±6 2±1.4 
Fluticasone 88±5 1.2±1.2 11±5 84±6 15±6 0.9±0.8 
Salmeterol 91±3 0.7±0.6 8±3 83±3 16±3 1±1 
Values are expressed in percentage [%] and as means ± S.D. ASM: airway smooth muscle. 
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Figure 1. Results of pulmonary mechanics and bronchodilator tests performed in study I (A, 
B) and II (C, D). Bronchodilator response was evaluated before and 30 minutes after the 
administration of albuterol 500 μg by inhalation in study I (B) and N-butyl-scopolamine 0.03 
mg/kg intravenously in study II. Values are expressed as means ± SEM. Dashed lines 
represent normal threshold in healthy horses. RL: pulmonary resistance; EL: pulmonary 
elastance; ΔPL: transpulmonary pressure; ‡: different from baseline of the same group for 
fluticasone/salmeterol (p<0.0001), ¤: different from baseline for antigen avoidance (p<0.05), 
*: different from baseline for fluticasone (p<0.0001), #: different from baseline for salmeterol 
(p<0.0001), §: difference between groups at the time point indicated (p<0.05).  
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Figure 2. Bronchoalveolar lavage fluid cytology of study I (A) and II (B). Values are 
expressed as means ± SEM. *: different from baseline of the same group (p<0.05); ‡: 
difference between groups at the time point indicated (p<0.05). BALF: bronchoalveolar lavage 
fluid cytology. 
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Figure 3. Peripheral airway smooth muscle remodeling. The corrected quantity of ASM, as 
well as ASM cell hypertrophy and hyperplasia were assessed by histology in study I (A, C, 
and E, respectively) and II (B, D, and F). *: Different from baseline of the same group 
(p<0.05); §: difference between groups at the time point indicated (p<0.05). ASM: airway 
smooth muscle; Pi: internal perimeter of the airway. Panels G and H show representative 
examples of the cumulative frequency distribution of peripheral ASM remodeling (ASM/Pi2 
data) in one horse treated with fluticasone/salmeterol (G, n=16 airways/time) and another one 
treated with antigen avoidance (H, n=19 airways/time). Dashed lines identify median values.  
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Figure 4. Proliferative and synthetic activities of peripheral ASM cells in study I (B, E) and II 
(C, F). Panel A shows a representative example of a peripheral airway stained by 
immunohistochemistry with anti-alpha-smooth muscle actin (pink) and PCNA (dark blue), 
counterstained with methyl-green. Black arrows indicate PCNA+ myocyte nuclei. Panel D 
illustrates a peripheral airway stained with the Russell-Movat pentachrome technique. White 
arrows indicate black-stained elastic fibers lying within the ASM layer. Scale is the same for 
all images. Each symbol represents one horse (mean value of multiple measures performed). 
Scale bar: 50 μm. *: Different from baseline of the same group (p<0.05). ASM: airway smooth 
muscle; PCNA: Proliferating Cellular Nuclear Antigen. ECM: extracellular matrix.  
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Figure 5. Peripheral remodeling of the lamina propria. A) Representative image of a small 
airway of an asthmatic horse  in which smooth muscle stains dark pink, collagen stains yellow, 
and elastin stains black (Russell-Movat penthachrome staining). Scale bar: 50 μm. B-E) 
Corrected area of total ECM and elastin lying within the lamina propria of small airways of 
the horses participating in study I (B, D) and II (C, E). Each symbol represents one horse 
(mean value of multiple measures performed). ECM: extracellular matrix; EF: elastic fibers; 
Pi: internal perimeter. 
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Figure 6. Assessment of central airway remodeling with EBUS. A) Representative image of a 
central airway obtained with EBUS in a horse with asthma. Thin white arrows indicate the 3 
hyperechoic layers of the bronchial wall representing, from the airway lumen going outwards, 
the bronchial epithelium, the inner, and the outer borders of the bronchial cartilage. The 
distance between the thick yellow arrows illustrates the thickness of L2. B) EBUS-assessed 
central airway remodeling in study I. C) Correlation between EBUS-assessed central airway 
remodeling and peripheral ASM remodeling assessed at histology in study I. Each symbol 
represents one horse (mean value of multiple measures performed). L2: second layer; EBUS: 
endobronchial ultrasound; ASM: airway smooth muscle; Pi: internal perimeter. *: Different 
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from baseline of the same group (p<0.05); §: difference between groups at the time point 
indicated (p<0.05). 
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Figure 7. Central airway inflammation was assessed with a semi-quantitative score in study I 
(A) and II (B). The x axis indicates time (weeks). Values are presented as means ± SEM. *: 
Different from baseline of the same group (p<0.05). 
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Figure 8. Endobronchial biopsy findings in study I. Uncorrected ASM area (A), myocyte 
proliferation density (B), myocyte size (C), ECM fraction of the ASM (D) and thickness of the 
ECM in the lamina propria were assessed. Values are shown as means ± SEM in panels A and 
B. In panels C, D, and E, each symbol represents one horse (mean value of multiple measures 
performed). Dashed line in panel E corresponds to the mean thickness of ECM reported in 
healthy horses in a previous study (37). *: Different from baseline of the same group (p<0.05).  
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Figure 9. Endobronchial biopsy findings in study II. Uncorrected ASM area (A), myocyte 
proliferation density (B), myocyte size (C), ECM fraction of the ASM (D), and thickness of 
the ECM in the lamina propria were assessed. Values are presented as means ± SEM in panels 
A and B. In panels C, D, and E, each symbol represents one horse (mean value of multiple 
measures performed). Dashed line in panel E corresponds to the mean thickness of ECM 
reported in healthy horses in a previous study (37). *: Different from baseline of the same 
group (p<0.05). ♮: p=0.05 from baseline of the same group.  
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Methods  
Animals and experimental design 
Nineteen horses with a known history of asthma were studied. After a 5-week antigen 
exposure consisting of stabling and hay-feeding, horses were treated for 12 weeks with one of 
four treatments. In study I, horses were either moved to a low-antigenic environment (pasture, 
considered the gold standard approach for controlling airway inflammation in equine asthma 
(1), n=7 horses) or administered inhaled fluticasone/salmeterol (Advair® 250 HFA MDI, 
GlaxoSmithKline, 2500/250 μg q12 h, n=6). During study II, horses were administered either 
inhaled fluticasone (Flovent® HFA MDI, GlaxoSmithKline, 2500 μg q12 h, n= 6) or 
salmeterol (Sigma-Aldrich, 250 μg q8 h, n=6 (2)). Horses receiving pharmacological 
treatments were kept in the offending environment (stable and hay diet). 
Fluticasone/salmeterol combination and fluticasone alone were administered by means of a 
equine aerosol chamber (AeroHippus, Trudell Medical International). Salmeterol powder was 
solubilized in sterile PBS at a concentration of 250 μg/ml, using Tween20 (Sigma-Aldrich) to 
facilitate solubility (3). Salmeterol was administered using a face-tight mask equipped with a 
mobile ultrasonic nebulizer (SaHoMa, NEBU-TEC International, Germany). Pulmonary 
function was performed at baseline (week 0), after 1 and 2 weeks of treatment, and then every 
other week throughout the duration of the study. Residual bronchoconstriction was assessed at 
the end of the treatment period using inhaled albuterol, (500 μg, in study I (4)) or N-butyl-
scopolammonium bromide (0.3 mg/kg IV, in study II).  Study design is summarized in Figure 
E1. Briefly, bronchoalveolar lavage (BAL) and EBBs were collected at baseline, and after 1, 
2, 4, 8, and 12 weeks of treatment. Peripheral biopsies were obtained at baseline and after 4 
and 12 weeks of treatment. Endobronchial endoscopy (EBUS) was performed only during 
study I, at baseline and after 4 and 12 weeks of treatment. All the procedures performed were 
approved by the Ethics Committee of the Université de Montréal (#Reach-1234). 
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Lung function 
Lung function was assessed as previously described (5). Briefly, transpulmonary pressure was 
estimated by means of an esophageal balloon and respiratory flow detected using a heated 
pneumotachograph connected to a face-tight mask placed on the horse’s nose. Pulmonary 
resistance and reactance were then computed using dedicated software (Labdat/Anadat 
program on MS-DOS, and flexiWare software, SCIREQ, Canada). A single-compartment 
linear model of the lung was employed, expressed as: PL = (EL×VT) + (RL×Vሶ ) + k, where PL: 
transpulmonary pressure, EL: pulmonary elastance, VT: tidal volume, RL: pulmonary 
resistance, Vሶ : respiratory flow, and k: transpulmonary end-expiratory pressure.  
 
Bronchoscopy 
Bronchoscopies were performed on standing sedated horses (detomidine/butorphanol 
administered IV at 0.015/0.015 mg/kg). BALF was first obtained from a lung, randomly 
chosen for each animal at baseline and then systemically changed at every time points, stored 
on ice and processed within 2 hours for cytology assessment (5). Differential cell counts were 
performed on a minimum of 400 cells on Wright-Giemsa stained cytospins of non-filtered 
BALF aliquots of 400 μm each. When cell density was too high to allow reliable counting, 
cytospins of 200 μm aliquots were prepared. Six to eight EBBs were obtained from the 
contralateral lung as previously described (6), fixed in PFA for 24 hours, and paraffin-
embedded. Care was taken to avoid biopsying twice the same bronchial bifurcation. EBUS 
images were obtained from the lung used for the BAL procedure following a protocol 
previously developed and validated in our laboratory (7). 
 
Thoracoscopy 
Thoracoscopies were performed on standing sedated horses (detomidine/butorphanol 
0.015/0.015 mg/kg IV), restrained in a stock. Large peripheral lung biopsies (>5 cm3) were 
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obtained by means of a cautery device (Ligasure, Covidien) and endoscopic staplers (Endo 
GIA, Covidien) as described in previous reports (8, 9), fixed in PFA for 72 hours, and 
paraffin-embedded. 
  
Histomorphometry 
Four-μm-thick histological sections were used for both histological and immunohistochemical 
staining. Morphometry was performed on Russell-Movat-stained tissues using ImageJ (NIH, 
Bethesda, USA) and newCAST (Visiopharm, Hoersholm, Deanmark). EBBs of good to 
optimal quality (6) and peripheral bronchi with a major to minor axis ratio<1.5, ASM 
surrounding at least 70% of their circumference, and intact epithelium were studied at 40x 
magnification. In peripheral biopsies (10), the area occupied by ASM, extracellular matrix 
(ECM), and elastic fibers (EF) as well as myocyte nuclei were measured/counted manually 
(ASM, ECM, nuclei) or by point counting (EF), and corrected by the square of the basal 
membrane length to account for variation in airway size (7). ASM bundle composition 
(fraction occupied by smooth muscle, collagen, and elastin) was assessed by point counting, 
each point corresponding to an area of 88 μm2. ASM cell size was indirectly calculated (ASM 
area x smooth muscle fraction of ASM bundle/myocyte nuclei). In EBBs, total biopsy area 
(Atot), ASM area (AASM), ASM% (AASM/Atot), ASM composition, ASM cell size, and lamina 
propria thickness (epithelium-ASM distance) were assessed (6). Proliferating myocytes 
(PCNA+/α-smooth muscle actin+ cells) were identified using immunohistochemistry (11) and 
counted manually. Myocyte proliferation density was expressed as number of proliferating 
cells per ASM area. Epithelial and subepithelial inflammation was assessed semi-
quantitatively with a score ranging from 0 to 2. 
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Figures 
 
Figure E1. Study design. BAL: bronchoalvelar lavage; EBB: endobronchial biopsies; EBUS: 
endobronchial ultrasound. 
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Figure E2. Composition of peripheral ASM bundles and effect of treatments. Panels A and D 
represent the total composition of peripheral ASM bundles in study I and II, respectively. Bars 
represent means ± SEM. The specific contribution of collagen and elastin is reported in panels 
B and C for study I, and in panels E and F for study II. Each point represents one horse (mean 
value of multiple measures). *: Different from baseline of the same group (p<0.05). ASM: 
airway smooth muscle. 
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Figure E3. Composition of central ASM bundles and effect of treatments. Panels A and D 
represents the total composition of central ASM bundles in study I and II, respectively. Bars 
represent means ± SEM. The specific contribution of collagen and elastin is reported in panels 
B and C for study I, and in panels E and F for study II. Each point represents one horse (mean 
value of multiple measures). *: Different from baseline of the same group (p<0.05). ASM: 
airway smooth muscle.  
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Article 5 
 
Environmental heat and airborne pollen concentration are associated with increased 
asthma severity in horses 
 
Summary 
During the experimental procedures described in Article 4 of this thesis, we have observed a 
worsening of the clinical signs of asthmatic horses during periods of hot environmental 
conditions, which we initially attributed to an alteration of their breathing pattern used in order 
to maintain thermoregulation. This study seeks to evaluate how environmental variables, 
namely temperature, relative humidity, and pollen concentration in the air, affect the breathing 
pattern and lung function of asthmatic horses during periods of disease exacerbation.  
The results obtained suggest that in asthmatic horses, airway obstruction worsens when they 
are exposed to rapid increases of environmental heat, whereas their breathing pattern remains 
unchanged. 
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Summary 
Reason for performing the study – Clinical exacerbations of severe equine asthma are more 
frequently reported during winter, when horses are exposed to airborne dusts during stabling. 
However, we have also observed a worsening of clinical signs on days of heatwave.  
Objectives – We sought to investigate the association between environmental temperature and 
humidity and clinical signs of asthmatic horses during clinical exacerbation of the disease. 
Study design – Retrospective longitudinal study.   
Methods – Historical data of 14 severe asthmatic horses exposed to a dusty environment and 
evaluated using a previously validated clinical score system were analyzed. Barn temperature 
and relative humidity values were obtained, and air enthalpy (h) was calculated. Correlation 
tests were used for studying the relationship between mean daily clinical scores of horses and 
environmental variables. Lung function parameters recorded at 4-day intervals during hot 
(25°C) and warm (18°C) barn conditions were compared using paired t-test.  
Results – Significant positive correlations were observed between the mean daily clinical 
score and temperature (r=0.58, p=0.01) and air enthalpy (r=0.55, p=0.02). Maximal daily 
temperature correlated with airborne pollen concentrations (r=0.51, p=0.0002). Higher barn 
temperature and enthalpy, in theabsence of changes in the management of horses, were 
associated with increased transpulmonary pressure (p=0.005), pulmonary resistance (p=0.008), 
and elastance values (p=0.005).  
Conclusions – Providing a cold environment could help to attenuate the severity of airway 
obstruction in uncontrolled exacerbation of severe equine asthma. Furthermore, variations in 
environmental heat and associated pollen concentrations should be taken into account when 
evaluating the response to therapy in clinical or research settings.  
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Introduction 
Severe equine asthma (also known as Recurrent Airway Obstruction, RAO, or heaves) is a 
chronic obstructive respiratory condition affecting 15 to 20% of adult horses living in 
temperate climate [1]. The risk of disease exacerbation increases during winter months [1; 2], 
when horses are stabled for extended periods of time and exposed to endotoxins, molds, mites, 
as well as other dust particulate matter present in hay and straw [3; 4]. Although not described 
in asthmatic horses, cold-induced bronchoconstriction could also play a role [5].  
We have occasionally observed unexpected worsening of clinical signs in severe asthmatic 
horses during hot summer months, driving the hypothesis that hot environmental conditions 
could negatively affect lung function in affected horses. A cholinergic-mediated reflex 
inducing bronchoconstriction in response of breathing hot humid air has been shown in 
asthmatic patients [6] and could be present also in the equine form of the disease, given the 
similarities among the two conditions [7]. Alternatively, the increased respiratory effort 
observed could have been secondary to thermoregulation strategies leading to altered 
breathing patterns with minimal changes in lung function (i.e. pulmonary resistance and 
elastance). Finally, pollens have been implicated as triggers for clinical manifestations of the 
summer form of equine asthma (SPAOPD) [8]. While evidence linking severe equine asthma 
exacerbations to these antigens is lacking [9], they could act as non-specific irritants for the 
reactive airways of affected horses. This study was therefore undertaken with the aim to 
investigate retrospectively the short-term effect of environmental temperature, humidity, and 
antigenic load (airborne pollens and spores) on the clinical status of asthmatic horses during 
clinical exacerbation of the disease.  
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Methods 
All the procedures described were performed as part of another study and approved by the 
local Ethics Committee (Rech-1324). Environmental data were obtained and analyzed 
retrospectively. Fourteen severe asthmatic horses aged 15.1±4.4 years (mean±SD; range: 7-30) 
and weighting 519±64 kg were studied. There were 5 Quarter Horse, 4 Standardbred, 2 
Canadian, 2 Paints and 1 Arab mixed breed, of which 4 were geldings and 10 females. Study 
design is summarized in Fig 1. All horses had been kept at pasture for at least 4 months before 
the beginning of the experimental phase of the study. Antigen exposure started on the 15th of 
April 2014 and was protracted for 6 weeks. During this period, horses were stabled and fed 
hay. Stabling conditions (bedding, ventilation, number of animals kept within the facility, hay 
type/batch and quantities administered) remained the same for the duration of the study. 
Horses were turned out in a paddock 2 to 6 hours/day in the afternoon. An 8-point clinical 
score previously validated in horses and ranging from 1 (normal) to 4 (severe effort) for both 
nasal and abdominal effort during breathing [10] was performed between 8:00 and 10:00 a.m. 
during the first 5 weeks of antigen exposure. Scoring was made by one of 3 trained operators 
in optimal agreement (interclass correlation coefficient>0.8), as this is part of the antigen 
challenge monitoring protocol of our laboratory. During the 6th week, pulmonary mechanics 
were performed in the stable where horses were housed between 8:00 and 10:00 a.m., on 
Monday (retrospectively considered a “hot” day based on the average temperature for this 
time of the year in our geographical area: 25°C, 60% relative humidity, RH, 55.27 kJ/kg 
enthalpy (h), indoor values at 8:00 a.m.; versus 19°C, 71% RH, 43.65 kJ/kg h outdoor) and on 
Friday (retrospectively considered a “warm” day: 18°C, 61% RH, 37.82 kJ/kg h indoor at 8:00 
a.m., versus 15.5°C, 77% RH, 36.82 kJ/kg h outdoor). Briefly, transpulmonary pressure was 
measured with an esophageal balloon catheter connected to a pressure transducer, and 
breathing flow signals obtained from a heated pneumotachograph connected to a mask.  
Pulmonary resistance and elastance values were derived using the flexiWare 7.6 softwarea.  
Temperature and relative humidity outside and within the stable at 8:00 a.m. were obtained 
from www.meteoblue.com and from the archives of the barn in which horses were housed, 
respectively. Temperature and humidity in the stable are recorded twice daily (8:00 a.m. and 
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4:00 p.m.). The concentrations of outside airborne pollens and spores were obtained from the 
Aerobiology Research Laboratoriesb information service. Measurements were performed at a 
station located 50 km west from the stable where the horses were kept. A complete list of the 
airborne allergens tested is provided online (Supplementary item 1). Enthalpy (h, expressed in 
kJ/kg) of the ambient air was calculated using the formula: h = T + x (2500 + 1.9T), where T 
is temperature and x is the specific humidity (or moisture content) of humid air. Further details 
on enthalpy calculation are provided online (Supplementary item 2).  Enthalpy was chosen as 
it approximates to which extent a given combination of temperature and humidity affects heat 
dissipation.  
Statistical analyses were performed with SAS/STAT softwarec and Prism 5d. A regression 
model was used to identify data to be included in the analysis. In order to avoid biases due to 
the concomitant effects of antigen exposure and season-related increase in temperature on the 
horses’ clinical scores, a piecewise regression model was employed for differentiating the 
initial rising phase of the clinical score curve, where barn antigen exposure is likely to exert a 
predominant effect, from the following plateau, where the effect of antigen exposure has 
reached a stable phase. We fitted a model including two different slopes and an inflexion 
point. The equation for the first segment before the inflexion time is score = a + b*time and 
the equation for the second segment is score = a + b*time + c*(time-inflexion time). Only 
data obtained during the second segment of the curve (stable phase) were studied. The effect 
of the environmental variables on the mean daily clinical score obtained from the horses was 
analyzed using Pearson or Spearman correlation test, depending on data distribution. Indoor 
and outdoor meteorological variables were compared with Pearson correlation tests. The effect 
of hot vs warm environment on lung function was assessed with paired t-tests. Pearson 
correlation coefficient was also calculated to determine whether the pairing was effective (that 
is, whether the direction and magnitude of the variation induced by the warm vs the hot 
conditions were similar in all horses). Normal distribution of data was assessed with the 
Kolmogorov-Smirnov test. P-values <0.05 were considered significant. 
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Results 
Fig 2 shows the time-trend of the mean clinical score (daily mean of all the horses studied, 
panel A) together with the environmental variables studied (panel B and C). The non-linear 
model indicates that the slope of the curve (‘b’) was significantly greater than 0 before the 
inflexion point (confidence interval not including 0), but it became not different from 0 after 
the inflexion point (confidence interval includes 0). The estimated inflexion point 
corresponded to 1st May 2014. These findings provided the rationale for including only the 
data observed after the first 15 days of antigen exposure into statistical analysis.  
From day 15 to 35, significant correlations were observed between the daily mean of 14 
individual clinical scores of the horses and the indoor temperature (r=0.58, p=0.01, Fig 3A) 
and enthalpy (r=0.55, p=0.02, Fig 3B). There was also some evidence of a correlation between 
the mean clinical score and the indoor RH, but it was not statistically significant (r=0.44, 
p=0.08, Fig 3C). Indoor and outdoor temperature (r=0.94, p<0.0001) and RH (r=0.62, 
p=0.002) recorded at 8:00 a.m. during the whole study period as well as indoor and outdoor 
enthalpy values (r=0.85, p<0.0001) were strongly correlated.  
Overall, during the period studied, daily airborne pollen concentrations correlated strongly 
with outdoor maximal daily temperature (r=0.51, p=0.0002), while spore concentrations 
correlated with minimal daily temperature and RH (r=0.44, p=0.002, and r=0.29, p=0.047, 
respectively). The most abundant outdoor airborne pollens during the period studied were tree 
pollens (deciduous trees > coniferous trees), with only limited concentrations of grass pollens. 
Most of the airborne spores were produced by ascomycetes (i.e. Oospora spp) and fungi 
imperfecti (i.e. Alternaria spp, Aspergillus spp). Mean clinical scores of the horses were not 
correlated with the total concentrations of airborne pollens (r=0.35, p=0.15) or spores (r=0.30, 
p=0.23) of the same day. However, a significant correlation was observed with total pollen but 
not with spore concentration of the previous day (r=0.5, p=0.03; and r=0.21, p=0.41, 
respectively). Significant correlations were observed between mean clinical score and specific 
airborne concentrations of pollens (mainly from Pinaceae (pine, fir, spruce), Betula (birch), 
 264 
 
and Morus (mulberry)) and spores from Oospora spp (powdery mildew). Further details are 
provided online (Supplementary item 1).  
Lung function values fell on warm days compared to hot days, as demonstrated by the 
reduction of transpulmonary pressure (p=0.005), pulmonary resistance (p=0.008) and 
elastance values (p=0.005, Fig 4). On average, a 32%, 27%, and 36% decrease was detected 
for transpulmonary pressure, pulmonary resistance, and pulmonary elastance, respectively. 
The statistical pairing was effective for all 3 parameters (r=0.56, p=0.03 for transpulmonary 
pressure; r=0.69, p=0.007 for resistance; and r=0.75, p=0.002 for pulmonary elastance), 
indicating that a similar improvement in lung function occurred proportionally in all subjects 
when environmental heat was reduced. Respiratory rate (p=0.48) and tidal volume (p=0.12) 
were not significantly affected by temperature and RH variations. The pairing was effective 
for tidal volume (r=0.6, p=0.02) but not for respiratory rate (r=0.3, p=0.18). As environmental 
conditions on the days preceding the lung function test could have exerted a carryover effect, 
their description is provided in Table 1. 
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Discussion 
Winter is considered a risk factor for exacerbations of severe equine asthma [1; 2], as horses 
spend more time in stables during this season, inhaling increased concentrations of molds and 
dusts. However, worsening of clinical signs of affected subjects has been reported also during 
summer months [11], even when horses were kept outdoor for most of the time [12]. During 2 
consecutive years, on periods of high environmental temperatures for our geographical area, 
we observed a worsening of the clinical signs of asthmatic horses kept at pasture (8 weeks 
post-exacerbation) or stabled and contemporarily treated with inhaled corticosteroids or 
bronchodilators. Results from this study indicate that an increase of environmental 
temperature and humidity (determinants of humid air enthalpy and strongly associated with 
the pollen and spore air content) negatively affects the lung function of asthmatic horses 
during disease exacerbations, further worsening airway obstruction. Transpulmonary pressure, 
resistance, and elastance values significantly improved over few days as a consequence of a 
reduction in environmental heat, in spite of unchanged breathing strategy or hay and bedding 
dust exposure.  
Increased environmental temperature and humidity, especially if sudden, hinders heat 
dissipation in animals, which in turn induces changes in their breathing strategy as a 
physiological response to avoid hyperthermia. Heat dissipation in horses occurs by 
evaporative cooling mainly from the skin and in part from the upper respiratory tract [13]. We 
initially postulated that the apparent deterioration of clinical conditions observed in asthmatic 
horses during hot environmental conditions would be the result of heat-induced 
thermoregulatory mechanisms altering their breathing pattern. A significant increase in 
respiratory frequency is indeed observed in horses in response to heat stress, and prevents 
hyperthermia during resting conditions [14; 15]. Asthmatic horses in exacerbation already 
have an increased respiratory rate compared to healthy animals, and mucus often covers an 
important portion of the tracheal mucosa, possibly hampering adequate thermoregulation in 
these animals. Furthermore, severe asthmatic horses are usually aged [2], which could further 
reduce their thermoregulatory ability [16] and increase the risk of hyperthermia even during 
resting conditions compared to healthy animals. However, contrarily to our initial hypothesis, 
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the worsening of the horses’ clinical conditions observed with increased temperatures was not 
associated with an altered respiratory strategy to improve thermoregulation, as breathing 
frequency or tidal volume were similar during warm and hot days.  
Breathing hot humid air increases bronchial temperature and causes bronchospasm in many 
species, especially in the presence of airway inflammation [6; 17; 18], as occurring in equine 
asthma. Interestingly, breathing hot humid air at increased respiratory frequencies induces a 
cholinergic-mediated bronchoconstriction also in human asthmatic patients [6], a condition 
that shares many pathophysiological similarities with equine asthma [7]. In our study, the 
significant correlation observed between environmental enthalpy and clinical scores, and 
significant increase in pulmonary resistance and elastance observed on the hotter day suggest 
that airway obstruction worsens when heat dissipation is prevented by increased temperature 
and/or RH, supporting the involvement of heat-induced bronchospasm in heaves pathobiology. 
The rapid development of severe airway obstruction after stabling a cohort of horses 
previously kept outdoors during winter in Quebec [19] and the identification of spending 
<15h/day outdoors during winter months as a risk factor for equine asthma exacerbation [1] 
provide further evidence for the occurrence of  heat-induced bronchospasm in diseased horses. 
It also stresses the importance of even moderate temperature increases as bronchoconstriction 
triggers rather than absolute cutoffs. However, further studies are needed to confirm this 
theory and the mechanisms implicated. 
Within the range of environmental conditions studied, heat dissipation is prevented to a greater 
extent by increases in temperature than in RH (i.e. RH should increase of 7-8% in order to 
produce the same effect on enthalpy as a 1°C-increase in temperature), which could explain 
why a more severe airway obstruction was detected on the hot day compared to the warm in 
the presence of similar RH but different temperature values. Furthermore, the correlation 
between RH and clinical scores did not reach significance at the 5% level but there was some 
weak evidence of a relationship, and this in spite of a significant correlation of the scores with 
temperature and enthalpy, which further highlight the great effect of temperature on heat 
dissipation. The study power was, however, only 0.54 for RH, and doubling the time points 
studied would have been necessary in order to raise the power to 0.8 with the same alpha level 
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(0.05). However, as enthalpy is determined by the integration of temperature and RH, both of 
them can be considered as causal factors associated to environmental heat. 
Increased temperature during spring and summer months is associated with increased airborne 
pollens and molds [8]. Pollens are considered triggering factors for exacerbations of SPAOPD 
[8], but evidence directly linking severe equine asthma exacerbations to these antigens is 
lacking. Nevertheless, they could act as non-specific irritants for the reactive airways of 
affected horses, and it has been estimated that up to approximately 30% of the variance in 
equine asthma prevalence in veterinary hospitals could be explained by the sum of climatic 
factors and their effect on aeroallergen concentrations in ambient air [11]. As the horses 
studied spent a few hours per day at pasture, we investigated whether airborne concentrations 
of pollens and spores could have affected disease severity. Our findings confirm and even 
strengthen the evidence for a correlation existing between daily outdoor temperature and RH 
values and airborne pollen and spore levels. Airborne pollen but not spore concentrations were 
correlated with the horses’ clinical scores, suggesting that they could play a role in disease 
severity. It is interesting to notice that the correlation was significant between the clinical 
scores and the pollen concentration of the previous day, as horses spent their afternoon outside 
and the scores were performed early in the morning. Also, outdoor concentration of pollens 
were increased on average 3-fold on the hot compared to the warm day during which 
pulmonary function tests were performed. In particular, increases in birch (Betulla, 5.4-fold 
increase on the hot day), ash (Fraxinus, 12.6-fold), mulberry (Morus, 5.5-fold), and oak 
(Quercus, 12-fold) pollens were most marked. The same trend was observed on the 3 days 
preceding the hot and the warm days. Alternaria and Aspergillus/Penicillum spore 
concentrations were also higher (4-fold and 6-fold, respectively) on the 3 days preceding the 
hot compared to the 3 days preceding the warm day. An association between monthly 
prevalence referrals for equine asthma exacerbations in veterinary hospitals and pollen counts 
measured 3 months before was observed for Quercus, Fraxinus, and Morus spp in a previous 
study, as well as with Alternaria spore counts measured during the same month [11]. Although 
these data would support an association between the increase in airborne pollens and equine 
asthma pathobiology, it is not possible to separate the specific role of environmental 
temperature/humidity and inhalable allergens based on our observations. However, the same is 
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true in clinical practice. With this study we have shown that a correlation exists between 
environmental heat and the severity of clinical signs in severe equine asthma. Albeit both heat-
induced bronchoconstriction and airway irritation caused by airborne particulates are likely to 
act synergically, environmental heat can be more easily predicted, assessed, and, at least 
partially, contained by means of preventive measures (i.e. improved ventilation).  
In conclusion, our study indicates that high environmental temperature and humidity can 
worsen the clinical signs of horses with severe equine asthma during disease exacerbation due 
to impaired lung function. Whether and in which proportion the negative effect of high 
environmental temperature and RH on lung function is worsened by inhalable pollens and 
molds, or by other undefined factors, remains to be ascertained. Nevertheless, these findings 
highlight the necessity of providing a temperate environment to severe asthmatic horses, 
especially during disease exacerbation or when exposure to stable antigens cannot be avoided. 
Also, changes in environmental temperature should be taken into account when evaluating the 
response to therapy in clinical or research settings. 
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Footnotes 
a SCIREQ Scientific Respiratory Equipment Inc., Montreal, QC, Canada. 
b Aerobiology Research Laboratories, Nepean, ON, Canada. 
c SAS Institute Inc., Cary, NC, USA. 
d GraphPad Software Inc., La Jolla, CA, USA.  
 
 
Supporting information  
Supplementary item 1: List of the airborne pollens and spores studied, and results of their 
correlation with clinical scores of the horses (Bonferroni correction for multiple comparisons 
was applied). 
Supplementary item 2: Details for enthalpy calculation. 
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Figures and tables 
Table 1. Environmental characteristics at the moment of lung function tests. 
 
Hot day Warm day 
p 
(paired t-test) 
Breathing frequency* [Hz] 0.344 (±0.084) 0.304 (±0.123) 0.48 
Tidal volume* [L] 5.6 (±0.9) 6.2 (±1.5) 0.12 
Indoor temperature (barn) 8h a.m.  25°C 18°C  - 
Indoor RH (barn) 8h a.m. 60% 61%  - 
Outdoor temperature 8h a.m.  19°C 15.5°C  - 
Outdoor RH 8h a.m. 71% 77%  - 
Indoor temperature (barn) 8h a.m. 
(mean previous 3 days)  
18.5°C 15.9°C  - 
Indoor RH (barn) 8h a.m.  
(mean previous 3 days) 
62.3% 61%  - 
Outdoor temperature 8h a.m. 
(mean previous 3 days)  
14°C 11.3°C  - 
Outdoor RH 8h a.m. (mean 
previous 3 days) 
88% 83%  - 
Pollens [P/m3] 249.2 85.4 - 
Spores [P/m3] 1737.1 2137.2  - 
Pollens [P/m3] 
(mean previous 3 days)  
102.1 34.8  - 
Spores [P/m3]  
(mean previous 3 days) 
2121.2 4040.5  - 
RH: relative humidity; P/m3: particles per cubic meter of air. *: daily mean ± SD of individual 
values observed in horses.  
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Figure 1. Experimental design. RH: relative humidity. 
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Figure 2. (A) Time trend of daily mean clinical score of the group of horses studied (n=14, 
error bars correspond to S.D.) for the whole period of antigen exposure. Data on the left of the 
dashed line were not considered for statistical analysis. (B, C) Time trend of daily mean 
clinical score, indoor and outdoor temperature, indoor relative humidity (RH) and enthalpy 
measured at 8:00 a.m. during the period studied. 
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Figure 3. Correlations of the mean clinical score (daily mean of the clinical scores of the 
horses studied, n=14) and (A) temperature, (B) enthalpy, and (C) RH measured at 8:00 a.m. in 
the stable where horses were housed. 
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Figure 4. Effect of temperature variation on pulmonary mechanics in asthmatic horses during 
disease exacerbation. Data are presented as median, 25th to 75th percentiles (boxes), and min-
max values (whiskers). ΔPL: transpulmonary pressure; RL: pulmonary resistance; EL: 
pulmonary elastance. 
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Supporting information 
 
ONLINE SUPPLEMENTARY ITEM 1 
 
Results 
Table S1. Aeroallergens studied and correlation with mean clinical score of the horses. 
 
Correlation between 
mean clinical score and 
allergen concentration 
on the same day 
Correlation between 
mean clinical score and 
allergen concentration on 
the previous day 
Correlation between 
mean clinical score and 
mean allergen 
concentration on the 
previous 3 days 
  r p r p r p 
POLLENS 
TOTAL GRASSES 0.4320 0.0734 0.4978 0.0355 -0.4927 0.0378 
CYPERACEAE (Sedge family) 0.08835 0.7274 0.2193 0.3820 -0.3711 0.1294 
GRAMINEAE (True Grasses) 0.5649 0.0146 0.5073 0.0317 -0.6222 0.0058 
TOTAL TREES 0.3535 0.1501 0.5034 0.0332 0.06615 0.7943 
TOTAL CONIFEROUS TREES -0.1465 0.5619 0.05179 0.8383 0.6944 0.0014 
CUPRESSACEAE (Cedar,Cypress,Juniper) -0.3874 0.1122 -0.1697 0.5008 0.6512 0.0034 
LARIX (Larch, Tamarak, Pseudotsuga) 
PINACEAE (Pine, Fir, Spruce) 0.8081 <0.0001 0.6617 0.0028 -0.4143 0.0874 
TSUGA CANADENSIS/TSUGA  
HETEROPHYLLA (Hemlock) 0.3512 0.1530 0.3043 0.2195 -0.2341 0.3498 
TOTAL DECIDUOUS TREES 0.3928 0.1069 0.4982 0.0354 -0.1654 0.5120 
ACER (Boxelder, Maple) -0.3435 0.1628 -0.04966 0.8448 0.4956 0.0365 
AESCULUS (Buckeye, Horse Chestnut) 
ALNUS (Alder) -0.2623 0.2930 -0.1423 0.5734 0.1577 0.5321 
BETULA (Birch) 0.6084 0.0074 0.7782 0.0001 -0.2891 0.2446 
Birch look-a-likes (Hornbeam,  
Hop-Hornbeam) 0.5452 0.0193 0.5855 0.0107 -0.3383 0.1697 
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CARYA (Hickory) 
CASTANEA (Chestnut) 
CELTIS (Hackberry) 
CORYLUS (Hazelnut) 
FAGUS (Beech) 0.3325 0.1776 0.5107 0.0303 -0.6146 0.0066 
FRAXINUS (Ash) 0.5386 0.0211 0.6173 0.0064 -0.1536 0.5427 
JUGLANS (Walnut) 0.007570 0.9762 0.3340 0.1755 -0.3576 0.1451 
MORUS (Mulberry) 0.5085 0.0312 0.7916 <0.0001 0.01882 0.9409 
OLEACEAE (Ligustrum, Syringa) 
PLATANUS (Sycamore) 
POPULUS (Aspen, Poplar) -0.2434 0.3305 -0.2339 0.3502 0.4050 0.0955 
PRUNUS, MALUS, CRATAEGUS   
(Apple, Plum, Pear, Hawthorn) 0.7110 0.0009 0.6840 0.0017 -0.4160 0.0860 
QUERCUS (Oak) 0.6948 0.0014 0.6056 0.0077 -0.3992 0.1008 
SALIX (Willow) 0.2063 0.4114 0.3464 0.1591 -0.1284 0.6117 
SAMBUCUS (Elderberry) 
TILIA (Basswood, Linden) 
ULMUS (Elm) -0.2914 0.2407 -0.3500 0.1545 0.6136 0.0068 
Misc. Trees and Shrubs 0.2093 0.4046 0.3512 0.1529 -0.2797 0.2610 
TOTAL WEEDS 
AMBROSIA (Ragweed) 
ARTEMISIA 
CRUCIFERAE (Mustards) 
LYTHRUM (Purple Loostrife) 
Misc. Compositeae 
Misc. Weeds 
PLANTAGO (Plantain) 
RUMEX (Dock, Rhubarb, Sorrel) 
S. PESTIFER (Russian Thistle) 
SOLIDAGO (Goldenrod) 
TYPHA (Cattail) 
UMBELLIFERAE (Wild Carrot) 
URTICACEAE (Nettles & Pellitory) 
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Unidentified pollen 
FILICINAE (Ferns)       
       
SPORES 
TOTAL ASCOMYCETES 0.3080 0.2137 0.1860 0.4598 0.1757 0.4855 
ASCOBOLUS       
CALOPLACA, XANTHORIA       
CHAETOMIUM 0.3512 0.1530 0.3043 0.2195 0.3043 0.2195 
DIATRYPACEAE 0.07938 0.7542 0.04626 0.8554 -0.3862 0.1134 
LEPTOSPHAERIA       
Leptosphaeria and Look-a-likes 0.2094 0.4043 -0.002069 0.9935 -0.2501 0.3168 
Leptosphaeria look-a-likes       
MASSARIA       
MASSARINA -0.5206 0.0268 -0.4216 0.0814 -0.6774 0.0020 
Misc. Ascospores 0.4682 0.0500 0.2580 0.3013 0.2408 0.3357 
OOSPORA (Powdery mildew) 0.7854 0.0001 0.4447 0.0645 0.4108 0.0904 
PERONOSPORA(Downey mildew) 0.1657 0.5112 0.3735 0.1268 0.4539 0.0585 
PLEOSPORA 0.09940 0.6948 -0.2439 0.3293 -0.4434 0.0654 
SORDARIA       
VENTURIA 0.3614 0.1406 0.3280 0.1839 0.3075 0.2145 
TOTAL BASIDIOMYCETES 0.08682 0.7319 0.1546 0.5402 -0.02377 0.9254 
BOLETUS       
BOLETUS, MELANOGASTER       
CALVATIA       
COPRINUS, COPRINELLUS 0.2418 0.3337 0.3368 0.1717 0.3559 0.1472 
GANODERMA 0.09364 0.7117 -0.06435 0.7997 0.01991 0.9375 
Misc. Basidiospores 0.2112 0.4002 -0.007768 0.9756 -0.3680 0.1330 
PANAEOLUS       
UREDINALES (Rusts) 0.04597 0.8563 0.01837 0.9423 0.1159 0.6471 
USTILAGINALES (Smuts) 0.3404 0.1669 0.4049 0.0956 0.5628 0.0150 
TOTAL FUNGI IMPERFECTI 0.1261 0.6181 0.3039 0.2202 -0.03618 0.8867 
ALTERNARIA 0.3321 0.1781 0.3497 0.1549 0.2310 0.3565 
ARTHRINIUM       
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ASPERGILLUS, PENICILLIUM 0.1458 0.5638 0.09235 0.7155 0.2563 0.3047 
BOTRYTIS 0.06359 0.8021 0.4003 0.0998 0.1453 0.5651 
CERCOSPORA       
CLADOSPORIUM 0.01240 0.9610 0.2760 0.2677 -0.08992 0.7227 
CURVULARIA       
DRECHSLERA 0.5148 0.0288 0.1639 0.5159 -0.1706 0.4984 
EPICOCCUM -0.1801 0.4746 -0.1321 0.6013 -0.05498 0.8285 
FUSARIELLA       
FUSARIUM       
FUSICLADIUM 0.3043 0.2195 -0.01136 0.9643 0.2308 0.3569 
HELICOMYCES 0.2503 0.3165 0.2104 0.4020 0.3868 0.1128 
LACCARIA       
Misc. Fungi Imperfecti 0.07032 0.7816 0.1085 0.6682 0.1013 0.6892 
NIGROSPORA       
PERICONIA       
PITHOMYCES -0.09364 0.7117 0.2559 0.3053 0.7622 0.0002 
POLYTHRINCIUM 0.3512 0.1530 0.3043 0.2195 0.3043 0.2195 
STEMPHYLIUM 0.09364 0.7117   0.4778 0.0449 
TETRAPLOA       
TORULA 0.5119 0.0299 0.1639 0.5159 -0.1706 0.4984 
ULOCLADIUM       
TOTAL MYXOMYCETES   -0.3980 0.1019 -0.3583 0.1443 
Misc. Myxomycetes   -0.3980 0.1019 -0.3583 0.1443 
TOTAL ZYGOMYCETES       
Misc. Zygomycetes       
Misc. Phycomycetes       
Unidentified spores -0.05678 0.8229 -0.09068 0.7205 -0.1532 0.5440 
Algae 0.3885 0.1111 0.2990 0.2281 0.4566 0.0568 
LYCOPODIUM (Club Moss) -0.3994 0.1005 0.1449 0.5662 0.5347 0.0222 
Analyses were performed using Spearman correlation test on data observed from 05/01/2014 
to 23/05/2014. Red: statistically significant after Bonferroni correction.  
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ONLINE SUPPLEMENTARY ITEM 2 
 
Methods 
Enthalpy calculation 
Enthalpy (h, expressed in kJ/kg) was calculated using the formula:  
 
h = T + x (2500 + 1.9T), 
 
where: T is temperature [°C] and x is the specific humidity of the air [kg/kg]. The specific 
humidity of the air is defined as the ratio of the mass of water vapor in an air parcel to the 
mass of dry air for the same parcel, and derived in turn with the formula:  
 
x = 0.622 (RH*Psat)/(P-RH*Psat). 
 
Psat is saturation pressure and P is the atmospheric pressure (101325 Pa). Psat corresponds to 
610.5eA. A is a temperature-dependent variable, which corresponds to (17.269T)/(T+237.3) 
when temperature is ≥0°C, and to (21.875T)/(T+265.5) when temperature is <0°C. 
 
   
  
General discussion 
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The aims of this thesis were 1) to develop and validate a tool for the reliable assessment of 
central airway remodeling in equine asthma, with a particular attention towards the ASM 
mass, and 2) to assess and compare the dynamics of central and peripheral airway remodeling 
reversal following long-term treatment with inhaled corticosteroids in the presence or absence 
of add-on bronchodilator administration (long-acting β2-agonist). We hypothesized that 1) 
central airways – like peripheral airways – undergo structural remodeling processes in severe 
equine asthma, that 2) airway remodeling reversibility occurs more rapidly in the central 
airways than in the peripheral airways with ICS monotherapy, and that 3) the combination of 
ICS/LABA enhances peripheral airway remodeling reversal via an enhanced control of 
inflammation. Overall, the objectives of the thesis have been achieved, and our hypotheses 
were either confirmed (hypotheses 1 and 2) or rejected (hypothesis 3). The main findings of 
this thesis are summarized and briefly discussed hereafter. 
 
 
1.  Endobronchial ultrasound but not endobronchial biopsy sampling allows to estimate 
the airway smooth muscle mass in the equine central airways  
Endobronchial biopsies provide valuable samples for studying qualitative but not quantitative 
changes of the ASM in the central airways of asthmatic horses.  
In the context of this thesis, we initially investigated the potential application of endobronchial 
biopsy samples for the evaluation of central airway remodeling and inflammation in equine 
asthma, with particular attention towards alterations of the bronchial smooth muscle layer. 
Overall, our results (Article 1 and Article 2) support the use of endobronchial biopsies for the 
assessment of inflammatory infiltrate and qualitative structural changes of most bronchial 
structures, with the exception of cartilages and adventitia, which are rarely sampled. They 
provide valuable samples also for the quantitative analyses of the epithelium and lamina 
propria components (vessels, lymphatics, nerves, ECM proteins). The underlying smooth 
muscle layer is often harvested only partially however, which prevents an accurate assessment 
of its thickness by endobronchial biopsy in the equine species. The uncorrected ASM area is 
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the only morphometric parameter found to be increased in asthmatic horses compared to 
healthy controls, but it is strongly influenced by the age of the horse and by disease status. The 
percentage of the biopsy occupied by ASM (ASM%) is similar in asthmatic and healthy 
animals, and it negatively correlates with lung resistance in asthmatic horses. Nevertheless, as 
biopsies were harvested after bronchodilator administration in our study, a thickened lamina 
propria rather than an increased ASM mass is more likely the cause of the reduced ASM% 
(Figure 13). Significant correlations between the lamina propria thickness (epithelium-ASM 
distance) and pulmonary resistance, or between the lamina propria thickness and ASM%, in 
support of this hypothesis were not observed however (Figure 14, in Annex I).  
 
 
 
Figure 13. Effect of bronchoconstriction and lamina propria thickness on endobronchial 
biopsy sampling. A) Effect of remodeling and bronchoconstriction on the sampling ability of 
endobronchial biopsy forceps. The black horizontal line indicates the theoretical sampling 
ability of the endobronchial biopsy forceps in different situations. In healthy airways (a-b), the 
administration of a bronchodilator has no effect on airway dimension and the forceps grasp a 
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constant proportion of the ASM layer. In the asthmatic airways, bronchoconstriction induces a 
dynamic thickening of the lamina propria which distances the ASM layer from the airway 
lumen, proportionally reducing the relative quantity of ASM sampled (c). When 
bronchodilation is induced in asthmatic airways (d), edema and increased deposition of ECM 
within the lamina propria of equine asthmatic airways remain the only determinants of the 
amount of ASM within the biopsy sample.  
 
A possible explanation of these findings could be related to the increased fragility of inflamed 
and edematous tissues. That is, in equine asthma the lamina propria is thickened, more likely 
in response to an increased deposition of ECM proteins and the presence of tissue edema and 
inflammation. Either of these processes can alter tissue firmness and elastic properties, and 
could cause regions of the lamina propria externally adjacent to the biopsy instrument to be 
torn off more easily. A similar phenomenon would affect ASM% but not the thickness of the 
lamina propria of the biopsy sample, which could explain why these two values were not 
correlated in our study. 
 
Endobronchial biopsy findings correlate with lung function  
In order to fully investigate the possible applications of endobronchial biopsy samples in 
equine asthma research, we developed a semi-quantitative histological score to evaluate 
endobronchial biopsy samples. We sought to verify whether inflammation or remodeling of 
the central airways could differentiate horses with asthma in clinical remission from controls. 
The score considered alterations occurring at the level of bronchial epithelium, lamina propria, 
and smooth muscle. Assessment of remodeling and inflammation of the outer airway wall 
(adventitia) was not attempted as this anatomical region is rarely sampled. As an example, 
among the endobronchial biopsy samples collected during the experimental protocol of Article 
4, cartilage and parenchymal tissue were present, respectively, in 292 and 45 out of 942 
samples (31% and 5%).  
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The histological parameters evaluated with the score could not identify the presence of 
asthma-associated tissue remodeling at any level of the bronchial wall, whereas they clearly 
indicated that, in the central airways, a severe inflammation of the bronchial epithelium and 
submucosa occurs during disease exacerbations. We also found increased mucus cells in 
horses with heaves. Overall, the score was a good indicator of the degree of central airway 
obstruction in asthmatic horses, as it significantly correlated with lung function in this group 
(Figure 2 of Article 2, page 158, and Figure 16 in Annex I).  
We are aware of a single previous study which applied a similar score in endobronchial biopsy 
samples of human asthmatic patients (Gordon, Husain et al. 2013). In agreement with our 
results, the authors found that goblet cell hyperplasia and inflammation of the epithelial and 
submucosal layers are important discriminants of asthma. However, they were also able to 
demonstrate that ASM mass is increased in endobronchial biopsy samples of asthmatic 
subjects while we could not. Interestingly, while they looked at the presence of “prominent 
ASM” (which I interpret as jutting out toward the epithelium), we assessed whether the 
abaxial border of the ASM layer was visible as an indirect indicator of ASM growth. This 
observation is in agreement with the different degree of remodeling observed in the lamina 
propria thickness in asthmatic men and horses. The thinner lamina propria observed in 
asthmatic patients would permit to assess the presence of “prominent ASM” in endobronchial 
biopsy samples. Contrarily, the thickened lamina propria observed in asthmatic horses may 
contribute to our inability to identify any increase in ASM mass in endobronchial biopsy 
samples of horses.  
The presence of central airway inflammation during asthma exacerbations in horses is in 
agreement with what is described in human asthma. However, contrarily to what is observed 
in people (Djukanovic, Roche et al. 1990), central airway inflammation decreased to normal 
levels during periods of disease remission, even when antigen exposure was protracted and 
remission was induced by corticosteroid administration (Article 2 and Article 4). Of note, our 
score was semi-quantitative, and may have masked qualitative or minimal but quantitatively 
significant changes.  
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Endobronchial ultrasound (EBUS) reliably estimates the ASM mass in central airways of 
asthmatic horses.  
Because of the anatomical differences existing between equine and human bronchi, especially 
the greater ASM mass in equine compared to human airways, a thorough validation protocol 
was required for EBUS before it could be used as a tool for bronchial remodeling 
quantification in horses, which is described in Article 3. Our goal was to define which portion 
of the bronchial submucosa (identified as a unique hypoechoic layer at EBUS, L2) consisted 
of smooth muscle in the equine airways. As expected, a certain degree of variation was 
observed among the multiple airways studied, which is in agreement with histological findings 
in human specimens (Jones, Elliot et al. 2014). However, analyzing 8-10 airways per animal 
allowed us to correct for such variability. The finding that overall 75% of L2 (the echographic 
layer representing the bronchial submucosa) consists of smooth muscle both in healthy and 
asthmatic horses indicates that a thickened submucosa visualized at EBUS reflects a 
histological increase of the ASM in the equine airways. The ability of EBUS to reliably 
estimate ASM mass is a new finding in respiratory research, as previous studies only showed a 
thickening of the submucosal layer using EBUS in asthmatic patients (Soja, Grzanka et al. 
2009), which was correlated with the degree of bronchial hyperresponsiveness (Kita, Fujimura 
et al. 2010). Endobronchial ultrasound is a non-invasive and repeatable procedure. It allows 
performing studies during which airway remodeling can be followed over time at the same 
bronchial site in both horses and humans, which is impossible by means of endobronchial 
biopsies. Nevertheless, how much of L2 consists of ASM vs. ECM in human bronchi remains 
to be determined. 
 
In conclusion, our results suggest that endobronchial biopsies are not valuable samples for the 
quantitative evaluation of central ASM remodeling in horses, although they provide enough 
ASM tissue to assess its composition and qualitative alterations. Also, endobronchial biopsy 
samples are useful in the assessment of epithelial and lamina propria remodeling and 
inflammation. Contrarily, EBUS allows a reliable estimation of the ASM mass in central 
airways. The advantages of this procedure are mainly linked to its non-invasive nature and to 
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the possibility to study the same site over time, because tissue harvesting is not required. 
Performing EBUS and endobronchial ultrasound during the same experimental design would 
allow a thorough assessment of airway remodeling in both quantitative and qualitative terms, 
and should be implemented in future studies on this subject.  
 
 
2.  Equine asthma is characterized by central airway remodeling and inflammation  
Central ASM mass is increased in equine asthma 
Using endobronchial ultrasonography, we have shown for the first time that the submucosal 
thickness is increased in the central airways of asthmatic horses (Article 3). Furthermore, we 
have characterized the histological structures causing such increase. In asthmatic horses, ASM 
was increased compared to controls while it was unclear whether a thickened lamina propria 
also occurred. When corrected by airway size (Pi2), a similar quantity of ECM was observed 
in the bronchial submucosa of asthmatic and control horses. Nonetheless, horses with asthma 
presented an increased thickness of the lamina propria assessed in airways of similar size. 
These findings are in agreement with the increased percentage of smooth muscle shortening 
reported in bronchial specimens of asthmatic patients (Elliot, Jones et al. 2015), and suggest 
that the airways of asthmatic horses may have been fixed in a (more) constricted state 
compared to those of healthy horses, which were fixed in a (more) dilated state. Whether this 
histologic bronchoconstriction reflects the presence of bronchospasm in vivo or it is a fixation 
artifact linked to the structural alterations observed in asthmatic airways (increased ASM 
mass, altered ASM or ECM composition with altered mechanical properties) remains to be 
ascertained. Also, there are no data specifically addressing the effect of fixation on smooth 
muscle and/or ECM morphology in bronchial specimens, or whether the mechanical properties 
of ASM and ECM may play a role in this process, which precludes further discussion on this 
subject.   
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Several mechanisms likely contribute to the increased ASM mass observed in equine central 
airways. Although we did not compare asthmatic and control horses, the decrease of ASM cell 
size and ECM fraction observed after pharmacological treatment in Article 4 suggests that 
myocyte hypertrophy and increased collagen deposition are important determinants of central 
ASM remodeling in equine asthma. We also observed a reduced number of proliferating 
myocytes with all treatments. However, due to the impossibility to obtain complete bronchial 
sections in vivo, it was not possible to determine whether it translated into a decreased number 
of myocytes around the airway. For this reason, the relative contribution of ASM hyperplasia 
to central airway remodeling in equine asthma could not be assessed and remains to be 
determined.  
In the perspective of human asthma research, reporting an increased smooth muscle mass in 
the central airways of asthmatic horses is meaningful for two reasons. First, central ASM 
remodeling is a known feature of human asthma (James, Elliot et al. 2012, Elliot, Jones et al. 
2015, Girodet, Allard et al. 2015), and the finding that it is also present in asthmatic horses 
strengthens its suitability as a model for the disease. Secondly, it permits comparing the 
responses of different bronchial sites to inflammatory insults and pharmacological 
interventions within the same subject. Besides central airway involvement, peripheral airway 
dysfunction is increasingly recognized in human asthma (Postma, Brightling et al. 2015). A 
recent study reports an overall prevalence of small airways disease of 50 to 60% among 
asthma cases (Usmani, Singh et al. 2016). However, given the physical/anatomical 
inaccessibility of peripheral bronchi, their remodeling and inflammation can hardly be 
assessed in vivo in asthmatic patients. A growing interest is now directed towards the 
implementation of transbronchial biopsies in asthma research, which however is challenging 
and not free of drawbacks (Balzar, Wenzel et al. 2002). Furthermore, harvested samples are 
often very small and contain incomplete sections of the small airways, which prevent accurate 
morphometrical studies. Peripheral lung sampling is instead well described in asthmatic horses 
(Lugo, Stick et al. 2002, Relave, David et al. 2008, Relave, David et al. 2010), and provides 
high quality samples for the assessment of airway remodeling and inflammation at this level of 
the lung. Simultaneous characterization of central and peripheral airway responses during 
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periods of equine asthma remission and exacerbation could lead to the identification of central 
markers of peripheral (dys)function.  
 
Equine asthma exacerbations induce lamina propria thickening in central airways  
We have observed that the ECM present in the lamina propria of the central airways 
undergoes remodeling in asthmatic horses. The distance between the epithelium and smooth 
muscle layer (corresponding to the lamina propria thickness) is increased in endobronchial 
biopsies obtained from asthmatic horses experiencing disease exacerbation compared to 
healthy animals. Of note, the lamina propria thickness in endobronchial biopsies is not 
influenced by ASM contraction, as the values measured in the biopsies of asthmatic horses 
experiencing disease exacerbation were similar when obtained after the administration of 
either bronchodilator or placebo (Figure 15 in Annex I).   
The increased lamina propria thickness observed in asthmatic horses compared to controls is 
in contradiction with what is described in human asthma. Indeed, two studies investigating this 
parameter in asthmatic patients have found a decreased epithelium-smooth muscle distance in 
occupational asthma compared to controls (Sumi, Foley et al. 2007), and in severe compared 
to moderate asthmatics (Pepe, Foley et al. 2005). In the first study, asthmatic patients were in 
remission from occupational asthma (not symptomatic and not taking any treatment) for more 
than 14 years on average. In the second study, severe asthmatics were on higher doses of 
corticosteroids treatment compared to moderate asthmatics. The hypothesis that this could 
have caused a greater decrease of the lamina propria thickness in that group is not supported 
by in vitro data (Jacques, Semlali et al. 2010). There are no obvious reasons explaining this 
discrepancy between asthmatic men and horses. A selective inward vs. outward growth of the 
ASM cells might be involved. In support of a preferential outward expansion of the smooth 
muscle layer in equine asthma, we have noticed that proliferating myocytes (PCNA+/α-smooth 
muscle actin+ cells) are often located proximally to the outer margin of the ASM layer in 
peripheral airways in asthmatic horses (see Figure 4 of Article 4, page 230). However, 
myocyte proliferation density was not assessed on complete sections of central bronchi in the 
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studies presented in this thesis and no data are available concerning human asthma. 
Endobronchial biopsy morphology often did not permit to draw clear conclusions about the 
preferential location of proliferating myocytes within the central airways of asthmatic horses. 
Future studies on isolated lung specimens may help to elucidate this aspect of ASM 
remodeling. In addition, a thinner lamina propria represents a decreased load opposing central 
ASM contraction. As it is observed in human asthmatics in remission of the disease and in 
severely affected patients, it is tempting to speculate that a thinner lamina propria could 
possibly facilitate bronchospasm and asthma development. Conversely, asthmatics developing 
a thicker lamina propria in response to inflammatory and/or mechanical stimuli could benefit 
from it and present milder forms of the disease. The decreased epithelium-smooth muscle 
distance observed in asthmatic children with persistent obstructive pattern compared to those 
without obstructive pattern (Tillie-Leblond, de Blic et al. 2008) suggests that, if such a 
mechanism exists, it might be implemented very early in disease development. However, no 
other data support this theory, which remains purely speculative at this time. 
 
In conclusion, we have reported for the first time that ASM mass and lamina propria thickness 
are increased in the central airways of asthmatic horses. While central ASM mass increase is 
also a feature of human asthma, the lamina propria is thinner in asthmatics than in healthy 
patients. The mechanisms involved in such bronchial remodeling remain to be elucidated.  
 
 
3.  Peripheral airway is the site of major dysfunction in equine asthma 
Physiological variability of the airway structures along the bronchial tree is not well-described 
in horses. Article 4 of this thesis has shed light upon interesting aspects of ASM structure in 
equine asthma, namely the uneven increase in ASM mass and the different composition of the 
ECM surrounding smooth muscle cells at the central and peripheral levels of the bronchial 
tree. Also, the finding that peripheral ASM remodeling is associated with disease severity is 
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new in the equine species. In asthmatic horses, ASM increase is more marked peripherally 
(+200-300% compared to healthy animals) than centrally (+50%). The ECM fraction of the 
ASM layer is mainly made up of elastin peripherally and of collagen centrally, which reflects 
the mechanical properties of the lungs. Also, it is in agreement with a human study showing 
that the fractional area of the elastic fibers within the ASM was higher in the small airways 
than in the large airways (Araujo, Dolhnikoff et al. 2008). Unfortunately, the lack of healthy 
control horses in the same study did not permit to establish whether the different composition 
of ECM along the bronchial tree is a consequence of the disease or is observed also in healthy 
animals. Further studies will need to clarify this aspect.  
In human asthma, ASM was reported to be increased 30% to 60% in peripheral airways and 
50% to 100% in the medium to large airways of nonfatal and fatal cases, respectively (Carroll, 
Elliot et al. 1993, James, Elliot et al. 2012). The composition of the ASM layer and its 
variability along the bronchial tree has been investigated in a limited number of human 
studies. James and colleagues reported that, on average, 18-20% of the ASM layer was 
occupied by ECM both in central and peripheral airways of asthmatics and healthy patients 
(James, Elliot et al. 2012), which is in agreement with our results. In that study, a significant 
decrease of ECM fraction was observed only in the central airways of fatal asthmatics 
compared to control subjects, in the presence of an increased ASM mass (James, Elliot et al. 
2012). Yick and colleagues reported similar values of elastin and collagen fraction in 
endobronchial biopsy samples of mild asthmatics and healthy subjects (Yick, Ferreira et al. 
2012). On average, elastin and collagen fraction of the central ASM were 1-3% and 10-30%, 
respectively. These values closely resemble those we observed in the central airways of 
asthmatic horses. Finally, Araujo and colleagues reported a similar elastin fraction in central 
and peripheral airways of the same subjects, which was however increased in fatal asthmatics 
(14-17%) compared to non-fatal asthmatics (2-3%) and healthy patients (7-8%) (Araujo, 
Dolhnikoff et al. 2008). Although apparently contrasting, the findings of James and Araujo are 
not in disagreement as they used staining methods that differed for their ability to identify 
elastic fibers. Overall, asthmatic horses appear to have elastin fractions similar to those 
reported in peripheral airways of fatal asthmatics and in central airways of mild asthmatics. 
Similarly, the collagen fraction observed in equine central airways is comparable to that 
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observed in mild to moderate asthmatics. Concerning collagen fraction in peripheral airways, 
it appears to be significantly less in horses compared to that of human bronchioles. However, 
as we do not know the peripheral ASM composition in normal horses, it is hard to conclude 
whether it is physiological rather than an effect of the disease. A recent study investigating 
collagen I and III deposition in equine membranous bronchi reported that no immunolabeling 
was noted in the ASM layer of either control or asthmatic horses (Furness, Bienzle et al. 
2010). This suggests that even if a difference exists in the collagen fraction of peripheral ASM 
of healthy and diseased horses, its magnitude is likely to be minimal.  
The lamina propria of peripheral airways also undergoes remodeling in equine asthma, which 
is characterized by increased collagen and elastic fiber deposition (Setlakwe, Lemos et al. 
2014). It is unclear whether the same changes are sustained by central airways of asthmatic 
horses. When measured on whole bronchial sections and corrected by the basal membrane 
length, the lamina propria of asthmatic horses was not greater than that of healthy animals, 
although it was thicker (Article 3). However, few horses were studied and control lungs were 
harvested from an abattoir. Lungs were included in the study only if macroscopically normal, 
which could have introduced a bias in the results. Future studies should ascertain these results 
using an improved experimental design. In asthmatic patients, the extent of thickening of the 
lamina propria of membranous airways, if any, remains to be determined. An increased 
deposition of collagen I and a decreased deposition of collagen III have been reported in fatal 
asthmatics compared to control patients, which are indicative of a pro-fibrotic process 
(Dolhnikoff, da Silva et al. 2009). As a consequence, even in the presence of an unvaried total 
quantity of collagen in the airways, its mechanical properties are likely to be altered.  
In conclusion, asthmatic horses appear to present ASM changes similar to those observed in 
fatal asthma in their peripheral airways, whereas their central airways resemble those of mild 
asthmatic patients in terms of ASM quantity and composition. As for the ECM within the 
lamina propria, it is increased in peripheral airways of asthmatic horses. Although conflicting 
data have been obtained, it is likely that the lamina propria of central airways also displays a 
significant degree of remodeling in equine asthma. Further studies are needed to clarify this 
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point, to investigate epithelial alterations, and to characterize the type of bronchial and 
bronchiolar inflammation observed in equine asthma. 
 
 
4.  ASM remodeling is maximally but incompletely reversed by ICS treatment  
Previous studies performed by our group have shown that peripheral ASM remodeling 
remains partly irreversible after up to 1-year ICS monotherapy in asthmatic horses (Leclere, 
Lavoie-Lamoureux et al. 2012). In that study, the decrease of ASM induced by ICS was 
already observed after 6 months of treatment, with no further improvement at 1 year. 
However, no information was provided concerning the kinetics of ASM remodeling reversal 
before 6 months of treatment. In this perspective, the experimental procedures described in 
Article 4 of this thesis were designed to accurately identify the amount of time required by 
ICS to induce the maximal degree of reversibility of ASM remodeling in equine asthma. 
Furthermore, we speculated that adding a bronchodilator to the ICS treatment (ICS/LABA 
combination) would facilitate peripheral ICS deposition and enhance the reversibility of ASM 
remodeling at the most distal bronchial sites in the same interval of time. 
 
Reversibility of peripheral ASM remodeling requires at least 3 months of ICS treatment in 
asthmatic horses, and it is not enhanced by LABA add-on treatment 
Article 4 confirms that peripheral ASM remodeling is only partly reversible, and that the 
maximal degree of reversibility is attained by the third month of ICS monotherapy when the 
offending antigens are not removed from the environment in which the horses were kept. 
Importantly, combining ICS with LABA did not enhance the proportion of ASM remodeling 
reversed with treatment. ASM mass was reduced on average by 30% in the horses studied, 
which corresponds to what has previously been observed after 6 months and 1 year of ICS 
treatment in the horse (Leclere, Lavoie-Lamoureux et al. 2012). These findings confirm the 
previously observed partial irreversibility of ASM remodeling in equine asthma, and are in 
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agreement with human studies reporting an increased ASM mass in controlled non-fatal 
asthma (James, Elliot et al. 2012). The awareness of an incomplete or at least insufficient 
effect of ICS monotherapy on peripheral airways is growing (Anderson, Zajda et al. 2012), but 
the reason because peripheral remodeling cannot be thoroughly reversed by this treatment 
remains unclear. Their inability at decreasing peripheral airway inflammation could be a 
reason (Martin 2002, Leclere, Lavoie-Lamoureux et al. 2012). Given the significant anti-
inflammatory effect they exert in the proximal airways (Djukanovic, Wilson et al. 1992), the 
inability of ICS monotherapy to reach the most distal lung sites has been proposed as a 
possible explanation for its ineffectiveness. However, even when combined with LABA 
(which should facilitate distal deposition of ICS and also act synergistically with ICS to reduce 
inflammation (Barnes 2002)), a similar degree of ASM remodeling reversal was attained in 
our study. Although a precise assessment of tissue inflammation was beyond the aims of this 
thesis, we investigated the effect of treatment on submucosal peripheral inflammation using 
the semi-quantitative score described for endobronchial biopsy samples in Article 2. The 
results obtained are shown in Annex I (Figure 17), and suggest that either ICS or ICS/LABA 
were ineffective at reducing peripheral airway inflammation in the submucosa. However, the 
effect might have been limited to a single cell type, as observed in BALF, or also it might have 
been greater at the epithelial or adventitial level, which we did not assess.  
In asthmatic patients, the administration of hydrofluoroalkane-flunisolide for 6 weeks was 
judged successful at controlling peripheral inflammation (Hauber, Gotfried et al. 2003), as it 
decreased eosinophilia while increasing the number of neutrophils and macrophages in 
transbronchial biopsy samples. This suggests that total cell number may not adequately reflect 
treatment efficacy. Future studies investigating this aspect of the disease in comparison to 
healthy subjects and its response to treatment would be required before concluding about the 
effectiveness of ICS with/without LABA in the peripheral airways of asthmatic horses.   
 
 
 297 
 
Decreased ASM cell size and ECM fraction are the main contributors to ASM remodeling 
reversal in the first 3 months of treatment 
Multiple mechanisms contributed to the decreased ASM mass in peripheral bronchi. Although 
myocyte proliferation was reduced by antigen avoidance and salmeterol treatments, the 
number of myocytes per basal membrane length remained unvaried in all the groups studied. It 
is possible that myocytes undergo a more rapid turnover during disease exacerbations, or that 
12 weeks is an insufficient amount of time to reduce their number even when their 
proliferating density has decreased. Interestingly, the number of myocytes per basal membrane 
length was reduced after one year of ICS treatment (Leclere, Lavoie-Lamoureux et al. 2012). 
In that case, a consistent but statistically non-significant reduction of myocyte proliferation 
was observed at 6 months. Summarizing, up to one year is required for ASM hyperplasia to be 
significantly reduced after a burden of asthma exacerbation, as predicted by a recently-
developed mathematical model of ASM growth in asthma (Chernyavsky, Croisier et al. 2014). 
Contrarily, ASM hypertrophy was rapidly reversed by antigen avoidance and 
fluticasone/salmeterol, although it was accompanied by a significant reduction of ASM mass 
only in ICS/LABA-treated horses. It is counterintuitive to observe an unvaried ASM mass in 
the presence of a reduced myocyte size and proliferation density, as it occurred after 4 weeks 
of antigen avoidance. Although statistically non-significant, the number of myocytes per basal 
membrane length increased by 30% on average in this group, and the hypothesis that it might 
have been caused by dramatically reduced apoptosis is not supported by recently published 
data obtained in vitro (Price, Shao et al. 2015). The effect of ECM composition was however 
disregarded in that study, and since many matrix proteins can regulate ASM proliferation and 
apoptosis, it also might have played a role.  
Extracellular matrix elements are synthetized by ASM cells, and could contribute to the 
observed increase of ASM mass in asthma (Araujo, Dolhnikoff et al. 2008, Yick, Ferreira et 
al. 2012). In Article 4, 12 weeks of fluticasone/salmeterol significantly decreased the ECM 
fraction within the peripheral ASM of asthmatic, indicating a synergistic effect of the 
ICS/LABA combination on ECM deposition or turnover, and possibly on myocyte phenotype 
or its synthetic response. Unexpectedly, it was the elastin fraction that was significantly 
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decreased. As ASM composition of healthy equine airways has not been established, it is 
impossible to comment on the effect of the treatment (normalization vs. worsening). Based on 
what is described in asthmatic patients (Araujo, Dolhnikoff et al. 2008), fluticasone/salmeterol 
seems to induce a normalization of the peripheral ASM layer composition in equine asthma. 
There is however scarce information about the role of pharmacological treatments on ASM 
elastin content in human asthma.  
 
In summary, once lung function has normalized, myocyte hyperproliferation appears to be the 
more rapidly reversible aspect of peripheral ASM remodeling in equine asthma, but it does not 
result in a concomitant decrease in ASM mass. It is, however, followed by a decrease in the 
ECM fraction of the ASM layer, with a maximum delay of 2 months. Whether this reflects a 
phenotype switch of the ASM cells (more proliferative/synthetic to more contractile) will have 
to be determined. Based on previously published data, a minimum of 1-year treatment could 
be necessary to reduce ASM peripheral hyperplasia. The kinetics of reversibility of ASM 
hypertrophy remains unclear. In our study, a great variability was observed at baseline among 
different subjects, and cell size was significantly reduced by 1 month of antigen avoidance or 
3 months of fluticasone/salmeterol, in concomitance with the decreased neutrophilia in BALF. 
 
 
5.  ICS/LABA combination synergistically decreased the deposition of collagen in central 
airways of asthmatic horses 
Collagen deposition within the ASM layer is synergistically reversed by ICS/LABA treatment 
The central ASM layer is made up of collagen in a greater proportion than in the peripheral 
ASM. Although we did not use immunohistolabelling, we were able to differentiate collagen 
as the yellow-staining structure using Russell-Movat pentachrome technique. This staining is 
commonly used to assess total collagen in morphometrical studies of cardiac remodeling 
(Stephens, Nguyen et al. 2008). Collagen and other ECM proteins not only act as a mechanical 
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support for ASM, but they profoundly impact the biological and immunological activities of 
ASM cells by means of integrin-mediated interactions (Burgess, Ceresa et al. 2009). 
Moreover, the synthesis of ECM proteins, such as collagen I, by asthmatic myocytes is 
increased (Johnson, Burgess et al. 2004). Collagen I induces a functionally hypocontractile, 
proliferative phenotype of human ASM (Dekkers, Schaafsma et al. 2007, D'Antoni, Torregiani 
et al. 2008, Dekkers, Bos et al. 2012), and it also impairs the anti-migratory effects of 
fluticasone propionate on ASM cells (Bonacci, Schuliga et al. 2006). Whether type I collagen 
is increased in central airways of asthmatic horses, and particularly in their ASM layer, is 
unknown and deserves to be investigated. Within the smooth muscle layer, collagen I and III 
are similarly expressed in asthmatics and control patients (Araujo, Dolhnikoff et al. 2008, 
Yick, Ferreira et al. 2012). However, this similarity could have been the result of the 
pharmacological treatment implemented. In asthmatic horses, total collagen within the smooth 
muscle layer of central airways was significantly reduced by fluticasone/salmeterol 
combination and also by salmeterol monotherapy. The latter finding is of particular interest in 
asthma. Indeed, due to its questionable safety profile, LABA monotherapy cannot be 
administered to asthmatic patients. Multiple studies and meta-analyses have been conducted 
and indicate that an increased incidence of adverse effects is associated with LABA 
administration (Sears 2011). For this reason, studies investigating specifically its clinical 
effects cannot be performed. Until now, the information concerning the efficacy of LABA at 
inhibiting ECM synthesis by ASM cells was limited to in vitro data but lacked an in vivo 
validation (Hirst, Twort et al. 2000, Hirst, Martin et al. 2004, Ammit, Burgess et al. 2009). 
Our results support the ability of long-term LABA treatment at decreasing ECM deposition 
within the ASM layer of central airways in asthma. This, however, occurred in the absence of 
reduction of central airway inflammation, ASM mass, myocyte proliferation density, and after 
myocyte size had decreased compared to baseline. In human patients, 12 weeks of salbutamol 
treatment reduced the tenascin but not the collagen content of endobronchial biopsy samples 
of mild asthmatic patients (Altraja, Laitinen et al. 1999). Taken together, these results suggest 
that decreasing the ECM deposition in the absence of a concomitant inhibition of airway 
inflammation and/or ASM remodeling could produce clinically deleterious effects. In the 
presence of bronchospasm, a “fibrotic” airway (with increased ECM deposition) may 
counteract airway obstruction. 
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It is interesting to note that the deposition of different ECM proteins is downregulated by 
fluticasone/salmeterol treatment at different levels of the bronchial tree. Differently from 
salmeterol, which induced a similar reduction of collagen in ASM of both central and 
peripheral airways, fluticasone/salmeterol decreased the collagen fraction centrally but the 
elastin fraction peripherally. There is no data regarding the role of elastin fraction of ASM and 
how it is affected by pharmacological treatments in asthma (Reddel, Weiss et al. 2012). A 
greater elastin fraction is observed in peripheral compared to central airways of healthy 
subjects, but this difference is lost in asthma (Araujo, Dolhnikoff et al. 2008). Elastin 
expression in endobronchial biopsy samples of asthmatic subjects is proportional to AHR 
(Slats, Janssen et al. 2008). An increased fraction of elastin is observed after fatal asthma 
attacks (Araujo, Dolhnikoff et al. 2008). Overall, an increased quantity of elastin within the 
ASM layer seems to be detrimental for the development and severity of AHR, while its 
reversibility in response to treatment remains to be established. 
 
Lamina propria thickening of the central airways is completely reversible by ICS/LABA 
Expression of types I and III collagens is higher in the lamina propria of patients with 
moderate-to-severe asthma compared to mild asthmatics and controls (Chakir, Shannon et al. 
2003). However, the same difference was not observed in another study (Dolhnikoff, da Silva 
et al. 2009) and the lamina propria of asthmatic bronchi appears to be thinner than that of 
healthy bronchi (Sumi, Foley et al. 2007). This occurs in spite of angiogenesis and impaired 
lymphangiogenesis which, together with other inflammatory insults, can contribute to edema 
development within the submucosal layer (Chetta, Zanini et al. 2007, Ebina 2008). As stated 
earlier, the lamina propria of central airways of asthmatic horses is thicker compared to that of 
healthy animals. This is true both when it is measured in complete bronchial sections and in 
endobronchial biopsy samples (Article 1 and 3, respectively). We have considered and 
previously discussed the possibility of this finding to be a technical artifact. However, the 
complete normalization of the lamina propria thickness observed after 3 months of treatment 
(while pulmonary function already normalized after 1 week) suggests that this finding is real, 
and not a technical consequence of bronchoconstriction. Secondly, a significant decrease of 
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ECM deposition was observed simultaneously within the ASM layer in the same animals, 
indicating that fluticasone/salmeterol produces a similar effect at both levels of the bronchial 
wall.  
Mechanical stress per se increases ECM deposition in asthmatic airways (Grainge, Lau et al. 
2011). To the same extent, our data suggest that bronchodilation per se can reverse ECM 
remodeling. Indeed, a reduced thickness of the lamina propria was observed with 
fluticasone/salmeterol and also with salmeterol monotherapy, at least until the 8th week, which 
is the period during which salmeterol was effective at inducing bronchodilation in asthmatic 
horses. However, fluticasone and antigen avoidance treatments were also effective at 
normalizing lung function (reducing airway obstruction, and thus reversing 
bronchoconstriction). These findings suggest that it is a β2-adrenoceptor-related mechanism 
rather than the simple non-contraction of ASM which is responsible for the decreased 
deposition of ECM proteins in asthmatic airways.  
Using EBUS, we have shown that the submucosal thickness of central airways of asthmatic 
horses had returned to almost normal values after 3 months of fluticasone/salmeterol 
administration. However, no change was observed after only 1 month of treatment. This 
reduction coincided with the normalization of lamina propria thickness and also with a 
reduction of uncorrected ASM area within endobronchial biopsy samples. As EBUS reliably 
estimates the ASM mass in asthmatic and control horses (Article 3), our findings suggest that 
fluticasone/salmeterol combination is effective at decreasing the central ASM mass in equine 
asthma. The constant proportion between lamina propria and ASM in central airway 
submucosa appears to be caused by the amount of ECM laying between the ASM fibers. The 
possibility that bronchoconstriction may have mimicked an increased ASM mass at EBUS at 
baseline has been considered. In fact, given the inability to accurately trace the airway 
epithelium on sonograms, a contracted airway would appear as a smaller one with a thicker 
bronchial wall. However, EBUS-assessed remodeling was unchanged at 1 month, when the 
lung function of horses had already normalized, which validates our results. That said, 
pretreating horses undergoing EBUS with a bronchodilator would guarantee that this type of 
bias is prevented, and we strongly suggest this precaution should be implemented in the future.   
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ECM remodeling reversal occurs faster in central than in peripheral airways of asthmatic 
horses 
In our study, we did not observe a significant reduction of ECM deposition within the lamina 
propria of peripheral airways after 3 months of either treatment, while it was observed after 
one year of ICS treatment in asthmatic horses (Leclere, Lavoie-Lamoureux et al. 2012). Based 
on these data, it appears that ECM remodeling reversal occurs more rapidly in central than in 
peripheral bronchi. The hypothesis that it is linked to inflammation control is not supported by 
available data. In fact, both peripherally and centrally, a reduced deposition of collagen within 
the lamina propria was observed in the presence of an unvaried degree of inflammation (semi-
quantitative score evaluating all cell types together). Furthermore, human studies have shown 
decreased inflammation in the absence of reduction of submucosal fibrosis (Hoshino, 
Takahashi et al. 1999). The specific contribution of each inflammatory cell type in equine 
asthma deserves however to be assessed in future studies. Alternatively, the possibility that 
LABA deposition is higher in central than in peripheral airways has to be considered, and 
could have accounted for the delayed peripheral effect. Studies showing a residual 
bronchoconstriction in small airways of asthmatic subjects in spite of a normal FEV1 support 
this scenario (Pisi, Tzani et al. 2013). In our study, we did not perform experiments to assess 
the bronchial/pulmonary deposition of the drugs we administered. In vitro studies using 
primary horse-derived fibroblasts support a synergic role of ICS/β2-agonists on cell 
proliferation, differentiation, and collagen synthesis (Franke and Abraham 2014). These 
results, contrarily to ours, do not support an anti-fibrotic effect of β2-agonists alone. However, 
serum-induced collagen synthesis in vitro may not reflect the stimulus existing in vivo, and the 
molecules tested did not include salmeterol, which could explain the discrepancy with our 
results.  
 
In conclusion, our results support the ability of long-term ICS/LABA treatment at decreasing 
ECM deposition within the ASM layer and lamina propria of central airways in horses. While 
an initial decrease of ECM deposition was also observed in LABA treated horses, it occurred 
in the absence of reduction of airway inflammation and finally led to worsen the lung function 
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in treated horses. These findings underline the importance to administer LABA only 
concomitantly with ICS. The blunted effect observed in the peripheral airways could be the 
consequence of a decreased drug deposition at this level of the bronchial tree that, in turn, did 
not reduce inflammation.  
 
 
6.  Environmental heat worsens bronchospasm in equine asthma 
During the experimental protocol of Article 4, we noticed on two occasions that the clinical 
condition of asthmatic horses worsened in concomitance with episodes of sudden 
environmental heat (week 8 of both Studies I and II). Importantly, the recrudescence of 
clinical signs observed with heat seemed to negatively impact the effect of certain drugs to 
control central airway remodeling and inflammation. For example, bronchial inflammation 
increased following these episodes both in fluticasone and fluticasone/salmeterol-treated 
horses. In fluticasone-treated horses, the tendency of myocyte proliferation and lamina propria 
thickness to decrease was reversed. Salmeterol-induced inhibition of ECM deposition within 
the lamina propria of central airways also appeared to be affected. However, peripheral airway 
remodeling and inflammation did not appear to be altered by heat-associated acute 
bronchospasm. These findings are in agreement with previous work in which up to one month 
of antigen exposure did not increase peripheral ASM mass, myocyte number or size (Leclere, 
Lavoie-Lamoureux et al. 2011).  
We then investigated whether and how environmental variables affect equine asthma 
presentation (Article 5). Our results are in agreement with observations made in human asthma 
indicating that high temperatures and humidity are associated with increased hospitalizations 
(Hayes, Collins et al. 2012, Kim, Lim et al. 2014). This is a new finding in asthmatic horses, 
for which the negative effect of cold temperatures had only been described up to now (Davis, 
Lockard et al. 2002, Davis, Malayer et al. 2005, Davis, Royer et al. 2006). However, we could 
not identify the relative contribution of heat, humidity, and airborne pollens to airway 
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obstruction. Prospective studies need to be performed to elucidate how these interconnected 
parameters can affect lung function, airway remodeling, and inflammation. 
  
 
  
 
Conclusions and perspectives 
A reliable protocol for the assessment of large airway remodeling has been developed, which 
comprises both EBUS and endobronchial biopsy sampling. With the samples provided by 
these two techniques, it is possible to obtain reliable data concerning quantitative and 
qualitative assessment of airway structure and inflammation in equine asthma.  
Using this integrated approach, we have confirmed the hypothesis that central airways of 
asthmatic horses display ASM remodeling although its magnitude is milder compared to 
peripheral airways. Both hypertrophy and increased collagen deposition are likely to 
contribute to central ASM remodeling, while myocyte hyperplasia could not be confirmed in 
our studies. This is because endobronchial biopsy sampling provides only partial-thickness 
specimens of the bronchial wall, which prevents an accurate quantification of the number of 
myocytes within the ASM layer. Synthesis and deposition of ECM proteins within the lamina 
propria, which is thickened in equine asthma, also contributes to central airway remodeling. 
Lastly, epithelial and submucosal inflammation characterizes the large airways of asthmatic 
horses during periods of disease exacerbation.  
Central airway remodeling and inflammation are reversible with clinical control of the disease, 
to the point that endobronchial biopsy samples of asthmatic horses in remission are 
indistinguishable from biopsy samples obtained from healthy horses. Conversely, differences 
have been consistently observed in previous studies between the membranous bronchioles of 
asthmatic horses and controls. Furthermore, the effect of pharmacological treatment on distal 
bronchioles appears to be limited to airway remodeling, while it does not reduce overall 
inflammation. These observations confirm that equine asthma is a disease primarily 
characterized (and possibly orchestrated) by peripheral airway dysfunction, although large 
airway involvement is common during exacerbations and contributes to the clinical 
manifestation of the disease. The blunted reversal of airway remodeling and inflammation 
observed in the peripheral compared to the central airway may be due to an inadequate drug 
deposition at this level of the lung or, alternatively, to an altered pulmonary environment 
which could foster corticoresistance. 
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Airway dysfunction is reversed with different dynamics and kinetics at the central and 
peripheral level of the bronchial tree. Also, the treatment strategy employed may differentially 
regulate the reversibility of specific aspects of airway remodeling and inflammation. Overall, 
the reversal of submucosal ECM remodeling (lamina propria thickening) and airway wall 
inflammation occur faster in central than peripheral airways. Fluticasone/salmeterol 
synergically inhibits ECM deposition within the lamina propria and ASM layer in central 
airways, while this effect is observed only in the ASM of peripheral airways. Also, BALF 
neutrophilia is reduced by fluticasone/salmeterol after 2 months, while the same drugs were 
ineffective when administered as monotherapies. Myocyte hypertrophy is rapidly reversed in 
central airways when disease is controlled, independently of the treatment strategy employed. 
Peripherally, myocyte hypertrophy cannot be reversed by fluticasone or salmeterol treatment 
given as monotherapy, but their combination is effective at reducing myocyte size after 3 
months.  The synergistic antinflammatory effect exerted by fluticasone/salmeterol on BALF 
neutrophils was not accompanied by a simultaneous enhancement of peripheral ASM 
remodeling reversal compared to fluticasone monotherapy.  
In summary, our results suggest that the enhanced therapeutic effect of ICS/LABA over ICS 
monotherapy in asthmatic patients may be associated with a reduction of ECM deposition, 
mainly observed within the large airways, and possibly also with a decreased neutrophilia in 
the bronchoalveolar lavage fluid. However, ICS/LABA does not provide any additional 
benefit to ICS monotherapy in terms of peripheral airway smooth muscle remodeling and 
submucosal inflammation as both induce a 30% decrease of the airway smooth muscle mass in 
3 months. 
Lastly, in the equine asthma model, the reversibility of central airway remodeling does not 
mirror structural changes occurring in peripheral airways. Based on our data, it is impossible 
to estimate the dynamics of small airway remodeling or its reversibility based on central 
airway findings. Nevertheless, monitoring central airway remodeling over time or during 
equine asthma exacerbation may help to establish a prognosis or to predict the response to 
treatment.   
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Perspectives 
This thesis has characterized central and peripheral airway remodeling in equine asthma, as 
well as their reversibility following several treatments. In order to gain a thorough picture of 
the dynamics of central ASM remodeling in equine asthma, it remains to be determined 
whether myocyte hyperplasia also contributes to the disease process. This cannot be 
performed on bronchial samples obtained by endobronchial biopsy samples. Post mortem lung 
would provide optimal specimens for this. Alternatively, bronchial biopsies obtained by means 
of cryoprobes could allow full-thickness sampling of the bronchial wall, which would permit 
to follow the effect of treatment longitudinally. We have described the ASM composition of 
equine asthmatic airways and how it is affected by several treatments, but ASM composition 
of healthy airways also needs to be determined in order to better understand the effect of such 
treatments. A more detailed description of ECM composition and mechanical properties could 
also reveal interesting aspects of the disease or of pharmacological interventions. Investigating 
the expression of MMPs and TIMPs could help to elucidate the mechanisms of ECM decrease 
we observed.  
We have focused our attention on ASM and ECM, as they are recognized as important 
determinants of airway obstruction in asthma. However, a substantial body of evidence 
suggests that the bronchial epithelium may be the main orchestrator of the inflammatory 
response, which is another hallmark of asthma. Characterizing epithelial activation as well as 
bronchial inflammatory response in peripheral and central airways of asthmatic horses may 
provide interesting information and help to clarify why drug-induced control of inflammation 
differs at these two levels of the bronchial tree.   
Finally, we have validated and optimized the use of endobronchial biopsy and EBUS as tools 
for the assessment of central remodeling in horses. Introducing these tools in equine clinical 
practice will allow to monitor bronchial remodeling over time in a large number of asthmatic 
subjects but also to investigate the presence of structural bronchial alterations in horses 
affected by inflammatory airway disease (IAD). 
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Annex I 
 
Annex I comprises additional results pertinent to this thesis but which were not included in the 
articles presented due to editorial choices. These data may be helpful in the interpretation of 
our results.  
 
 
ii 
Additional results of Article 1 
 
Figure 14 (Figure 1, Annex I). Correlation between lamina propria thickness and lung 
function data.  
 
Left panel: correlation between the lamina propria thickness and pulmonary resistance at 5 Hz 
(R, expressed in kPa/L/s). Right panel: correlation between the lamina propria thickness and 
the percentage of the biopsy sample occupied by airway smooth muscle (ASM%). Of note, 
pulmonary resistance at 5 Hz was measured after the administration of a bronchodilator 
(Buscopan ® 0.3 mg/kg IV) in all horses studied.  
 
Figure 15 (Figure 2, Annex I). Effect of bronchoconstriction on lamina propria thickness. 
 
Horses were studied during asthma exacerbation using a cross-sectional approach (see the 
methods of Article 1), Buscopan or placebo were administered 4 days apart. Each point 
represents one horse and corresponds to the mean values obtained by the analysis of 6 biopsy 
samples. Paired t-test was performed as statistical test (p=0.47). 
 
 
iii 
 
Additional results of Article 2 
 
Figure 16 (Figure 3, Annex I). Relationship between biopsy score and lung function. 
 
The biopsy score correlates with different parameters of airway obstruction measured by 
impulse oscillometry in asthmatic horses. Left panel: correlation with expiratory resonance 
frequency. Values of 4 horses were missing as their reactance curves did not cross the x axis. 
Right panel: correlation with the ratio between resistance at 5 Hz and 10 Hz, a previously 
validated parameter of airway obstruction in asthmatic horses (van Erck, Votion et al. 2003). 
Black circles: horses with asthma in exacerbation of the disease. Black and white circles: 
horses with asthma in remission of the disease.  
 
 
 
 
 
 
 
 
 
iv 
 
Additional results of Article 4 
 
Figure 17 (Figure 4, Annex I). Effect of pharmacological treatments and antigen 
avoidance on bronchiolar inflammation  
 
A) Study I. B) Study II. Statistical analysis performed with non-parametric paired t-test 
(Wilcoxon). For one horse treated with antigen avoidance group (#383) and one treated with 
salmeterol (#391), assessment at 12 weeks was not possible due to low quality of the 
histological images.  
  
 
 
v 
Annex II 
 
Annex II includes additional publications I have co-authored and pertinent to the subject of 
this thesis.  
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Article 6 
 
Asthma “of horses and men” – how can equine heaves help us better understand human 
asthma immunopathology and its functional consequences?  
Michela Bullone and Jean-Pierre Lavoie 
 
 
Summary 
This review summarizes the immunological aspects which support the use of the equine model 
of asthma. Similarities and differences between equine and human asthma are discussed.  
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Animal  models  have  been  studied  to unravel  etiological,  immunopathological,  and  genetic  attributes
leading  to asthma.  However,  while  experiments  in  which  the  disease  is  artiﬁcially  induced  have  helped
discovering  biological  and  molecular  pathways  leading  to  allergic  airway  inﬂammation,  their contribution
to  the understanding  of the  causality  of  the  disease  has been  more  limited.  Horses  naturally  suffer  from  an
asthma-like  condition  called  “heaves”  which  presents  sticking  similarities  with  human  asthma.  It is char-
acterized  by  reversible  airway  obstruction,  airway  neutrophilic  inﬂammation,  and  a predominant  Th2
immune  response.  This  model  allows  one  to investigate  the  role  of  neutrophils  in  asthma,  which  remains
contentious,  the  regulation  of  chronic  neutrophilic  inﬂammation,  and  their  possible  implication  in pul-
monary  allergic  responses.  Furthermore,  the pulmonary  remodeling  features  in heaves  closely  resemblemmunology
orse
irway remodeling
nﬂammation
those of  human  asthma,  which  makes  this  model  unique  to investigate  the kinetics,  reversibility,  as  well
as the physiological  consequences  of tissue  remodeling.  In  conclusion,  heaves  and asthma  share  com-
mon  clinical  presentation  and  also  important  immunological  and  tissue  remodeling  features.  This makes
heaves  an  ideal  model  for  the  discovery  of  novel  pathways  implicated  in  the asthmatic  inﬂammation  and
associated  tissue  remodeling.
© 2014  Elsevier  Ltd. All  rights  reserved.. Introduction
Major discoveries related to human diseases have been gained
hrough animal experiments. It is undoubted that mice models have
elped uncovering novel immunological mechanisms responsible
or the development of different disease processes. Nevertheless,
herapeutic strategies derived from these studies have been for
he most part disappointing when translated to human diseases,
ncluding asthma (Clienti et al., 2011; Giembycz and Newton, 2011;
air et al., 2012). This may  be in part due to different transcrip-
ional responses to acute inﬂammatory insults in mice and men
Seok et al., 2013).
Development of animal models better mimicking human dis-
ases not only in their clinical presentation, but also taking into
ccount genetic diversity and the complexity of immunopatho-
ogical mechanisms leading to disease ontogeny, is considered
∗ Corresponding author at: Department of Clinical Sciences, Faculty of Veterinary
edicine, Université de Montréal, 3200 rue Sicotte, St-Hyacinthe, QC, Canada J2S
C7. Tel.: +1 450 773 8521.
E-mail address: Jean-Pierre.Lavoie@umontreal.ca (J.-P. Lavoie).
ttp://dx.doi.org/10.1016/j.molimm.2014.12.005
161-5890/© 2014 Elsevier Ltd. All rights reserved.crucial for the discovery of novel therapeutic approaches (Hein and
Griebel, 2003). Domestic animal species spontaneously develop
diseases having striking similarities with human conditions. Life-
span and size of large animals are more similar to men  than to
rodents, as is their developmental, innate, and mucosal immunity.
For instance, mice lack the gene encoding for the interleukin-8 (Hol
et al., 2010), a cytokine implicated in severe neutrophilic asthma
and in respiratory virus-induced asthma exacerbations (Nakagome
et al., 2012; Rohde et al., 2014), and also essential for neutrophil
recruitment in men, cattle, and horses (Caswell et al., 1999, 2001;
Cook et al., 2009; Douglass et al., 1996; Franchini et al., 1998; Kaur
and Singh, 2013).
2. Equine heaves, as a naturally occurring model of asthma
Horses naturally develop an asthma-like condition currently
known in the veterinary scientiﬁc community as “heaves” or RAO
(recurrent airway obstruction) (Robinson, 2001). This condition has
also been known in the past as chronic bronchiolitis, broken-wind,
hay sickness, emphysema, small airway disease, allergic airway dis-
ease, and chronic obstructive pulmonary disease. As “heaves” was
the term used to introduce the horse as an animal model for asthma,
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e will employ this term in this review. The name “inﬂammatory
irway disease” (IAD) has been coined to describe a milder form of
quine respiratory inﬂammatory disease in which no respiratory
ffort is observable at rest. It is characterized by mild clinical signs
nasal discharge, cough, decreased athletic performance) detected
n the presence of inﬂammatory abnormalities of the bronchoalveo-
ar lavage ﬂuid (BALF) cytology (Couetil et al., 2007). It has recently
een proposed that heaves and IAD in all their clinical variants are
rouped together under the deﬁnition of “equine asthma” (Lavoie,
ersonal communication).
Both human asthma and equine heaves are heterogeneous dis-
ases which might present in a variety of clinical forms depending
pon the stage of the disease, the chronicity of the condition, and
ossibly upon different pathogenetic pathways leading to its devel-
pment. We  recognize that not all forms or stages of human asthma
ecessarily share the same attributes as equine heaves. Based on the
eﬁnition of the most recent GINA guidelines (GSAMP, 2014), we
elieve that heaves represent an ideal animal model for the study
f non-allergic asthma, late-onset asthma, and severe asthma.
.1. “Heaves” and asthma
Heaves is a chronic obstructive respiratory condition naturally
ffecting 10–15% of adult horses living in temperate climates
Hotchkiss et al., 2007). It shares remarkable similarities with
uman asthma (Table 1). In heaves, disease exacerbations, during
hich horses suffer from respiratory distress episodes comparableo those affecting severe asthma patients, are triggered by inhala-
ion of environmental antigens (Pirie et al., 2003). It had been
ostulated that heaves was analogous to allergic pneumonitis
n man  (Farmer’s lung disease), as moldy hay is an important
able 1
imilarities and differences between equine respiratory conditions and asthma.
IAD 
Epidemiology and etiology
Naturally occurring disease
• Early in life
• Adult-onset
√
√
Environmental component
√ 
Genetic component
↑  Endotoxin sensitivity √
Pathophysiology
Airway hyperresponsiveness
• Early phase
• Late phase
√ 
Airway obstruction Sub-clinical 
High  temperature/humidity induced
exacerbations ?
Tissue  remodeling
• ↑ ASM mass
• ↑ ECM mass
• ↑ basal membrane thickness
• ↑ mucous producing cells
•  Associated bronchiectasis
?
?
?
?
?
Hypercoagulability state ?
Immunology
Airway neutrophilia †
Airway eosinophilia †  
Airway mastocytosis †  
Tissue  inﬂammation ?
Th2-mediated inﬂammatory response
√ 
Th1-mediated inﬂammatory response
√ 
Th17-mediated inﬂammatory response †
IgE  mediated response ? 
Associated atopy ? 
Innate  immune activation
• Systemic inﬂammation †
•  ↑ Endotoxin sensitivity †
: present †:  may  be present. *: may  be only partly reversible. ?: Not evaluated to our knmunology 66 (2015) 97–105
triggering factor for both diseases. However, these two condi-
tions are otherwise different in their clinical presentation, lung
pathology, and underlying immunopathological mechanisms. For
instance, bronchiolitis and alveolitis with granuloma formation
and extensive ﬁbrosis leads to a restrictive respiratory pattern in
allergic pneumonitis (Costabel et al., 2012), while in heaves these
changes are not present.
The exposure to hay and dusts leading to heaves is rather a
consequence of the human inﬂuence on horses’ natural environ-
ment. Molds and fungi are indeed common antigens in the stables,
suggesting that heaves is a disease of “domestication”. However,
horses can develop a similar condition while at pasture, with grass
pollen being then the likely triggering factor (Dixon and McGorum,
1990; Seahorn and Beadle, 1993). Therefore, the antigens toward
which horses develop an asthma-type response vary according to
environmental exposure.
During clinical exacerbation of heaves, horses develop a pul-
monary neutrophilic inﬂammation (Jean et al., 2011) (Fig. 1). While
asthma is commonly described as an eosinophilic disease, it is
now recognized that neutrophilic inﬂammation may be present in
asthma of all severities, although it is more common in severe asth-
matic patients and during acute disease exacerbations (Nakagome
et al., 2012; Qiu et al., 2007; Wenzel, 2012). Eosinophils, metachro-
matic cells, or neutrophils may  inﬁltrate the airway lumen when
horses develop the mild-to-moderate asthmatic-type response
seen in IAD.
Both heaves and asthma are characterized by reversible airﬂow
obstruction, as a consequence of bronchospasms, increased mucus
production, airway hyperresponsiveness, and pulmonary remod-
eling (Fig. 2). During periods of remission of the disease, when
offending antigens are removed from the horses’ environment,
Heaves Mild asthma Severe asthma
†√
√
√
√
√
√ √ √
√ √ †√ √ √
√
–√
√
√
√
√
√
√
Reversible* Reversible Partly
reversible
√ √ √
√
√
†√
†
√
√
√
√
†
√
√
√
√
†√ √ √
√ †  †
- †  †
†  (rare) †√ √ √
√ √ √
√ †  †√ √ √
† √ √
†  †  †
√ † √√ √ √
owledge.
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Fig. 1. (A, B) Horses with heaves during clinical remission of the disease have pulmonary resistance (RL) values and neutrophil percentages in BALF similar to those of healthy
controls. However, after antigen exposure, sustained increased in RL and neutrophil percentages in BALF are present only in horses with heaves (reprinted from Joubert et al.,
2011  with the permission of Elsevier, license number: 3423941179982). (C–E) BAL ﬂuid cytology of a horse with heaves during exacerbation (C) and remission (D) of the
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fisease, and of a healthy horse (E). Note the presence of mucus (upper right), the inc
uffering  from heaves during exacerbation of the disease. Neutrophils are indicate
rrows.
orses with heaves are clinically indistinguishable from healthy
nimals, and their airway function and bronchial cytology nor-
alize (Leclere et al., 2011). However, as reported in neutrophilic
uman asthma (Wood et al., 2012), systemic inﬂammation (Lavoie-
amoureux et al., 2012a,b) and subclinical airway obstruction
Leclere et al., 2012a; Van Erck et al., 2006) persist in these horses.
he latter is explained, at least in part, by a persistent remodeling
f the airways (Lanctot Setlakwe et al., 2014; Leclere et al., 2012a).
.2. Advantages of the equine asthma modelHeaves is a naturally occurring disease in which pathogenetical
echanisms are likely to be similar to those observed in human
sthma, possibly triggered by immunological “defects” rather than
rom external manipulations as it happens in rodent models. Also, cellularity of BAL ﬂuids and also the increase in neutrophil percentage in the horse
lack arrowheads; lymphocytes by black arrows and macrophages by transparent
similar to the natural history of human asthma, horses with heaves
experience repeated episodes of airway obstruction occurring over
periods of years or sometimes even decades. This contrasts with
rodent models in which chronicity can rarely be achieved for
more than a 3-month period (Nials and Uddin, 2008; Yang et al.,
2013). Furthermore, as the environmental triggering conditions are
known, disease status may  be modulated as required by speciﬁc
research needs, avoiding the use of drugs or antigens irrelevant
to disease development to induce bronchoconstriction. This repre-
sents a unique strength of equine heaves for the study of human
asthma.The horse is especially well suited for prospective studies
requiring multiple analyses repeated over time and on the same
subjects. Indeed, additional advantages of horses are those linked
to their size. Venipuncture and blood analysis can be performed
100 M. Bullone, J.-P. Lavoie / Molecular Immunology 66 (2015) 97–105
Fig. 2. (A) Endoscopic image of the trachea of a horse suffering from heaves during disease exacerbation. Note the mucus accumulation. (B) Histologic section of the lung
p s are ﬁlled with mucus (green) containing inﬂammatory and epithelial cells. Epithelial
m ate is also evident. Airway smooth muscle mass is increased compared to normal horses
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Table 2
Efﬁcacy of several treatments on asthma in equine and rodent animal models, as
well  as in man.
Horse Rodents Man
Antinﬂammatory agents
Inhaled corticosteroids
√ √ √
Systemic corticosteroids
√ √ √
Anti-leukotriens —
√
(
√
)*
Cromones (
√
)
√
(
√
)*
Non-steroidal antinﬂammatory drugs — —
Bronchodilators
-adrenergic agents (
√
),* (
√
) (
√
),*
Anticholinergic agents (
√
),*
√
(
√
),*
Phosphodiesterase (PDE) inhibitors
Methylxanthine inhibitors (
√
),*
√
(
√
),*
Selective PDE inhibitors —
√
—
Antioxidants (
√
)
√
(
√
),*
Expectorant, mucolytic and mucokinetic agents — (
√
) —
Immunomodulators ?
√
(
√
)
Antibiotics √ √arenchyma of a horse with heaves. The bronchial lumens of the smaller airway
ucus-producing cells are increased in number. Sub-epithelial inﬂammatory inﬁltr
scale bar = 100 m).  ASM: airway smooth muscle; M:  mucus; e: bronchial epitheli
ecurrently allowing the non-invasive collection of large quantities
f circulating cells without altering the animal immune response.
ronchoscopy is performed in standing sedated animals, allowing
ucus collection, tracheal wash (TW) aspirates, bronchoalveolar
avage (BAL), and/or bronchial epithelial brushing. Furthermore,
he equine tracheobronchial tree offers more than 40 reachable
arinae for endobronchial biopsy collection (Fig. 3). Although
ndobronchial biopsies have been shown to be inadequate sam-
les for quantitative studies of airway smooth muscle (ASM)
ass (Bullone et al., 2014a), they provide valuable information
egarding epithelial, extracellular matrix components, and ASM
ell phenotypes (Jeffery et al., 2003; Leclere et al., 2011, 2012a;
eguillette et al., 2009; Pini et al., 2007). Horses’ lungs also permit
arvesting large peripheral lung biopsies by means of thoraco-
copic surgery (Lugo et al., 2002; Relave et al., 2008, 2010), which
akes heaves perhaps the only animal model allowing the study
f small airways remodeling over time in the same subjects. Fur-
hermore, techniques such as spirometry, impulse oscillometry,
nd endobronchial ultrasound among others allow studying lung
unction as well as structural remodeling in this species (Bullone
t al., 2014b; Couetil et al., 2000; Van Erck et al., 2006).
ig. 3. Endobronchial biopsy procedure in a horse. Carinae from which endo-
ronchial biopsies can be withdrawn are numerous (marked with yellow stars).
iopsies may be withdrawn from carinae of 1st, 2nd, 3rd, and 4th generation. This
s  due to the branching pattern of the equine bronchial tree (monopodial), in which
everal lateral ancillary bronchi stems from the main caudal bronchus before reach-
ng  the maximal caudal accessible sites where it is possible to lodge the endoscope.
Macrolides ? ( ),*
Cellular therapy
Adoptive transfer of stem cells —
√
?
√
: treatment with demonstrated efﬁcacy in that species. (
√
): treatment whose efﬁ-cacy in that species is supported by a low level of scientiﬁc evidence. —: treatment
with no demonstrated efﬁcacy in that species. ?: treatment with unknown efﬁcacy
in that species. *: treatment suggested as possible add-on therapy in selected cases.
The effect of aging on immunological variables is often disre-
garded when rodent models are employed in experimental settings,
but evidences support important immunological functions to be
dependent on or to change with age (Busse and Mathur, 2010;
Lee et al., 2012). Horses’ lifespan (≈30 years) is undoubtedly more
similar to that of man  than those of rodents, cats, or dogs. Also,
horses develop heaves in their adulthood, which is reminiscent of
late-onset human asthma, with both conditions generally display-
ing neutrophilic pulmonary inﬂammation and a less pronounced
allergic component (Brazil et al., 2005; Wenzel, 2012).
The treatments of choice for heaves are corticosteroids,
either inhaled or systemically administered. Also, both adrener-
gic and anticholinergic bronchodilators have been proved effective
at inhibiting the bronchospasm associated with heaves. Many
molecules targeting speciﬁc intracellular pathways or mediators
shown to be involved in murine asthma models were effective
when tested in mice, but not in horses or in man  (Table 2). For
instance, p38 MAPK inhibitors (Bhavsar et al., 2010; Chopra et al.,
2008; Lavoie et al., 2008), PDE4 inhibitors (Giembycz and Newton,
ular Im
2
l
h
s
P
t
t
l
h
i
2
d
s
p
h
w
t
A
e
b
e
ﬁ
t
s
c
a
3
3
c
r
i
e
(
t
e
2
e
i
a
s
e
f
l
i
r
d
(
2
e
o
F
a
e
a
t
t
eM. Bullone, J.-P. Lavoie / Molec
011; Lavoie et al., 2006; Matera et al., 2014), as well as cysteinyl-
eukotriene antagonists, were poorly effective as sole therapy in
orses with heaves (Kolm et al., 2003; Lavoie et al., 2002) despite
howing promising outcomes in rodent models (Bos et al., 2007;
era et al., 2011). These drugs are now considered either ineffec-
ive or only as add-on therapies for uncontrolled asthma rather
han as ﬁrst-choice monotherapies in asthma international guide-
ines (Busse and Lemanske, 2007; Turner et al., 2011). Thus, equine
eaves appears to be a valuable preclinical model for reliably test-
ng the efﬁcacy of new drugs for asthmatic patients.
.3. Disadvantages of the equine model of asthma
Using horses as an asthma animal model is not free of
rawbacks. A direct consequence of their large size is limited acces-
ibility and higher cost for drugs, breeding facilities and equipment,
rocedure materials, and ordinary care. An equine tissue bank
as been developed for respiratory research (http://www.ertb.ca),
hich makes this model available to researchers lacking the facili-
ies or the technical expertise required for handling these animals.
lso, few antibodies have been validated for this species (Schnabel
t al., 2013) and newly discovered immune system cells may  not yet
e characterized in horses. However, the equine genome has been
ntirely sequenced (Wade et al., 2009), which facilitates the identi-
cation of homologous sequences among different species in order
o improve cross-reactivity. Studying subjects of different breed,
ize, age, and origin increases intra-group variability and further
omplicates data analysis and interpretation. However, it provides
 heterogeneous population as seen in human.
. Heaves and immunology
.1. Neutrophils and the Th2 paradigm in asthma
Asthma is generally considered as an eosinophilic disease, espe-
ially in its allergic form, driven by a Th2-type inﬂammatory
esponse. However, the kinetic of inﬂammatory cell recruitment
nto the airway lumen of antigen-challenged asthmatics identiﬁed
osinophil accumulation to occur after the early asthmatic response
Lommatzsch et al., 2006). Interestingly, neutrophil recruitment to
he airway lumen is common in acute asthma exacerbations (Fahy
t al., 1995; Lopuhaa et al., 2002; Norzila et al., 2000; Ordonez et al.,
000) and occurs as early as 4 h after allergen challenge (Nocker
t al., 1999). These ﬁndings support a role for neutrophils dur-
ng uncontrolled phases of the disease (exacerbations or asthma
ttacks). However, while neutrophil recruitment in experimental
ettings is a clear consequence of antigenic challenge, it is not
stablished whether during real-life asthma attacks, it precedes or
ollows the fall in lung function. Also, the immunologic mechanisms
inking neutrophil activation/recruitment to the Th2-predominant
mmune response in asthma remain incompletely elucidated.
In horses with heaves, a predominant Th2-type immune
esponse associated with an airway neutrophilia has been
escribed both in the acute and chronic phases of the diseases
Beadle et al., 2002; Cordeau et al., 2004; Klukowska-Rotzler et al.,
012a; Lavoie et al., 2001). Pulmonary neutrophilia develops as
arly as 5–6 h after antigen exposure, preceding the development
f airway obstruction (Brazil et al., 2005; Fairbairn et al., 1993;
ranchini et al., 2000). Peripheral neutrophils are primed in heaves,
lso during periods of remission of the disease (Lavoie-Lamoureux
t al., 2012a). An increased number of neutrophils express IL-5
nd IL-9 receptors in heaves-affected horses compared to con-
rols, which could link the observed Th2-type immune response
o the neutrophilic chronic inﬂammatory phenotype (Dewachi
t al., 2006). Also, recombinant equine IL-4 stimulation inducedmunology 66 (2015) 97–105 101
an increase in IL-8 and IL-4R expression in equine neutrophil ex
vivo, suggesting that Th2 cytokines may  contribute to the recruit-
ment and activation of neutrophils during allergic inﬂammation
(Lavoie-Lamoureux et al., 2010).
Disease chronicity has also been associated with induc-
tion/activation of Th17-mediate immunity in heaves (Ainsworth
et al., 2006; Debrue et al., 2005). Th17 cytokines may  therefore
contribute to the sustained airway neutrophilic inﬂammation in
this disease, as reported in human asthma (Linden and Dahlen,
2014). However, Th17 and Th2 responses may  not be mutually
exclusive but rather sequentially expressed in the airways (Lavoie-
Lamoureux et al., 2010), hallmarks of consecutive phases of the
inﬂammatory process. Also, and as reported in human asthma, mul-
tiple molecular phenotypes or endotypes possibly occur in heaves,
as predominant Th1 and mixed Th1/Th2-type responses has been
reported, suggesting complex immune processes contributing to
the disease in some circumstances (Ainsworth et al., 2003, 2006;
Beadle et al., 2002; Giguere et al., 2002). Clearly, and similar to
human asthma, the pathways responsible for the asthmatic phe-
notype in heaves are likely to be complex and inﬂuenced by both
genetic and environmental factors.
3.2. Unraveling the mechanisms linking asthma clinical signs,
inﬂammation, and tissue remodeling
Asthma is a chronic obstructive disease characterized by airway
hyperresponsiveness, inﬂammation, and remodeling. The identiﬁ-
cation of excessive and possibly inappropriate airway inﬂammation
as a phenomenon underlying asthma pathophysiology was recog-
nized in the late 1980s and led to the proposal of the “inﬂammatory
paradigm”, by which local chronic inﬂammation would trigger tis-
sue remodeling and consequently amplify the constrictive effect of
airway hyperresponsiveness (Walter and Holtzman, 2005). Remod-
eling has been documented to occur at all levels of the bronchial
wall, with ASM being the structure whose architectural and phe-
notypical alterations more profoundly impact asthma clinical
manifestations (Lambert et al., 1993; Oliver et al., 2007). Never-
theless, the mechanisms regulating remodeling and inﬂammation
in asthma as well as their effect on airway hyperresponsiveness are
far from clear and are subject of extensive research.
The study of remodeling features in asthmatic patients is com-
plicated by both a difﬁculty in obtaining tissue samples (mainly
small airways) and by technical impossibility of controlling for sev-
eral variables linked to the environment in which the patient live
(antigen exposure, alimentary habits, environmental temperature
and humidity, medication adherence, and compliance), which can
affect asthma clinical presentations and thus remodeling features.
The horse is a model that, despite the biological/genetic variability
among different subjects, allows removal of most of the “envi-
ronmental noise”. Furthermore, lung samples can be sequentially
obtained from both central and peripheral airways from the same
horses.
While studying equine heaves as an asthma model, our group
has shown that, following corticosteroid inhalation therapy, clin-
ical manifestations of the disease, and small ASM remodeling
were dissociated from pulmonary neutrophilia (Leclere et al.,
2012a). Conversely, when remission of the disease was achieved
by long-term antigen avoidance strategies, normalization of air-
way neutrophilia preceded the decrease in ASM mass. Also, IL-8 and
TNF- mRNA expression in BAL cells remained elevated in horses
receiving inhaled ﬂuticasone when compared to horses treated
with antigen avoidance strategies. These results indicate that a
greater degree of activated neutrophils were indeed present within
the bronchi of horses showing the better outcome in terms of ASM
remodeling features. Alterations in the architecture of the airway
wall are not limited to the ASM cells in asthma. The extracellular
1 ular Immunology 66 (2015) 97–105
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atrix (ECM), a dynamic three-dimensional ﬁbrous network essen-
ial to the mechanical properties of the airways, is also altered in
uantity and composition in the asthmatic airways (Roche et al.,
989; Wilson and Li, 1997). We  recently reported an increase in col-
agen and elastic ﬁber content in the peripheral airways of horses
ith heaves in remission, which was correlated with alterations
n airway function (Lanctot Setlakwe et al., 2014). These ﬁndings
ndicate that increased collagen content contribute to the resid-
al airway obstruction in asthmatic horses, while increased and
isorganized elastic ﬁber content decreased the elastic properties
compliance) of the lung. Interestingly, while collagen remodel-
ng is considered poorly responsive to intervention, we  observed
 reduction in airway collagen content after a 1-year treatment
ith either inhaled corticosteroids or antigen avoidance strategies
Leclere et al., 2012b). The reduced collagen content was  not asso-
iated with decreased TGF-ß or inﬂammatory cytokine expression
y BAL cells in these horses. Taken together, these ﬁndings suggest
hat BAL neutrophilic inﬂammation is not strictly associated with
mall airway remodeling or airway obstruction in chronic disease,
ut a direct link seems to exist between airway hyperreactivity and
issue remodeling.
.3. Mechanical regulation of the bronchial immune response
Increasing evidences suggest that mechanical stimulation of the
irways prompts activation of several resident cells, with conse-
uent upregulation of inﬂammatory gene expression and changes
n phenotype of structural components (Le Bellego et al., 2009;
udwig et al., 2004; Mohamed et al., 2010; Park et al., 2010; Park
nd Tschumperlin, 2009). Interestingly, smooth muscle cells can
witch from their normal contractile phenotype to a more prolif-
rative/synthetic one when chronic mechanical loads are imposed
DiSanto et al., 2003; Hirota et al., 2009). The (+)insert smooth mus-
le myosin heavy chain (SMMHC) isoform is a marker of the smooth
uscle proliferative/hypercontractile phenotype and was  found to
e signiﬁcantly increased in endobronchial biopsies from asthmat-
cs compared to controls (Leguillette et al., 2009). To the same
xtent, (+)insert SMMHC is overexpressed in central and periph-
ral airways of horses with heaves compared to controls, indicating
henotype switching of ASM along the bronchial tree (Boivin et al.,
014). The relative contribution of mechanical load and inﬂam-
ation to (+)insert SMMHC  regulation is unknown. However, as
orticosteroid administration and long-term antigen avoidance led
o a signiﬁcant reduction of the (+)insert expression in the airways
f heaves-affected horses (Boivin et al., 2014), inﬂammation likely
ontributes to this process.
.4. Innate immune activation is a feature of neutrophilic asthma
Chronic innate immune activation is present in neutrophilic
uman asthma as in equine heaves, which persists also during
emission of the disease (Fu et al., 2013; Lavoie-Lamoureux et al.,
012a; Wood et al., 2012). It has been speculated that the chronic
nﬂammatory response of the asthmatic airways could be the result
f a defective innate immune system. An inappropriately developed
r altered innate immune response could lead to an exaggerated
eaction to normally no-noxious stimuli. Alternatively, there may
e an inability of such system to be “switch off” after being acti-
ated. Indeed, chronic activation itself could prevent adequate
egative feedback systems to act properly.
Neutrophils are ﬁrst-line defense cells of the innate immune
ystem. They are considered the hallmark of acute inﬂamma-
ory processes, as they quickly congregate at sites of damaged or
nfected tissues in response of several chemotactic agents liberated
uring the initial insult. They directly ﬁght the noxious agent by
iberating antimicrobial and protease-rich granules, by producingpresence of NETs, as indicated by the black arrow heads (40× magniﬁcation, scale
bar = 50 m).
extracellular traps (NETs; Fig. 4), and through phagocytosis. They
also liberate several pro- and anti-inﬂammatory cytokines, thus
possibly modulating the inﬂammatory response. Peripheral blood
neutrophils are activated in human asthma and in equine heaves
(Dewachi et al., 2006; Lavoie-Lamoureux et al., 2012a; Mann and
Chung, 2006; Marr et al., 1997; Tremblay et al., 1993; Wood et al.,
2012). Available data support an early neutrophilic wave to happen
as early as 5 h after antigen exposure in both asthma and heaves
(Brazil et al., 2005; Nocker et al., 1999). Interestingly, healthy
human and equine subjects develop mild but signiﬁcant neu-
trophilic pulmonary inﬂammation after allergen challenge, which
spontaneously resolves within few days/hours despite protraction
of the stimulus (Leclere et al., 2011; Nocker et al., 1999). Such
natural clearance is not observed in asthma or in heaves. Further-
more, neutrophils recruited to the airways are activated in horses
with heaves but not in control animals exposed to the same envi-
ronment, as shown by the increased identiﬁcation of NETs in the
ﬁrst group only (Cote et al., 2014). Whether systemic neutrophilic
activation results from an intrinsic defect of the neutrophils, or neu-
trophils are activated secondary to the lung inﬂammation remains
to be deﬁnitively determined. Basal peripheral neutrophil activa-
tion is not dissimilar between horses with heaves in remission and
controls, but changes in response to speciﬁc stimuli, suggesting that
alterations of the innate immune response to speciﬁc noxa may  be
associated with heaves pathology (Lavoie-Lamoureux et al., 2012a).
These differences being found even in the absence of lung inﬂam-
mation provides some evidence of an intrinsic defect of neutrophil
activation in heaves.
3.5. Role of the bronchial epithelium in heaves
The ASM-centric paradigm leading asthma research in the
last decades is slowly evolving toward asthma pathogenesis
being driven by both the ASM and the bronchial epithelium (Erle
and Sheppard, 2014). Bronchial epithelial cells obtained before
and after antigen challenge showed an increased expression of
transcription factors able to regulate the immunologic response
(NF-K,  AP-1, and CREB) in horses with heaves compared to
controls (Bureau et al., 2000; Couetil et al., 2006). Protein expres-
sion of IL-6, IL-10, and TNF- and gene expression of CXCL1
and TLR4 were similar in bronchial epithelial cells of heaves and
healthy horses early after antigen challenge (Ainsworth et al.,
2006; Riihimaki et al., 2008). Bronchial epithelial cell cultured
from horses with heaves and controls showed a similar increase
in TLSP gene expression 6 h after hay dust suspension challenge
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Klukowska-Rotzler et al., 2012a). However, epithelial cells from
orses with heaves showed an increased expression of IL-8 and
LR-4 compared to controls later on in the development of the
isease (Ainsworth et al., 2006; Berndt et al., 2007), suggesting that
hese cells likely contribute to the persistent airway inﬂammation.
.6. Heaves and immunity toward helminths
As suggested by the “hygiene hypothesis”, regular use of mod-
rn antihelmintics and a decreased exposure to parasites could
ncrease the risk for horses developing heaves and other aller-
ic diseases (Strachan, 1989). Clearance of extracellular parasites,
ncluding helminths, is mediated by Th2-type immune response.
quine studies linking heaves to parasite immunity have been
erived from data collected from 2 half-sibling families of Swiss
orses affected with heaves (Ramseyer et al., 2007). Some of these
orses (all belonging to the same family) have an increased resis-
ance to intestinal parasite infestation when compared to the other
amily of heaves affected horses, or to control animals (Brundler
t al., 2011; Neuhaus et al., 2010). These differences between the
wo heaves-affected families were associated with microsatellite
arkers near the gene of the IL-4 receptor alpha chain (IL4R),
ffecting its expression during disease exacerbations (Jost et al.,
007; Klukowska-Rotzler et al., 2012b; Racine et al., 2011). Also, hay
ust and cyathostomin extract increased the expression of IL4R,
L-4, and IL-10 by isolated blood leukocytes only in the family show-
ng increased parasite resistance (Lanz et al., 2013). Interestingly,
L4R is associated with defense against parasites in humans and
nimals, and a correlation between susceptibility to asthma and
esistance to parasitic infections has been reported for asthmatics
s well (Barnes et al., 2005; Hopkin, 2009). These ﬁndings suggest
hat a Th2-biased immune response is “genetically programmed” in
ome equine and human subjects, rather than being a consequence
f an increased hygiene. While this genetic trait would be advan-
ageous by providing increased parasite protection in the wild, it
ay  be disadvantageous when the horse is moved into a domes-
icated milieu and exposed to high burdens of inhaled allergens,
romoting an exaggerated and inappropriate pulmonary immune
esponse.
.7. Aging
Asthma incidence in the elderly population is growing and
hese patients are more likely to be underdiagnosed and under-
reated than young asthmatic subjects (Hanania et al., 2011). Aging
n healthy individuals is a physiological process associated with
mportant changes in the immune function collectively known as
mmunosenescence or “inﬂamm-ageing”. It results in a reduced
apacity to cope with a variety of stressors and in a progressive pro-
nﬂammatory status (Franceschi et al., 2000). Inﬂamm-aging has
een demonstrated to occur in horses (Fermaglich and Horohov,
002; Horohov et al., 2010), supporting the use of these animals
or age-related immunological studies. Speciﬁcally, T-cells of aged
orses (>20 years old) show a decreased proliferative response
Adams et al., 2008; Horohov et al., 2002) when compared to
ounger animals and an increased production of IFN and TNF
y lymphocytes and monocytes, respectively (Hansen et al., 2013,
014; Katepalli et al., 2008). Furthermore, speciﬁc immune-aging
rocesses appear to vary according to the anatomical locations.
or instance, TNF production increases with age in peripheral
ononuclear cells but not in BALF cells. Also, while IL-1 mRNA
xpression increases with age in peripheral blood, they decrease
n BALF cells (Adams et al., 2008; Hansen et al., 2013). Whether
nd how these ﬁndings correlate with the development of airway
iseases and whether they are affected by common anti-asthma
edications remains to be elucidated.munology 66 (2015) 97–105 103
4. Conclusions
In conclusion, heaves and asthma share common clinical pre-
sentation but also important immunological basis. While equine
heaves does not necessarily share the same attributes of all forms
or stages of human asthma, the natural history of the disease and
the similarities in the airway remodeling processes make heaves
an ideal model to study the cellular and molecular pathways asso-
ciated with the asthmatic airway response and its reversibility,
especially regarding late-onset and severe asthma. Signiﬁcant simi-
larities in the therapeutic responses between horses suffering from
heaves and asthmatic patients further support the study of equine
heaves as a model for human asthma. Finally, the role of neutrophils
in asthma (and in heaves) remains to be established. Progress in this
area fostering the ability of regulating or re-programming the neu-
trophilic response in subjects with heaves could be important for
elucidating the implication of such cells into asthma development.
Acknowledgments
This work was supported by the Canadian Institutes of Health
(#102751 ) and by a PBEEE-V1 Scholarship from the FRQNT (Fonds
de Recherche du Québec - Nature et Technologies).
References
Adams, A.A., Breathnach, C.C., Katepalli, M.P., Kohler, K., Horohov, D.W., 2008.
Advanced age in horses affects divisional history of T cells and inﬂammatory
cytokine production. Mech. Ageing Dev. 129, 656–664.
Ainsworth, D.M., Grunig, G., Matychak, M.B., Young, J., Wagner, B., Erb, H.N., Antczak,
D.F., 2003. Recurrent airway obstruction (RAO) in horses is characterized by
IFN-gamma and IL-8 production in bronchoalveolar lavage cells. Vet. Immunol.
Immunopatol. 96, 83–91.
Ainsworth, D.M., Wagner, B., Franchini, M., Grunig, G., Erb, H.N., Tan, J.Y., 2006.
Time-dependent alterations in gene expression of interleukin-8 in the bronchial
epithelium of horses with recurrent airway obstruction. Am. J. Vet. Res. 67,
669–677.
Barnes, K.C., Grant, A.V., Gao, P., 2005. A review of the genetic epidemiology of resis-
tance to parasitic disease and atopic asthma: common variants for common
phenotypes? Curr. Opin. Allergy Clin. Immunol. 5, 379–385.
Beadle, R.E., Horohov, D.W., Gaunt, S.D., 2002. Interleukin-4 and interferon-gamma
gene expression in summer pasture-associated obstructive pulmonary disease
affected horses. Equine Vet. J. 34, 389–394.
Berndt, A., Derksen, F.J., Venta, P.J., Ewart, S., Yuzbasiyan-Gurkan, V., Robinson, N.E.,
2007. Elevated amount of Toll-like receptor 4 mRNA in bronchial epithelial
cells is associated with airway inﬂammation in horses with recurrent airway
obstruction. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L936–L943.
Bhavsar, P., Khorasani, N., Hew, M.,  Johnson, M.,  Chung, K.F., 2010. Effect of p38 MAPK
inhibition on corticosteroid suppression of cytokine release in severe asthma.
Eur. Respir. J. 35, 750–756.
Boivin, R., Vargas, A., Lefebvre-Lavoie, J., Lauzon, A.M., Lavoie, J.P., 2014. Inhaled
corticosteroids modulate the (+)insert smooth muscle myosin heavy chain in
the equine asthmatic airways. Thorax 69, 1113–1119.
Bos, I.S., Gosens, R., Zuidhof, A.B., Schaafsma, D., Halayko, A.J., Meurs, H., Zaagsma,
J.,  2007. Inhibition of allergen-induced airway remodelling by tiotropium and
budesonide: a comparison. Eur. Respir. J. 30, 653–661.
Brazil, T.J., Dagleish, M.P., McGorum, B.C., Dixon, P.M., Haslett, C., Chilvers, E.R., 2005.
Kinetics of pulmonary neutrophil recruitment and clearance in a natural and
spontaneously resolving model of airway inﬂammation. Clin. Exp. Allergy 35,
854–865.
Brundler, P., Frey, C.F., Gottstein, B., Nussbaumer, P., Neuhaus, S., Gerber, V., 2011.
Lower shedding of strongylid eggs by Warmblood horses with recurrent airway
obstruction compared to unrelated healthy horses. Vet. J. 190, e12–e15.
Bullone, M.,  Chevigny, M.,  Allano, M.,  Martin, J.G., Lavoie, J.P., 2014a. Technical and
physiological determinants of airway smooth muscle mass in endobronchial
biopsy samples of asthmatic horses. J. Appl. Physiol. 117, 806–815.
Bullone, M.,  Godbout, M.,  Martin, G.J., Lavoie, J.P., 2014b. Endobronchial ultraso-
nography of isolated bronchi reveals increased airway smooth muscle mass in
large airways of asthmatic horses. Am. J. Respir. Crit. Care Med. 189, A2382.
Busse, P.J., Mathur, S.K., 2010. Age-related changes in immune function: effect on
airway inﬂammation. J. Allergy Clin. Immunol. 126, 690–699, quiz 700-1.
Bureau, F., Bonizzi, G., Kirschvink, N., Delhalle, S., Desmecht, D., Merville, M.P.,
Bours, V., Lekeux, P., 2000. Correlation between nuclear factor-kappaB activ-
ity  in bronchial brushing samples and lung dysfunction in an animal model of
asthma. Am.  J. Resp. Crit. Care Med. 161, 1314–1321.
Busse, W.W.,  Lemanske Jr., R.F., 2007. Expert Panel Report 3: moving forward to
improve asthma care. J. Allergy Clin. Immunol. 120, 1012–1014.
1 ular Im
C
C
C
C
C
C
C
C
C
C
C
D
D
D
D
D
E
F
F
F
F
F
F
F
G
G
G
H04 M. Bullone, J.-P. Lavoie / Molec
aswell, J.L., Middleton, D.M., Gordon, J.R., 1999. Production and functional charac-
terization of recombinant bovine interleukin-8 as a speciﬁc neutrophil activator
and chemoattractant. Vet. Immunol. Immunopathol. 67, 327–340.
aswell, J.L., Middleton, D.M., Gordon, J.R., 2001. The importance of interleukin-8 as
a  neutrophil chemoattractant in the lungs of cattle with pneumonic pasteurel-
losis. Can. J. Vet. Res. 65, 229–232.
hopra, P., Kanoje, V., Semwal, A., Ray, A., 2008. Therapeutic potential of inhaled
p38 mitogen-activated protein kinase inhibitors for inﬂammatory pulmonary
diseases. Expert Opin. Investig. Drugs 17, 1411–1425.
lienti, S., Morjaria, J.B., Basile, E., Polosa, R., 2011. Monoclonal antibodies for the
treatment of severe asthma. Curr. Allergy Asthma Rep. 11, 253–260.
ook, V.L., Neuder, L.E., Blikslager, A.T., Jones, S.L., 2009. The effect of lidocaine
on  in vitro adhesion and migration of equine neutrophils. Vet. Immunol.
Immunopathol. 129, 137–142.
ordeau, M.E., Joubert, P., Dewachi, O., Hamid, Q., Lavoie, J.P., 2004. IL-4, IL-5 and
IFN-gamma mRNA expression in pulmonary lymphocytes in equine heaves. Vet.
Immunol. Immunopathol. 97, 87–96.
ostabel, U., Bonella, F., Guzman, J., 2012. Chronic hypersensitivity pneumonitis.
Clin. Chest Med. 33, 151–163.
ote, O., Clark, M.E., Viel, L., Labbe, G., Seah, S.Y., Khan, M.A., Douda, D.N., Palaniyar,
N., Bienzle, D., 2014. Secretoglobin 1A1 and 1A1A differentially regulate neu-
trophil reactive oxygen species production, phagocytosis and extracellular trap
formation. PloS One 9, e96217.
ouetil, L.L., Art, T., de Moffarts, B., Becker, M.,  Melotte, D., Jaspar, F., Bureau,
F.,  Lekeux, P., 2006. Effect of beclomethasone dipropionate and dexametha-
sone isonicotinate on lung function, bronchoalveolar lavage ﬂuid cytology, and
transcription factor expression in airways of horses with recurrent airway
obstruction. J. Vet. Intern. Med. 20, 399–406.
ouetil, L.L., Hoffman, A.M., Hodgson, J., Buechner-Maxwell, V., Viel, L., Wood, J.L.,
Lavoie, J.P., 2007. Inﬂammatory airway disease of horses. J. Vet. Intern. Med. 21,
356–361.
ouetil, L.L., Rosenthal, F.S., Simpson, C.M., 2000. Forced expiration: a test for airﬂow
obstruction in horses. J. Appl. Physiol. 88, 1870–1879.
ebrue, M.,  Hamilton, E., Joubert, P., Lajoie-Kadoch, S., Lavoie, J.P., 2005. Chronic
exacerbation of equine heaves is associated with an increased expres-
sion of interleukin-17 mRNA in bronchoalveolar lavage cells. Vet. Immunol.
Immunopathol. 105, 25–31.
ewachi, O., Joubert, P., Hamid, Q., Lavoie, J.P., 2006. Expression of interleukin
(IL)-5 and IL-9 receptors on neutrophils of horses with heaves. Vet. Immunol.
Immunopathol. 109, 31–36.
iSanto, M.E., Stein, R., Chang, S., Hypolite, J.A., Zheng, Y., Zderic, S., Wein, A.J.,
Chacko, S., 2003. Alteration in expression of myosin isoforms in detrusor smooth
muscle following bladder outlet obstruction. Am. J. Physiol. Cell Physiol. 285,
C1397–C1410.
ixon, P.M., McGorum, B., 1990. Pasture-associated seasonal respiratory disease in
two horses. Vet. Rec. 126, 9–12.
ouglass, J., Dhami, D., Bulpitt, M.,  Lindley, I.J., Shute, J., Church, M.K., Holgate, S.T.,
1996. Intradermal challenge with interleukin-8 causes tissue oedema and neu-
trophil accumulation in atopic and non-atopic human subjects. Clin. Exp. Allergy
26,  1371–1379.
rle, D.J., Sheppard, D., 2014. The cell biology of asthma. J. Cell. Biol. 205, 621–631.
ahy, J.V., Kim, K.W., Liu, J., Boushey, H.A., 1995. Prominent neutrophilic inﬂamma-
tion in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol.
95, 843–852.
airbairn, S.M., Page, C.P., Lees, P., Cunningham, F.M., 1993. Early neutrophil but
not eosinophil or platelet recruitment to the lungs of allergic horses following
antigen exposure. Clin. Exp. Allergy 23, 821–828.
ermaglich, D.H., Horohov, D.W., 2002. The effect of aging on immune responses.
Vet. Clin. North Am.  Equine Pract. 18, 621–630, ix.
ranceschi, C., Bonafe, M.,  Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., De
Benedictis, G., 2000. Inﬂamm-aging: an evolutionary perspective on immunose-
nescence. Ann. NY Acad. Sci. 908, 244–254.
ranchini, M.,  Gill, U., von Fellenberg, R., Bracher, V.D., 2000. Interleukin-8 concen-
tration and neutrophil chemotactic activity in bronchoalveolar lavage ﬂuid of
horses with chronic obstructive pulmonary disease following exposure to hay.
Am.  J. Vet. Res. 61, 1369–1374.
ranchini, M., Gilli, U., Akens, M.K., Fellenberg, R.V., Bracher, V., 1998. The role of neu-
trophil chemotactic cytokines in the pathogenesis of equine chronic obstructive
pulmonary disease (COPD). Vet. Immunol. Immunopathol. 66, 53–65.
u, J.J., Baines, K.J., Wood, L.G., Gibson, P.G., 2013. Systemic inﬂammation is associ-
ated with differential gene expression and airway neutrophilia in asthma. OMICS
17, 187–199.
iembycz, M.A., Newton, R., 2011. Harnessing the clinical efﬁcacy of phos-
phodiesterase 4 inhibitors in inﬂammatory lung diseases: dual-selective
phosphodiesterase inhibitors and novel combination therapies. Handb. Exp.
Pharmacol., 415–446.
iguere, S., Viel, L., Lee, E., MacKay, R.J., Hernandez, J., Franchini, M., 2002. Cytokine
induction in pulmonary airways of horses with heaves and effect of ther-
apy with inhaled ﬂuticasone propionate. Vet. Immunol. Immunopathol. 85,
147–158.
lobal Strategy for Asthma Management and Prevention, Global Initiative for
Asthma (GINA), 2014. Available from: http://www.ginasthma.org/
anania, N.A., King, M.J., Braman, S.S., Saltoun, C., Wise, R.A., Enright, P., Falsey, A.R.,
Mathur, S.K., Ramsdell, J.W., Rogers, L., Stempel, D.A., Lima, J.J., Fish, J.E., Wil-
son, S.R., Boyd, C., Patel, K.V., Irvin, C.G., Yawn, B.P., Halm, E.A., Wasserman, S.I.,
Sands, M.F., Ershler, W.B., Ledford, D.K., 2011. Asthma in the elderly: currentmunology 66 (2015) 97–105
understanding and future research needs – a report of a National Institute on
Aging (NIA) workshop. J. Allergy Clin. Immunol. 128, S4–S24.
Hansen, S., Baptiste, K.E., Fjeldborg, J., Betancourt, A., Horohov, D.W., 2014. A compar-
ison of pro-inﬂammatory cytokine mRNA expression in equine bronchoalveolar
lavage (BAL) and peripheral blood. Vet. Immunol. Immunopathol. 158, 238–243.
Hansen, S., Sun, L., Baptiste, K.E., Fjeldborg, J., Horohov, D.W., 2013. Age-related
changes in intracellular expression of IFN-gamma and TNF-alpha in equine lym-
phocytes measured in bronchoalveolar lavage and peripheral blood. Dev. Comp.
Immunol. 39, 228–233.
Hein, W.R., Griebel, P.J., 2003. A road less travelled: large animal models in immuno-
logical research. Nat. Rev. Immunol. 3, 79–84.
Hirota, J.A., Nguyen, T.T., Schaafsma, D., Sharma, P., Tran, T., 2009. Airway smooth
muscle in asthma: phenotype plasticity and function. Pulm. Pharmacol. Ther.
22,  370–378.
Hol, J., Wilhelmsen, L., Haraldsen, G., 2010. The murine IL-8 homologues KC, MIP-2,
and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade
bodies. J. Leukoc. Biol. 87, 501–508.
Hopkin, J., 2009. Immune and genetic aspects of asthma, allergy and parasitic worm
infections: evolutionary links. Parasite Immunol. 31, 267–273.
Horohov, D.W., Adams, A.A., Chambers, T.M., 2010. Immunosenescence of the equine
immune system. J. Comp. Pathol. 142 (Suppl. 1), S78–S84.
Horohov, D.W., Kydd, J.H., Hannant, D., 2002. The effect of aging on T cell responses
in  the horse. Dev. Comp. Immunol. 26, 121–128.
Hotchkiss, J.W., Reid, S.W., Christley, R.M., 2007. A survey of horse owners in Great
Britain regarding horses in their care. Part 2: Risk factors for recurrent airway
obstruction. Equine Vet. J. 39, 301–308.
Jean, D., Vrins, A., Beauchamp, G., Lavoie, J.P., 2011. Evaluation of variations in bron-
choalveolar lavage ﬂuid in horses with recurrent airway obstruction. Am.  J. Vet.
Res. 72, 838–842.
Jeffery, P., Holgate, S., Wenzel, S., 2003. Methods for the assessment of endobronchial
biopsies in clinical research: application to studies of pathogenesis and the
effects of treatment. Am. J. Respir. Crit. Care Med. 168, S1–S17.
Jost, U., Klukowska-Rotzler, J., Dolf, G., Swinburne, J.E., Ramseyer, A., Bugno, M.,
Burger, D., Blott, S., Gerber, V., 2007. A region on equine chromosome 13 is linked
to  recurrent airway obstruction in horses. Equine Vet. J. 39, 236–241.
Joubert, P., Cordeau, M.E., Lavoie, J.P., 2011. Cytokine mRNA expression of pulmonary
macrophages varies with challenge but not with disease state in horses with
heaves or in controls. Vet. Immunol. Immunopathol. 142, 236–242.
Katepalli, M.P., Adams, A.A., Lear, T.L., Horohov, D.W., 2008. The effect of age and
telomere length on immune function in the horse. Dev. Comp. Immunol. 32,
1409–1415.
Kaur, M.,  Singh, D., 2013. Neutrophil chemotaxis caused by chronic obstructive
pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors
CXCR1/CXCR2. Pharmacol. Exp. Ther. 347, 173–180.
Klukowska-Rotzler, J., Marti, E., Lavoie, J.P., Ainsworth, D.M., Gerber, V., Zurbriggen,
A., Janda, J., 2012a. Expression of thymic stromal lymphopoietin in equine recur-
rent  airway obstruction. Vet. Immunol. Immunopathol. 146, 46–52.
Klukowska-Rotzler, J., Swinburne, J.E., Drogemuller, C., Dolf, G., Janda, J., Leeb, T.,
Gerber, V., 2012b. The interleukin 4 receptor gene and its role in recurrent airway
obstruction in Swiss Warmblood horses. Anim. Genet. 43, 450–453.
Kolm, G., Zappe, H., Schmid, R., Riedelberger, K., Van den Hoven, R., 2003. Efﬁcacy of
montelukast in the treatment of chronic obstructive pulmonary disease in ﬁve
horses. Vet. Rec. 152, 804–806.
Lambert, R.K., Wiggs, B.R., Kuwano, K., Hogg, J.C., Pare, P.D., 1993. Functional signif-
icance of increased airway smooth muscle in asthma and COPD. J. Appl. Physiol.
74,  2771–2781.
Lanctot Setlakwe, E.L., Lemos, K.R., Lavoie-Lamoureux, A., Duguay, J.D., Lavoie,
J.P., 2014. Airway collagen and elastic ﬁber content correlates with
lung function in equine heaves. Am. J. Physiol. Lung Cell. Mol. Physiol.,
http://dx.doi.org/10.1152/ajplung.00019.2014.
Lanz, S., Gerber, V., Marti, E., Rettmer, H., Klukowska-Rotzler, J., Gottstein, B.,
Matthews, J.B., Pirie, S., Hamza, E., 2013. Effect of hay dust extract and cyathos-
tomin antigen stimulation on cytokine expression by PBMC in horses with
recurrent airway obstruction. Vet. Immunol. Immunopathol. 155, 229–237.
Lavoie-Lamoureux, A., Beauchamp, G., Quessy, S., Martin, J.G., Lavoie, J.P., 2012a.
Systemic inﬂammation and priming of peripheral blood leukocytes persist dur-
ing clinical remission in horses with heaves. Vet. Immunol. Immunopathol. 146,
35–45.
Lavoie-Lamoureux, A., Leclere, M.,  Lemos, K., Wagner, B., Lavoie, J.P., 2012b. Mark-
ers  of systemic inﬂammation in horses with heaves. J. Vet. Intern. Med. 26,
1419–1426.
Lavoie-Lamoureux, A., Moran, K., Beauchamp, G., Mauel, S., Steinbach, F., Lefebvre-
Lavoie, J., Martin, J.G., Lavoie, J.P., 2010. IL-4 activates equine neutrophils and
induces a mixed inﬂammatory cytokine expression proﬁle with enhanced neu-
trophil chemotactic mediator release ex vivo. Am.  J. Physiol. Lung Cell Mol.
Physiol. 299, L472–L482.
Lavoie, J.P., Leguillette, R., Pasloske, K., Charette, L., Sawyer, N., Guay, D., Mur-
phy, T., Hickey, G.J., 2002. Comparison of effects of dexamethasone and the
leukotriene D4 receptor antagonist L-708,738 on lung function and airway cyto-
logic ﬁndings in horses with recurrent airway obstruction. Am. J. Vet. Res. 63,
579–585.Lavoie, J.P., Maghni, K., Desnoyers, M.,  Taha, R., Martin, J.G., Hamid, Q.A., 2001.
Neutrophilic airway inﬂammation in horses with heaves is characterized by a
Th2-type cytokine proﬁle. Am.  J. Respir. Crit. Care Med. 164, 1410–1413.
Lavoie, J.P., Pasloske, K., Joubert, P., Cordeau, M.E., Mancini, J., Girard, Y., Friesen, R.W.,
Frenette, R., Blouin, M., Young, R.N., Hickey, G., 2006. Lack of clinical efﬁcacy of
ular Im
L
L
L
L
L
L
L
L
L
L
L
L
M
M
M
M
N
N
N
N
N
N
O
O
P
P
P
matory phenotype is associated with systemic inﬂammation in asthma. Chest
142, 86–93.M. Bullone, J.-P. Lavoie / Molec
a phosphodiesterase-4 inhibitor for treatment of heaves in horses. J. Vet. Intern.
Med. 20, 175–181.
avoie, J.P., Thompson, D., Hamilton, E., Debrue, M.,  David, F., Hickey, G., 2008. Effects
of  a MAPK p38 inhibitor on lung function and airway inﬂammation in equine
recurrent airway obstruction. Equine Vet. J. 40, 577–583.
e Bellego, F., Perera, H., Plante, S., Chakir, J., Hamid, Q., Ludwig, M.S., 2009. Mechani-
cal strain increases cytokine and chemokine production in bronchial ﬁbroblasts
from asthmatic patients. Allergy 64, 32–39.
eclere, M.,  Lavoie-Lamoureux, A., Gelinas-Lymburner, E., David, F., Martin, J.G.,
Lavoie, J.P., 2011. Effect of antigenic exposure on airway smooth muscle remod-
eling in an equine model of chronic asthma. Am. J. Respir. Cell Mol. Biol. 45,
181–187.
eclere, M.,  Lavoie-Lamoureux, A., Joubert, P., Relave, F., Lanctot Setlakwe, E.,
Beauchamp, G., Couture, C., Martin, J.G., Lavoie, J.P., 2012a. Corticosteroids and
antigen avoidance decrease airway smooth muscle mass in an equine asthma
model. Am.  J. Respir. Cell Mol. Biol. 47, 589–596.
eclere, M.,  Lavoie-Lamoureux, A., Joubert, P., Relave, F., Setlakwe, E.L., Beauchamp,
G., Couture, C., Martin, J.G., Lavoie, J.P., 2012b. Corticosteroids and antigen avoid-
ance  decrease airway smooth muscle mass in an equine asthma model. Am.  J.
Respir. Cell Mol. Biol. 47, 589–596.
ee, N., Shin, M.S., Kang, I., 2012. T-cell biology in aging, with a focus on lung disease.
J.  Gerontol. A: Biol. Sci. Med. Sci. 67, 254–263.
eguillette, R., Laviolette, M.,  Bergeron, C., Zitouni, N., Kogut, P., Solway, J., Kachmar,
L.,  Hamid, Q., Lauzon, A.M., 2009. Myosin, transgelin, and myosin light chain
kinase: expression and function in asthma. Am. J. Respir. Crit. Care Med. 179,
194–204.
inden, A., Dahlen, B., 2014. Interleukin-17 cytokine signalling in patients with
asthma. The Eur. Respir. J., http://dx.doi.org/10.1183/09031936.00002314.
ommatzsch, M.,  Julius, P., Kuepper, M.,  Garn, H., Bratke, K., Irmscher, S., Luttmann,
W.,  Renz, H., Braun, A., Virchow, J.C., 2006. The course of allergen-induced leuko-
cyte inﬁltration in human and experimental asthma. J. Allergy Clin. Immunol.
118, 91–97.
opuhaa, C.E., Out, T.A., Jansen, H.M., Aalberse, R.C., van der Zee, J.S., 2002. Allergen-
induced bronchial inﬂammation in house dust mite-allergic patients with or
without asthma. Clin. Exp. Allergy 32, 1720–1727.
udwig, M.S., Ftouhi-Paquin, N., Huang, W.,  Page, N., Chakir, J., Hamid, Q., 2004.
Mechanical strain enhances proteoglycan message in ﬁbroblasts from asthmatic
subjects. Clin. Exp. Allergy 34, 926–930.
ugo, J., Stick, J.A., Peroni, J., Harkema, J.R., Derksen, F.J., Robinson, N.E., 2002. Safety
and  efﬁcacy of a technique for thoracoscopically guided pulmonary wedge
resection in horses. Am.  J. Vet. Res. 63, 1232–1240.
ann, B.S., Chung, K.F., 2006. Blood neutrophil activation markers in severe asthma:
lack of inhibition by prednisolone therapy. Respir. Res. 7, 59.
arr, K.A., Foster, A.P., Lees, P., Cunningham, F.M., Page, C.P., 1997. Effect of antigen
challenge on the activation of peripheral blood neutrophils from horses with
chronic obstructive pulmonary disease. Res. Vet. Sci. 62, 253–260.
atera, M.G., Page, C., Cazzola, M.,  2014. PDE inhibitors currently in early clinical
trials for the treatment of asthma. Expert. Opin. Investig. Drugs, 1–9.
ohamed, J.S., Lopez, M.A., Boriek, A.M., 2010. Mechanical stretch up-
regulates microRNA-26a and induces human airway smooth muscle hyper-
trophy by suppressing glycogen synthase kinase-3beta. J. Biol. Chem. 285,
29336–29347.
air, P., Gaga, M.,  Zervas, E., Alagha, K., Hargreave, F.E., O’Byrne, P.M., Stryszak, P.,
Gann, L., Sadeh, J., Chanez, P., 2012. Safety and efﬁcacy of a CXCR2 antagonist in
patients with severe asthma and sputum neutrophils: a randomized, placebo-
controlled clinical trial. Clin. Exp. Allergy 42, 1097–1103.
akagome, K., Matsushita, S., Nagata, M.,  2012. Neutrophilic inﬂammation in severe
asthma. Int. Arch. Allergy Immunol. 158 (Suppl 1), 96–102.
euhaus, S., Bruendler, P., Frey, C.F., Gottstein, B., Doherr, M.G., Gerber, V., 2010.
Increased parasite resistance and recurrent airway obstruction in horses of a
high-prevalence family. J. Vet. Intern. Med. 24, 407–413.
ials, A.T., Uddin, S., 2008. Mouse models of allergic asthma: acute and chronic
allergen challenge. Dis. Model. Mech. 1, 213–220.
ocker, R.E., Out, T.A., Weller, F.R., Mul, E.P., Jansen, H.M., van der Zee, J.S., 1999. Inﬂux
of neutrophils into the airway lumen at 4 h after segmental allergen challenge
in  asthma. Int. Arch. Allergy Immunol. 119, 45–53.
orzila, M.Z., Fakes, K., Henry, R.L., Simpson, J., Gibson, P.G., 2000. Interleukin-8
secretion and neutrophil recruitment accompanies induced sputum eosinophil
activation in children with acute asthma. Am.  J. Respir. Crit. Care Med. 161,
769–774.
liver, M.N., Fabry, B., Marinkovic, A., Mijailovich, S.M., Butler, J.P., Fredberg, J.J.,
2007. Airway hyperresponsiveness, remodeling, and smooth muscle mass: right
answer, wrong reason? Am.  J. Respir. Cell Mol. Biol. 37, 264–272.
rdonez, C.L., Shaughnessy, T.E., Matthay, M.A., Fahy, J.V., 2000. Increased neutrophil
numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and
biologic signiﬁcance. Am.  J. Respir. Crit. Care Med. 161, 1185–1190.
ark, J.A., Drazen, J.M., Tschumperlin, D.J., 2010. The chitinase-like protein YKL-40 is
secreted by airway epithelial cells at base line and in response to compressive
mechanical stress. J. Biol. Chem. 285, 29817–29825.
ark, J.A., Tschumperlin, D.J., 2009. Chronic intermittent mechanical stress increases
MUC5AC protein expression. Am.  J. Respir. Cell Mol. Biol. 41, 459–466.era, T., Zuidhof, A., Valadas, J., Smit, M.,  Schoemaker, R.G., Gosens, R., Maarsingh, H.,
Zaagsma, J., Meurs, H., 2011. Tiotropium inhibits pulmonary inﬂammation and
remodelling in a guinea pig model of COPD. Eur. Respir. J. 38, 789–796.munology 66 (2015) 97–105 105
Pini, L., Hamid, Q., Shannon, J., Lemelin, L., Olivenstein, R., Ernst, P., Lemiere, C.,
Martin, J.G., Ludwig, M.S., 2007. Differences in proteoglycan deposition in the
airways of moderate and severe asthmatics. Eur. Respir. J. 29, 71–77.
Pirie, R.S., Collie, D.D., Dixon, P.M., McGorum, B.C., 2003. Inhaled endotoxin and
organic dust particulates have synergistic proinﬂammatory effects in equine
heaves (organic dust-induced asthma). Clin. Exp. Allergy 33, 676–683.
Qiu, Y., Zhu, J., Bandi, V., Guntupalli, K.K., Jeffery, P.K., 2007. Bronchial mucosal
inﬂammation and upregulation of CXC chemoattractants and receptors in severe
exacerbations of asthma. Thorax 62, 475–482.
Racine, J., Gerber, V., Feutz, M.M.,  Riley, C.P., Adamec, J., Swinburne, J.E., Couetil, L.L.,
2011. Comparison of genomic and proteomic data in recurrent airway obstruc-
tion affected horses using ingenuity pathway analysis. BMC  Vet. Res. 7, 48.
Ramseyer, A., Gaillard, C., Burger, D., Straub, R., Jost, U.,  Boog, C., Marti, E., Gerber,
V.,  2007. Effects of genetic and environmental factors on chronic lower airway
disease in horses. J. Vet. Intern. Med. 21, 149–156.
Relave, F., David, F., Leclere, M., Alexander, K., Bussieres, G., Lavoie, J.P., Marcoux,
M.,  2008. Evaluation of a thoracoscopic technique using ligating loops to obtain
large lung biopsies in standing healthy and heaves-affected horses. Vet. Surg.
37, 232–240.
Relave, F., David, F., Leclere, M.,  Alexander, K., Helie, P., Meulyzer, M.,  Lavoie, J.P.,
Marcoux, M.,  2010. Thoracoscopic lung biopsies in heaves-affected horses using
a  bipolar tissue sealing system. Vet. Surg. 39, 839–846.
Riihimaki, M.,  Raine, A., Pourazar, J., Sandstrom, T., Art, T., Lekeux, P., Couetil, L.,
Pringle, J., 2008. Epithelial expression of mRNA and protein for IL-6, IL-10 and
TNF-alpha in endobronchial biopsies in horses with recurrent airway obstruc-
tion. BMC  Vet. Res. 4, 8.
Robinson, N.E., 2001. International Workshop on Equine Chronic Airway Disease,
Michigan State University 16–18 June 2000. Equine Vet. J. 33, 5–19.
Roche, W.R., Beasley, R., Williams, J.H., Holgate, S.T., 1989. Subepithelial ﬁbrosis in
the  bronchi of asthmatics. Lancet 1, 520–524.
Rohde, G., Message, S.D., Haas, J.J., Kebadze, T., Parker, H., Laza-Stanca, V., Khaitov,
M.R., Kon, O.M., Stanciu, L.A., Mallia, P., Edwards, M.R., Johnston, S.L., 2014. Cxc-
chemokines and antimicrobial peptides in rhinovirus-induced experimental
asthma exacerbations. Clin. Exp. Allergy 44, 930–939.
Schnabel, C.L., Wagner, S., Wagner, B., Duran, M.C., Babasyan, S., Nolte, I., Pfarrer,
C.,  Feige, K., Murua Escobar, H., Cavalleri, J.M., 2013. Evaluation of the reactivity
of  commercially available monoclonal antibodies with equine cytokines. Vet.
Immunol. Immunopathol. 156, 1–19.
Seahorn, T.L., Beadle, R.E., 1993. Summer pasture-associated obstructive pul-
monary disease in horses: 21 cases (1983–1991). J. Am.  Vet. Med. Assoc. 202,
779–782.
Seok, J., Shaw Warren, H., Cuenca, A.G., Mindrinos, M.N., Baker, H.V., Wu,  W.,
Richards, D.R., McDonald-Smith, G.P., Gao, H., Hennessy, L., Finnerty, C.C., Lopez,
C.M., Honari, S., Moore, E.E., Minei, J.P., Cuschieri, J., Bankey, P.E., Johnson,
J.L.,  Sperry, J., Nathens, A.B., Billiar, T.R., West, M.A., Jeschke, M.G., Klein, M.B.,
Gamelli, R.L., Gibran, N.S., Brownstein, B.H., Miller-Graziano, C., Calvano, S.E.,
Mason, P.H., Cobb, J.P., Rahme, L.G., Lowry, S.F., Maier, R.V., Moldawer, L.L., Hern-
don, D.N., Davis, R.W., Xiao, W.,  Tompkins, R.G., Inﬂammation and Host Response
to  Injury L. S. C. R. P., 2013. Genomic responses in mouse models poorly mimic
human inﬂammatory diseases. Proc. Natl. Acad. Sci. U.S.A 110, 3507–3512.
Strachan, D.P., 1989. Hay fever, hygiene, and household size. BMJ  299, 1259–1260.
Tremblay, G.M., Ferland, C., Lapointe, J.M., Vrins, A., Lavoie, J.P., Cormier, Y., 1993.
Effect of stabling on bronchoalveolar cells obtained from normal and COPD
horses. Equine Vet. J. 25, 194–197.
Turner, S., Paton, J., Higgins, B., Douglas, G., British Guidelines on the Management
of  Asthma, 2011. British guidelines on the management of asthma: what’s new
for 2011? Thorax 66, 1104–1105.
Van Erck, E., Votion, D., Art, T., Lekeux, P., 2006. Qualitative and quantitative eval-
uation of equine respiratory mechanics by impulse oscillometry. Equine Vet. J.
38, 52–58.
Wade, C.M., Giulotto, E., Sigurdsson, S., Zoli, M.,  Gnerre, S., Imsland, F., Lear, T.L.,
Adelson, D.L., Bailey, E., Bellone, R.R., Blocker, H., Distl, O., Edgar, R.C., Garber, M.,
Leeb, T., Mauceli, E., MacLeod, J.N., Penedo, M.C., Raison, J.M., Sharpe, T., Vogel, J.,
Andersson, L., Antczak, D.F., Biagi, T., Binns, M.M.,  Chowdhary, B.P., Coleman, S.J.,
Della  Valle, G., Fryc, S., Guerin, G., Hasegawa, T., Hill, E.W., Jurka, J., Kiialainen,
A.,  Lindgren, G., Liu, J., Magnani, E., Mickelson, J.R., Murray, J., Nergadze, S.G.,
Onofrio, R., Pedroni, S., Piras, M.F., Raudsepp, T., Rocchi, M.,  Roed, K.H., Ryder,
O.A., Searle, S., Skow, L., Swinburne, J.E., Syvanen, A.C., Tozaki, T., Valberg, S.J.,
Vaudin, M.,  White, J.R., Zody, M.C., Lander, E.S., Lindblad-Toh, K., Broad Institute
Genome Sequencing Platform, Broad Institute Whole Genome Assembly Team,
2009. Genome sequence, comparative analysis, and population genetics of the
domestic horse. Science 326, 865–867.
Walter, M.J., Holtzman, M.J., 2005. A centennial history of research on asthma patho-
genesis. Am.  J. Respir. Cell Mol. Biol. 32, 483–489.
Wenzel, S.E., 2012. Asthma phenotypes: the evolution from clinical to molecular
approaches. Nat. Med. 18, 716–725.
Wilson, J.W., Li, X., 1997. The measurement of reticular basement membrane and
submucosal collagen in the asthmatic airway. Clin. Exp. Allergy 27, 363–371.
Wood, L.G., Baines, K.J., Fu, J., Scott, H.A., Gibson, P.G., 2012. The neutrophilic inﬂam-Yang, Y.G., Tian, W.M.,  Zhang, H., Li, M.,  Shang, Y.X., 2013. Nerve growth factor exac-
erbates allergic lung inﬂammation and airway remodeling in a rat model of
chronic asthma. Exp. Ther. Med. 6, 1251–1258.
 
 
vii 
Article 7 
 
Endoscopic evaluation of angiogenesis in the large airways of horses with heaves using 
narrow band imaging  
Nicolas Herteman, Michela Bullone, Jean-Pierre Lavoie  
 
 
Summary 
The lamina propria of central airways is thickened in equine asthma. In order to assess the 
contribution of increased bronchial vascularity to this aspect of central airway remodeling, we 
have assessed airway angiogenesis using an endoscopic technique that facilitates the 
visualization of submucosal vessels. We observed an increased vascularity only in the tracheal 
mucosa of asthmatic horses. 
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Abstract 
Background: Heaves is a severe debilitating condition of horses, characterized by lower 
airway inflammation and permanent structural changes of the bronchial wall. Chronic 
inflammation promotes the formation of new vessels, a phenomenon known as angiogenesis. 
Narrow band imaging (NBI) endoscopy is a non-invasive technique that enhances the 
visualization of submucosal vessels, and commonly is employed for the study of angiogenesis 
in human patients.  
Objectives: Using NBI, we aimed to determine whether or not the central airways of horses 
with heaves undergo angiogenesis. 
Animals: Horses with heaves during exacerbation of the disease (n=5) and healthy controls 
(n=6).  
Methods: A library of NBI images was established from previously recorded 
videoendoscopies. Images were acquired by an operator blinded to horse ID. Images were 
obtained from 3 sites:  130 from the trachea (14±9.3 [mean±SD] images per horse with heaves 
and 10±5.4 from controls; p=0.45), 58 from the carina (5.4±3.2 from horses with heaves and 
5.2±2.8 from controls; p>0.99) and 167 from the intermediate bronchi (17.8±6.7 from horses 
with heaves and 13±5.6 from controls; p=0.17). Using dedicated stereology software 
(NewCAST, Visiopharm; Denmark), the volume density of superficial and deep vessels was 
calculated blindly by point counting at each site for all horses. 
Results: In the trachea, the volume density of superficial vessels was increased in horses with 
heaves compared to controls (p=0.02). No difference was found between groups for the 
volume density of both superficial and deep vessels at the carina or intermediate bronchi. 
Conclusion and clinical relevance: NBI imaging of the airways was easily performed in 
standing sedated horses.   
 
 
3 
Introduction 
Heaves, also known as recurrent airway obstruction, is a disease of horses characterized by 
episodes of respiratory distress at rest accompanied by neutrophilic pulmonary inflammation 
during exacerbations. This condition affects approximately 10-15% of adult horses >5-7 years 
of age in the northern hemisphere1. Exacerbations are triggered by exposure to environmental 
antigens, and can be reversed by enhancing environmental control or using steroids, 
bronchodilators or both.  
Airway remodeling1-3 leads to the thickening of the bronchial wall, contributing to airflow 
obstruction in heaves. Hyperplasia and hypertrophy of airway myocytes and fibrosis of the 
lamina propria are mainly involved in this process2. However, angiogenesis develops 
concurrently with inflammation and remodeling in human with asthma4, increasing bronchial 
wall thickness, and therefore could be present in horses with heaves given the similarities 
between these conditions1. If present, targeting new blood vessel formation could represent a 
possible strategy to control inflammation and remodeling in heaves.  
Angiogenesis is observed both in physiological (e.g. embryonic development, exercise, 
scarring) and pathological (e.g. tumor growth, inflammation) conditions4-7. It has been 
quantified using several methods. Among these, narrow band imaging (NBI) is a recently 
developed, non-invasive technique allowing an enhanced visualization of submucosal vessels 
during endoscopy. It employs filters producing light of specific blue and green wavelengths 
instead of the white light used during conventional endoscopy, which correspond to the peak 
light absorption of hemoglobin5. This technique facilitates visualizing blood vessels because 
they appear as contrasting structures (black or dark green, depending on their depth within the 
bronchial tissue) beneath the clear bronchial mucosa.  
Despite the availability of new imaging techniques and the likelihood of angiogenesis 
contributing to remodeling in heaves, no study has attempted to quantify airway blood vessels 
in this condition. We hypothesized that NBI would allow identification of an increased density 
of blood vessels (i.e. angiogenesis) in the airways of horses with heaves compared to controls. 
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Material and methods 
Animals and study design 
A library of NBI images was established from videoendoscopies previously recorded. 
Additional details are provided elsewhere3. Eleven horses were studied (5 with heaves and 6 
controls of similar age and weight) using an observational study design. Horses with heaves 
were part of our research herd and had a documented history of abnormal lung function when 
exposed to hay. The control horses were part of the teaching herd at our faculty. They were 
determined to be healthy based on history, physical examination and endoscopic evaluation of 
the respiratory tract. All horses were stabled and exposed to hay starting 2 weeks before the 
study period, in order to induce exacerbations of the disease in affected animals. 
Bronchoscopy 
Horses were sedated using detomidine (0.012 mg/kg IV) and butorphanol (0.01 mg/kg IV). An 
endoscope (13 mm Ø, CF-H180ALa) was passed through the ventral meatus of a nostril. Once 
past the larynx, lidocaine solution (0.5%) was instilled as needed to topically anesthetize the 
airways and prevent coughing episodes. Lower airway endoscopy of 1 randomly selected lung 
was performed in each horse. Endoscopies were performed using the NBI mode while 
advancing from the larynx towards the most distal bronchial site, and recorded on a computer 
in order to be analyzed retrospectively. 
Selection of images 
Images of the bronchial mucosa (tiff files, 1280x800 pixels) were acquired by an operator 
blinded to horse ID. Images were acquired when the submucosal vessels were clearly visible. 
Images in which mucus covered a considerable part of the bronchial mucosa were excluded. 
Images were obtained from 3 sites (Figure 1A): trachea, carina and between the 2nd and 9th 
branches of the main caudal bronchus. Each image was renamed and the order of analysis 
mixed by someone different from the person who conducted the morphometry using the 
stereology software.  
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Angiogenesis assessment 
Vascularity was blindly assessed with NewCast software version 4.5.1.324b. A region of 
interest (ROI) was defined for each image by someone who was blinded to the group in order 
to exclude the darkest area of the image and the regions where accumulated mucus prevented 
a reliable assessment of submucosal vascularity. Superficial and deep vessels were 
differentiated based on their color. Superficial vessels appeared black whereas deep vessels 
appeared dark green during NBI endoscopy. Vascular density was assessed by point counting 
using grids with 256 crosses per screen, because this point density allowed reliable estimation 
of the vascular density in endoscopic images (data not shown). Blood vessel density was 
calculated for each horse as follow: Vvessel = ΣPvessel / ΣPbronchial wall, where ΣPvessel indicates the 
sum of the points falling onto the vessels and ΣPbronchial wall the sum of the points falling onto 
the bronchial wall in each image.  
Statistical analysis 
Analyses were performed using Prism 5c. Non-parametric Mann-Whitney tests were used to 
compare the 2 groups. The level of statistical significance was set at p<0.05. 
 
Results 
A total of 130 images for the trachea (14±9.3 [mean±SD] images per horse with heaves and 
10±5.4 for controls; p=0.45), 58 images for the carina (5.4±3.2 for horses with heaves and 
5.2±2.8 for controls; p>0.99), and 167 images for intermediate bronchi (17.8±6.7 for horses 
with heaves and 13±5.6 for controls; p=0.17) were obtained. The number of images analyzed 
in the 2 groups was similar (mean±SD, 37±17.9 images per horse with heaves and 28±13.3 in 
the control group; p=0.62) and for each site.  
No significant differences (Figure 1-B) were observed for the number of deep vessels in 
trachea (p=0.43), carina (p=0.93), and bronchi (p=0.53) between the 2 groups. Superficial 
vessel density was not different between the 2 groups at the level of the carina (p=0.93) and 
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the bronchi (p=0.53). Horses with heaves however had significantly increased tracheal 
superficial vessel density (p=0.02) compared to controls. 
 
Discussion 
Angiogenesis consists of the formation of new vessels (especially venules) from the pre-
existing vascular tree, forming a capillary-like network. Many pathological conditions are 
associated with angiogenesis, presumably to provide adequate amounts of oxygen to tissues 
with increased metabolism, such as growing, inflamed, or neoplastic tissues. Contrary to what 
we hypothesized, no increase in vascular density of the bronchial tree was observed in heaves-
affected horses compared to controls using NBI, whether evaluating superficial or deep 
vessels. The only significant difference observed was for superficial vessels of the trachea. 
These results suggest that either angiogenesis is only a tracheal feature in horses with heaves 
or that NBI is not sufficiently sensitive to evaluate angiogenesis occurring in the bronchi of 
affected horses. 
Angiogenesis has been quantified using several methods. Unfortunately, most of these assays 
have limited clinical application because of their cost and invasiveness. Airway angiogenesis 
was first studied in endobronchial biopsies of asthmatic patients in research settings. It was 
shown to be associated with disease severity in children with asthma4,6. In recent years, several 
non-invasive imaging techniques have been developed and used as tools to evaluate 
angiogenesis8. Of particular interest, high magnification endoscopy provides an adequate 
assessment of the submucosal vascular network in asthmatic patients7. Narrow band imaging 
allows differentiation of blood vessels based on their depth, by making superficial blood 
vessels appear as brown or black and deep vessels as blue or green structures under the 
bronchial mucosa. It is used primarily in gastroenterology (e.g. adenomas in laparoscopy, 
inflammatory bowel disease, Barrett's esophagus), urology (e.g. bladder tumors, cystitis), and 
less frequently in pneumology 5 (during thoracoscopy for assessment of angiogenesis in lung 
tumors). 
 
 
7 
In this study, NBI was easily performed on sedated standing horses during routine 
bronchoscopy. Our results identified an increase in tracheal superficial vascularity in horses 
with heaves compared to controls. A similar finding has been reported in human asthmatic 
patients7, but the clinical relevance of this observation is uncertain. The presence of luminal 
tracheal inflammatory mediators in heaves possibly could contribute to the increased 
vascularity we observed in these animals. 
Administration of α2-agonists results in activation of peripheral receptors (α1 and α2) on the 
blood vessels leading to vasoconstriction, thus possibly affecting NBI measurements. 
However, although these effects were reported to be ≤ 8 minutes in duration9, NBI was 
performed between 8 to 10 minutes after the first injection, thus likely minimizing this 
phenomenon. Also, differences between groups were observed only in the trachea, and we 
would have expected to see an effect at all sites if the sedation had an impact on blood vessel 
measurements. 
An increase in the vascular network density in the bronchi of horses with heaves was not 
observed, unlike what is reported in human medicine4,6,7. Alternatively, angiogenesis might be 
present only during the establishment of the disease or a period of 2 weeks of antigen exposure 
may not have been long enough to generate angiogenesis. Finally, edema in the respiratory 
tract, bronchospasm, and mucus might have prevented optimal visualization of bronchial 
blood vessels in these horses.  
Airways have a tubular shape, and endoscopic images were obtained with the camera oriented 
longitudinally to their axis. Some area of the tracheobronchial mucosal might have been 
analyzed twice on different images, introducing a bias in our results. However, this is unlikely 
to have occurred in our study for 2 reasons. First, when generating the library, care was taken 
to avoid selecting images in which overlapping mucosal fields could be identified (for trachea 
and bronchi). Second, during analysis, only the mucosal areas proximal to the endoscope had 
adequate conditions of brightness and contrast and therefore were included in the ROI. An 
additional bias could have resulted from the analysis of a 3-dimensional image using markers 
arranged in a bidimensional grid that does not take into account the image perspective. We 
 
 
8 
believe that the bias introduced by our approach, if it occurred, would have been similar in 
both groups because airway anatomy (dimensions) was very similar among the horses we 
studied. 
In conclusion, evaluation of airway vascularity with NBI technology is easily performed in 
standing sedated horses. The clinical relevance of the increased tracheal vascularity observed 
in heaves-affected horses remains to be ascertained. 
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Footnotes 
a Olympus; Richmond Hill, ON, Canada. 
b NewCAST, Visiopharm; Denmark. 
c GraphPad Software Inc; CA, USA.   
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Figures  
 
Figure 1: A- Narrow Band Imaging images of the trachea, the main carina and bronchi of 
control (upper panels) and affected horses (lower panels). B- Vessel area densities in the 
trachea (left), the main carina (center) and the bronchi (right). Each diagram has been divided 
in superficial and deep vessels. 
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